



Cancer in Brazil



Data from the Population- Based Registries

EXECUTIVE SUMMARY



vol. IV

Ministry of Health
National Cancer Institute
José Alencar Gomes da Silva (INCA)



MINISTRY OF HEALTH
NATIONAL CANCER INSTITUTE
JOSÉ ALENCAR GOMES DA SILVA (INCA)

Cancer in Brazil

Data from the Population-Based Registries

EXECUTIVE SUMMARY

vol. IV

Rio de Janeiro, RJ
INCA | 2013

© 2013 Brazilian National Cancer Institute José Alencar Gomes da Silva/Ministry of Health.

All rights reserved. The reproduction, adaptation, modification or use of this content, in part or in full, are expressly prohibited without previous written consent from the INCA or for any commercial end sale prohibited. Distribution free.

This work may be accessed in full in the Thematic Area Cancer Control of the Virtual Health Library - BVS/MS (http://bvsmms.saude.gov.br/bvs/controle_cancer) and at INCA's Portal (<http://www.inca.gov.br>).

Preparation, distribution and information

MINISTRY OF HEALTH
Brazilian National Cancer Institute José Alencar Gomes da Silva (INCA)
Prevention and Surveillance Coordination (Conprev)
Department of Information and Situation Analysis
Rua Marquês de Pombal, 125 – Centro
20230-240 – Rio de Janeiro – RJ
Phone: +55 (21) 3207-5500
e-mail: conprev@inca.gov.br
www.inca.gov.br

Executive Editorial Committee

Bruna Príncipe Vieira Cordeiro
Danielle Nogueira Ramos
Elisângela Siqueira Costa Cabral
Isabelle Martins Santos
Juliana Moreira de Oliveira Ferreira
Julio Fernando Pinto Oliveira
Marceli de Oliveira Santos
Maria do Carmo Esteves da Costa
Marise Souto Rebelo
Rejane de Souza Reis

Edition

Edition and Information Technical-Scientific Service
Rua Marquês de Pombal, 125 – Centro
20230-240 - Rio de Janeiro – RJ
Phone: +55 (21) 3207-5500

Advisory Editorial Committee

Ana Lucia do Amaral Eisenberg
Ana Paula Roque da Silva
Berenice Navarro Antoniazzi
Camila Moura de Mello
Cynthia Asturian Laporte
Edésio Martins
Elmando Sampaio Silva
Isabella Vitral Pinto
Josefa Ângela Pontes de Aquino
Lucrecia Aline Cabral Formigosa
Miren Maite Uribe Arregi
Nazira Maharyri
Paulo Antônio de Paiva Rebelo
Paulo Recena Grassi (*in memoriam*)

Editorial Supervision: Letícia Casado | **Editorial Production:** Taís Facina | **Layout:** g-dés | **Card Catalog:** Mônica de Jesus Carvalho | **English Version:** ATO Training and Translation Center | **Original Graphic Project:** Comunica Design

Printed in Brazil by: Flama

I59c National Cancer Institute José Alencar Gomes da Silva (INCA)
Cancer in Brazil: data from the population-based registries,
volume 4/ National Cancer Institute José Alencar Gomes da Silva
(INCA). – Rio de Janeiro: INCA, 2013.
197p.: il.

ISBN 978-85-7318-220-0 (print version)
ISBN 978-85-7318-221-7 (electronic version)

1. Neoplasms – epidemiologia. 2. Neoplasias – mortalidad.
3. Medical oncology – statistics & numeral data. 4. Brazil I. Title.

CDD 614.59990981

The knowledge about cancer incidence, as well as the most frequent types in a given area, is valuable information for the definition of priorities for cancer control. The data about cancer incidence allow us to know the real magnitude of the disease and play an essential role in the planning and evaluation of the Oncology Care National Policy actions.

In Brazil, the surveillance of the cancer incidence in the population has as one of its main pillars the Population-Based Cancer Registries (PBCR), currently present in 28 cities, 21 of which are capital and seven non-capital cities. With time, the Brazilian PBCRs have become more and more qualified, allowing for a safe comparison using national and international information regarding the incidence profile of several types of cancer. The coverage and quality of the information contained in the Brazilian PBCRs have been improving progressively, and positively, as we can verify in this publication and in the evolution achieved since the last publication, in 2003.

The organization of the information produced by the PBCRs about the global incidence of the disease, as well as their distribution throughout the five continents, is carried out by the International Agency for Research on Cancer (IARC), linked to the World Health Organization (WHO), responsible for assessing the quality of the data and their regular disclosure. In Brazil, the organization and management of these information centers are the National Cancer Institute José de Alencar Gomes da Silva (INCA) responsibility, using the IARC's recommendations and divulging them, providing technical training to the teams of the Brazilian registries. These activities are included in the surveillance of the diseases and disorders no transmissible, coordinated by the Health Surveillance Secretariat (Secretaria de Vigilância à Saúde – SVS/MS), and receive regular financial support in the scope of the Unified Health System (Sistema Único de Saúde - SUS) since 2006.

We hope that a new publication with this format is released every five years so as to provide relevant information that enables an improved management of the cancer control actions in the country. For this volume IV, despite the introduction of criteria for quality assessment in compliance with the international parameters, the number of qualified PBCRs has increased and can be considered very significant.

We also emphasize that this publication is the result of a joint effort by 17 PBCRs, which, along with a group of INCA's specialists, present the results of their hard work, developed in order to put into effect a quality cancer surveillance, capable of promoting positive actions, in consonance with the commitment to reduce the disease burden, incidence and mortality in our country, and improve the patients quality of life.

National Cancer Institute José Alencar Gomes da Silva



Foreword	3
Illustrations	7
Introduction	19
Methodology	21
Population-based cancer registry of Aracaju/SE	25
Population-based cancer registry of Belém/PA	33
Population-based cancer registry of Belo Horizonte/MG	41
Population-based cancer registry of Campo Grande/MS.....	51
Population-based cancer registry of Cuiabá/MT	61
Population-based cancer registry of Curitiba/PR	69
Population-based cancer registry of Fortaleza/CE.....	77
Population-based cancer registry of Goiânia/GO.....	85
Population-based cancer registry of Jaú/SP.....	93
Population-based cancer registry of João Pessoa/PB	101
Population-based cancer registry of Manaus/AM.....	109
Population-based cancer registry of Natal/RN	117
Population-based cancer registry of Palmas/TO.....	125
Population-based cancer registry of Porto Alegre/RS	131
Population-based cancer registry of Recife/PE	139
Population-based cancer registry of Salvador/BA.....	147
Population-based cancer registry of São Paulo/SP	155
Main sites.....	163
Comments	173
Childhood cancers	181
References.....	186
Annexes	197



List of Tables

Table 1	23
Quality indicators for both genders by PBCR and period of reference	
Table 2	26
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Aracaju)	
Table 3	28
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Aracaju)	
Table 4	30
Quality indicators, per primary site (Male/Aracaju)	
Table 5	30
Quality indicators, per primary site (Female/Aracaju)	
Table 6	32
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Aracaju)	
Table 7	34
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Belém)	
Table 8	36
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Belém)	
Table 9	38
Quality indicators, per primary site (Male/Belém)	
Table 10	38
Quality indicators, per primary site (Female/Belém)	
Table 11	40
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Belém)	
Table 12	43
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Belo Horizonte)	
Table 13	45
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Belo Horizonte)	
Table 14	47
Quality indicators, per primary site (Male/ Belo Horizonte)	
Table 15	47
Quality indicators, per primary site (Female/ Belo Horizonte)	
Table 16	49
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Belo Horizonte)	
Table 17	53
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Campo Grande)	
Table 18	55
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Campo Grande)	
Table 19	57
Quality indicators, per primary site (Male/Campo Grande)	
Table 20	57
Quality indicators, per primary site (Female/Campo Grande)	

Table 2159
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Campo Grande)	
Table 2262
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Cuiabá)	
Table 2364
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Cuiabá)	
Table 2466
Quality indicators, per primary site (Male/Cuiabá)	
Table 2566
Quality indicators, per primary site (Female/Cuiabá)	
Table 2668
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Cuiabá)	
Table 2770
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Curitiba)	
Table 2872
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Curitiba)	
Table 2974
Quality indicators, per primary site (Male/Curitiba)	
Table 3074
Quality indicators, per primary site (Female/Curitiba)	
Table 3176
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Curitiba)	
Table 3278
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Fortaleza)	
Table 3380
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Fortaleza)	
Table 3482
Quality indicators, per primary site (Male/Fortaleza)	
Table 3582
Quality indicators, per primary site (Female/Fortaleza)	
Table 3684
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Fortaleza)	
Table 3786
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Goiânia)	
Table 3888
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Goiânia)	
Table 3990
Quality indicators, per primary site (Male/Goiânia)	
Table 4090
Quality indicators, per primary site (Female/Goiânia)	
Table 4192
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Goiânia)	

Table 42	94
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Jaú)	
Table 43	96
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Jaú)	
Table 44	98
Quality indicators, per primary site (Male/Jaú)	
Table 45	98
Quality indicators, per primary site (Female/Jaú)	
Table 46	100
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Jaú)	
Table 47	102
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (João Pessoa)	
Table 48	104
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (João Pessoa)	
Table 49	106
Quality indicators, per primary site (Male/João Pessoa)	
Table 50	106
Quality indicators, per primary site (Female/João Pessoa)	
Table 51	108
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (João Pessoa)	
Table 52	110
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Manaus)	
Table 53	112
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Manaus)	
Table 54	114
Quality indicators, per primary site (Male/Manaus)	
Table 55	114
Quality indicators, per primary site (Female/Manaus)	
Table 56	116
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Manaus)	
Table 57	118
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Natal)	
Table 58	120
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Natal)	
Table 59	122
Quality indicators, per primary site (Male/Natal)	
Table 60	122
Quality indicators, per primary site (Female/Natal)	
Table 61	124
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Natal)	
Table 62	126
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Palmas)	

Table 63	127
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Palmas)	
Table 64	128
Quality indicators, per primary site (Male/Palmas)	
Table 65	128
Quality indicators, per primary site (Female/Palmas)	
Table 66	130
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Palmas)	
Table 67	132
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Porto Alegre)	
Table 68	134
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Porto Alegre)	
Table 69	136
Quality indicators, per primary site (Male/Porto Alegre)	
Table 70	136
Quality indicators, per primary site (Female/Porto Alegre)	
Table 71	138
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Porto Alegre)	
Table 72	140
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Recife)	
Table 73	142
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Recife)	
Table 74	144
Quality indicators, per primary site (Male/Recife)	
Table 75	144
Quality indicators, per primary site (Female/Recife)	
Table 76	146
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Recife)	
Table 77	148
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (Salvador)	
Table 78	150
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (Salvador)	
Table 79	152
Quality indicators, per primary site (Male/Salvador)	
Table 80	152
Quality indicators, per primary site (Female/Salvador)	
Table 81	154
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (Salvador)	
Table 82	156
Specific, crude and age-adjusted incidence rates, per 100 thousand men, per tumor primary site and age group (São Paulo)	
Table 83	158
Specific, crude and age-adjusted incidence rates, per 100 thousand women, per tumor primary site and age group (São Paulo)	

Table 84	160
Quality indicators, per primary site (Male/São Paulo)	
Table 85	160
Quality indicators, per primary site (Female/São Paulo)	
Table 86	162
Specific, crude and age-adjusted incidence rates, per 1 million male and female children and adolescents (São Paulo)	
Table 87	197
Quality indicators per primary site, for Latin America, 1998 to 2002 (Male)	
Table 88	197
Quality indicators per primary site, for Latin America, 1998 to 2002 (Female)	



List of Figures

Figure 1	25
Distribution of the population in Aracaju	
Figure 2	25
Proportion of new cases, compared to the year of highest frequency (Aracaju)	
Figure 3	31
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Aracaju)	
Figure 4	31
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Aracaju)	
Figure 5	33
Distribution of the population in Belém	
Figure 6	33
Proportion of new cases, compared to the year of highest frequency (Belém)	
Figure 7	39
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Belém)	
Figure 8	39
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Belém)	
Figure 9	41
Distribution of the population in Belo Horizonte	
Figure 10	42
Proportion of new cases, compared to the year of highest frequency (Belo Horizonte)	
Figure 11	48
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Belo Horizonte)	
Figure 12	48
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/ Belo Horizonte)	
Figure 13	51
Distribution of the population in Campo Grande	
Figure 14	52
Proportion of new cases, compared to the year of highest frequency (Campo Grande)	
Figure 15	58
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/ Campo Grande)	
Figure 16	58
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/ Campo Grande)	
Figure 17	61
Distribution of the population in Cuiabá	
Figure 18	61
Proportion of new cases, compared to the year of highest frequency (Cuiabá)	
Figure 19	67
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/ Cuiabá)	
Figure 20	67
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Cuiabá)	

Figure 21	69
Distribution of the population in Curitiba	
Figure 22	69
Proportion of new cases, compared to the year of highest frequency (Curitiba)	
Figure 23	75
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Curitiba)	
Figure 24	75
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Curitiba)	
Figure 25	77
Distribution of the population in Fortaleza	
Figure 26	77
Proportion of new cases, compared to the year of highest frequency (Fortaleza)	
Figure 27	83
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Fortaleza)	
Figure 28	83
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Fortaleza)	
Figure 29	85
Distribution of the population in Goiânia	
Figure 30	85
Proportion of new cases, compared to the year of highest frequency (Goiânia)	
Figure 31	91
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Goiânia)	
Figure 32	91
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Goiânia)	
Figure 33	93
Distribution of the population in Jaú	
Figure 34	93
Proportion of new cases, compared to the year of highest frequency (Jaú)	
Figure 35	99
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Jaú)	
Figure 36	99
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Jaú)	
Figure 37	101
Distribution of the population in João Pessoa	
Figure 38	101
Proportion of new cases, compared to the year of highest frequency (João Pessoa)	
Figure 39	107
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/João Pessoa)	
Figure 40	107
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/João Pessoa)	
Figure 41	109
Distribution of the population in Manaus	

Figure 42	109
Proportion of new cases, compared to the year of highest frequency (Manaus)	
Figure 43	115
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Manaus)	
Figure 44	115
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Manaus)	
Figure 45	117
Distribution of the population in Natal	
Figure 46	117
Proportion of new cases, compared to the year of highest frequency (Natal)	
Figure 47	123
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Natal)	
Figure 48	123
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Natal)	
Figure 49	125
Distribution of the population in Palmas	
Figure 50	125
Proportion of new cases, compared to the year of highest frequency (Palmas)	
Figure 51	129
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Palmas)	
Figure 52	129
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Palmas)	
Figure 53	131
Distribution of the population in Porto Alegre	
Figure 54	131
Proportion of new cases, compared to the year of highest frequency (Porto Alegre)	
Figure 55	137
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Porto Alegre)	
Figure 56	137
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Porto Alegre)	
Figure 57	139
Distribution of the population in Recife	
Figure 58	139
Proportion of new cases, compared to the year of highest frequency (Recife)	
Figure 59	145
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Recife)	
Figure 60	145
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Recife)	
Figure 61	147
Distribution of the population in Salvador	
Figure 62	147
Proportion of new cases, compared to the year of highest frequency (Salvador)	

Figure 63	153
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/Salvador)	
Figure 64	153
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/Salvador)	
Figure 65	155
Distribution of the population in São Paulo	
Figure 66	155
Proportion of new cases, compared to the year of highest frequency (São Paulo)	
Figure 67	161
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Male/São Paulo)	
Figure 68	161
Incidence rates of the ten most frequent primary sites, adjusted by age, per 100 thousand (Female/São Paulo)	
Figure 69	163
All neoplasms (C00–C96, D46 except for non–melanoma skin cancer – C44)	
Figure 70	164
Non-Melanoma Skin Cancer (C44)	
Figure 71	164
Esophagus Cancer (C15)	
Figure 72	165
Stomach Cancer (C16)	
Figure 73	165
Colorectal Cancer (C18–C20)	
Figure 74	166
Cancer of the Liver and Intrahepatic Biliary Ducts (C22)	
Figure 75	166
Larynx Cancer (C32)	
Figure 76	167
Trachea, Bronchus and Lung Cancer (C33–C34)	
Figure 77	167
Female Breast Cancer (C50)	
Figure 78	168
Cervical Uteri Cancer (C53)	
Figure 79	168
Endometrial Cancer (C54)	
Figure 80	169
Ovary Cancer (C56)	
Figure 81	169
Prostate Cancer (C61)	
Figure 82	170
Bladder Cancer (C67)	
Figure 83	170
Cancer of the Central Nervous System (C70–C72)	

Figure 84	171
Thyroid Cancer (C73)	
Figure 85	171
Cervical Carcinoma in situ (D06)	
Figure 86	181
Leukemia (Group I)	
Figure 87	182
Lymphoma (Group II)	
Figure 88	183
Tumors of the Central Nervous System (Group III)	
Figure 89	184
Malignant Bone Tumors (Group VIII)	



Information about cancer is fundamental for the research and planning of programs for its control. The surveillance monitors the performance of cancer control programs, generating knowledge of the magnitude and impact of the neoplasia, as well as its trends and risk factors, and the effect of the prevention actions, early detection, treatment and palliative care. The Population-Based Cancer Registries (PBCR) are important cancer surveillance tools and contain information about incidence, trends and survival. They have subsidies for the planning, assessment and establishment of priorities in the fight against this disease.

The most recent global estimates, disclosed by GLOBOCAN 2008, confirm there were 12.7 million new cases of cancer and 7.6 deaths.

For Brazil, this publication, the fourth volume in the series, offers information to 17 PBCRs, mostly located in the capital cities. In this edition, the information of the registries has the same reference period – 2000 to 2005 (either in its entirety or in part) and, in addition to the comparative table containing the general quality indicators, it also presents detailed quality indicators by primary sites selected for each PBCR. Comparative charts were prepared, according to the ten main sites by gender and also for the four main tumors in childhood and adolescence.

The highest average incidence rates in men were found in Porto Alegre (404.16/100 thousand), Goiânia (365.43/100 thousand) and São Paulo (315.82/ 100 thousand). The same profile was observed in women, with average rates of 286.19/100 thousand in Porto Alegre; 262.82/100 thousand in Goiânia and 250.98/100 thousand in São Paulo.

The ten most frequent primary sites in men were non-melanoma skin (ranging from 211.30 to 16.55), prostate (129.62 to 50.01), lung (66.61 to 14.29), colon and rectum (33.96 to 8.77), stomach (24.97 to 11.83), esophagus (18.19 to 4.65), bladder (15.59 to 4.58), larynx (11.65 to 7.23), liver (11.96 to 1.72) and the central nervous system (9.50 to 3.96). In women, the ten main site were non-melanoma skin (190.26 to 12.87), breast (91.79 to 49.61), cervix uteri (50.59 to 10.23), cervical carcinoma in situ (40.17 to 9.85), colon and rectum (24.70 to 9.38), lung (23.32 to 5.37), thyroid (18.03 to 3.80), stomach (11.32 to 5.16), ovary (12.05 to 6.28) and endometrium (10.05 to 3.97). The fact that the thyroid and ovary tumors are among the ten main sites for women should be emphasized. We also highlight the presence of cervical carcinoma in situ as one of the most frequent. This is a clear demonstration of the PBCRs' contribution in the assessment of programs. The increase in the rates, especially from 2000 on, reflects the nationwide implementation of the Cervical Uteri Cancer Control Program.

It is worth emphasizing that the information obtained cannot be generalized. However, the set of information and the geographical distribution enable us to draw a profile for similar populations, as well as offer an overview of the current scenario. The availability of information contributes to improve the cancer information system, enabling subsidies for the cancer control actions in Brazil.



Information Sources

Incidence

This publication had the collaboration of 17 Population-Based Cancer Registries – PBCRs. Among the participating cancer registries, 16 are located in capital cities, one of them being in a non-capital city. The collaborating PBCRs and their respective period of consolidated information are described below.

- PBCR of Aracaju (2000-2004)
- PBCR of Belém (2000-2001)
- PBCR of Belo Horizonte (2000-2003)
- PBCR of Campo Grande (2000-2002)
- PBCR of Cuiabá (2000-2005)
- PBCR of Curitiba (2000-2005)
- PBCR of Fortaleza (2000-2005)
- PBCR of Goiânia (2000-2005)
- PBCR of Jaú (2000-2005)
- PBCR of João Pessoa (2000-2005)
- PBCR of Manaus (2000-2004)
- PBCR of Natal (2000-2004)
- PBCR of Palmas (2000-2004)
- PBCR of Porto Alegre (2000-2004)
- PBCR of Recife (2000-2003)
- PBCR of Salvador (2000-2004)
- PBCR of São Paulo (2000-2005)

Reports were sent to all the 17 PBCRs containing information about the number of new cases, absolute values and age-specific rates, as well as the crude and age-adjusted rates. For the period information, the rate values refer to the average yearly values.

A comparative chart was prepared for the main neoplasms according to the PBCR. These charts considered the entire period available (less than 5 years) or the last five years.

Inclusion/exclusion criteria

All cases with confirmed cancer diagnosis were collected in a given year. That includes primary malignant tumours, in situ or invasive; the secondary location or metastatic tumors and the malignant tumors of unknown site. The benign tumors and those of uncertain behavior were not collected. For the 17 PBCRs included in this publication, the data was active collected.

The cases considered eligible were the cases of cancer diagnosis confirmed by anatomopathologic (histopathologic and cytopathologic) and hematologic examinations or complete blood count, surgical exploration, imaging, clinical examination, necropsy or any other means of diagnosis, as long as authorized by the physician responsible for the patient or the information provided; and as long as the patient resided in the area covered by that particular PBCR.

The cases identified by death certificate were compared to the files of the registry, and those that were not registered were identified. Then, the case was confirmed with the reporting source. The remaining cases were included as cases redeemed Death Certificate Only (DCO).

The 17 PBCRs included in this publication have as main reporting sources cancer hospitals, specialized and general (public or private), pathologic anatomy laboratories, chemotherapy and radiotherapy services. Some of them include even hematology and necropsy services, nursing homes, dermatologic clinics, medical clinics, as well as information obtained from the health information national systems.

Information collected

The 17 PBCRs included in this publication routinely collect the following variables:

Identification variables

- patient name;
- mother's name;
- medical registry and/or examination number.

Demographic variables

- gender;
- skin color;
- date of birth;
- age at date of diagnosis;
- profession;
- full address.

Tumor-related variables

- year of diagnosis;
- primary site of the tumor;
- morphology;
- means of diagnosis;
- extent of the disease;
- date of diagnosis;
- date of death;
- type of death (whether by cancer or not).

Classification and coding

From 1996 on, the International Classification of Diseases for Oncology, 2nd edition (ICD-02), and from 2005 on, the International Classification of Diseases for Oncology, 3rd edition (ICD-03), has been used by all PBCRs. The information was published according to the International Classification of Diseases, 10th edition (ICD-10).

Data processing

From the 17 PBCRs included in this publication, 15 used the Computerized System for Population-Based Cancer Registries (SisBasepop), developed by INCA/MS (Aracaju, Belém, Belo Horizonte, Campo Grande, Cuiabá, Curitiba, Fortaleza, Jaú, João Pessoa, Manaus, Natal, Palmas, Porto Alegre, Recife and Salvador). Two PBCRs used their own system (Goiânia e São Paulo).

The two PBCRs that did not use the SisBasepop sent the already converted information in the established format and the appropriate classification – International Classification of Diseases, 10th edition (ICD-10) and the International Classification of Childhood Cancer, 2nd edition (ICCC-2).

The 15 PBCRs that used the SisBasepop were able to use the resources of the system. Such resources include verification of consistency from the data entry to the choice of the eligible case (or cases). The verified items include:

- compatibility between topography and gender;
- compatibility between topography and morphology;
- compatibility between morphology and extent of the disease;

- compatibility between date of birth and date of diagnosis;
- compatibility between topography and age;
- compatibility between morphology and age;
- compatibility between date of death (if applicable), date of birth and date of diagnosis.

Reference population

The population estimates, both census (2000) and inter-census surveys (2001, 2002, 2003, 2004, 2005) used as denominators for calculating the rates, we obtained through Datasus and were supplied by the Brazilian Institute of Geography and Statistics (IBGE). The populations were classified by 5-year age group. The young people were classified using the following age group: less than a year old, 1 to 4 years old, 5 to 9 years old, 10 to 14 years old and 15 to 19 years old.

Aiming at identifying the population age structure of the areas covered by the PBCRs, a population pyramid was prepared based on the population indicated by the 2000 census.

The world standard population used in this publication was the one proposed by Segi (1960), modified by Doll et al. (1966), the same one used in the publications of the International Cancer Incidence in Five Continents series, by the International Agency for Research on Cancer (IARC). The use of this standard population enables a comparison between the Brazilian and the international registries, as well as the assessment of changes in the incidence through the comparison with previous publications. Such population was based on a combination of age structures from developed and developing countries.

Statistical Methods

Percentage distribution

It corresponds to the relative frequency of the number of events (new cases) of a given topography compared to the total number of cases.

$$\text{Percentage} = \frac{\text{total number of events of a given topography}}{\text{total number of cases}} \times 100$$

Crude rate

The crude incidence rate per 100 thousand men and women or per 1 million children and adolescents refers to the incidence risk of an event (new case). It is expressed by the quotient between the total number of events and the population under risk. The crude rate is calculated by using the formula below:

$$\text{Percentage} = \frac{\text{total number of events of a given topography}}{\text{total number of cases}} \times 100$$

Specific rate

The specific rate per 100 thousand men and women or 1 million children and adolescents refers to the incidence risk of an event (new case) due to a given attribute (age, gender, marital status, socioeconomic status, etc.). It is expressed by the quotient between the total number of events due to a given attribute and the population under risk. The most frequently used specific rate is the specific rate by age, calculated by using the formula below:

$$\text{Specific rate} = \frac{\text{total number of events, by age, gender and determined period}}{\text{population of reference, by age, gender and determined period}} \times 100,000 \text{ or } 1,000,000$$

Age-adjusted rate

The adjustment of the incidence rate makes it possible to eliminate (or minimize) the effect of the age differences among populations (or in the same population in different periods), so that geographical or time differences cannot be

attributed to differences in the age structure. The adjustment by age, through the direct method, is made by using a single standard population, which works as a common group of weights for calculating the weighted rates (adjusted or standardized). It should be emphasized that the objective of the standardization is, essentially, to establish parameters of comparison.

The standard population used was the world standard population, previously described. The age-adjusted rate is calculated by using the formula below:

$$\text{age-adjusted rate} = \frac{\sum (\text{specific rate by age}) \times (\text{global standard population in the age group})}{\sum \text{global standard population}}$$

Pieces of information from 17 PBCRs with two years or more of updated information available for the period from 2000 to 2005 were assessed. None of the assessed PBCRs presented values for %C80 (unknown or ill-defined primary site) above 5% and the proportion of cases for which age was unknown at the PBCRs was below 11%. For the editorial process, the observations were categorized into two groups (A and B), according to the quality indicators. Only the PBCRs categorized into group A were included in the PBCR comparative charts.

The table containing the Information Quality Indexes by PBCR is presented below. For purposes of comparability, Annex I brings the table with the minimum and maximum values of the Quality Indexes for the Latin American PBCRs included in the publication Cancer Incidence in Five Continents, volume IX.

Table 1 – Quality indicators for both genders by PBCR and period of reference

PBCR	DCO (%)	Age Unknown (%)	MV (%)	DCO (%)	M/I (%)
Aracaju (2000-2004)	1.3	0.5	88.3	8.5	40.6
Belém (2000-2001)	2.1	1.7	70.8	26.6	66.9
Belo Horizonte (2000 - 2003)	2.9	0.6	80.9	17.9	38.3
Campo Grande (2000 - 2002)	3.5	1.7	62.2	25.2	58.8
Cuiabá (2001 - 2005)	1.7	0.9	79.6	12.7	29.8
Curitiba (2001-2005)	2.7	0.1	76.1	20.8	52.5
Fortaleza (2001-2005)	2.9	0.4	89.0	15.3	47.8
Goiânia (2001-2005)	2.6	0.2	91.4	6.5	34.3
Jatú (2001-2005)	1.9	0.1	94.5	1.9	44.9
João Pessoa (2001-2005)	1.6	0.0	97.0	2.5	47.8
Manaus (2000 - 2004)	2.7	1.6	67.2	28.9	58.5
Natal (2000-2004)	3.8	7.2	62.3	27.3	40.5
Palmas (2000-2004)	2.2	9.1	69.0	27.3	39.1
Porto Alegre (2000-2004)	2.4	1.4	75.6	19.2	42.2
Recife (2000-2003)	1.6	1.3	70.3	18.0	57.3
Salvador (2000-2004)	3.2	1.8	73.8	14.7	47.3
São Paulo (2001-2005)	3.4	10.9	80.6	7.4	26.8

Death certificate only, DCO; Microscopical verification, MV

Parameters suggested for the PBCR assessment:

Group A: MV% > 70%; DCO% < 25%; C80% < 10%; Age unknown% < 20%. Group B: 55% < MV% < 70%; 25% < DCO% < 30%; 10% < C80% < 20%; Age unknown% > 20%.

Information regarding C00-96, D46/ C44.

Sources: Data from Population-Based Cancer Registries.

MS/INCA/Conprev/Divisão de Informação e Análise de Situação.



Aracaju - SE, 2000 - 2004




Figure 1. Distribution of the population* in Aracaju

* Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Aracaju

Coordinator

Carlos Anselmo Lima

Registrars and Data Collectors

José Erinaldo Lôbo de Oliveira

Elma Santana de Oliveira

Sueli Pina Vieira

Data Entry Clerks

Maria Rosania

Advisory Committee

Sônia Maria Lima Santana Marcena (pathologist)

José Geraldo Dantas Bezerra (oncologist)

Anselmo Mariano Fonte (oncologist)

Rosana Cipolotti (oncologist)

Infrastructure and Data Source

This PBCR was created in 1998, whereas the data collection started in 1996. It is located at Avenida Tancredo Neves, no number, at the Oncology Center of the Sergipe Urgency Hospital “Governador João Alves Filho”, Capucho, postal code nº 49095-000, in Aracaju, Sergipe, and financially supported by the HSS/MH Ordinance nº 2,607.




Figure 2. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 2 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C92	Myeloid leukemia	24	1.85	0.00	0.85	0.76	0.00	1.00	2.25	3.77	0.00	3.68	2.30	10.05	9.15	13.46	0.00	53.41	0.00	0.00	2.17	2.85
C95	Unspecified cell leukemia	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.26	1.49	1.84	0.00	0.00	0.00	6.73	17.80	0.00	45.74	27.93	0.81	1.20
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.73	0.00	0.00	0.00	0.00	0.09	0.20
C00-96, D46	All invasive primary malignant neoplasms	3,580	17.59	15.20	13.59	15.28	23.26	35.16	68.72	169.79	242.15	426.67	650.07	1,309.53	1,889.21	2,733.27	4,156.28	5,394.58	6,197.12	5,502.79	323.05	503.36
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	2,063	17.59	15.20	11.90	14.51	18.28	18.08	31.54	71.69	133.03	196.78	372.12	773.66	1,088.70	1,716.71	2,269.49	3,151.29	3,613.08	3,519.55	186.16	292.07
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.35	0.00	0.00	0.09	0.13
D01	Carcinoma in situ of other organs of the gastrointestinal tract	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.87	0.00	0.09	0.11
D02	Carcinoma in situ of the middle ear and respiratory system	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.49	0.00	0.00	3.35	4.57	0.00	0.00	0.00	22.87	0.00	0.36	0.52
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.09
D04	Skin carcinoma in situ	23	0.00	0.00	0.00	0.00	0.83	0.00	0.00	1.26	0.00	3.68	0.00	16.75	22.87	13.46	17.80	0.00	68.60	55.87	2.08	3.33
D07	Carcinoma in situ of other sex organs and unspecified organs	2	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00	1.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.18	0.18
D09	Carcinoma in situ of other locations and unspecified locations	9	0.00	0.00	0.00	0.00	0.00	1.00	1.13	3.77	0.00	0.00	2.30	0.00	0.00	0.00	17.80	0.00	22.87	0.00	0.81	0.96
C00-96, D00-09, D46	All primary malignant neoplasms	3,621	17.59	15.20	13.59	15.28	24.09	36.17	70.97	174.82	245.14	432.18	652.36	1,329.63	1,916.66	2,746.73	4,191.88	5,407.93	6,334.32	5,558.66	326.75	508.69

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Aracaju - SE, 2000 - 2004

Table 3

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	3.30	0.00	0.00	14.67	11.87	25.68	0.56	0.57
C02	Other parts of the tongue	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.91	2.70	6.59	0.00	5.14	7.33	23.73	25.68	0.87	0.99
C03	Gingiva	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.29	0.00	0.00	12.84	0.24	0.27
C04	Floor of the mouth	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	7.33	0.00	0.00	0.16	0.17
C05	Palate	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.07	1.27	1.52	0.00	0.00	0.00	0.00	5.14	0.00	23.73	12.84	0.63	0.58
C06	Other parts of the mouth	5	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	1.95	0.00	0.00	0.00	5.14	0.00	11.87	12.84	0.40	0.38
C07	Parotid gland	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.04	0.00	2.70	3.30	0.00	5.14	7.33	11.87	0.00	0.56	0.66
C08	Other larger salivary glands	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	1.95	5.39	0.00	0.00	0.00	0.00	0.00	0.00	0.32	0.39
C09	Amygdala	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.30	4.33	0.00	0.00	0.00	0.00	0.16	0.26
C10	Oropharynx	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	0.00	2.70	6.59	0.00	0.00	0.00	0.00	12.84	0.40	0.51
C11	Nasopharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.15
C13	Hypopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.10
C14	Inaccurate locations of the lip, oral cavity and pharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	7.33	0.00	0.00	0.16	0.17
C15	Esophagus	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	1.52	0.00	0.00	9.89	4.33	5.14	7.33	11.87	0.00	0.71	0.93
C16	Stomach	76	0.00	0.00	0.00	0.00	0.00	1.71	2.85	2.07	5.08	6.07	15.63	13.48	23.08	25.97	66.86	66.01	59.33	102.74	6.03	6.93
C17	Small intestine	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	0.00	4.33	5.14	0.00	35.60	0.00	0.48	0.52
C18	Colon	94	0.00	0.00	0.00	0.71	0.00	1.71	3.79	3.10	5.08	6.07	13.68	24.26	26.37	17.31	102.85	66.01	106.80	128.42	7.45	8.40
C19	Rectosigmoid junction	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.52	1.95	2.70	6.59	4.33	10.29	0.00	0.00	0.63	0.90	
C20	Rectum	42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.07	3.81	6.07	5.86	18.87	9.89	4.33	25.71	29.34	23.73	102.74	3.33	3.73
C21	Anus and anal canal	14	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	3.04	3.91	10.78	0.00	8.66	5.14	7.33	11.87	0.00	1.11	1.36
C22	Liver and intrahepatic biliary ducts	45	0.96	0.00	0.00	0.71	0.00	0.00	0.95	2.07	2.54	4.56	5.86	10.78	9.89	12.98	20.57	14.67	106.80	89.89	3.57	3.84
C23	Gallbladder	48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.63	16.17	23.08	30.30	36.00	22.00	83.07	38.53	3.81	4.81
C24	Other parts of the biliary ducts	27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.04	7.72	2.70	9.89	4.33	30.86	22.00	59.33	25.68	2.14	2.47
C25	Pancreas	58	0.00	0.00	0.00	0.71	0.00	0.00	0.00	1.03	0.00	1.52	9.77	13.48	23.08	34.62	46.28	51.34	35.60	141.26	4.60	5.53
C26	Inaccurate locations in the gastrointestinal tract	7	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	1.95	0.00	0.00	0.00	5.14	14.67	11.87	12.84	0.56	0.53
C30	Nasal cavity and middle ear	1	0.00	0.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.10
C32	Larynx	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	1.52	7.82	0.00	3.30	4.33	5.14	7.33	0.00	0.00	0.79	1.00
C34	Bronchus and lungs	102	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	5.08	10.63	19.54	29.65	42.86	56.26	51.43	95.35	130.53	115.58	8.09	9.78
C37	Thymus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.06
C40	Bones and limb joints	5	0.96	0.97	0.00	0.71	1.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.39
C41	Bones and joints of other locations	8	0.00	0.00	0.85	0.71	0.72	1.71	0.00	0.00	0.00	0.00	0.00	0.00	3.30	0.00	5.14	0.00	0.00	12.84	0.63	0.63
C43	Malignant skin melanoma	38	0.00	0.00	0.00	0.00	0.72	0.85	1.90	3.10	1.27	7.59	1.95	8.09	13.19	12.98	15.43	22.00	35.60	64.21	3.01	3.32
C44	Other malignant skin neoplasms	1,490	0.00	0.00	0.00	4.94	8.64	11.09	24.66	57.95	120.55	170.09	261.84	331.51	415.39	692.49	930.83	1,224.88	1,447.73	1,720.82	118.17	134.87
C46	Kaposi's sarcoma	2	0.00	0.00	0.00	0.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.30	0.00	0.00	0.00	0.00	0.16	0.20
C47	Peripheral nerves and autonomic nervous system	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	0.00	0.00	3.30	0.00	0.00	0.00	0.00	0.00	0.16	0.21
C48	Retroperitoneum and peritoneum	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	1.52	1.95	5.39	0.00	0.00	5.14	29.34	11.87	0.00	0.87	0.94
C49	Connective tissue and other soft tissues	20	0.00	0.00	0.85	0.00	0.72	0.85	2.85	1.03	2.54	3.04	1.95	5.39	3.30	8.66	0.00	14.67	0.00	12.84	1.59	1.69
C50	Breast	615	0.00	0.00	0.00	0.00	2.16	7.68	11.38	54.84	88.83	126.05	171.95	172.49	201.10	177.45	246.85	322.72	261.07	179.79	48.77	56.89
C51	Vulva	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.07	0.00	1.52	0.00	2.70	9.89	0.00	0.00	7.33	11.87	25.68	0.95	0.98
C52	Vagina	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.91	2.70	6.59	8.66	5.14	7.33	11.87	0.00	0.79	1.06
C53	Cervix	326	0.00	0.00	0.00	0.00	5.04	9.39	24.66	37.25	44.41	56.19	62.53	59.29	108.79	125.51	118.28	139.36	106.80	64.21	25.85	29.13
C54	Endometrium	71	0.00	0.00	0.00	0.00	0.00	0.00	1.90	3.10	5.08	6.07	15.63	35.04	49.45	34.62	30.86	36.67	23.73	12.84	5.63	7.34
C55	Uterus, nos	6	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	1.52	3.91	0.00	0.00	0.00	5.14	7.33	0.00	0.00	0.48	0.52
C56	Ovary	94	0.96	0.97	0.85	0.00	1.44	2.56	2.85	7.24	7.61	16.71	19.54	35.04	29.67	34.62	30.86	58.68	59.33	0.00	7.45	8.78
C57	Other female sex organs, nos	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.33	0.00	0.00	11.87	0.00	0.16	0.19
C58	Placenta	3	0.00	0.00	0.00	0.71	0.00	1.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.20
C64	Kidney	26	0.00	0.00	0.00	0.00	0.72	0.85	0.00	3.10	1.27	4.56	3.91	10.78	6.59	17.31	0.00	22.00	0.00	25.68	2.06	2.42
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.11
C67	Bladder	19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	1.52	1.95	2.70	3.30	8.66	25.71	14.67	47.47	12.84	1.51	1.73
C69	Eyes and appendages	6	0.00	0.00	0.00	0.71	0.72	0.00	0.00	0.00	2.54	1.52	0.00	0.00	0.00	0.00	0.00	7.33	0.00	0.00	0.48	0.44
C70	Meninges	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.15
C71	Encephalon	51	0.96	0.97	3.38	0.00	5.04	1.71	2.85	1.03	1.27	7.59	5.86	16.17	6.59	12.98	20.57	22.00	23.73	38.53	4.04	4.36
C72	Spinal cord and other parts of the central nervous system	1	0.00	0.00	0.00	0.00	0.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.06
C73	Thyroid gland	196	0.00	0.00	0.00	2.82	6.48	13.65	18.02	39.32	30.46	21.26	42.99	45.82	36.26	30.30	36.00	14.67	0.00	25.68	15.54	15.74
C74	Adrenal gland	4	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	3.04	0.00	0.00	0.00	0.00	5.14	0.00	0.00	0.00	0.32	0.34
C76	Other inaccurate locations	6	0.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.29	0.00	0.00	38.53	0.48	0.51
C80	Unknown primary site	56	0.00	0.00	0.00	0.71	0.00	0.85	1.90	2.07												

Table 3 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00-96, D46	All invasive primary malignant neoplasms	3,838	7.71	6.78	9.30	16.93	39.60	62.29	110.98	233.86	354.05	507.23	752.29	954.10	1,176.94	1,462.89	2,041.66	2,501.10	2,954.79	3,223.32	304.37	347.96
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	2,348	7.71	6.78	9.30	11.99	30.96	51.19	86.32	175.92	233.49	337.14	490.45	622.59	761.55	770.40	1,110.83	1,276.22	1,507.06	1,502.50	186.21	213.09
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.33	0.00	0.00	0.08	0.07
D01	Carcinoma in situ of other organs of the gastrointestinal tract	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.52	0.00	0.00	0.00	4.33	0.00	0.00	0.00	0.00	0.16	0.22
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.06
D03	Melanoma in situ	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	0.00	0.00	0.00	0.00	5.14	0.00	0.00	0.00	0.16	0.18
D04	Skin carcinoma in situ	36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.07	0.00	7.59	3.91	8.09	16.48	8.66	20.57	22.00	59.33	64.21	2.86	3.27
D05	Breast carcinoma in situ	12	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	1.27	6.07	3.91	5.39	0.00	8.66	0.00	0.00	0.00	0.00	0.95	1.17
D06	Cervical carcinoma in situ	386	0.00	0.00	0.00	3.53	20.88	58.87	63.56	81.75	59.64	48.60	54.71	26.95	36.26	12.98	10.29	7.33	0.00	25.68	30.61	27.97
D07	Carcinoma in situ of other sex organs and unspecified organs	13	0.00	0.00	0.00	0.00	0.72	0.00	1.90	3.10	1.27	1.52	1.95	2.70	0.00	0.00	0.00	14.67	0.00	12.84	1.03	0.94
D09	Carcinoma in situ of other locations and unspecified locations	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	1.95	2.70	0.00	0.00	0.00	7.33	0.00	0.00	0.32	0.35
C00-96, D00-09, D46	All primary malignant neoplasms	4,295	7.71	6.78	9.30	20.45	61.92	121.16	177.39	320.79	418.77	572.53	818.73	999.92	1,229.68	1,497.51	2,077.65	2,559.78	3,014.12	3,326.06	340.62	382.19

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Aracaju - SE, 2000 - 2004

Male

Table 4

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	108	15.19	98.1	0.9	37.0
C15 Esophagus	32	4.65	71.9	18.8	75.0
C16 Stomach	116	16.58	90.5	6.0	49.1
C18-21 Large intestine, anal canal and anus	92	13.22	95.7	3.3	28.3
C22 Liver	41	5.73	56.1	26.8	100.0
C25 Pancreas	29	4.12	44.8	41.4	96.6
C32 Larynx	73	10.68	93.2	5.5	24.7
C33-34 Trachea, bronchus and lungs	179	26.20	80.4	11.7	89.9
C43 Skin melanoma	27	211.30	96.3	3.7	22.2
C61 Prostate	752	116.04	91.6	6.0	21.3
C70-72 Central Nervous System	58	5.99	60.3	22.4	75.9
C73 Thyroid	30	3.28	100.0	0.0	6.7
C91-95 Leukemia	53	6.24	71.7	28.3	75.5
C81-85, C96 Lymphoma	99	11.57	97.0	2.0	33.3
C00-96, D46 All primary invasive malignant Neoplasms	3,580	503.36	92.5	5.3	23.5
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	2,063	292.07	87.2	9.1	40.4

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 5

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	43	3.74	95.3	4.7	32.6
C15 Esophagus	9	0.93	88.9	11.1	144.4
C16 Stomach	76	6.93	86.8	9.2	44.7
C18-21 Large intestine, anal canal and anus	158	14.39	93.0	5.7	32.3
C22 Liver	45	3.84	46.7	48.9	100.0
C25 Pancreas	58	5.53	39.7	46.6	82.8
C32 Larynx	10	1.00	90.0	10.0	40.0
C33-34 Trachea, bronchus and lungs	102	9.78	77.5	15.7	91.2
C43 Skin melanoma	38	134.87	100.0	0.0	13.2
C50 Breast	615	56.89	97.9	0.8	27.2
C53 Cervix	326	29.13	95.4	1.8	27.9
C70-72 Central Nervous System	54	4.57	57.4	33.3	72.2
C73 Thyroid	196	15.74	98.5	1.0	2.0
C91-95 Leukemia	47	4.20	74.5	25.5	80.9
C81-85, C96 Lymphoma	67	5.76	94.0	4.5	35.8
C00-96, D46 All primary invasive malignant Neoplasms	3,838	347.96	93.3	4.9	25.1
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	2,348	213.09	89.2	7.9	40.8

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Aracaju - SE, 2000 - 2004

Male




Figure 3

Female




Figure 4

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Aracaju - SE, 2000 - 2004

Table 6

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	9	27.19	29.47	11	23.81	26.28	6	18.44	18.57	6	12.84	14.39
Ia. Lymphoid leukemia	6	18.13	19.85	7	15.15	17.10	6	18.44	18.57	6	12.84	14.39
Ib. Acute myeloid leukemia	2	6.04	6.05	2	4.33	4.69	0	0.00	0.00	0	0.00	0.00
Ic. Myeloproliferative chronic diseases	0	0.00	0.00	1	2.16	1.72	0	0.00	0.00	0	0.00	0.00
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	3.02	3.58	1	2.16	2.77	0	0.00	0.00	0	0.00	0.00
II. Reticuloendothelial lymphomas and neoplasms	9	27.19	27.84	14	30.31	30.17	4	12.29	11.82	8	17.13	15.51
Ila. Hodgkin's lymphoma	1	3.02	2.47	3	6.49	5.35	1	3.07	3.12	4	8.56	7.18
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	2	6.04	7.16	5	10.82	10.70	3	9.22	8.70	4	8.56	8.33
Ilc. Burkitt's lymphoma	4	12.08	12.17	4	8.66	9.43	0	0.00	0.00	0	0.00	0.00
Ile. Unspecified lymphoma	2	6.04	6.05	2	4.33	4.69	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	15	45.32	46.74	16	34.64	37.94	6	18.44	16.67	6	12.84	12.92
IIIa. Ependymoma and choroid plexus tumor	0	0.00	0.00	1	2.16	1.72	0	0.00	0.00	0	0.00	0.00
IIIb. Astrocytoma	11	33.23	35.17	11	23.81	27.25	5	15.37	14.22	5	10.70	11.02
IIIc. Intracranial and intraspinal embryonic tumors	2	6.04	6.05	2	4.33	4.69	1	3.07	2.45	1	2.14	1.90
IIIf. Unspecified intracranial and intraspinal tumors	2	6.04	5.53	2	4.33	4.29	0	0.00	0.00	0	0.00	0.00
IV. Neuroblastoma and other peripheral nervous cell tumor	3	9.06	9.13	3	6.49	7.08	0	0.00	0.00	0	0.00	0.00
IVa. Neuroblastoma and ganglioneuroblastoma	2	6.04	6.66	2	4.33	5.17	0	0.00	0.00	0	0.00	0.00
IVb. Other peripheral nervous cell tumors	1	3.02	2.47	1	2.16	1.91	0	0.00	0.00	0	0.00	0.00
V. Retinoblastoma	2	6.04	6.64	2	4.33	5.15	0	0.00	0.00	0	0.00	0.00
VI. Renal tumors	3	9.06	10.27	3	6.49	7.96	0	0.00	0.00	0	0.00	0.00
VIa. Nephroblastoma and other renal non-epithelial tumors	3	9.06	10.27	3	6.49	7.96	0	0.00	0.00	0	0.00	0.00
VII. Hepatic tumors	1	3.02	3.06	2	4.33	4.09	1	3.07	3.72	2	4.28	4.47
VIIa. Hepatoblastoma	1	3.02	3.06	1	2.16	2.37	1	3.07	3.72	1	2.14	2.88
VIIb. Hepatocellular carcinoma	0	0.00	0.00	1	2.16	1.72	0	0.00	0.00	1	2.14	1.59
VIII. Malignant bone tumors	1	3.02	2.47	4	8.66	7.07	2	6.15	5.58	4	8.56	7.50
VIIIa. Osteosarcoma	1	3.02	2.47	3	6.49	5.35	1	3.07	3.12	2	4.28	4.01
VIIIb. Chondrosarcoma	0	0.00	0.00	1	2.16	1.72	0	0.00	0.00	0	0.00	0.00
VIIIc. Ewing's sarcoma and related bone sarcomas	0	0.00	0.00	0	0.00	0.00	1	3.07	2.45	2	4.28	3.49
IX. Soft-tissue and other extraosseous sarcomas	3	9.06	8.00	7	15.15	13.07	3	9.22	9.31	4	8.56	8.80
IXa. Rhabdomyosarcoma	3	9.06	8.00	4	8.66	7.92	2	6.15	6.86	2	4.28	5.31
IXc. Kaposi's sarcoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	2.14	1.59
IXd. Other unspecified soft-tissue sarcomas	0	0.00	0.00	1	2.16	1.72	0	0.00	0.00	0	0.00	0.00
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	2	4.33	3.44	1	3.07	2.45	1	2.14	1.90
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	1	3.02	3.06	1	2.16	2.37	3	9.22	9.31	4	8.56	8.80
Xa. Intracranial and intraspinal germ cell tumors	1	3.02	3.06	1	2.16	2.37	0	0.00	0.00	0	0.00	0.00
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	2.14	1.59
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	0	0.00	0.00	2	6.15	6.86	2	4.28	5.31
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	1	3.07	2.45	1	2.14	1.90
XI. Other malignant epithelial neoplasms and melanomas	4	12.08	9.87	8	17.32	14.52	0	0.00	0.00	19	40.67	30.15
XIb. Thyroid carcinoma	0	0.00	0.00	2	4.33	3.44	0	0.00	0.00	4	8.56	6.35
XId. Malignant melanoma	1	3.02	2.47	1	2.16	1.91	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	2	6.04	4.93	3	6.49	5.54	0	0.00	0.00	7	14.98	11.11
XIf. Other carcinomas and unspecified carcinomas	1	3.02	2.47	2	4.33	3.63	0	0.00	0.00	8	17.13	12.70
XII. Other malignant and unspecified neoplasms	0	0.00	0.00	0	0.00	0.00	1	3.07	3.72	2	4.28	4.47
XIIb. Other unspecified malignant tumors	0	0.00	0.00	0	0.00	0.00	1	3.07	3.72	2	4.28	4.47
All neoplasms	51	154.08	156.56	71	153.71	155.70	26	79.91	78.69	55	117.74	107.01

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação





Figure 5. Distribution of the population* in Belém¹

¹Includes Anariindeua

* Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Belém

Coordinator

Lucrecia Aline Cabral Formigosa

Registrars

Shirley Conceição Andrade Fróes

Ivan dos Santos Corrêa

Data Collectors

Luiz Guilherme Nunes Santiago

Shirley Conceição Andrade Fróes

Ivan dos Santos Corrêa

Technical advisor

Antenor Madeira Neto

Infrastructure and Data Source

This PBCR was created in 1987, year when the data collection started. It is hierarchically subordinated to the Department of Chronic and Degenerative Disease Control/Oncology, of the Health Secretariat of the State of Pará, and is located in the Ofir Loiola Hospital, at avenida Magalhães Barata, 992, 7th floor.




Figure 6. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 7 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C95	Unspecified cell leukemia	6	0.59	0.00	0.00	1.07	0.57	0.00	0.00	0.88	1.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.33
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.40	0.00	0.00	0.06	0.10
C00-96, D46	All invasive primary malignant neoplasms	1,692	11.77	8.44	7.79	10.18	20.34	19.75	21.51	36.91	59.31	135.13	212.30	413.37	652.60	940.71	1,389.95	2,070.54	2,450.38	2,153.05	104.67	175.25
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	1,527	11.77	8.44	7.19	10.18	18.65	19.75	19.97	34.27	55.15	120.41	187.53	385.98	620.30	793.87	1,262.43	1,872.85	2,065.61	1,919.58	94.47	158.03
D01	Carcinoma in situ of other organs of the gastrointestinal tract	1	0.00	0.00	0.00	0.00	0.00	0.00	0.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.05
D09	Carcinoma in situ of other locations and unspecified locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.38	0.00	0.00	0.00	0.06	0.13
C00-96, D00-09, D46	All primary malignant neoplasms	1,694	11.77	8.44	7.79	10.18	20.34	19.75	22.28	36.91	59.31	135.13	212.30	413.37	652.60	940.71	1,396.33	2,070.54	2,450.38	2,153.05	104.80	175.42

¹Includes Ananindeua

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 8 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.27	0.00	0.00	0.00	0.00	0.06	0.10
D04	Skin carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.28	0.00	0.00	0.00	0.06	0.09
D05	Breast carcinoma in situ	12	0.00	0.00	0.00	0.00	0.00	0.00	0.80	1.86	2.35	4.57	2.05	2.52	3.27	4.28	0.00	0.00	0.00	0.00	0.68	0.90
D06	Cervical carcinoma in situ	304	0.00	0.00	0.00	0.49	6.11	23.66	36.75	42.18	34.34	32.89	21.30	34.93	40.34	26.17	17.12	20.23	0.00	21.68	17.15	16.71
D07	Carcinoma in situ of other sex organs and unspecified organs	3	0.00	0.00	0.00	0.00	0.00	0.59	0.00	0.00	0.93	0.00	0.00	0.00	0.00	0.00	6.74	0.00	0.00	0.17	0.17	
C00-96, D00-09, D46	All primary malignant neoplasms	1,928	10.39	6.22	4.68	8.32	15.79	40.22	88.47	116.99	186.54	198.49	269.34	339.02	446.28	516.91	603.60	768.56	747.55	726.44	108.79	130.46

¹Includes Ananindeua

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belém¹ - PA, 2000 - 2001

Male

Table 9

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	61	6.18	72.1	26.2	49.2
C15	Esophagus	31	3.37	41.9	54.8	96.8
C16	Stomach	277	30.92	59.6	39.0	69.7
C18-21	Large intestine, anal canal and anus	74	7.41	66.2	31.1	52.7
C22	Liver	61	6.32	36.1	63.9	90.2
C25	Pancreas	34	3.61	35.3	61.8	88.2
C32	Larynx	41	4.59	73.2	26.8	63.4
C33-34	Trachea, bronchus and lungs	230	25.21	47.4	48.3	77.8
C43	Skin melanoma	9	17.22	100.0	0.0	33.3
C61	Prostate	235	26.26	70.2	28.1	43.8
C70-72	Central Nervous System	37	3.04	51.4	45.9	83.8
C73	Thyroid	9	0.68	88.9	11.1	33.3
C91-95	Leukemia	65	5.01	93.8	0.0	61.5
C81-85, C96	Lymphoma	64	4.57	98.4	0.0	48.4
C00-96, D46	All primary invasive malignant Neoplasms	1,857	175.25	59.3	29.5	53.4
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	1,692	158.03	55.4	32.4	57.7

¹Includes Ananindeua

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 10

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	27	2.03	85.2	18.5	51.9
C15	Esophagus	6	0.39	50.0	50.0	166.7
C16	Stomach	91	6.75	61.5	36.3	119.8
C18-21	Large intestine, anal canal and anus	79	5.87	79.7	19.0	64.6
C22	Liver	30	2.17	43.3	50.0	163.3
C25	Pancreas	17	1.22	35.3	58.8	188.2
C32	Larynx	6	0.43	33.3	50.0	100.0
C33-34	Trachea, bronchus and lungs	80	6.06	46.3	47.5	145.0
C43	Skin melanoma	10	9.71	100.0	0.0	10.0
C50	Breast	303	21.28	91.4	8.6	37.0
C53	Cervix	395	26.97	88.6	9.4	45.6
C70-72	Central Nervous System	22	1.43	72.7	27.3	90.9
C73	Thyroid	24	1.35	87.5	4.2	12.5
C91-95	Leukemia	54	3.48	100.0	0.0	79.6
C81-85, C96	Lymphoma	38	2.24	97.4	0.0	92.1
C00-96, D46	All primary invasive malignant Neoplasms	1,744	112.50	75.8	14.3	59.3
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	1,607	102.80	73.7	15.5	64.0

¹Includes Ananindeua

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade– SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belém¹ - PA, 2000 - 2001

Male




Figure 7

Female




Figure 8

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belém¹ - PA, 2000 - 2001

Table 11

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	18	35.81	37.40	22	31.92	33.81	20	40.39	42.86	26	37.17	39.83
Ia. Lymphoid leukemia	16	31.83	33.18	16	23.21	25.71	14	28.27	29.38	18	25.73	27.18
Ib. Acute myeloid leukemia	0	0.00	0.00	0	0.00	0.00	3	6.06	6.38	5	7.15	7.15
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	1.99	1.94	3	4.35	3.92	0	0.00	0.00	0	0.00	0.00
Ie. Specified leukemias and other unspecified leukemias	1	1.99	2.28	3	4.35	4.18	3	6.06	7.10	3	4.29	5.50
II. Reticuloendothelial lymphomas and neoplasms	9	17.91	17.15	12	17.41	16.91	3	6.06	6.07	5	7.15	6.91
Ila. Hodgkin's lymphoma	6	11.94	10.85	7	10.16	9.62	1	2.02	1.70	2	2.86	2.42
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	3	5.97	6.30	4	5.80	6.09	2	4.04	4.37	2	2.86	3.39
Ile. Unspecified lymphoma	0	0.00	0.00	1	1.45	1.21	0	0.00	0.00	1	1.43	1.10
III. CNS and misc. of intracranial and intraspinal neoplasms	3	5.97	5.96	4	5.80	5.83	2	4.04	4.37	3	4.29	4.49
IIIb. Astrocytomas	1	1.99	1.74	1	1.45	1.35	0	0.00	0.00	0	0.00	0.00
IIIc. Intracranial and intraspinal embryonic tumors	0	0.00	0.00	0	0.00	0.00	2	4.04	4.37	2	2.86	3.39
IIIf. Unspecified intracranial and intraspinal tumors	2	3.98	4.22	3	4.35	4.48	0	0.00	0.00	1	1.43	1.10
IV. Neuroblastoma and other peripheral nervous cell tumor	1	1.99	2.27	1	1.45	1.76	0	0.00	0.00	0	0.00	0.00
Iva. Neuroblastoma and ganglioneuroblastoma	1	1.99	2.27	1	1.45	1.76	0	0.00	0.00	0	0.00	0.00
V. Retinoblastoma	1	1.99	2.28	1	1.45	1.77	1	2.02	2.37	1	1.43	1.83
VI. Renal tumors	4	7.96	8.45	4	5.80	6.55	1	2.02	2.01	1	1.43	1.56
Via. Nephroblastoma and other renal non-epithelial tumors	4	7.96	8.45	4	5.80	6.55	1	2.02	2.01	1	1.43	1.56
VIII. Malignant bone tumors	0	0.00	0.00	2	2.90	2.41	2	4.04	3.71	3	4.29	3.97
VIIIa. Osteosarcoma	0	0.00	0.00	1	1.45	1.21	1	2.02	1.70	1	1.43	1.32
VIIIc. Ewing's sarcoma and related bone sarcomas	0	0.00	0.00	0	0.00	0.00	1	2.02	2.01	1	1.43	1.56
VIIIe. Unspecified malignant bone tumors	0	0.00	0.00	1	1.45	1.21	0	0.00	0.00	1	1.43	1.10
IX. Soft-tissue and other extrasosseous sarcomas	2	3.98	3.89	2	2.90	3.01	3	6.06	6.43	3	4.29	4.99
IXa. Rhabdomyosarcoma	1	1.99	1.94	1	1.45	1.51	3	6.06	6.43	3	4.29	4.99
IXe. Unspecified soft-tissue sarcomas	1	1.99	1.94	1	1.45	1.51	0	0.00	0.00	0	0.00	0.00
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	0	0.00	0.00	1	1.45	1.21	1	2.02	1.70	2	2.86	2.42
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	1	1.45	1.21	0	0.00	0.00	0	0.00	0.00
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	1	2.02	1.70	2	2.86	2.42
XI. Other malignant epithelial neoplasms and melanomas	2	3.98	3.48	6	8.71	7.52	1	2.02	2.36	7	10.01	8.44
XIb. Thyroid carcinoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	1.43	1.10
XId. Malignant melanoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	1.43	1.10
XIe. Skin carcinoma	1	1.99	1.74	1	1.45	1.35	0	0.00	0.00	1	1.43	1.10
XIf. Other carcinomas and unspecified carcinomas	1	1.99	1.74	5	7.25	6.17	1	2.02	2.36	4	5.72	5.13
XII. Other malignant and unspecified neoplasms	7	13.93	14.54	11	15.96	16.09	1	2.02	2.01	1	1.43	1.56
XIIb. Other unspecified malignant tumors	7	13.93	14.54	11	15.96	16.09	1	2.02	2.01	1	1.43	1.56
All neoplasms	47	93.51	95.42	66	95.76	96.86	35	70.68	73.89	52	74.34	75.99

¹Includes Ananindeua

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação




Figure 9. Distribution of the population* in Belo Horizonte

* Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Belo Horizonte

Coordinator-Epidemiologist

Berenice Navarro Antoniazzi

Information Systems Analyst

Davidysson Abreu Alvarenga

Statisticians

Renato Azeredo Teixeira

Thays Aparecida Leão D’Alessandro

Field supervisor/nurse

Karina Elizabeth Evangelista

Cancer Registrars/Data Collectors

Carla Cristiana de Souza

Evandro Brígido Damasceno

Gilcea Aparecida Martinho

Marcondes Soares de Azevedo

Maria Eliza de Matos Saldanha Rosa

Maria Helena Oliveira Silva

Nivia Rodrigues Alves de Oliveira

Petrina Teixeira Santos

Registrars/codifier

Ângela Maria do Amparo

Technical Support

Maria Cristina Viegas Caçado (radiotherapist doctor)

Claudina Agnese Casale (field supervisor of the RHC-MG)

Advisory Committee

Berenice Navarro Antoniazzi (epidemiologist)

Davidysson Abreu Alvarenga (systems analyst)

Renato Azeredo Teixeira (statistician)

Thays Aparecida Leão D’Alessandro (statistician)

Maria Nunes Álvares (oncologist doctor)

Maria Cristina Viegas Caçado (radiotherapist doctor)

Belo Horizonte - MG, 2000 - 2003

Infrastructure and Data Source

This PBCR was created in 2001, whereas the data collection started in 2000. It is located in the Health Surveillance Sub-secretariat of the Health Secretariat of the State of Minas Gerais. The Belo Horizonte PBCR is financially supported by the Health Surveillance Financial Ceiling, as per Ordinance GM No. 2,607/2005.




Figure 10. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary site and age group

Belo Horizonte - MG, 2000 - 2003

Table 12

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.67	1.25	1.04	0.00	0.88	1.17	1.70	0.00	0.00	0.00	0.26	0.29
C01	Tongue base	83	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.29	1.34	4.17	5.73	10.46	7.88	11.68	11.93	19.89	30.35	14.52	1.93	2.40
C02	Other parts of the tongue	91	0.00	0.00	0.00	0.00	0.00	0.00	0.28	1.17	3.34	5.01	7.82	9.76	7.00	14.02	11.93	11.37	5.06	14.52	2.12	2.52
C03	Gingiva	10	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.00	0.00	0.00	0.00	2.09	2.63	0.00	1.70	5.68	0.00	0.00	0.23	0.30
C04	Floor of the mouth	44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.59	1.67	1.67	3.13	2.79	7.88	3.50	13.63	8.53	0.00	0.00	1.03	1.28
C05	Palate	40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	2.00	2.09	3.13	1.39	5.25	5.84	5.11	11.37	10.12	0.00	0.93	1.13
C06	Other parts of the mouth	57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	1.34	2.09	1.56	5.58	7.88	14.02	8.52	19.89	5.06	7.26	1.33	1.69
C07	Parotid gland	21	0.00	0.28	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.52	0.70	3.50	3.50	8.52	5.68	5.06	7.26	0.49	0.66
C08	Other larger salivary glands	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.70	1.75	0.00	1.70	2.84	0.00	14.52	0.19	0.26
C09	Amygdala	45	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.29	1.34	2.50	4.69	5.58	7.00	3.50	5.11	2.84	5.06	0.00	1.05	1.26
C10	Oropharynx	65	0.00	0.00	0.26	0.00	0.00	0.00	0.00	0.29	2.67	5.01	3.13	7.67	6.13	11.68	5.11	11.37	0.00	14.52	1.51	1.85
C11	Nasopharynx	44	0.00	0.00	0.52	0.45	0.22	0.26	0.57	2.34	2.00	2.09	1.04	3.49	2.63	4.67	1.70	5.68	0.00	0.00	1.03	1.07
C12	Piriform sinus	28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.42	0.52	6.27	2.63	5.84	10.22	2.84	0.00	0.00	0.65	0.86	
C13	Hypopharynx	43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.59	0.67	0.42	4.17	4.88	5.25	9.35	6.82	5.68	10.12	7.26	1.00	1.27
C14	Inaccurate locations of the lip, oral cavity and pharynx	74	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.59	1.00	6.68	5.21	6.27	9.63	11.68	10.22	8.53	15.18	0.00	1.72	2.13
C15	Esophagus	411	0.00	0.00	0.00	0.00	0.00	0.26	0.57	2.34	8.01	21.70	32.32	43.23	51.64	58.41	74.98	62.52	91.06	50.81	9.58	11.98
C16	Stomach	672	0.00	0.00	0.00	0.00	0.88	0.78	1.98	2.64	6.34	14.60	33.36	51.59	61.27	103.98	177.23	278.49	293.42	275.80	15.66	20.14
C17	Small intestine	31	0.00	0.00	0.00	0.00	0.00	0.00	0.57	0.00	1.00	0.00	2.09	1.39	3.50	8.18	3.41	11.37	10.12	7.26	0.72	0.91
C18	Colon	409	0.00	0.00	0.26	0.00	0.00	0.78	0.85	3.52	4.01	10.01	17.20	35.56	48.14	73.60	105.65	113.67	141.65	130.64	9.53	12.22
C19	Rectosigmoid junction	130	0.00	0.00	0.00	0.00	0.44	0.00	0.85	2.34	3.00	2.50	5.21	9.76	17.51	18.69	27.27	36.94	35.41	43.55	3.03	3.78
C20	Rectum	134	0.00	0.00	0.00	0.00	0.22	1.30	0.57	1.47	3.34	3.34	4.69	9.76	14.00	22.20	35.79	34.10	30.35	36.29	3.12	3.88
C21	Anus and anal canal	24	0.00	0.00	0.00	0.00	0.00	0.26	1.13	0.00	0.67	0.83	1.04	2.09	3.50	0.00	1.70	2.84	5.06	21.77	0.56	0.65
C22	Liver and intrahepatic biliary ducts	193	0.82	0.28	0.00	0.45	0.44	0.26	1.70	0.59	4.34	5.84	11.47	11.16	18.38	24.53	27.27	85.25	70.83	65.32	4.50	5.54
C23	Gallbladder	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	2.09	0.00	5.84	6.82	2.84	15.18	14.52	4.49	0.62
C24	Other parts of the biliary ducts	37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.00	0.00	1.56	2.79	2.63	10.51	13.63	8.53	15.18	21.77	0.86	1.17
C25	Pancreas	163	0.00	0.00	0.00	0.00	0.00	0.00	0.57	0.88	2.34	2.50	8.34	7.67	15.75	32.71	39.19	71.04	55.65	94.35	3.80	4.96
C26	Inaccurate locations in the gastrointestinal tract	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.59	0.67	1.25	1.56	2.09	6.13	3.50	10.22	8.53	10.12	29.03	0.89	1.15
C30	Nasal cavity and middle ear	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00	1.75	1.17	1.70	2.84	0.00	7.26	0.16	0.23
C31	Paranasal sinuses	15	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.59	0.67	1.25	1.56	0.00	1.75	1.17	0.00	2.84	0.00	0.00	0.35	0.38
C32	Larynx	347	0.00	0.00	0.00	0.00	0.00	0.00	0.57	0.59	3.67	8.76	26.07	31.37	45.51	77.11	80.09	71.04	75.88	79.84	8.08	10.60
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.06
C34	Bronchus and lungs	732	0.00	0.00	0.00	0.00	0.00	0.26	1.13	2.64	5.34	16.69	31.28	61.35	85.78	154.21	184.04	258.60	293.42	181.45	17.05	22.29
C37	Thymus	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.83	0.52	0.00	0.00	0.00	1.70	0.00	0.00	0.00	0.16	0.17
C38	Heart, mediastine and pleura	24	0.00	0.00	0.00	0.00	0.00	0.26	0.28	0.29	0.33	0.00	1.04	0.00	2.63	7.01	1.70	11.37	15.18	7.26	0.56	0.70
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.00	2.79	1.75	0.00	1.70	0.00	5.06	0.00	0.23	0.29
C40	Bones and limb joints	34	0.00	0.28	1.03	3.40	1.10	0.26	0.28	0.29	0.00	0.42	0.52	0.00	0.88	0.00	1.70	2.84	0.00	0.00	0.79	0.72
C41	Bones and joints of other locations	33	0.27	0.56	0.52	0.68	0.22	0.26	0.85	0.59	0.67	0.00	1.56	1.39	2.63	3.50	3.41	2.84	0.00	14.52	0.77	0.87
C43	Malignant skin melanoma	123	0.00	0.00	0.00	0.68	0.44	0.26	3.39	2.34	3.34	2.79	11.38	12.85	23.86	31.26	20.24	43.55	2.87	3.34		
C44	Other malignant skin neoplasms	2,290	0.00	0.00	0.52	1.81	1.98	2.33	9.61	17.00	24.04	57.16	74.55	135.26	252.95	339.97	521.45	792.84	875.20	1,284.66	53.35	65.63
C45	Mesothelioma	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.70	0.00	0.00	1.70	2.84	10.12	0.00	0.19	0.20
C46	Kaposi's sarcoma	41	0.00	0.00	0.00	0.00	0.88	0.78	2.26	3.52	1.67	1.25	0.00	0.70	1.75	1.17	1.70	0.00	5.06	0.00	0.96	0.85
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C48	Retroperitoneum and peritoneum	25	0.82	0.00	0.26	0.23	0.00	0.00	0.00	0.00	0.33	0.83	0.52	2.09	2.63	1.17	6.82	8.53	5.06	7.26	5.08	0.74
C49	Connective tissue and other soft tissues	64	0.54	0.00	0.52	0.68	1.54	0.78	0.85	2.05	1.00	2.09	3.65	3.49	2.63	7.01	6.82	8.53	0.00	7.26	1.49	1.61
C50	Breast	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.42	1.04	2.09	4.38	2.34	3.41	0.00	0.00	7.26	0.40	0.53
C60	Penis	68	0.00	0.00	0.00	0.00	0.00	0.52	0.85	1.47	2.00	2.09	3.13	3.49	3.50	8.18	15.34	17.05	25.29	29.03	1.58	1.86
C61	Prostate	3,420	0.00	0.00	0.00	0.00	0.00	0.00	0.57	1.47	3.34	24.20	71.42	226.59	416.62	760.54	1,182.65	1,537.37	1,284.97	1,560.46	79.68	107.14
C62	Testicles	80	0.54	0.28	0.26	2.04	3.52	3.37	3.11	2.05	4.01	0.42	0.00	2.09	0.88	2.34	0.00	0.00	0.00	0.00	1.86	1.61
C63	Other male sex organs, nos	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.00	0.00	0.70	1.75	1.17	1.70	5.68	0.00	7.26	0.21	0.28	
C64	Kidney	156	2.45	0.84	0.00	0.00	0.22	0.00	1.70	2.05	1.67	10.01	5.21	11.16	18.38	23.37	20.45	28.42	35.41	29.03	3.63	4.48
C65	Renal pelvis	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.70	1.75	0.00	1.70	0.00	0.00	0.00	0.00	0.09	0.13
C66	Ureters	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.12	0.00	0.05	0.05
C67	Bladder	354	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.88	2.67	3.76	5.21	21.61	28.01	70.10	115.88	187.55	202.36	166.93	8.25	10.85
C68	Other organs of the urinary system, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00	0.00	2.34	0.00	0.00	0.00	0.00	0.07	0.10
C69	Eyes and appendages	22	0.27	0.84	0.00	0.00	0.44	0.00	0.00	0.29	0.33	0.42	1.56	0.70	2.63	2.34	1.70	2.84	10.12	0.00	0.51	0.61
C70	Meninges	6	0.00	0.00	0.00	0.00	0.00	0.28	0.00	0.00	0.00	0.00	0.52	0.00	0.88	0.00	3.41	0.00	0.00	7.26	0.14	0.18
C71	Encephalon	249	2.72	1.67	2.32	1.36	0.88															

Belo Horizonte - MG, 2000 - 2003

Table 12 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C84	Peripheral and cutaneous T-cell lymphoma	5	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.00	0.33	0.00	0.00	0.70	0.00	2.34	0.00	0.00	0.00	0.00	0.12	0.13
C85	Other types of non-Hodgkin lymphoma, nos	159	0.27	0.28	0.26	1.36	1.10	1.56	1.70	2.05	3.67	6.68	7.30	8.37	12.25	17.52	23.86	39.78	50.59	29.03	3.70	4.25
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.88	0.00	0.00	0.00	0.00	0.00	0.02	0.04
C90	Multiple myeloma and malignant plasmacyte neoplasms	124	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.29	1.67	4.59	4.69	10.46	16.63	28.04	34.08	19.89	35.41	36.29	2.89	3.81
C91	Lymphoid leukemia	121	4.35	3.62	3.10	0.91	1.10	0.78	0.57	0.29	1.34	2.50	1.04	2.79	7.00	7.01	13.63	31.26	25.29	79.84	2.82	3.44
C92	Myeloid leukemia	130	0.82	0.84	1.29	2.04	0.44	3.11	1.70	1.47	2.67	1.25	3.65	3.49	7.00	19.86	20.45	31.26	45.53	36.29	3.03	3.52
C93	Monocytic leukemia Leucemia monocitica	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.17	0.00	0.00	5.06	0.00	0.05	0.06
C94	Other specified-type cell leukemias	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
C95	Unspecified cell leukemia	17	0.54	0.00	0.00	0.00	0.44	0.00	0.28	0.00	0.33	0.00	0.52	2.09	1.75	0.00	1.70	5.68	0.00	14.52	0.40	0.48
C96	Other malignant lymphatic tissue neoplasms and correlates	7	0.27	0.00	0.00	0.23	0.44	0.26	0.00	0.00	0.00	0.00	0.52	0.00	0.88	0.00	0.00	0.00	0.00	0.00	0.16	0.17
D46	Myelodysplastic syndromes	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.17	0.00	2.84	0.00	0.00	0.05	0.06
C00-96, D46	All invasive primary malignant neoplasms	12,444	16.87	13.38	16.00	20.41	21.99	28.00	50.30	80.30	141.90	286.66	461.37	855.48	1,357.53	2,148.44	3,079.31	4,146.06	4,052.21	4,775.73	289.93	367.42
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	10,154	16.87	13.38	15.48	18.60	20.01	25.66	40.70	63.30	117.86	229.49	386.82	720.22	1,104.58	1,808.47	2,557.85	3,353.23	3,177.01	3,491.07	236.57	301.78
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.52	0.00	0.88	1.17	3.41	2.84	5.06	7.26	0.21	0.28
D01	Carcinoma in situ of other organs of the gastrointestinal tract	2	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.04
D02	Carcinoma in situ of the middle ear and respiratory system	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	2.09	1.39	0.88	3.50	5.11	2.84	5.06	0.00	0.40	0.50
D03	Melanoma in situ	19	0.00	0.00	0.00	0.23	0.00	0.26	0.00	0.59	0.33	0.00	0.52	2.09	1.75	2.34	3.41	5.68	5.06	7.26	0.44	0.53
D04	Skin carcinoma in situ	43	0.00	0.00	0.00	0.00	0.00	0.26	0.28	0.00	0.33	1.25	0.52	3.49	3.50	8.18	8.52	19.89	10.12	29.03	1.00	1.25
D07	Carcinoma in situ of other sex organs and unspecified organs	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.00	0.00	0.52	0.00	0.00	0.00	0.00	0.00	5.06	0.00	0.09	0.07
D09	Carcinoma in situ of other locations and unspecified locations	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.67	0.00	1.56	0.00	0.88	1.17	5.11	2.84	5.06	0.00	0.30	0.36
C00-96, D00-09, D46	All primary malignant neoplasms	12,551	16.87	13.38	16.00	20.64	21.99	28.51	50.87	81.47	143.91	288.33	467.11	863.15	1,365.40	2,164.80	3,104.87	4,180.16	4,087.62	4,819.28	292.42	370.45

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belo Horizonte - MG, 2000 - 2003

Table 13 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C80	Unknown primary site	391	0.00	0.00	0.52	0.22	0.41	0.48	0.76	2.31	4.58	10.68	14.88	21.93	30.50	35.51	59.24	62.33	74.80	99.61	8.15	7.82
C81	Hodgkin's disease	94	0.28	0.00	0.26	3.04	4.11	1.67	3.06	1.28	1.72	1.38	1.28	2.81	1.99	4.13	2.12	3.20	2.49	8.79	1.96	1.75
C82	Non-Hodgkin follicular lymphoma	23	0.00	0.00	0.22	0.21	0.00	0.00	0.00	0.00	0.34	1.70	1.12	0.00	5.78	1.06	6.39	4.99	0.00	0.48	0.47	
C83	Non-Hodgkin diffuse lymphoma	113	0.28	1.14	0.00	0.65	1.03	0.72	2.04	0.51	0.29	2.07	2.13	6.75	11.27	8.26	12.69	19.18	14.96	17.58	2.36	2.32
C84	Peripheral and cutaneous T-cell lymphoma	14	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.51	0.29	0.69	0.43	2.25	0.00	0.00	1.06	0.00	4.99	0.00	0.29	0.27
C85	Other types of non-Hodgkin lymphoma, nos	158	0.00	0.00	0.52	0.00	0.82	1.44	1.27	2.57	1.43	4.82	3.40	7.87	7.29	9.91	22.22	33.56	29.92	38.09	3.29	3.03
C90	Multiple myeloma and malignant plasmacyte neoplasms	128	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.51	1.43	2.07	4.68	7.87	11.94	18.17	23.27	19.18	22.44	14.65	2.67	2.69
C91	Lymphoid leukemia	92	4.77	2.27	1.56	0.22	0.82	0.72	0.51	0.51	0.29	1.03	1.70	1.69	3.32	8.26	9.52	7.99	7.48	14.65	1.92	2.14
C92	Myeloid leukemia	132	0.00	0.85	0.26	1.09	1.23	0.24	1.27	3.85	2.29	3.79	2.98	4.50	9.28	8.26	10.58	9.59	27.43	29.30	2.75	2.54
C95	Unspecified cell leukemia	22	0.56	0.28	0.00	0.00	0.21	0.00	0.00	0.00	0.29	0.69	0.00	0.56	0.00	3.30	2.12	0.00	4.99	17.58	0.46	0.45
C96	Other lymphatic tissue malignant neoplasms and correlates	3	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.29	0.00	0.00	0.00	0.00	0.83	0.00	0.00	0.00	0.00	0.06	0.06
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.93	0.02	0.01
C00-96, D46	All invasive primary malignant neoplasms	12,841	15.15	11.64	10.16	12.61	25.06	34.44	71.36	134.04	250.20	369.34	516.02	699.08	909.80	1,172.66	1,478.90	1,863.60	2,174.18	2,384.86	267.77	255.63
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	10,726	14.59	11.64	10.16	12.61	22.80	31.34	62.19	123.51	219.89	329.72	463.32	610.78	764.57	967.03	1,205.97	1,462.43	1,600.72	1,746.16	223.67	216.08
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	0.00	0.00	1.06	0.00	2.49	0.00	0.08	0.08
D01	Carcinoma in situ of other organs of the gastrointestinal tract	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	0.66	0.83	1.06	1.60	0.00	0.00	0.13	0.13
D02	Carcinoma in situ of the middle ear and respiratory system	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.00	0.00	0.00	0.00	0.00	2.12	0.00	0.00	0.00	0.06	0.06
D03	Melanoma in situ	18	0.00	0.00	0.00	0.00	0.21	0.24	0.25	0.51	0.57	0.69	1.28	0.00	0.66	0.00	1.06	4.79	0.00	0.00	0.38	0.32
D04	Skin carcinoma in situ	27	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.00	0.29	1.38	0.43	1.12	1.99	1.65	0.00	7.99	4.99	17.58	0.56	0.50
D05	Breast carcinoma in situ	361	0.00	0.00	0.26	0.00	0.41	0.24	1.02	5.91	11.15	19.64	27.63	25.31	25.86	25.60	21.16	22.38	22.44	11.72	7.53	7.35
D06	Cervical carcinoma in situ	924	0.00	0.00	0.00	2.39	11.92	24.40	31.60	37.75	42.03	38.93	22.10	22.50	27.19	21.47	25.39	23.97	7.48	8.79	19.27	16.70
D07	Carcinoma in situ of other sex organs and unspecified organs	36	0.00	0.00	0.00	0.00	0.21	0.24	0.76	1.03	0.57	1.38	0.85	1.12	4.64	0.83	6.35	3.20	2.49	0.00	0.75	0.73
D09	Carcinoma in situ of other locations and unspecified locations	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.51	0.00	0.00	0.00	0.00	0.66	0.00	0.00	0.00	0.00	0.00	0.08	0.06
C00-96, D00-09, D46	All primary malignant neoplasms	14,224	15.15	11.64	10.42	15.00	37.80	59.56	105.26	179.75	305.11	431.35	568.30	751.38	971.47	1,223.04	1,537.08	1,927.53	2,214.08	2,422.95	296.61	281.57

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belo Horizonte - MG, 2000 - 2003

Male

Table 14

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	446	12.72	91.0	7.8	32.7
C15 Esophagus	411	11.98	84.2	13.9	66.7
C16 Stomach	672	20.14	76.0	21.6	59.4
C18-21 Large intestine, anal canal and anus	697	20.53	86.2	13.1	33.0
C22 Liver	193	5.54	42.5	55.4	86.5
C25 Pancreas	163	4.96	27.0	66.3	100.0
C32 Larynx	347	10.60	86.5	11.2	37.2
C33-34 Trachea, bronchus and lungs	734	22.35	63.1	35.1	83.1
C43 Skin melanoma	123	65.63	91.1	6.5	30.1
C61 Prostate	3.420	107.14	90.3	8.9	16.8
C70-72 Central Nervous System	262	6.88	64.9	33.2	71.4
C73 Thyroid	56	1.45	92.9	3.6	10.7
C91-95 Leukemia	272	7.55	60.3	37.1	63.2
C81-85, C96 Lymphoma	456	11.93	84.9	14.7	34.2
C00-96, D46 All primary invasive malignant Neoplasms	12.444	367.42	84.1	14.7	32.5
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	10.154	301.78	80.7	17.9	39.6

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 15

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	141	2.75	90.8	9.2	32.6
C15 Esophagus	154	3.16	81.8	15.6	50.0
C16 Stomach	487	9.44	74.5	25.1	59.5
C18-21 Large intestine, anal canal and anus	921	18.34	83.0	16.1	42.1
C22 Liver	158	3.08	48.1	51.9	84.2
C25 Pancreas	222	4.31	33.3	62.2	92.8
C32 Larynx	64	1.36	79.7	15.6	26.6
C33-34 Trachea, bronchus and lungs	366	7.56	58.7	41.3	76.5
C43 Skin melanoma	138	39.55	90.6	8.7	26.1
C50 Breast	3.573	72.67	91.1	8.5	19.0
C53 Cervix	1.008	20.36	91.7	7.8	22.1
C70-72 Central Nervous System	268	5.55	56.7	39.2	69.0
C73 Thyroid	199	3.80	97.5	2.5	5.5
C91-95 Leukemia	246	5.12	61.4	36.2	63.8
C81-85, C96 Lymphoma	405	7.90	84.9	14.3	34.1
C00-96, D46 All primary invasive malignant Neoplasms	12,843	255.63	84.0	15.0	31.2
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	10,728	216.08	81.0	17.9	37.1

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Belo Horizonte - MG, 2000 - 2003

Male




Figure 11

Female




Figure 12

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 16

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	54	48.48	49.24	67	43.09	44.79	38	34.78	36.89	44	28.34	31.53
Ia. Lymphoid leukemia	41	36.81	37.53	45	28.94	31.13	31	28.37	30.30	32	20.61	23.97
Ib. Acute myeloid leukemia	8	7.18	6.75	15	9.65	8.80	3	2.75	2.59	6	3.86	3.47
Ic. Myeloproliferative chronic diseases	2	1.80	1.95	4	2.57	2.53	0	0.00	0.00	1	0.64	0.49
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	0.90	0.90	1	0.64	0.70	1	0.92	0.92	2	1.29	1.20
Ie. Specified leukemias and other unspecified leukemias	2	1.80	2.11	2	1.29	1.63	3	2.75	3.08	3	1.93	2.39
II. Reticuloendothelial lymphomas and neoplasms	32	28.73	26.99	57	36.66	33.67	9	8.24	8.10	27	17.39	15.08
Ila. Hodgkin's lymphoma	16	14.36	12.89	31	19.94	17.64	2	1.83	1.84	16	10.31	8.27
Ilb. Non-Hodgkin lymphoma (exc ept for Burkitt's lymphoma)	10	8.98	8.55	18	11.58	10.71	4	3.66	3.34	8	5.15	4.55
Ilc. Burkitt's lymphoma	4	3.59	3.60	5	3.22	3.30	3	2.75	2.92	3	1.93	2.26
Ild. Miscellany of lymphoreticular neoplasms	1	0.90	1.05	2	1.29	1.33	0	0.00	0.00	0	0.00	0.00
Ile. Unspecified lymphoma	1	0.90	0.90	1	0.64	0.70	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	26	23.34	23.57	32	20.58	21.33	27	24.71	24.32	36	23.19	23.25
Illa. Ependymoma and choroid plexus tumor	0	0.00	0.00	1	0.64	0.51	2	1.83	1.83	3	1.93	1.91
IIlb. Astrocytoma	8	7.18	7.21	10	6.43	6.61	8	7.32	7.02	10	6.44	6.42
IIlc. Intracranial and intraspinal embryonic tumors	4	3.59	3.75	4	2.57	2.91	2	1.83	1.84	2	1.29	1.43
IIId. Other gliomas	4	3.59	3.15	6	3.86	3.46	6	5.49	5.18	7	4.51	4.50
IIle. Other intracranial and intraspinal neoplasms	1	0.90	0.90	1	0.64	0.70	0	0.00	0.00	0	0.00	0.00
IIIf. Unspecified intracranial and intraspinal tumors	9	8.08	8.57	10	6.43	7.15	9	8.24	8.45	14	9.02	8.99
IV. Neuroblastoma and other peripheral nervous cell tumor	7	6.28	7.38	7	4.50	5.72	6	5.49	6.18	6	3.86	4.79
Iva. Neuroblastoma and ganglioneuroblastoma	7	6.28	7.38	7	4.50	5.72	6	5.49	6.18	6	3.86	4.79
V. Retinoblastoma	3	2.69	2.85	3	1.93	2.21	3	2.75	3.26	3	1.93	2.53
VI. Renal tumors	12	10.77	12.17	12	7.72	9.43	14	12.81	14.51	14	9.02	11.24
Via. Nephroblastoma and other renal non-epithelial tumors	9	8.08	9.17	9	5.79	7.11	14	12.81	14.51	14	9.02	11.24
Vic. Unspecified malignant renal tumors	3	2.69	3.00	3	1.93	2.33	0	0.00	0.00	0	0.00	0.00
VII. Hepatic tumors	3	2.69	3.16	5	3.22	3.47	0	0.00	0.00	2	1.29	0.98
VIIa. Hepatoblastoma	2	1.80	2.10	2	1.29	1.63	0	0.00	0.00	0	0.00	0.00
VIIb. Hepatocellular carcinoma	1	0.90	1.06	3	1.93	1.84	0	0.00	0.00	2	1.29	0.98
VIII. Malignant bone tumors	9	8.08	7.50	27	17.37	14.99	9	8.24	7.12	14	9.02	7.97
VIIIa. Osteosarcoma	3	2.69	2.25	17	10.93	8.89	9	8.24	7.12	10	6.44	6.01
VIIIb. Chondrosarcoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.64	0.49
VIIIc. Ewing's sarcoma and related bone sarcomas	3	2.69	2.70	4	2.57	2.60	0	0.00	0.00	0	0.00	0.00
VIIId. Other specified malignant bone tumors	0	0.00	0.00	1	0.64	0.51	0	0.00	0.00	0	0.00	0.00
VIIIe. Unspecified malignant bone tumors	3	2.69	2.55	5	3.22	2.99	0	0.00	0.00	3	1.93	1.47
IX. Soft-tissue and other extraosseous sarcomas	9	8.08	7.80	12	7.72	7.57	6	5.49	5.50	10	6.44	6.22
IXa. Rhabdomyosarcoma	4	3.59	3.60	4	2.57	2.79	4	3.66	3.83	4	2.58	2.97
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	1	0.90	0.75	1	0.64	0.58	0	0.00	0.00	1	0.64	0.49
IXd. Other unspecified soft-tissue sarcomas	3	2.69	2.70	3	1.93	2.09	2	1.83	1.67	4	2.58	2.27
IXe. Unspecified soft-tissue sarcomas	1	0.90	0.75	4	2.57	2.11	0	0.00	0.00	1	0.64	0.49
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	5	4.49	4.36	15	9.65	8.48	5	4.58	5.09	8	5.15	5.41
Xa. Intracranial and intraspinal germ cell tumors	1	0.90	0.75	1	0.64	0.58	0	0.00	0.00	0	0.00	0.00
Xb. Malignant intracranial and intraspinal germ cell tumors	1	0.90	0.75	2	1.29	1.09	2	1.83	2.18	3	1.93	2.18
Xc. Malignant gonadal germ cell tumors	2	1.80	1.81	8	5.15	4.46	1	0.92	0.92	3	1.93	1.69
Xd. Gonadal carcinomas	0	0.00	0.00	1	0.64	0.51	0	0.00	0.00	0	0.00	0.00
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	1	0.90	1.05	3	1.93	1.84	2	1.83	2.00	2	1.29	1.55
XI. Other malignant epithelial neoplasms and melanomas	7	6.28	5.54	21	13.51	11.44	10	9.15	8.38	29	18.68	15.78
XIb. Thyroid carcinoma	0	0.00	0.00	0	0.00	0.00	3	2.75	2.27	6	3.86	3.23
XIc. Nasopharynx carcinoma	2	1.80	1.50	4	2.57	2.18	0	0.00	0.00	0	0.00	0.00
XId. Malignant melanoma	0	0.00	0.00	4	2.57	2.04	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	1	0.90	0.75	9	5.79	4.66	2	1.83	2.17	2	1.29	1.68
XIf. Other carcinomas and unspecified carcinomas	4	3.59	3.30	4	2.57	2.55	5	4.58	3.94	21	13.53	10.88
XII. Other malignant and unspecified neoplasms	5	4.49	4.35	5	3.22	3.37	8	7.32	7.03	11	7.08	6.92
XIIb. Other unspecified malignant tumors	5	4.49	4.35	5	3.22	3.37	8	7.32	7.03	11	7.08	6.92
All neoplasms	172	154.41	154.92	263	169.15	166.50	135	123.56	126.39	204	131.39	131.70

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação






Figure 13. Distribution of the population* in Campo Grande
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Campo Grande

Coordinator

Gláucia da Silva Nunes de Freitas

Registrars

Heloyza Lima da Silva

Carlos Venâncio de Oliveira

Information technology technician

Tiago Oliveira Vargas

Epidemiologist

Hilda Guimarães de Freitas

Consultant

Carmencita Sanches Lang

Advisory Committee

Aparecida Mitsuko Miura (oncologist)

Arlete de Araújo Christensen (nurse)

Arlete Delfina Marques Maia (hematologist)

Carmencita Sanches Lang (oncologist)

Eloni Basso Rohde (high-complexity actions)

Eulálio Arantes Correa da Costa (oncologist)

Jeferson Baggio Cavalcante (oncologist)

Jesusmar Modesto Ramos (oncologist)

Luís Henrique Mascarenhas Moreira (hematologist)

Maçanori Odashiro (pathologist)

Márcia Bogena Cereser Tomasi (nurse)

Márcia Lourdes Rondon de Andrade (state health surveillance technician)

Maria Inês Carvalho Silva (Forum of the SUS Patients)

Mirna Aquemi Yamamoto (state health auditor)

Rogério Marcio Alves Souto (vacancy regulation)

Sandra Regina Kometki Ortega (state health auditor)

Solange Glória de Oliveira (medium-complexity actions)

Suelyly Antonialli (biochemist of the Public Health Central Laboratory)

Vera Lúcia Canalli Bernardi (auditor of the Municipal Health Secretariat/Dourados/MS)

Viviane Andreatta (oncologist)

Campo Grande - MS, 2000 - 2002

Infrastructure and Data Source

This PBCR was created in 2000, whereas the data collection started in 2002. It is located in the State Health Secretariat/Basic Care State Coordination Office/Women's Health/SES/MS, and financially supported by Ordinance No. 2,607, of 2005, SES/SMS




Figure 14. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand men, per tumor primary site and age group

Campo Grande - MS, 2000 - 2002

Table 17

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.33	0.00	1.95	0.00	0.00	4.30	5.87	0.00	13.07	0.00	0.00	0.51	0.68
C01	Tongue base	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	0.00	4.98	3.44	0.00	5.87	0.00	13.07	0.00	0.00	0.61	0.79
C02	Other parts of the tongue	18	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	1.55	15.59	2.49	6.89	4.30	17.60	8.49	0.00	0.00	0.00	1.82	2.37
C03	Gingiva	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.49	0.00	0.00	5.87	0.00	0.00	0.00	0.00	0.20	0.30
C04	Floor of the mouth	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	2.49	3.44	0.00	11.73	0.00	0.00	0.00	0.00	0.51	0.73
C05	Palate	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.66	0.00	1.95	4.98	0.00	8.60	5.87	0.00	0.00	44.49	0.00	1.01	1.27
C06	Other parts of the mouth	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	1.95	4.98	6.89	4.30	0.00	0.00	0.00	0.00	0.00	0.71	0.91
C07	Parotid gland	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.24	0.20	0.28
C08	Other larger salivary glands	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.44	4.30	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.31
C09	Amygdala	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	1.95	0.00	3.44	4.30	5.87	0.00	13.07	0.00	0.00	0.61	0.83
C10	Oropharynx	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.11	1.95	2.49	0.00	17.20	5.87	8.49	0.00	22.25	0.00	1.11	1.57
C11	Nasopharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.49	0.00	4.30	0.00	0.00	0.00	0.00	0.00	0.20	0.30
C12	Pitiform sinus	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	7.79	4.98	0.00	4.30	5.87	0.00	0.00	0.00	0.00	0.91	1.16
C13	Hypopharynx	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.90	7.47	6.89	0.00	5.87	8.49	0.00	0.00	0.00	0.91	1.23
C14	Inaccurate locations of the lip, oral cavity and pharynx	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	3.44	0.00	11.73	33.94	0.00	22.25	0.00	0.91	1.40
C15	Esophagus	87	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	9.33	7.79	19.91	41.32	68.79	52.80	101.83	117.65	111.23	99.73	8.79	12.35
C16	Stomach	110	0.00	0.00	0.00	0.00	0.00	1.17	1.25	1.33	7.77	13.64	12.45	34.43	64.49	111.46	161.24	143.79	200.22	132.98	11.11	15.79
C17	Small intestine	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.44	0.00	0.00	0.00	13.07	0.00	0.00	0.20	0.27
C18	Colon	57	0.00	0.00	0.00	0.00	7.05	2.50	1.33	6.22	0.00	22.40	30.99	25.80	35.20	50.92	65.36	22.25	33.24	5.76	7.56	
C19	Rectosigmoid junction	11	0.00	0.00	0.00	0.00	1.17	0.00	0.00	0.00	0.00	2.49	3.44	4.30	17.60	8.49	13.07	22.25	0.00	1.11	1.47	
C20	Rectum	40	0.00	0.00	0.00	0.95	1.02	2.35	2.50	2.66	3.11	3.90	7.47	13.77	12.90	52.80	8.49	39.22	66.74	33.24	4.04	5.17
C21	Anus and anal canal	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.49	3.44	0.00	0.00	0.00	13.07	0.00	0.00	0.30	0.39
C22	Liver and intrahepatic biliary ducts	28	0.00	0.00	0.97	0.95	1.02	0.00	1.25	0.00	0.00	5.85	2.49	6.89	30.10	5.87	25.46	52.29	44.49	33.24	2.83	3.88
C23	Gallbladder	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.49	0.00	0.00	0.00	0.10	0.17
C24	Other parts of the biliary ducts	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	5.87	0.00	13.07	22.25	33.24	0.51	0.70
C25	Pancreas	32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.66	3.90	7.47	10.33	17.20	35.20	59.40	26.14	0.00	33.24	3.23	4.66
C26	Inaccurate locations in the gastrointestinal tract	10	0.00	0.00	0.00	0.95	1.02	0.00	0.00	0.00	0.00	0.00	3.44	8.60	11.73	16.97	0.00	0.00	33.24	1.01	1.51	
C30	Nasal cavity and middle ear	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.44	0.00	0.00	0.00	0.00	0.00	33.24	0.20	0.30
C31	Paranasal sinuses	5	0.00	0.00	0.00	0.00	0.00	1.17	0.00	0.00	1.55	0.00	0.00	0.00	0.00	5.87	8.49	13.07	0.00	0.00	0.51	0.66
C32	Larynx	65	1.08	0.00	0.00	0.00	0.00	0.00	0.00	1.33	6.22	13.64	19.91	24.10	38.70	46.93	84.86	65.36	0.00	166.22	6.57	9.50
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.44	4.30	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.31
C34	Bronchus and lungs	140	1.08	0.00	0.00	0.00	0.00	0.00	0.00	6.66	6.22	9.74	32.36	58.53	85.99	111.46	135.78	313.73	266.96	99.73	14.14	19.92
C38	Heart, mediastine and pleura	4	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	0.00	3.90	2.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.43
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.49	0.00	0.00	0.00	0.10	0.17
C40	Bones and limb joints	14	0.00	0.00	1.95	3.79	2.05	2.35	1.25	0.00	0.00	0.00	2.49	0.00	5.87	0.00	13.07	0.00	0.00	0.00	1.41	1.37
C41	Bones and joints of other locations	8	0.00	0.00	0.00	0.95	0.00	0.00	1.25	0.00	0.00	0.00	0.00	3.44	0.00	11.73	25.46	0.00	0.00	0.00	0.81	1.16
C43	Malignant skin melanoma	16	1.08	0.00	0.00	0.00	1.02	0.00	0.00	0.00	0.00	11.69	7.47	10.33	0.00	0.00	0.00	13.07	22.25	0.00	1.62	1.94
C44	Other malignant skin neoplasms	229	0.00	0.00	1.95	0.00	2.35	2.50	6.66	32.65	17.54	49.79	72.31	81.69	164.25	195.18	522.88	511.68	299.20	23.14	30.69	
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.08
C46	Kaposi's sarcoma	1	0.00	0.00	0.00	0.00	0.00	1.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.09
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.08
C48	Retroperitoneum and peritoneum	6	0.00	1.01	0.00	0.00	1.02	0.00	0.00	1.33	0.00	0.00	2.49	0.00	0.00	5.87	0.00	13.07	0.00	0.00	0.61	0.69
C49	Connective tissue and other soft tissues	11	1.08	0.00	0.97	0.00	2.05	1.17	0.00	0.00	3.11	0.00	0.00	3.44	0.00	5.87	8.49	0.00	0.00	33.24	1.11	1.31
C50	Breast	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	0.00	0.00	3.44	0.00	0.00	0.00	13.07	0.00	0.00	0.30	0.36
C60	Penis	18	0.00	0.00	0.00	0.00	0.00	0.00	1.25	2.66	0.00	11.69	9.96	10.33	4.30	5.87	0.00	0.00	0.00	0.00	1.82	2.20
C61	Prostate	198	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	9.96	34.43	60.19	181.85	356.42	575.16	622.91	698.14	20.00	29.34
C62	Testicles	16	2.16	0.00	0.00	0.00	3.07	3.52	2.50	1.33	3.11	0.00	0.00	0.00	11.73	0.00	0.00	0.00	0.00	0.00	1.62	1.56
C64	Kidney	16	3.24	1.01	0.00	0.00	0.00	0.00	1.25	0.00	0.00	1.95	2.49	3.44	4.30	11.73	0.00	26.14	44.49	0.00	1.62	1.95
C67	Bladder	24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	0.00	2.49	3.44	8.60	41.06	25.46	52.29	44.49	99.73	2.42	3.68
C69	Eyes and appendages	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.30	0.00	8.49	0.00	0.00	33.24	0.30	0.51
C70	Meninges	1	0.00	0.00	0.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.09
C71	Encephalon	45	1.08	4.05	1.95	0.95	4.10	2.35	2.50	0.00	6.22	3.90	12.45	13.77	12.90	29.33	16.97	26.14	0.00	33.24	4.55	5.40
C72	Spinal cord and other parts of the central nervous system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.12
C73	Thyroid gland	3	0.00	0.00	0.00	0.00	1.02	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	13.07	0.00	0.00	0.30	0.33
C74	Adrenal gland	1	0.00	1.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.10
C76	Other inaccurate locations	22	2.16	0.00	0.97	0.00	1.02	1.17	0.00	1.33	3.11	1.95	7.47	0.00	12.90	0.00	33.94	13.07	22.25	33.24	2.22	2.88
C80	Unknown primary site	60	0.00	0.00	0.00	0.00	2.35	1.25	0.00	3.11	9.74	4.98	30.99	17.20	82.13	84.86	104.5					

Campo Grande - MS, 2000 - 2002

Table 17 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.49	0.00	0.00	0.00	0.10	0.17	
C90	Multiple myeloma and malignant plasmacyte neoplasms	19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.33	0.00	5.85	2.49	10.33	4.30	23.46	25.46	26.14	22.25	0.00	1.92	2.73	
C91	Lymphoid leukemia	19	4.32	4.05	0.97	1.89	1.02	1.17	1.25	0.00	0.00	1.95	2.49	3.44	0.00	0.00	8.49	0.00	0.00	33.24	1.92	2.15	
C92	Myeloid leukemia	36	0.00	1.01	2.92	0.95	3.07	1.17	2.50	0.00	3.11	3.90	4.98	10.33	4.30	23.46	33.94	65.36	44.49	0.00	3.64	4.45	
C93	Monocytic leukemia Leucemia monocitica	2	1.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22	
C95	Unspecified cell leukemia	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.30	17.60	8.49	0.00	0.00	0.00	0.51	0.87	
C96	Other malignant lymphatic tissue neoplasms and correlates	2	1.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.25
C00-96, D46	All invasive primary malignant neoplasms	1,567	22.67	15.18	19.45	17.03	25.61	31.71	35.05	38.62	118.14	192.89	306.19	506.15	657.84	1,243.62	1,612.36	2,535.95	2,335.93	2,061.17	158.32	213.96	
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	1,338	22.67	15.18	17.51	17.03	25.61	29.36	32.55	31.96	85.50	175.36	256.40	433.84	576.15	1,079.37	1,417.18	2,013.07	1,824.25	1,761.97	135.18	183.27	
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.30	0.00	0.00	0.00	0.00	0.00	0.10	0.17	
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.87	0.00	0.00	0.00	0.00	0.10	0.18	
D04	Skin carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.07	0.00	0.00	0.10	0.13	
D07	Carcinoma in situ of other sex organs and unspecified organs	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.49	0.00	0.00	5.87	0.00	0.00	0.00	0.00	0.20	0.30	
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.60	0.00	0.00	0.00	0.00	0.00	0.20	0.34	
C00-96, D00-09, D46	All primary malignant neoplasms	1,574	22.67	15.18	19.45	17.03	25.61	31.71	35.05	38.62	118.14	192.89	308.68	506.15	670.74	1,255.35	1,612.36	2,549.02	2,335.93	2,061.17	159.02	215.08	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Campo Grande - MS, 2000 - 2002

Table 18 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C90	Multiple myeloma and malignant plasmacyte neoplasms	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.16	0.00	0.00	4.55	12.32	7.54	20.11	13.81	21.33	17.87	0.00	1.72	2.27	
C91	Lymphoid leukemia	23	6.71	7.28	3.03	1.86	0.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.91	21.33	17.87	0.00	2.20	2.49	
C92	Myeloid leukemia	30	0.00	0.00	0.00	1.86	0.98	2.17	2.31	1.16	2.79	3.47	4.55	9.24	7.54	0.00	13.81	10.67	0.00	104.54	2.87	2.81	
C93	Monocytic leukemia	3	0.00	1.04	0.00	0.00	0.00	0.00	1.16	0.00	1.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.26	
C95	Unspecified cell leukemia	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.54	0.00	0.00	21.33	0.00	0.00	0.38	0.51	
C96	Other lymphatic tissue malignant neoplasms and correlates	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.91	0.00	0.00	20.91	0.19	0.24	
C00-96, D46	All invasive primary malignant neoplasms	1,797	16.77	10.40	13.11	14.88	12.68	34.80	53.17	120.74	173.25	296.69	391.71	566.90	761.72	889.98	1,056.63	1,567.83	1,679.77	1,798.03	171.85	201.63	
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	1,623	16.77	10.40	13.11	13.95	12.68	34.80	50.86	117.26	163.47	279.34	362.10	517.61	693.84	849.76	842.54	1,343.86	1,322.37	1,421.70	155.21	182.01	
D04	Skin carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.87	0.00	0.10	0.09
D05	Breast carcinoma in situ	22	0.00	0.00	0.00	0.00	0.00	0.00	1.16	1.40	10.41	6.83	9.24	11.31	5.03	27.62	0.00	0.00	0.00	0.00	2.10	2.65	
D06	Cervical carcinoma in situ	38	0.00	0.00	0.00	0.00	0.00	2.17	4.62	4.64	9.78	10.41	2.28	6.16	0.00	25.14	20.72	10.67	35.74	20.91	3.63	3.86	
D07	Carcinoma in situ of other sex organs and unspecified organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.08	
C00-96, D00-09, D46	All primary malignant neoplasms	1,859	16.77	10.40	13.11	14.88	12.68	36.97	57.79	126.55	185.82	317.52	400.82	582.31	773.03	920.15	1,104.97	1,578.50	1,733.38	1,818.94	177.78	208.31	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Campo Grande - MS, 2000 - 2002

Male

Table 19

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	70	9.44	81.4	14.3	38.6
C15	Esophagus	87	12.35	58.6	35.6	72.4
C16	Stomach	110	15.79	56.4	30.9	88.2
C18-21	Large intestine, anal canal and anus	111	14.60	65.8	24.3	54.1
C22	Liver	28	3.88	28.6	53.6	121.4
C25	Pancreas	32	4.66	21.9	50.0	100.0
C32	Larynx	65	9.50	62.9	24.6	83.1
C33-34	Trachea, bronchus and lungs	142	20.23	39.4	42.3	92.3
C43	Skin melanoma	16	30.69	81.3	12.5	68.8
C61	Prostate	198	29.34	49.0	37.4	67.7
C70-72	Central Nervous System	47	5.61	44.7	36.2	80.9
C73	Thyroid	3	0.33	100.0	0.0	0.0
C91-95	Leukemia	62	7.69	61.3	29.0	77.4
C81-85, C96	Lymphoma	79	9.47	73.4	20.3	51.9
C00-96, D46	All primary invasive malignant Neoplasms	1,567	213.96	61.6	26.1	60.8
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	1,338	183.27	56.4	30.5	71.0

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 20

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	24	3.03	75.0	16.7	50.0
C15	Esophagus	24	3.02	54.2	37.5	75.0
C16	Stomach	55	5.96	41.8	47.3	87.3
C18-21	Large intestine, anal canal and anus	133	15.71	72.2	23.3	53.4
C22	Liver	16	1.69	12.5	62.5	131.3
C25	Pancreas	31	3.67	16.1	45.2	100.0
C32	Larynx	15	1.77	46.7	20.0	46.7
C33-34	Trachea, bronchus and lungs	81	9.67	44.4	35.8	77.8
C43	Skin melanoma	15	19.62	73.3	20.0	33.3
C50	Breast	497	54.96	83.9	10.9	27.6
C53	Cervix	232	24.85	78.5	9.5	32.3
C70-72	Central Nervous System	44	4.98	29.5	40.9	90.9
C73	Thyroid	5	0.49	60.0	20.0	60.0
C91-95	Leukemia	60	6.07	66.7	16.7	61.7
C81-85, C96	Lymphoma	55	6.13	76.4	10.9	27.3
C00-96, D46	All primary invasive malignant Neoplasms	1,797	201.63	69.3	18.9	44.3
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	1,623	182.01	66.9	20.8	48.7

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Campo Grande - MS, 2000 - 2002

Male




Figure 15

Female




Figure 16

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Campo Grande - MS, 2000 - 2002

Table 21

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	0-14 Adjusted*	No.	0-19 Crude	0-19 Adjusted*	No.	0-14 Crude	0-14 Adjusted*	No.	0-19 Crude	0-19 Adjusted*
I. Leukemia	14	47.58	48.68	17	42.51	44.12	17	59.69	61.40	21	53.53	55.96
Ia. Lymphoid leukemia	9	30.58	32.63	11	27.50	29.55	16	56.18	58.05	18	45.88	49.17
Ib. Acute myeloid leukemia	5	16.99	16.05	6	15.00	14.57	1	3.51	3.35	3	7.65	6.78
II. Reticuloendothelial lymphomas and neoplasms	13	44.18	43.32	19	47.51	46.35	2	7.02	8.60	4	10.20	10.85
Ila. Hodgkin's lymphoma	4	13.59	13.06	6	15.00	14.38	0	0.00	0.00	2	5.10	4.18
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	7	23.79	21.97	8	20.00	19.16	1	3.51	4.30	1	2.55	3.33
Ilc. Burkitt's lymphoma	1	3.40	4.15	2	5.00	5.34	1	3.51	4.30	1	2.55	3.33
Ild. Miscellany of lymphoreticular neoplasms	1	3.40	4.15	1	2.50	3.21	0	0.00	0.00	0	0.00	0.00
Ile. Unspecified lymphoma	0	0.00	0.00	2	5.00	4.26	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	8	27.19	25.68	9	22.50	22.03	6	21.07	19.79	7	17.84	17.43
Illa. Ependymoma and choroid plexus tumor	2	6.80	7.41	2	5.00	5.74	0	0.00	0.00	0	0.00	0.00
Ilb. Astrocytoma	2	6.80	6.09	3	7.50	6.85	3	10.53	8.78	4	10.20	8.90
Illc. Intracranial and intraspinal embryonic tumors	0	0.00	0.00	0	0.00	0.00	1	3.51	3.35	1	2.55	2.60
Ille. Other intracranial and intraspinal neoplasms	1	3.40	2.82	1	2.50	2.19	0	0.00	0.00	0	0.00	0.00
Ilf. Unspecified intracranial and intraspinal tumors	3	10.19	9.35	3	7.50	7.25	2	7.02	7.65	2	5.10	5.93
IV. Neuroblastoma and other peripheral nervous cell tumor	2	6.80	6.53	2	5.00	5.06	2	7.02	8.75	2	5.10	6.78
Iva. Neuroblastoma and ganglioneuroblastoma	2	6.80	6.53	2	5.00	5.06	2	7.02	8.75	2	5.10	6.78
V. Retinoblastoma	0	0.00	0.00	0	0.00	0.00	1	3.51	4.45	1	2.55	3.45
VI. Renal tumors	4	13.59	15.70	4	10.00	12.17	4	14.05	16.13	4	10.20	12.50
Via. Nephroblastoma and other renal non-epithelial tumors	4	13.59	15.70	4	10.00	12.17	3	10.53	13.20	3	7.65	10.23
Vib. Renal carcinomas	0	0.00	0.00	0	0.00	0.00	1	3.51	2.93	1	2.55	2.27
VII. Hepatic tumors	1	3.40	2.82	2	5.00	4.32	0	0.00	0.00	0	0.00	0.00
Vilb. Hepatocellular carcinoma	1	3.40	2.82	2	5.00	4.32	0	0.00	0.00	0	0.00	0.00
VIII. Malignant bone tumors	2	6.80	5.65	5	12.50	10.77	1	3.51	2.93	4	10.20	8.55
VIIIa. Osteosarcoma	1	3.40	2.82	4	10.00	8.58	1	3.51	2.93	4	10.20	8.55
VIIIc. Ewing's sarcoma and related bone sarcomas	1	3.40	2.82	1	2.50	2.19	0	0.00	0.00	0	0.00	0.00
IX. Soft-tissue and other extraosseous sarcomas	6	20.39	23.72	8	20.00	22.64	2	7.02	5.85	4	10.20	8.72
IXa. Rhabdomyosarcoma	3	10.19	12.44	3	7.50	9.64	1	3.51	2.93	1	2.55	2.27
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	1	3.40	4.31	1	2.50	3.34	0	0.00	0.00	1	2.55	2.09
IXd. Other unspecified soft-tissue sarcomas	2	6.80	6.97	4	10.00	9.66	1	3.51	2.93	2	5.10	4.36
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	1	3.40	4.15	1	2.50	3.21	3	10.53	8.78	5	12.74	10.99
Xa. Intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	2.55	2.09
Xc. Malignant gonadal germ cell tumors	1	3.40	4.15	1	2.50	3.21	1	3.51	2.93	2	5.10	4.36
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	1	3.51	2.93	1	2.55	2.27
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	0	0.00	0.00	1	3.51	2.93	1	2.55	2.27
XI. Other malignant epithelial neoplasms and melanomas	4	13.59	14.11	5	12.50	13.06	0	0.00	0.00	1	2.55	2.09
XId. Malignant melanoma	1	3.40	4.15	1	2.50	3.21	0	0.00	0.00	1	2.55	2.09
XIe. Skin carcinoma	2	6.80	5.65	2	5.00	4.38	0	0.00	0.00	0	0.00	0.00
XIf. Other carcinomas and unspecified carcinomas	1	3.40	4.31	2	5.00	5.47	0	0.00	0.00	0	0.00	0.00
XII. Other malignant and unspecified neoplasms	1	3.40	2.82	2	5.00	4.32	0	0.00	0.00	1	2.55	2.09
XIib. Other unspecified malignant tumors	1	3.40	2.82	2	5.00	4.32	0	0.00	0.00	1	2.55	2.09
All neoplasms	56	190.30	193.18	74	185.03	188.04	38	133.43	136.68	54	137.64	139.40

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação



Cuiabá¹ - MT, 2000 - 2005




Figure 17. Distribution of the population* in Cuiabá¹

¹Includes Várzea Grande

*Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Cuiabá

Coordinator

Beatriz Alves de Castro Soares

Registrars

Maria José Lemes de Oliveira Salles

Maria Ilma Castilho

Marcia Cristina Claudiano

Paulo Cesar Fernande

Data Collectors

Anny Karoline Freire

Cynthia Laura de Amorim Silva

Cleoany Gonçalves Galvão

Elisabeth Fernanda da Silva

Maria José Lemes de Oliveira Salles

Maria Ilma Castilho

Paulo Cesar Fernande

Data Entry Clerks

Maria José Lemes de Oliveira Salles

Maria Ilma Castilho

Marcia Cristina Claudiano

Paulo Cesar Fernande

Advisory Committee

Beatriz Alves de Castro Soares (epidemiologist)

Dirceu Gonçalves Almeida Costa (clinical oncologist)

Infrastructure and Data Source

This PBCR was created in 1999, whereas the data collection started in 2000. It is coordinated by the Epidemiologic Surveillance Service of the Health Secretariat of the State of Mato Grosso and financially supported by Ordinance No. 2,607, of 2005.




Figure 18. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Comprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary site and age group

Cuiabá¹ - MT, 2000 - 2005

Table 22

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	1.73	2.23	2.94	0.00	8.71	0.00	6.02	0.00	0.00	0.00	0.60	0.90	
C01	Tongue base	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.00	3.34	0.00	4.24	5.81	0.00	0.00	0.00	18.19	0.00	0.49	0.74	
C02	Other parts of the tongue	34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	2.60	7.80	7.36	12.73	8.71	16.37	18.06	0.00	0.00	50.23	1.86	3.00	
C03	Gingiva	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.12	2.90	0.00	0.00	0.00	0.00	0.00	0.16	0.20	
C04	Floor of the mouth	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.73	1.11	1.47	10.61	5.81	12.28	6.02	0.00	0.00	0.00	0.82	1.39	
C05	Palate	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.68	0.00	0.87	1.11	1.47	6.36	5.81	4.09	0.00	10.13	0.00	25.11	0.71	1.07
C06	Other parts of the mouth	31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.73	4.45	10.31	10.61	5.81	8.18	24.08	40.54	18.19	0.00	1.70	2.77	
C07	Parotid gland	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	0.00	2.12	0.00	4.09	0.00	10.13	0.00	0.00	0.27	0.36	
C08	Other larger salivary glands	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	
C09	Amygdala	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.73	6.68	2.94	2.12	0.00	4.09	18.06	0.00	0.00	0.00	0.82	1.22	
C10	Oropharynx	23	0.00	0.00	0.00	0.00	0.00	0.00	0.68	1.48	0.87	4.45	5.89	10.61	5.81	4.09	0.00	10.13	0.00	25.11	1.26	1.75	
C11	Nasopharynx	7	0.00	0.00	0.00	0.00	0.51	0.00	0.00	0.74	0.00	0.00	2.94	0.00	2.90	4.09	0.00	0.00	18.19	0.00	0.38	0.56	
C12	Pyiform sinus	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	8.71	4.09	6.02	0.00	0.00	0.00	0.38	0.67	
C13	Hypopharynx	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	1.47	0.00	2.90	12.28	6.02	0.00	0.00	0.00	0.00	0.38	0.73	
C14	Inaccurate locations of the lip, oral cavity and pharynx	15	0.00	0.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	1.47	8.48	2.90	20.46	6.02	0.00	18.19	0.00	0.82	1.47	
C15	Esophagus	105	0.00	0.00	0.00	0.00	0.51	0.61	0.00	0.74	3.47	8.91	13.25	40.30	46.46	61.38	96.32	91.20	72.77	50.23	5.75	10.30	
C16	Stomach	190	0.00	0.54	0.00	0.48	0.51	0.61	2.71	3.71	7.80	22.27	27.98	36.06	69.69	102.30	168.56	172.27	200.11	125.57	10.40	17.80	
C17	Small intestine	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.23	1.47	0.00	0.00	0.00	6.02	0.00	0.00	25.11	0.33	0.45	
C18	Colon	106	0.00	0.00	0.50	0.00	0.00	0.00	1.35	3.71	7.80	11.14	19.14	31.82	37.75	53.19	60.20	70.94	54.58	75.34	5.80	9.38	
C19	Rectosigmoid junction	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.48	3.47	1.11	4.42	4.24	0.00	20.46	6.02	20.27	18.19	0.00	1.15	1.78	
C20	Rectum	58	0.00	0.00	0.00	0.00	0.51	2.44	2.71	1.48	1.73	5.57	5.89	10.61	29.04	36.83	42.14	20.27	36.38	25.11	3.18	5.26	
C21	Anus and anal canal	11	0.00	0.00	0.00	0.00	0.00	0.61	0.68	0.00	5.20	0.00	1.47	0.00	2.90	0.00	0.00	0.00	0.00	25.11	0.60	0.72	
C22	Liver and intrahepatic biliary ducts	32	0.00	0.00	0.00	0.00	0.00	0.00	0.68	0.00	0.00	5.57	10.31	10.61	8.71	20.46	24.08	10.13	0.00	25.11	1.75	2.98	
C23	Gallbladder	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	0.00	0.00	0.00	4.09	6.02	0.00	0.00	0.00	0.16	0.30	
C24	Other parts of the biliary ducts	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	4.24	0.00	4.09	30.10	10.13	0.00	25.11	0.60	1.19	
C25	Pancreas	40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.48	4.33	3.34	7.36	14.85	11.61	8.18	54.18	30.40	0.00	0.00	2.19	3.61	
C26	Inaccurate locations in the gastrointestinal tract	12	0.00	0.00	0.00	0.00	0.00	0.00	0.68	0.74	0.00	1.11	2.94	2.12	2.90	4.09	12.04	10.13	0.00	0.00	0.66	0.97	
C30	Nasal cavity and middle ear	6	1.13	0.00	0.50	0.00	0.00	0.00	0.00	0.74	0.00	0.00	0.00	2.12	2.90	0.00	0.00	0.00	0.00	0.00	0.33	0.43	
C31	Paranasal sinuses	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.00	2.90	4.09	0.00	0.00	0.00	0.00	0.16	0.31	
C32	Larynx	99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.23	2.60	11.14	30.92	36.06	40.65	32.73	60.20	60.80	72.77	75.34	5.42	9.11	
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	0.00	0.00	0.00	4.09	0.00	0.00	0.00	0.00	0.11	0.17	
C34	Bronchus and lungs	232	0.00	0.00	0.00	0.00	0.51	0.00	1.35	3.71	4.33	17.82	27.98	63.63	110.34	143.21	180.60	314.15	200.11	226.02	12.70	23.21	
C38	Heart, mediastine and pleura	20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.87	0.00	4.42	0.00	2.90	16.37	18.06	40.54	18.19	50.23	1.10	2.03	
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.09	0.00	0.00	0.00	0.00	0.05	0.12	
C40	Bones and limb joints	14	0.00	0.00	1.50	1.93	0.51	1.22	1.35	0.00	0.00	0.00	0.00	0.00	2.90	0.00	0.00	10.13	0.00	0.00	0.77	0.75	
C41	Bones and joints of other locations	25	0.00	0.00	0.00	0.48	0.51	1.22	0.68	2.23	0.87	3.34	4.42	0.00	2.90	16.37	18.06	0.00	36.38	0.00	1.37	1.98	
C43	Malignant skin melanoma	27	0.00	0.00	0.00	0.00	0.00	0.61	1.35	1.48	2.60	1.11	2.94	4.24	20.33	16.37	6.02	10.13	0.00	25.11	1.48	2.41	
C44	Other malignant skin neoplasms	837	0.57	0.00	0.50	0.00	1.54	4.88	12.19	14.10	55.46	75.72	128.10	173.92	313.59	417.37	650.17	770.17	764.05	753.39	45.83	76.79	
C46	Kaposi's sarcoma	7	0.00	0.00	0.00	0.00	0.00	0.61	2.03	0.74	0.87	1.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.33	
C48	Retroperitoneum and peritoneum	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.87	2.23	2.94	2.12	2.90	12.28	0.00	10.13	0.00	0.00	0.66	1.05	
C49	Connective tissue and other soft tissues	26	0.57	0.00	0.00	0.00	1.03	1.22	1.35	0.74	1.73	2.23	4.42	6.36	8.71	0.00	0.00	30.40	36.38	0.00	1.42	1.92	
C50	Breast	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	4.24	0.00	4.09	0.00	0.00	0.00	0.00	0.27	0.36	
C60	Penis	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.97	0.00	0.00	8.83	6.36	14.52	8.18	0.00	10.13	18.19	0.00	1.20	1.89	
C61	Prostate	861	0.00	0.00	0.00	0.00	0.00	0.68	1.48	2.60	13.36	32.39	152.71	380.37	658.78	993.32	1,428.86	1,291.61	1,607.23	47.15	92.44		
C62	Testicles	25	0.00	0.00	0.00	0.97	1.54	2.44	2.03	2.23	2.60	1.11	1.47	2.12	5.81	0.00	12.04	0.00	0.00	0.00	1.37	1.52	
C63	Other male sex organs, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	2.90	0.00	0.00	0.00	0.00	25.11	0.16	0.32	
C64	Kidney	32	1.13	0.00	0.50	0.00	0.00	0.68	0.00	2.60	1.11	7.36	2.12	23.23	16.37	6.02	20.27	18.19	0.00	1.75	2.73		
C67	Bladder	83	0.00	0.00	0.00	0.48	0.00	0.61	1.35	2.23	0.00	4.45	8.83	12.73	29.04	32.73	90.30	152.01	163.73	75.34	4.54	8.19	
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.90	0.00	0.00	0.00	0.00	0.00	0.05	0.12	
C69	Eyes and appendages	8	0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	4.24	2.90	8.18	0.00	10.13	0.00	0.00	0.44	0.77	
C70	Meninges	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.02	10.13	0.00	0.00	0.11	0.22	
C71	Encephalon	77	3.39	1.61	0.00	2.42	1.54	1.22	2.71	1.48	2.60	3.34	16.20	19.09	14.52	28.64	36.12	60.80	18.19	25.11	4.22	6.18	
C72	Spinal cord and other parts of the central nervous system	5	0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	2.12	0.00	4.09	0.00	0.00	0.00	25.11	0.27	0.47	
C73	Thyroid gland	13	0.00	0.00	0.00	0.48	0.00	0.00	0.68	0.74	0.87	1.11	1.47	4.24	2.90	4.09	0.00	10.13	36.38	0.00	0.71	1.01	
C74	Adrenal gland	6	1.13	0.54	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.19	0.00	0.33	0.33	
C75	Other endocrine glands and related structures	6	0.00	0.00	0.00	0.97	0.00	0.00	0.00	0.00	0.00	1.11	0.00	2.12	2.90	0.00	0.00	10.13	0.00	0.00	0.33	0.46	
C76	Other inaccurate locations	34	0.00	0.54	0.00	1.45	0.00	0.6															

Table 22 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C96	Other malignant lymphatic tissue neoplasms and correlates	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.90	0.00	0.00	0.00	0.00	0.00	0.05	0.12
C00-96, D46	All invasive primary malignant neoplasms	3,588	22.62	11.84	10.98	17.39	15.93	28.07	48.08	69.00	142.13	258.35	450.56	797.51	1,347.27	1,968.17	2,829.45	3,627.89	3,329.09	3,515.82	196.47	335.48
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	2,751	22.05	11.84	10.48	17.39	14.39	23.18	35.89	54.90	86.66	182.63	322.46	623.58	1,033.68	1,550.80	2,179.28	2,857.72	2,565.04	2,762.43	150.64	258.69
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.00	0.00	0.00	0.00	20.27	0.00	0.00	0.16	0.27
D01	Carcinoma in situ of other organs of the gastrointestinal tract	1	0.00	0.00	0.00	0.00	0.00	0.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
D02	Carcinoma in situ of the middle ear and respiratory system	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	0.00	0.00	2.90	0.00	0.00	0.00	0.00	0.00	0.11	0.17
D04	Skin carcinoma in situ	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	2.94	0.00	5.81	4.09	0.00	0.00	0.00	0.00	0.33	0.57
D07	Carcinoma in situ of other sex organs and unspecified organs	29	0.00	0.00	0.00	0.00	0.00	0.00	0.68	0.74	0.00	0.00	1.47	4.24	20.33	12.28	42.14	40.54	0.00	0.00	1.59	2.76
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.00	0.00	0.00	6.02	0.00	0.00	0.00	0.11	0.19
C00-96, D00-09, D46	All primary malignant neoplasms	3,631	22.62	11.84	10.98	17.39	15.93	28.68	48.76	69.74	142.99	261.69	454.97	801.75	1,376.31	1,984.53	2,877.61	3,688.69	3,329.09	3,515.82	198.83	339.48

¹Includes Várzea Grande

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand women, per tumor primary site and age group

Cuiabá¹ - MT, 2000 - 2005

Table 23

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	0.00	2.10	2.63	3.69	0.00	17.88	0.00	0.00	0.32	0.53	
C01	Tongue base	2	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.81	0.11	0.12
C02	Other parts of the tongue	12	0.00	0.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.36	6.29	0.00	11.07	0.00	8.94	0.00	0.00	0.63	0.95	
C03	Gingiva	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.69	8.94	0.00	0.00	0.21	0.30	
C04	Floor of the mouth	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	
C05	Palate	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.21	0.00	0.00	2.63	0.00	5.35	0.00	0.00	0.00	15.81	0.32	0.48
C06	Other parts of the mouth	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.91	2.10	2.63	0.00	10.69	17.88	14.02	0.00	0.48	0.80	
C07	Parotid gland	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	0.00	2.10	0.00	0.00	0.00	8.94	0.00	0.00	0.16	0.22	
C09	Amygdala	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.91	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.23	
C10	Oropharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	2.10	0.00	3.69	0.00	0.00	0.00	0.00	0.00	0.16	0.24	
C11	Nasopharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.00	0.00	3.69	0.00	0.00	0.00	0.00	0.00	0.11	0.15	
C13	Hypopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.06	
C14	Inaccurate locations of the lip, oral cavity and pharynx	6	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	2.14	1.45	2.10	0.00	0.00	0.00	0.00	14.02	0.00	0.32	0.39	
C15	Esophagus	31	0.00	0.00	0.00	0.00	0.00	0.00	0.69	1.62	4.28	2.91	4.19	7.88	25.83	16.04	17.88	14.02	47.44	1.64	2.61		
C16	Stomach	113	0.00	0.00	0.51	0.47	0.00	2.26	3.12	2.74	5.67	10.69	14.54	37.73	31.54	22.14	64.16	62.59	98.15	142.31	5.98	8.88	
C17	Small intestine	10	0.00	0.00	0.00	0.47	0.00	0.00	0.00	1.37	0.81	1.07	1.45	2.10	0.00	7.38	0.00	0.00	14.02	0.00	0.53	0.69	
C18	Colon	92	0.00	0.00	0.00	0.00	0.48	0.56	1.87	5.48	3.24	8.55	8.72	18.86	28.91	36.91	58.81	71.53	84.13	94.88	4.87	7.47	
C19	Rectosigmoid junction	31	0.00	0.00	0.00	0.00	0.00	0.56	0.62	0.69	2.43	2.14	7.27	8.38	18.40	3.69	16.04	17.88	14.02	0.00	1.64	2.51	
C20	Rectum	58	0.00	0.00	0.00	0.00	0.00	0.56	1.25	1.37	7.29	7.48	11.63	8.38	10.51	14.76	58.81	35.77	28.04	0.00	3.07	4.54	
C21	Anus and anal canal	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.81	3.21	1.45	2.10	13.14	3.69	5.35	8.94	0.00	0.00	0.85	1.27	
C22	Liver and intrahepatic biliary ducts	26	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00	0.81	1.07	2.91	10.48	10.51	11.07	5.35	8.94	42.06	47.44	1.38	2.16	
C23	Gallbladder	15	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.69	0.00	1.07	1.45	0.00	2.63	14.76	10.69	8.94	0.00	15.81	0.79	1.20	
C24	Other parts of the biliary ducts	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	1.45	2.10	5.26	3.69	16.04	8.94	0.00	0.00	0.53	0.95		
C25	Pancreas	43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.24	0.00	8.72	10.48	10.51	22.14	32.08	35.77	84.13	31.63	2.27	3.71	
C26	Inaccurate locations in the gastrointestinal tract	10	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	1.07	1.45	2.10	2.63	0.00	5.35	17.88	14.02	15.81	0.53	0.80		
C30	Nasal cavity and middle ear	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.07	
C31	Paranasal sinuses	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	1.45	0.00	0.00	3.69	5.35	0.00	0.00	0.00	0.21	0.34	
C32	Larynx	22	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.69	3.24	5.34	4.36	6.29	2.63	3.69	10.69	0.00	0.00	15.81	1.16	1.58	
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.69	0.00	0.00	0.00	0.00	0.05	0.11	
C34	Bronchus and lungs	113	0.59	0.00	0.51	0.00	0.48	1.69	0.00	2.06	3.24	7.48	18.90	27.25	47.30	40.60	80.20	125.18	42.06	94.88	5.98	9.74	
C37	Thymus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.07	
C38	Heart, mediastine and pleura	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.45	4.19	0.00	3.69	0.00	0.00	14.02	15.81	0.32	0.50	
C39	Inaccurate locations in the respiratory system and intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.08	
C40	Bones and limb joints	14	0.00	0.55	1.53	1.88	0.48	0.00	0.62	0.00	1.62	0.00	0.00	0.00	0.00	3.69	5.35	0.00	0.00	0.00	0.74	0.75	
C41	Bones and joints of other locations	21	0.59	0.00	1.53	1.88	0.48	0.56	0.62	0.00	0.00	1.07	1.45	0.00	7.88	0.00	10.69	8.94	14.02	15.81	1.11	1.40	
C43	Malignant skin melanoma	29	0.00	0.00	0.00	0.00	0.48	1.13	0.62	1.37	2.43	0.00	7.27	10.48	5.26	0.00	26.73	17.88	14.02	0.00	1.53	2.17	
C44	Other malignant skin neoplasms	853	0.00	0.00	0.00	0.94	1.45	7.34	10.00	23.31	36.46	68.41	135.23	155.09	270.69	361.68	470.51	876.25	799.21	616.70	45.12	68.97	
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.04	
C46	Kaposi's sarcoma	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.69	16.04	0.00	0.00	0.00	0.21	0.43	
C48	Retroperitoneum and peritoneum	29	0.00	0.55	0.51	0.00	0.00	0.00	0.00	1.37	0.00	5.34	4.36	8.38	5.26	11.07	10.69	35.77	28.04	0.00	1.53	2.31	
C49	Connective tissue and other soft tissues	20	0.59	0.00	0.00	0.47	0.48	0.00	1.25	1.37	0.81	3.21	4.36	2.10	2.63	0.00	10.69	17.88	0.00	0.00	1.06	1.35	
C50	Breast	702	0.00	0.00	0.00	0.47	2.42	6.78	23.12	41.13	85.89	114.38	142.50	161.38	160.31	147.62	176.44	268.24	322.49	142.31	37.13	49.61	
C51	Vulva	8	0.00	0.00	0.00	0.47	0.00	0.00	0.62	0.00	0.81	1.07	0.00	0.00	0.00	3.69	10.69	0.00	14.02	0.00	0.42	0.59	
C52	Vagina	11	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	0.81	1.07	1.45	2.10	0.00	3.69	16.04	8.94	0.00	0.00	0.58	0.87	
C53	Cervix	510	0.00	0.00	0.00	0.94	2.91	7.91	23.75	41.82	55.91	68.41	79.97	117.37	128.77	140.24	144.36	160.94	84.13	63.25	26.97	35.63	
C54	Endometrium	47	0.00	0.00	0.00	0.00	0.00	0.56	1.87	0.00	0.81	5.34	7.27	10.48	10.51	33.22	37.43	17.88	0.00	63.25	2.49	3.97	
C55	Uterus, nos	37	0.00	0.00	0.00	0.00	0.97	1.69	0.00	0.69	4.05	6.41	8.72	6.29	18.40	3.69	16.04	0.00	0.00	0.00	1.96	2.74	
C56	Ovary	90	0.00	0.00	0.51	0.94	0.97	2.82	1.25	4.11	8.91	9.62	23.27	14.67	23.65	14.76	32.08	44.71	56.09	15.81	4.76	6.45	
C57	Other female sex organs, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.91	0.00	2.63	0.00	0.00	0.00	0.00	0.00	0.16	0.25	
C64	Kidney	22	1.77	0.55	0.00	0.00	0.00	0.00	0.00	1.37	0.81	1.07	7.27	2.10	2.63	7.38	5.35	17.88	14.02	15.81	1.16	1.67	
C66	Ureters	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.63	0.00	0.00	0.00	0.00	0.00	0.05	0.11	
C67	Bladder	26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.14	1.45	8.38	10.51	14.76	16.04	26.82	14.02	63.25	1.38	2.38	
C69	Eyes and appendages	4	0.59	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.00	0.00	0.00	0.00	5.26	0.00	0.00	0.00	0.00	0.00	0.21	0.32	
C70	Meninges	3	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	0.00	2.10	0.00	0.00	5.35	0.00	0.00	0.00	0.16	0.23	
C71	Encephalon	87	1.18	3.88	3.05	0.94	1.45	1.13	3.12	1.37	4.05	7.48	8.72	20.96	15.77	29.52	26.73	44.71	84.13	0.00	4.60	6.25	
C72	Spinal cord and other parts of the central nervous system	2	0.00	0.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.12	
C73	Thyroid gland	64	0.00	0.00	0.00	0.00	3.88	1.13	4.37	5.48	9.72	8.5											

Table 23 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C84	Peripheral and cutaneous T-cell lymphoma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
C85	Other types of non-Hodgkin lymphoma, nos	63	1.18	0.00	1.02	0.94	2.42	0.56	5.00	0.69	2.43	6.41	8.72	16.77	13.14	7.38	26.73	53.65	0.00	0.00	3.33	4.35
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.08
C90	Multiple myeloma and malignant plasmacyte neoplasms	32	0.00	0.00	0.00	0.00	0.56	0.00	0.69	0.00	0.00	0.00	4.36	6.29	7.88	25.83	32.08	35.77	0.00	15.81	1.69	2.72
C91	Lymphoid leukemia	47	5.89	5.54	2.55	1.88	1.45	0.00	0.62	0.69	0.81	2.14	4.36	2.10	2.63	3.69	5.35	17.88	0.00	15.81	2.49	2.91
C92	Myeloid leukemia	35	0.59	0.00	0.00	0.48	1.13	1.87	2.74	2.43	1.07	4.36	8.38	5.26	18.45	16.04	8.94	0.00	15.81	1.85	2.49	
C93	Monocytic leukemia	2	0.00	0.00	0.00	0.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.02	0.00	0.11	0.11	
C95	Unspecified cell leukemia	5	0.00	0.00	0.00	0.00	0.00	0.62	0.69	0.00	0.00	1.45	2.10	0.00	0.00	5.35	0.00	0.00	0.00	0.00	0.26	0.34
C96	Other lymphatic tissue malignant neoplasms and correlates	2	0.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.13
C00-96, D46	All invasive primary malignant neoplasms	3,578	15.32	14.42	12.22	15.97	23.74	45.74	94.37	155.61	256.05	388.04	599.08	754.51	948.73	1,147.77	1,593.33	2,181.69	2,005.05	1707.78	189.24	269.78
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	2,725	15.32	14.42	12.22	15.03	22.29	38.40	84.37	132.31	219.58	319.63	463.85	599.42	678.04	786.09	1,122.81	1,305.44	1,205.83	1,091.08	144.13	200.81
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.69	0.00	0.00	0.00	0.00	0.05	0.11
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.04
D03	Melanoma in situ	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.15
D04	Skin carcinoma in situ	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.37	0.81	0.00	0.00	0.00	0.00	0.00	5.35	17.88	14.02	0.00	0.37	0.49
D05	Breast carcinoma in situ	24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.37	3.24	10.69	5.82	2.10	2.63	0.00	5.35	8.94	0.00	0.00	1.27	1.59
D06	Cervical carcinoma in situ	503	0.00	0.00	0.51	2.35	15.99	45.74	45.00	52.10	52.67	50.24	42.17	69.16	39.42	59.05	48.12	26.82	70.11	15.81	26.60	27.08
D07	Carcinoma in situ of other sex organs and unspecified organs	12	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.69	3.24	2.14	1.45	6.29	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.73
D09	Carcinoma in situ of other locations and unspecified locations	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	28.04	0.00	0.16	0.22
C00-96, D00-09, D46	All primary malignant neoplasms	4,131	15.32	14.42	12.73	18.31	40.22	91.48	139.37	211.83	316.01	451.11	651.43	834.15	990.78	1,210.51	1,652.14	2,235.34	2,117.22	1,723.59	218.49	300.19

¹Includes Várzea Grande

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Cuiabá¹ - MT, 2000 - 2005

Male

Table 24

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	154	13.03	91.6	4.5	26.0
C15 Esophagus	105	10.30	76.2	15.2	46.7
C16 Stomach	190	17.80	75.8	16.8	44.2
C18-21 Large intestine, anal canal and anus	196	17.15	88.3	6.6	26.0
C22 Liver	32	2.98	56.3	46.9	103.1
C25 Pancreas	40	3.61	45.0	42.5	75.0
C32 Larynx	99	9.11	90.9	5.1	29.3
C33-34 Trachea, bronchus and lungs	234	23.39	59.8	33.3	66.7
C43 Skin melanoma	27	76.79	100.0	0.0	11.1
C61 Prostate	861	92.44	85.8	8.1	15.3
C70-72 Central Nervous System	84	6.86	51.2	36.9	59.5
C73 Thyroid	13	1.01	100.0	0.0	7.7
C91-95 Leukemia	104	7.43	55.8	21.2	42.3
C81-85, C96 Lymphoma	105	7.32	82.9	5.7	30.5
C00-96, D46 All primary invasive malignant Neoplasms	3,588	335.48	83.4	10.7	25.3
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	2,751	258.69	79.0	13.9	32.7

¹Includes Várzea Grande

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade- SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 25

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	46	3.69	89.1	2.2	15.2
C15 Esophagus	31	2.61	80.7	9.7	25.8
C16 Stomach	113	8.88	77.0	15.9	46.9
C18-21 Large intestine, anal canal and anus	197	15.80	84.3	6.6	24.4
C22 Liver	26	2.16	23.1	73.1	92.3
C25 Pancreas	43	3.71	32.6	46.5	83.7
C32 Larynx	22	1.58	86.4	13.6	13.6
C33-34 Trachea, bronchus and lungs	114	9.85	62.3	26.3	60.5
C43 Skin melanoma	29	68.97	100.0	0.0	31.0
C50 Breast	702	49.61	90.9	4.0	14.7
C53 Cervix	510	35.63	90.8	3.9	11.8
C70-72 Central Nervous System	92	6.60	52.2	34.8	55.4
C73 Thyroid	64	3.85	81.3	4.7	7.8
C91-95 Leukemia	89	5.86	51.7	22.5	46.1
C81-85, C96 Lymphoma	86	5.81	77.9	8.1	20.9
C00-96, D46 All primary invasive malignant Neoplasms	3,579	269.78	84.5	8.7	20.7
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	2,726	200.81	80.3	11.4	26.9

¹Includes Várzea Grande

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade - SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Cuiabá¹ - MT, 2000 - 2005

Male




Figure 19

Female




Figure 20

¹Inclui Várzea Grande
 *World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Cuiabá¹ - MT, 2000 - 2005

Table 26

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	37	65.71	69.74	44	57.13	61.66	26	47.58	50.47	31	40.82	44.40
Ia. Lymphoid leukemia	26	46.17	49.25	30	38.96	42.51	25	45.75	48.10	29	38.19	41.50
Ib. Acute myeloid leukemia	4	7.10	7.86	5	6.49	7.18	1	1.83	2.37	2	2.63	2.90
Ic. Myeloproliferative chronic diseases	1	1.78	1.45	1	1.30	1.12	0	0.00	0.00	0	0.00	0.00
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	1.78	1.45	1	1.30	1.12	0	0.00	0.00	0	0.00	0.00
Ie. Specified leukemias and other unspecified leukemias	5	8.88	9.74	7	9.09	9.72	0	0.00	0.00	0	0.00	0.00
II. Reticuloendothelial lymphomas and neoplasms	15	26.64	26.85	24	31.16	30.59	6	10.98	12.11	11	14.48	14.67
Ila. Hodgkin's lymphoma	5	8.88	8.55	9	11.69	10.98	1	1.83	2.26	4	5.27	4.92
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	8	14.21	14.37	13	16.88	16.57	4	7.32	7.47	6	7.90	7.91
Ilc. Burkitt's lymphoma	1	1.78	2.18	1	1.30	1.69	0	0.00	0.00	0	0.00	0.00
Ild. Miscellany of lymphoreticular neoplasms	0	0.00	0.00	0	0.00	0.00	1	1.83	2.37	1	1.32	1.84
Ile. Unspecified lymphoma	1	1.78	1.74	1	1.30	1.34	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	9	15.98	18.32	12	15.58	17.46	17	31.11	29.17	19	25.02	24.72
Illa. Ependymoma and choroid plexus tumor	1	1.78	1.74	2	2.60	2.43	0	0.00	0.00	0	0.00	0.00
IIlb. Astrocytoma	4	7.10	7.84	5	6.49	7.16	4	7.32	6.53	6	7.90	7.18
IIlc. Intracranial and intraspinal embryonic tumors	1	1.78	2.18	2	2.60	2.78	3	5.49	5.21	3	3.95	4.04
IIld. Other gliomas	0	0.00	0.00	0	0.00	0.00	2	3.66	4.05	2	2.63	3.14
IIle. Other intracranial and intraspinal neoplasms	0	0.00	0.00	0	0.00	0.00	1	1.83	1.79	1	1.32	1.39
IIIf. Unspecified intracranial and intraspinal tumors	3	5.33	6.55	3	3.90	5.08	7	12.81	11.59	7	9.22	8.98
IV. Neuroblastoma and other peripheral nervous cell tumor	5	8.88	9.76	5	6.49	7.56	5	9.15	9.10	5	6.58	7.05
Iva. Neuroblastoma and ganglioneuroblastoma	5	8.88	9.76	5	6.49	7.56	5	9.15	9.10	5	6.58	7.05
V. Retinoblastoma	1	1.78	2.18	1	1.30	1.69	1	1.83	2.26	1	1.32	1.75
VI. Renal tumors	3	5.33	5.82	3	3.90	4.51	4	7.32	8.68	4	5.27	6.73
Via. Nephroblastoma and other renal non-epithelial tumors	3	5.33	5.82	3	3.90	4.51	3	5.49	6.42	3	3.95	4.98
Vib. Renal carcinomas	0	0.00	0.00	0	0.00	0.00	1	1.83	2.26	1	1.32	1.75
VIII. Malignant bone tumors	3	5.33	4.35	8	10.39	8.80	7	12.81	10.66	15	19.75	16.71
VIIIa. Osteosarcoma	2	3.55	2.90	6	7.79	6.59	5	9.15	7.70	9	11.85	10.19
VIIIb. Chondrosarcoma	1	1.78	1.45	1	1.30	1.12	1	1.83	1.48	2	2.63	2.20
VIIIc. Ewing's sarcoma and related bone sarcomas	0	0.00	0.00	1	1.30	1.09	1	1.83	1.48	1	1.32	1.15
VIIIe. Unspecified malignant bone tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	3	3.95	3.17
IX. Soft-tissue and other extraosseous sarcomas	2	3.55	3.63	4	5.19	4.99	4	7.32	8.57	7	9.22	9.81
IXa. Rhabdomyosarcoma	1	1.78	2.18	3	3.90	3.87	1	1.83	2.26	2	2.63	2.81
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	1	1.78	1.45	1	1.30	1.12	1	1.83	2.26	1	1.32	1.75
IXd. Other unspecified soft-tissue sarcomas	0	0.00	0.00	0	0.00	0.00	1	1.83	1.79	2	2.63	2.44
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	0	0.00	0.00	1	1.83	2.26	2	2.63	2.81
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	0	0.00	0.00	5	6.49	5.43	2	3.66	3.27	4	5.27	4.64
Xa. Intracranial and intraspinal germ cell tumors	0	0.00	0.00	2	2.60	2.17	1	1.83	1.79	1	1.32	1.39
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	1	1.30	1.09	0	0.00	0.00	0	0.00	0.00
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	2	2.60	2.17	1	1.83	1.48	2	2.63	2.20
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	1.32	1.06
XI. Other malignant epithelial neoplasms and melanomas	5	8.88	9.00	7	9.09	9.15	3	5.49	4.43	14	18.44	15.06
XIb. Thyroid carcinoma	0	0.00	0.00	1	1.30	1.09	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	1	1.78	2.18	1	1.30	1.69	0	0.00	0.00	2	2.63	2.11
XIf. Other carcinomas and unspecified carcinomas	4	7.10	6.82	5	6.49	6.37	3	5.49	4.43	12	15.80	12.95
XII. Other malignant and unspecified neoplasms	4	7.10	7.86	6	7.79	8.27	2	3.66	4.05	5	6.58	6.31
XIIb. Other unspecified malignant tumors	4	7.10	7.86	6	7.79	8.27	2	3.66	4.05	5	6.58	6.31
All neoplasms	84	149.18	157.51	119	154.52	160.11	77	140.90	142.76	116	152.75	151.85

¹Includes Várzea Grande

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Curitiba - PR, 2001 - 2005




Figure 21. Distribution of the population* in Curitiba

*Demographic Census of 2000 – IBGE
Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Curitiba

Coordinator

Cyntia Asturian Laporte

Registrars/Data Collectors

Cintia da Costa Marques
Kenia Maria Brero Del Pino
Maria Rita Ostrovski Martins
Teresinha Ascari Brandini
Vivian de Fátima Blanchet

Data Entry Clerk

Edir Walewski

Advisory Committee

Fabio Antonio
Karin Luhn

Infrastructure and Data Source

This PBCR was created in 1997, whereas the data collection started in 1998. It is located in the Municipal Health Secretariat, at the Epidemiology Center, and financially supported by both the Curitiba Municipal Health Fund and the National Health Fund/MS, as per Ordinance No. 2,449, of 2007.




Figure 22. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 27 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C73	Thyroid gland	56	0.00	0.00	0.28	0.25	0.24	0.81	0.87	1.87	2.54	3.44	3.29	4.62	3.94	5.34	5.50	6.26	6.45	0.00	1.39	1.53
C74	Adrenal gland	15	1.73	0.57	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.00	1.65	0.00	0.99	0.00	0.00	0.00	6.45	9.68	0.37	0.49
C75	Other endocrine glands and related structures	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.77	1.97	0.00	0.00	0.00	0.00	9.68	0.10	0.16
C76	Other inaccurate locations	30	0.29	0.00	0.00	0.00	0.00	0.27	0.29	0.31	0.00	2.15	1.65	0.77	2.96	2.67	14.66	6.26	0.00	19.35	0.75	0.99
C80	Unknown primary site	310	0.29	0.28	0.28	0.00	0.48	0.54	1.73	1.87	2.54	6.88	18.66	30.80	34.50	54.75	84.28	112.73	103.22	193.54	7.71	10.43
C81	Hodgkin's disease	84	0.29	1.70	1.10	3.98	2.18	3.79	1.73	0.62	2.54	1.29	2.19	3.08	2.96	2.67	1.83	0.00	6.45	9.68	2.09	2.06
C82	Non-Hodgkin follicular lymphoma	23	0.00	0.00	0.00	0.25	0.00	0.27	0.29	0.00	0.36	0.43	1.65	1.54	3.94	2.67	3.66	3.13	19.35	0.00	0.57	0.69
C83	Non-Hodgkin diffuse lymphoma	121	0.00	1.14	1.38	0.50	0.48	1.35	3.75	4.05	2.54	2.58	7.13	6.16	5.91	20.03	20.15	21.92	6.45	29.03	3.01	3.44
C84	Peripheral and cutaneous T-cell lymphoma	14	0.00	0.00	0.28	0.00	0.00	0.27	0.29	0.00	1.09	0.43	1.10	0.77	0.00	2.67	3.66	0.00	0.00	0.35	0.39	0.39
C85	Other types of non-Hodgkin lymphoma, nos	113	0.00	0.00	0.55	0.50	0.48	1.08	2.02	3.12	2.18	2.58	9.88	2.31	6.90	14.69	23.82	37.58	45.16	29.03	2.81	3.34
C88	Malignant immunoproliferative diseases	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.43	0.00	0.00	1.97	0.00	0.00	0.00	0.00	0.00	0.07	0.10
C90	Multiple myeloma and malignant plasmacyte neoplasms	95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	1.09	3.01	5.49	9.24	16.76	21.37	23.82	21.92	45.16	19.35	2.36	3.24
C91	Lymphoid leukemia	112	4.62	5.11	2.20	2.24	1.45	1.08	0.58	0.31	1.45	0.43	3.29	4.62	7.89	10.68	12.83	9.39	19.35	19.35	2.78	3.36
C92	Myeloid leukemia	126	2.31	1.70	0.83	1.99	2.90	1.08	0.29	1.56	1.81	3.87	2.74	9.24	5.91	16.02	25.65	31.31	32.26	9.68	3.13	3.73
C93	Monocytic leukemia Leucemia monocitica	1	0.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C95	Unspecified cell leukemia	17	0.00	0.00	0.00	0.25	0.48	0.00	0.29	0.31	0.00	0.86	0.55	0.00	0.99	2.67	3.66	3.13	6.45	19.35	0.42	0.54
C96	Other malignant lymphatic tissue neoplasms and correlates	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	0.00	0.00	0.00	0.00	0.05	0.04
D46	Myelodysplastic syndromes	5	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.00	0.00	0.00	0.99	2.67	0.00	0.00	6.45	0.00	0.12	0.17
C00-96, D46	All invasive primary malignant neoplasms	9,465	15.29	15.05	10.47	20.65	24.68	36.31	46.48	62.93	129.13	227.87	459.80	756.13	1,168.02	1,793.34	2,248.12	3,356.71	3,896.52	4,693.25	235.31	314.24
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	8,116	15.00	15.05	10.47	20.40	24.68	34.14	41.28	53.27	110.63	194.33	388.47	654.49	989.61	1,565.00	1,949.47	2,768.04	3,335.27	3,686.86	201.77	268.68
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.86	0.00	0.77	0.99	2.67	0.00	3.13	0.00	9.68	0.20	0.28
D01	Carcinoma in situ of other organs of the gastrointestinal tract	10	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.00	0.00	0.77	1.97	2.67	5.50	0.00	6.45	0.00	0.25	0.35
D02	Carcinoma in situ of the middle ear and respiratory system	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.43	0.00	0.77	0.00	0.00	1.83	0.00	0.00	0.00	0.07	0.09
D03	Melanoma in situ	19	0.00	0.00	0.28	0.00	0.24	0.00	0.29	0.31	0.36	1.29	0.55	0.00	3.94	1.34	3.66	6.26	6.45	0.00	0.47	0.57
D04	Skin carcinoma in situ	43	0.00	0.00	0.00	0.00	0.00	0.00	0.62	1.45	1.72	0.55	4.62	1.97	6.68	9.16	21.92	32.26	19.35	1.07	1.38	1.38
D05	Breast carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	0.00	0.00	0.02	0.04
D07	Carcinoma in situ of other sex organs and unspecified organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	0.00	0.00	0.02	0.04
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.43	0.00	0.00	0.99	0.00	0.00	0.00	0.00	0.00	0.05	0.07
C00-96, D00-09, D46	All primary malignant neoplasms	9,552	15.29	15.05	10.74	20.65	24.92	36.58	46.77	63.86	130.94	232.60	460.90	763.06	1,179.85	1,806.70	2,268.27	3,388.03	3,941.68	4,722.28	237.47	317.06

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Curitiba - PR, 2001 - 2005

Table 28

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	14	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.27	0.00	0.00	0.95	0.64	0.79	0.96	4.96	0.00	9.74	0.00	0.32	0.32
C01	Tongue base	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.00	1.58	0.96	1.24	3.77	0.00	0.00	0.16	0.18
C02	Other parts of the tongue	23	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.31	0.74	0.95	0.64	1.58	4.80	3.72	7.54	3.25	4.48	0.53	0.55
C03	Gingiva	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.00	0.00	0.96	1.24	1.89	3.25	4.48	0.14	0.13
C04	Floor of the mouth	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.37	0.47	1.92	0.79	0.96	0.00	0.00	0.00	0.00	0.18	0.20
C05	Palate	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.64	1.58	1.92	0.00	7.54	0.00	8.96	0.27	0.28
C06	Other parts of the mouth	14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.79	4.80	2.48	3.77	3.25	8.96	0.32	0.34
C07	Parotid gland	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.47	0.64	0.79	0.96	1.24	1.89	3.25	4.48	0.23	0.23
C08	Other larger salivary glands	6	0.00	0.00	0.00	0.00	0.23	0.26	0.00	0.00	0.31	0.00	0.47	0.00	0.00	0.00	0.00	1.89	0.00	4.48	0.14	0.12
C09	Amygdala	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.37	0.00	0.00	2.37	0.00	0.00	0.00	3.25	0.00	0.14	0.15
C10	Oropharynx	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.64	0.79	2.88	1.24	5.66	3.25	4.48	0.27	0.28
C11	Nasopharynx	16	0.00	0.00	0.28	0.73	0.00	0.00	0.00	0.27	0.31	0.00	1.42	0.00	0.00	2.88	1.24	1.89	3.25	4.48	0.37	0.37
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C13	Hypopharynx	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.74	0.00	0.64	1.58	0.00	1.24	0.00	0.00	4.48	0.18	0.20
C14	Inaccurate locations of the lip, oral cavity and pharynx	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.64	0.00	0.00	0.00	5.66	0.00	0.00	0.11	0.10
C15	Esophagus	99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.74	4.26	6.40	10.27	14.39	19.82	35.83	35.70	4.48	2.27	2.37
C16	Stomach	370	0.00	0.00	0.00	0.00	0.70	1.53	3.76	4.11	4.05	9.19	12.78	19.85	30.01	44.14	55.75	86.74	103.86	129.98	8.47	8.55
C17	Small intestine	19	0.00	0.00	0.00	0.00	0.00	0.51	0.00	0.27	0.31	0.74	1.42	0.00	0.00	3.84	1.24	7.54	0.00	4.48	0.43	0.43
C18	Colon	492	0.00	0.00	0.00	0.00	0.23	1.02	2.95	3.56	7.79	12.13	19.40	26.25	40.28	57.58	73.09	120.68	136.31	201.69	11.26	11.40
C19	Rectosigmoid junction	122	0.00	0.00	0.00	0.00	0.00	0.26	0.54	1.92	2.81	4.78	5.21	12.17	8.69	14.39	14.87	11.31	22.72	35.86	2.79	2.85
C20	Rectum	209	0.00	0.00	0.00	0.00	0.23	1.53	0.54	1.10	3.74	5.51	9.94	13.45	25.27	20.15	23.54	56.57	51.93	40.34	4.78	4.94
C21	Anus and anal canal	43	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.74	5.21	2.56	4.74	7.68	9.91	0.00	6.49	4.48	0.98	1.10
C22	Liver and intrahepatic biliary ducts	102	0.60	0.30	0.00	0.00	0.47	0.77	0.54	0.27	0.31	0.74	0.47	7.04	11.06	9.60	18.58	24.51	38.95	49.30	2.33	2.41
C23	Gallbladder	68	0.00	0.00	0.00	0.00	0.23	0.00	0.00	0.27	0.31	0.37	2.37	6.40	5.53	13.43	12.39	9.43	22.72	26.89	1.56	1.66
C24	Other parts of the biliary ducts	62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	1.47	1.89	2.56	5.53	10.56	11.15	7.54	19.47	53.79	1.42	1.51
C25	Pancreas	211	0.00	0.00	0.00	0.00	0.23	0.00	0.00	0.00	2.49	3.68	5.21	9.60	27.64	31.67	34.69	69.77	68.16	49.30	4.83	5.07
C26	Inaccurate locations in the gastrointestinal tract	25	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.00	0.47	0.64	3.16	0.96	6.19	9.43	6.49	22.41	0.57	0.58
C30	Nasal cavity and middle ear	6	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.00	0.31	0.00	0.00	0.64	0.79	0.96	0.00	1.89	0.00	0.00	0.14	0.14
C31	Paranasal sinuses	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.31	0.00	0.47	0.00	0.00	0.96	2.48	0.00	0.00	0.00	0.14	0.14
C32	Larynx	44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	1.10	1.42	5.76	7.90	8.64	3.72	5.66	3.25	8.96	1.01	1.15
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	1.24	0.00	0.00	0.00	0.05	0.06
C34	Bronchus and lungs	448	0.00	0.00	0.00	0.00	0.23	0.26	0.27	3.01	4.05	7.35	15.15	34.58	54.49	68.13	95.39	88.63	90.88	98.61	10.25	11.03
C37	Thymus	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	1.28	0.79	0.00	0.00	1.89	0.00	0.00	0.11	0.13
C38	Heart, mediastine and pleura	23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.95	1.92	3.95	4.80	3.72	3.77	0.00	4.48	0.53	0.58
C40	Bones and limb joints	19	0.00	0.00	0.84	0.73	0.47	0.77	0.00	0.55	0.00	0.37	1.42	0.00	0.00	0.00	1.24	0.00	0.00	4.48	0.43	0.41
C41	Bones and joints of other locations	27	0.00	0.30	0.28	0.73	1.17	0.26	0.54	0.27	0.31	1.10	0.00	1.28	0.00	0.96	2.48	1.89	3.25	8.96	0.62	0.58
C43	Malignant skin melanoma	210	0.00	0.00	0.00	0.00	0.70	1.28	3.22	3.56	5.92	8.82	11.83	18.57	13.43	13.43	17.34	35.83	29.21	31.37	4.81	4.73
C44	Other malignant skin neoplasms	1,348	0.60	0.00	0.28	0.73	0.47	2.04	4.83	9.04	20.89	31.62	46.86	72.35	88.45	148.74	194.50	375.25	464.12	649.90	30.85	30.80
C45	Mesothelioma	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.00	0.47	0.00	0.00	0.00	0.00	1.89	0.00	0.00	0.07	0.06
C46	Kaposi's sarcoma	5	0.00	0.00	0.00	0.00	0.00	0.00	0.54	0.00	0.31	0.00	0.47	0.00	0.00	0.00	0.00	0.00	0.00	4.48	0.11	0.10
C48	Retropertoneum and peritoneum	21	0.30	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.62	0.37	1.42	1.28	2.37	0.96	3.72	5.66	0.00	4.48	0.48	0.51
C49	Connective tissue and other soft tissues	53	0.90	0.59	1.12	0.24	0.23	0.77	1.61	0.55	0.94	0.74	0.00	2.56	3.95	4.80	6.19	7.54	6.49	4.48	1.21	1.26
C50	Breast	2,882	0.00	0.00	0.00	0.24	2.34	7.41	24.69	49.02	79.19	148.52	188.37	223.47	232.96	255.26	284.94	324.34	370.00	389.94	65.96	66.96
C51	Vulva	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.62	1.84	2.37	0.64	1.58	1.92	9.91	5.66	6.49	31.37	0.87	0.87
C52	Vagina	11	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.27	0.00	0.00	0.37	0.00	2.37	0.96	1.24	1.89	3.25	4.48	0.25	0.26
C53	Cervix	683	0.00	0.00	0.00	0.00	1.88	6.90	9.66	16.70	18.40	24.63	39.76	48.02	60.81	61.42	74.33	67.88	58.42	49.30	15.63	15.75
C54	Endometrium	313	0.00	0.00	0.00	0.00	0.23	0.00	1.07	1.64	2.81	6.25	14.67	26.25	35.54	46.06	64.42	62.23	58.42	35.86	7.16	7.69
C55	Uterus, nos	62	0.00	0.00	0.00	0.00	0.00	0.00	0.54	0.27	0.31	1.84	2.84	5.76	6.32	5.76	11.15	5.66	22.72	22.41	1.42	1.48
C56	Ovary	352	0.00	0.00	0.28	0.73	0.47	2.30	3.22	4.11	9.04	11.76	19.88	28.81	26.85	37.42	49.56	47.14	51.93	31.37	8.06	8.22
C57	Other female sex organs, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.64	0.00	0.00	0.00	0.00	3.25	0.00	0.07	0.07
C58	Placenta	2	0.00	0.00	0.00	0.00	0.00	0.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.04
C64	Kidney	115	0.90	0.00	0.00	0.24	0.00	0.26	0.27	1.37	2.81	2.21	7.10	8.96	14.21	15.35	9.91	20.74	16.23	8.96	2.63	2.82
C67	Bladder	124	0.00	0.00	0.00	0.24	0.00	0.26	0.00	0.27	1.56	1.84	2.37	8.96	6.32	18.23	21.06	43.37	45.44	49.30	2.84	2.87
C68	Other organs of the urinary system, nos	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	1.89	0.00	0.00	0.05	0.04
C69	Eyes and appendages	22	0.60	0.30	0.28	0.24	0.23	0.00	0.27	0.00	0.31	0.37	0.95	1.92	0.79	1.92	3.72	1.89	3.25	0.00	0.50	0.55
C70	Meninges	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
C71	Encephalon	211	1.81	3.25	1.40	2.20	0.47	2.55	1.34	3.56	4.05	5.51	9.									

Table 28 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C85	Other types of non-Hodgkin lymphoma, nos	106	0.00	0.00	0.28	0.24	0.47	1.28	0.81	1.64	1.25	4.04	1.42	7.04	7.90	10.56	14.87	15.09	25.96	44.82	2.43	2.44
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
C90	Multiple myeloma and malignant plasmacyte neoplasms	94	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	1.56	2.21	2.37	10.24	9.48	10.56	23.54	18.86	16.23	17.93	2.15	2.30
C91	Lymphoid leukemia	101	6.02	3.25	1.69	0.73	0.47	0.26	0.81	0.82	0.62	0.74	0.95	3.20	3.95	6.72	9.91	20.74	16.23	22.41	2.31	2.64
C92	Myeloid leukemia	102	0.00	0.00	0.28	0.98	0.70	1.02	1.61	0.82	1.56	2.94	3.31	5.76	7.90	9.60	12.39	18.86	25.96	17.93	2.33	2.32
C93	Monocytic leukemia	1	0.00	0.00	0.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C94	Other specified-type cell leukemias	1	0.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.04
C95	Unspecified cell leukemia	20	0.30	0.00	0.28	0.00	0.00	0.00	0.27	0.27	0.31	0.37	0.00	0.00	0.79	0.96	3.72	5.66	6.49	17.93	0.46	0.45
C96	Other lymphatic tissue malignant neoplasms and correlates	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.96	0.00	0.00	0.00	0.00	0.05	0.06
D46	Myelodysplastic syndromes	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.89	0.00	8.96	0.07	0.06
C00-96, D46/ C44	All invasive primary malignant neoplasms	10,322	14.45	9.47	10.67	13.68	22.74	45.22	79.70	124.87	204.53	338.59	483.23	684.49	852.10	1,089.16	1,349.14	1,827.23	2,022.01	2,438.26	236.24	241.03
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	8,974	13.85	9.47	10.39	12.94	22.28	43.18	74.87	115.83	183.64	306.97	436.38	612.13	763.65	940.42	1,154.64	1,451.98	1,557.89	1,788.36	205.39	210.23
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.96	0.00	0.00	3.25	4.48	0.09	0.09
D01	Carcinoma in situ of other organs of the gastrointestinal tract	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.79	1.92	0.00	0.00	3.25	0.00	0.11	0.13
D03	Melanoma in situ	33	0.00	0.00	0.00	0.00	0.00	0.26	0.54	0.27	0.31	1.47	1.42	1.28	0.79	6.72	4.96	5.66	9.74	4.48	0.76	0.76
D04	Skin carcinoma in situ	77	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.82	0.31	1.84	3.31	4.48	2.37	11.52	14.87	28.29	16.23	26.89	1.76	1.78
D05	Breast carcinoma in situ	165	0.00	0.00	0.00	0.00	0.00	0.51	0.54	3.29	6.55	13.97	11.83	12.81	15.79	9.60	9.91	7.54	6.49	4.48	3.78	3.85
D06	Cervical carcinoma in situ	1,175	0.00	0.00	0.00	8.06	28.84	59.78	59.04	49.84	42.09	33.45	14.67	22.41	23.69	23.03	14.87	22.63	6.49	35.86	26.89	22.88
D07	Carcinoma in situ of other sex organs and unspecified organs	35	0.00	0.00	0.00	0.00	0.47	0.51	0.81	1.10	0.94	1.10	2.84	1.92	3.16	1.92	0.00	3.77	0.00	4.48	0.80	0.78
D09	Carcinoma in situ of other locations and unspecified locations	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.00	0.79	0.00	1.24	0.00	0.00	4.48	0.09	0.10
C00-96, D00-09, D46	All primary malignant neoplasms	11,820	14.45	9.47	10.67	21.73	52.05	106.28	140.89	180.19	255.04	390.43	517.31	728.67	899.48	1,144.81	1,394.98	1,895.12	2,067.44	2,523.42	270.53	271.40

*World Standard Population, modified by Doll et al. (1966)
Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Curitiba - PR, 2001 - 2005

Male

Table 29

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	427	13.48	90.4	8.0	5 6.9
C15 Esophagus	353	11.78	70.3	26.1	85.8
C16 Stomach	642	21.59	67.1	28.5	74.0
C18-21 Large intestine, anal canal and anus	804	27.05	75.5	19.8	54.1
C22 Liver	151	4.93	45.7	45.7	96.0
C25 Pancreas	194	6.45	39.7	47.4	104.6
C32 Larynx	263	8.91	82.9	11.0	55.9
C33-34 Trachea, bronchus and lungs	756	26.32	59.0	36.2	93.5
C43 Skin melanoma	189	45.56	88.4	9.5	41.3
C61 Prostate	1,758	63.42	80.6	16.6	29.9
C70-72 Central Nervous System	256	7.46	55.5	41.4	91.4
C73 Thyroid	56	1.53	91.1	3.6	12.5
C91-95 Leukemia	256	7.66	77.0	23.4	64.1
C81-85, C96 Lymphoma	357	9.97	83.2	15.4	43.1
C00-96, D46 All primary invasive malignant Neoplasms	9,465	314.24	77.1	19.6	50.3
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	8,116	268.68	73.5	22.7	58.3

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 30

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	102	2.44	83.3	12.7	45.1
C15 Esophagus	99	2.37	65.7	30.3	77.8
C16 Stomach	370	8.55	70.3	26.0	66.8
C18-21 Large intestine, anal canal and anus	866	20.30	74.0	22.9	51.4
C22 Liver	102	2.41	43.1	55.9	98.0
C25 Pancreas	211	5.07	36.5	50.2	100.0
C32 Larynx	44	1.15	77.3	18.2	59.1
C33-34 Trachea, bronchus and lungs	450	11.08	62.7	32.0	92.9
C43 Skin melanoma	210	30.80	90.0	10.5	29.5
C50 Breast	2,882	66.96	89.3	9.8	25.9
C53 Cervix	683	15.75	87.9	10.7	37.9
C70-72 Central Nervous System	217	5.24	49.3	47.9	94.0
C73 Thyroid	327	6.90	93.3	2.1	8.0
C91-95 Leukemia	225	5.47	67.1	34.7	72.9
C81-85, C96 Lymphoma	332	7.63	85.8	14.8	44.9
C00-96, D46 All primary invasive malignant Neoplasms	10,323	241.03	81.0	16.7	41.4
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	8,975	210.23	78.5	19.1	47.3

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Curitiba - PR, 2001 - 2005

Male




Figure 23

Female




Figure 24

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Curitiba - PR, 2001 - 2005

Table 31

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I.Leukemia	60	56.51	58.61	78	53.29	55.50	42	40.93	43.45	49	34.13	37.52
Ia.Lymphoid leukemia	42	39.56	40.66	51	34.85	36.55	37	36.06	38.68	40	27.86	31.62
Ib.Acute myeloid leukemia	17	16.01	17.04	24	16.40	17.13	3	2.92	2.79	7	4.88	4.36
Ic.Myeloproliferative chronic diseases	1	0.94	0.92	2	1.37	1.27	0	0.00	0.00	0	0.00	0.00
Ie.Specified leukemias and other unspecified leukemias	0	0.00	0.00	1	0.68	0.56	2	1.95	1.98	2	1.39	1.53
II.Reticuloendothelial lymphomas and neoplasms	23	21.66	19.87	44	30.06	27.16	14	13.64	12.32	29	20.20	17.79
Ila.Hodgkin's lymphoma	11	10.36	9.81	27	18.45	16.56	5	4.87	4.08	16	11.14	9.20
Ilb.Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	6	5.65	4.80	10	6.83	5.96	7	6.82	6.47	10	6.97	6.66
Ilc.Burkitt's lymphoma	6	5.65	5.26	6	4.10	4.08	2	1.95	1.77	2	1.39	1.37
Ile.Unspecified lymphoma	0	0.00	0.00	1	0.68	0.56	0	0.00	0.00	1	0.70	0.55
III.CNS and misc. of intracranial and intraspinal neoplasms	27	25.43	25.48	34	23.23	23.66	22	21.44	21.56	30	20.90	21.11
IIIa.Ependymoma and choroid plexus tumor	3	2.83	3.02	3	2.05	2.34	1	0.97	1.16	1	0.70	0.90
IIIb.Astrocytoma	4	3.77	3.74	9	6.15	5.70	9	8.77	8.95	12	8.36	8.59
IIIc.Intracranial and intraspinal embryonic tumors	10	9.42	9.12	11	7.52	7.63	8	7.80	7.77	9	6.27	6.57
IIId.Other gliomas	4	3.77	4.25	5	3.42	3.85	4	3.90	3.68	4	2.79	2.85
IIIe.Unspecified intracranial and intraspinal tumors	6	5.65	5.34	6	4.10	4.14	0	0.00	0.00	4	2.79	2.20
IV.Neuroblastoma and other peripheral nervous cell tumor	7	6.59	7.42	7	4.78	5.75	5	4.87	5.85	5	3.48	4.53
IVa.Neuroblastoma and ganglioneuroblastoma	7	6.59	7.42	7	4.78	5.75	5	4.87	5.85	5	3.48	4.53
V.Retinoblastoma	1	0.94	1.11	1	0.68	0.86	3	2.92	3.28	3	2.09	2.54
VI.Renal tumors	2	1.88	2.22	2	1.37	1.72	3	2.92	3.51	4	2.79	3.27
VIa.Nephroblastoma and other renal non-epithelial tumors	2	1.88	2.22	2	1.37	1.72	2	1.95	2.32	2	1.39	1.80
VIb.Renal carcinomas	0	0.00	0.00	0	0.00	0.00	1	0.97	1.18	2	1.39	1.47
VII.Hepatic tumors	0	0.00	0.00	0	0.00	0.00	3	2.92	3.28	3	2.09	2.54
VIIa.Hepatoblastoma	0	0.00	0.00	0	0.00	0.00	2	1.95	2.12	2	1.39	1.64
VIIc.Unspecified malignant hepatic tumors	0	0.00	0.00	0	0.00	0.00	1	0.97	1.16	1	0.70	0.90
VIII.Malignant bone tumors	5	4.71	4.69	17	11.62	10.35	5	4.87	4.22	10	6.97	6.02
VIIIa.Osteosarcoma	3	2.83	2.98	13	8.88	7.90	1	0.97	0.82	3	2.09	1.73
VIIIc.Ewing's sarcoma and related bone sarcomas	2	1.88	1.72	3	2.05	1.89	4	3.90	3.40	7	4.88	4.28
VIIIe.Unspecified malignant bone tumors	0	0.00	0.00	1	0.68	0.56	0	0.00	0.00	0	0.00	0.00
IX.Soft-tissue and other extraosseous sarcomas	6	5.65	6.04	9	6.15	6.36	9	8.77	7.96	13	9.06	8.37
IXa.Rhabdomyosarcoma	2	1.88	2.22	3	2.05	2.28	6	5.85	5.52	7	4.88	4.82
IXb.Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	3	2.83	2.71	4	2.73	2.66	1	0.97	0.82	1	0.70	0.63
IXd.Other unspecified soft-tissue sarcomas	1	0.94	1.11	1	0.68	0.86	0	0.00	0.00	1	0.70	0.55
IXe.Unspecified soft-tissue sarcomas	0	0.00	0.00	1	0.68	0.56	2	1.95	1.63	4	2.79	2.36
X.Germ cell tumors, trophoblastic tumors and gonadal neoplasms	3	2.83	3.05	18	12.30	10.76	4	3.90	4.34	7	4.88	5.02
Xa.Intracranial and intraspinal germ cell tumors	1	0.94	1.11	2	1.37	1.42	0	0.00	0.00	0	0.00	0.00
Xb.Malignant intracranial and intraspinal germ cell tumors	1	0.94	1.14	2	1.37	1.45	3	2.92	3.53	3	2.09	2.74
Xc.Malignant gonadal germ cell tumors	1	0.94	0.80	14	9.57	7.90	1	0.97	0.82	4	2.79	2.28
XI.Other malignant epithelial neoplasms and melanomas	9	8.48	8.40	14	9.57	9.31	8	7.80	7.75	53	36.92	30.73
XIa.Adrenal cortex carcinoma	0	0.00	0.00	0	0.00	0.00	3	2.92	2.93	3	2.09	2.27
XIb.Thyroid carcinoma	1	0.94	0.80	2	1.37	1.18	2	1.95	1.63	6	4.18	3.46
XIc.Nasopharynx carcinoma	0	0.00	0.00	0	0.00	0.00	1	0.97	0.82	4	2.79	2.28
XId.Malignant melanoma	2	1.88	1.94	4	2.73	2.63	0	0.00	0.00	0	0.00	0.00
XIe.Skin carcinoma	1	0.94	1.11	2	1.37	1.42	2	1.95	2.37	5	3.48	3.48
XIf.Other carcinomas and unspecified carcinomas	5	4.71	4.54	6	4.10	4.08	0	0.00	0.00	35	24.38	19.23
XII.Other malignant and unspecified neoplasms	2	1.88	1.94	4	2.73	2.63	0	0.00	0.00	1	0.70	0.55
XIIa.Other specified malignant tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.70	0.55
XIIb.Other unspecified malignant tumors	2	1.88	1.94	4	2.73	2.63	0	0.00	0.00	0	0.00	0.00
All neoplasms	145	136.57	138.83	228	155.78	154.06	118	114.99	117.51	207	144.19	139.97

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Fortaleza - CE, 2000 - 2005





Figure 25. Distribution of the population* in Fortaleza
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Fortaleza

Coordinator

Miren Maite Uribe Arregi

Supervisor

Francisco de Assis Oliveira Falcão

Registrars

Antônio José de Moura
 Maria do Socorro Bevilaqua
 Raimunda Nonata de Paulo

Infrastructure and Data Source

This PBCR was created in 1971, year when the data collection started. It is located in the State Health Secretariat/Epidemiologic Surveillance, at avenida Almirante Barroso, 600, Praia de Iracema, postal code 60060-440, in Fortaleza, Ceará.




Figure 26. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Fortaleza - CE, 2000 - 2005

Table 32

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.00	0.82	0.00	0.73	0.00	3.83	6.39	14.24	14.43	6.12	0.40	0.58
C01	Tongue base	47	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.33	2.47	4.01	5.84	5.28	10.22	4.79	9.50	4.81	6.12	0.89	1.38
C02	Other parts of the tongue	101	0.00	0.00	0.00	0.00	0.00	0.00	0.46	0.50	2.98	2.47	10.02	14.60	14.97	10.22	11.18	14.24	19.24	0.00	1.91	2.84
C03	Gingiva	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.50	0.73	0.88	1.28	0.00	2.37	0.00	0.00	0.11	0.17
C04	Floor of the mouth	32	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.00	0.33	4.12	1.50	4.38	7.04	1.28	0.00	4.75	0.00	0.00	0.60	0.90
C05	Palate	47	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.00	1.98	2.47	1.50	3.65	6.16	6.39	6.39	14.24	14.43	6.12	0.89	1.31
C06	Other parts of the mouth	81	0.00	0.00	0.00	0.17	0.00	0.22	0.23	0.25	0.99	5.77	5.51	10.22	7.92	10.22	11.18	11.87	24.05	0.00	1.53	2.24
C07	Parotid gland	37	0.00	0.00	0.17	0.00	0.00	0.44	0.00	0.00	1.65	1.24	0.50	3.65	0.88	5.11	3.19	4.75	33.67	24.49	0.70	0.99
C08	Other larger salivary glands	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.88	2.55	0.00	2.37	0.00	6.12	0.09	0.17
C09	Amygdala	35	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.33	2.06	3.00	7.30	5.28	1.28	4.79	2.37	0.00	0.00	0.66	0.99
C10	Oropharynx	49	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.25	0.99	2.88	2.00	5.84	9.68	7.66	4.79	11.87	0.00	0.00	0.92	1.43
C11	Nasopharynx	22	0.00	0.18	0.35	0.17	0.00	0.00	0.00	0.25	1.65	0.82	5.00	2.19	1.76	1.28	1.60	2.37	0.00	6.12	0.41	0.54
C12	Piriform sinus	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.24	1.00	2.19	3.52	1.28	0.00	0.00	4.81	0.00	0.28	0.42
C13	Hypopharynx	51	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.66	1.24	1.50	8.03	6.16	6.39	19.16	7.12	9.62	12.25	0.96	1.53
C14	Inaccurate locations of the lip, oral cavity and pharynx	29	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.25	0.00	0.82	3.51	5.11	0.88	5.11	0.00	9.50	9.62	0.00	0.55	0.79
C15	Esophagus	239	0.00	0.00	0.00	0.00	0.00	0.00	0.23	1.01	2.65	7.00	11.52	29.92	39.61	48.54	25.55	54.60	67.35	55.10	4.51	7.14
C16	Stomach	661	0.00	0.00	0.00	0.00	0.38	1.77	1.62	3.78	8.60	18.54	26.04	52.54	71.30	118.78	135.74	185.15	216.47	306.13	12.47	19.12
C17	Small intestine	27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.66	1.65	2.00	2.92	2.64	3.83	0.00	7.12	14.43	0.00	0.51	0.73
C18	Colon	235	0.00	0.00	0.00	0.17	0.38	0.00	1.16	2.01	5.29	8.24	11.52	21.89	29.93	38.32	35.13	49.85	76.97	42.86	4.43	6.65
C19	Rectosigmoid junction	52	0.00	0.00	0.00	0.00	0.00	0.22	0.23	0.25	1.32	0.82	3.00	5.84	6.16	11.50	12.78	2.37	14.43	6.12	0.98	1.53
C20	Rectum	140	0.18	0.00	0.17	0.00	0.38	0.22	0.46	0.76	2.98	4.53	5.51	12.41	14.97	20.44	28.74	33.23	67.35	12.25	2.64	3.90
C21	Anus and anal canal	20	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.25	0.99	0.41	1.00	2.19	2.64	1.28	1.60	2.37	4.81	0.00	0.38	0.50
C22	Liver and intrahepatic biliary ducts	99	0.00	0.00	0.00	0.34	0.19	0.44	0.46	0.76	0.33	2.47	6.01	5.84	10.56	14.05	25.55	30.86	28.86	18.37	1.87	2.76
C23	Gallbladder	26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.41	1.00	2.19	1.76	11.50	7.98	4.75	4.81	0.00	0.49	0.83
C24	Other parts of the biliary ducts	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.00	0.41	1.50	2.19	5.28	7.66	7.98	23.74	9.62	6.12	0.72	1.12
C25	Pancreas	123	0.00	0.00	0.00	0.00	0.00	0.22	0.46	0.50	0.33	4.53	8.01	6.57	12.32	21.71	20.76	35.61	52.92	61.23	2.32	3.52
C26	Inaccurate locations in the gastrointestinal tract	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.46	0.88	2.55	4.79	2.37	0.00	6.12	0.19	0.32
C30	Nasal cavity and middle ear	6	0.00	0.18	0.17	0.00	0.00	0.00	0.00	0.25	0.33	0.41	0.00	0.00	0.00	0.00	1.60	0.00	0.00	0.00	0.11	0.13
C31	Paranasal sinuses	15	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.33	1.24	0.00	0.73	0.88	1.28	3.19	9.50	4.81	0.00	0.28	0.39
C32	Larynx	297	0.00	0.00	0.00	0.00	0.38	0.22	0.23	0.50	2.98	6.18	16.03	23.35	50.18	60.03	60.68	71.21	86.59	73.47	5.60	8.91
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.88	1.28	0.00	0.00	0.00	0.00	0.04	0.07
C34	Bronchus and lungs	776	0.00	0.18	0.17	0.34	0.19	1.33	1.39	2.52	5.62	20.19	28.55	66.41	93.31	167.32	193.22	199.40	259.77	220.41	14.64	23.06
C37	Thymus	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.73	0.00	0.00	0.00	0.00	0.00	0.04	0.05
C38	Heart, mediastine and pleura	32	0.18	0.00	0.00	0.34	0.19	0.66	0.00	0.76	0.99	0.82	1.50	1.46	3.52	3.83	4.79	2.37	0.00	6.12	0.60	0.81
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.60	0.00	0.00	0.00	0.02	0.03
C40	Bones and limb joints	44	0.00	0.00	1.38	1.85	1.13	0.44	0.70	0.50	0.00	0.41	0.50	2.19	1.76	3.83	0.00	2.37	0.00	6.12	0.83	0.87
C41	Bones and joints of other locations	39	0.18	0.00	0.35	0.00	0.38	0.44	0.70	1.01	0.99	0.82	0.50	0.73	2.64	3.83	6.39	9.50	9.62	12.25	0.74	0.94
C43	Malignant skin melanoma	80	0.00	0.00	0.00	0.00	0.19	0.44	0.46	2.27	1.32	1.65	3.00	5.11	11.44	10.22	15.97	11.87	28.86	18.37	1.51	2.19
C44	Other malignant skin neoplasms	1,437	0.00	0.00	0.35	0.67	1.70	3.54	4.41	12.09	21.83	34.19	68.11	105.09	147.01	210.75	301.81	367.94	509.91	624.50	27.11	40.06
C45	Mesothelioma	3	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.00	0.00	0.00	0.00	0.73	0.00	1.28	0.00	0.00	0.00	0.00	0.06	0.08
C46	Kaposi's sarcoma	11	0.00	0.00	0.00	0.00	0.00	0.44	0.23	1.01	0.33	0.82	0.00	0.00	0.00	0.00	0.00	0.00	4.81	0.00	0.21	0.20
C47	Peripheral nerves and autonomic nervous system	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.73	0.88	0.00	0.00	0.00	0.00	0.00	0.04	0.06
C48	Retropertoneum and peritoneum	38	0.00	0.18	0.00	0.00	0.19	0.22	0.23	0.25	0.33	0.41	0.50	3.65	6.16	5.11	7.98	7.12	14.43	18.37	0.72	1.09
C49	Connective tissue and other soft tissues	88	0.73	0.54	0.69	0.84	1.51	0.66	0.93	1.26	1.32	2.06	3.51	2.92	6.16	3.83	4.79	23.74	38.48	6.12	1.66	2.00
C50	Breast	16	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.00	0.33	0.41	1.00	0.73	2.64	1.28	6.39	0.00	0.00	6.12	0.30	0.46
C60	Penis	69	0.00	0.00	0.00	0.00	0.38	0.22	0.23	1.01	2.98	1.65	2.00	5.11	7.92	8.94	12.78	9.50	28.86	18.37	1.30	1.88
C61	Prostate	1,830	0.00	0.00	0.00	0.00	0.00	0.00	0.25	1.98	3.71	24.04	84.66	175.18	401.06	536.55	871.18	1,120.84	1,206.15	34.52	55.06	
C62	Testicles	46	0.00	0.00	0.69	0.50	1.89	1.11	1.16	0.76	1.65	0.82	0.50	2.19	1.76	1.28	0.00	0.00	0.00	6.12	0.87	0.86
C63	Other male sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.73	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C64	Kidney	99	0.55	0.54	0.35	0.17	0.00	0.44	0.00	1.01	0.99	2.88	8.51	10.22	13.20	11.50	12.78	11.87	24.05	6.12	1.87	2.73
C66	Ureters	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.73	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C67	Bladder	157	0.18	0.18	0.00	0.17	0.00	0.22	0.46	0.25	2.32	2.47	4.51	10.22	14.08	31.93	38.33	52.22	72.16	73.47	2.96	4.58
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.12	0.02	0.03
C69	Eyes and appendages	20	1.27	0.18	0.00	0.00	0.00	0.00	0.23	1.26	0.00	0.41	0.50	0.00	0.00	1.28	0.00	4.75	0.00	6.12	0.38	0.43
C70	Meninges	5	0.00	0.00	0.00	0.00	0.19	0.00	0.23	0.00	0.00	0.00	0.00	0.73	0.00	0.00	1.60	2.37	0.00	0.00	0.09	0.11
C71	Encephalon	242	0.73	2.17	2.25	1.51	2.83	2.65	4.41	3.27	8.27	7.42	8.01	13.87	14.97	24.27	23.95	28.49	14.43	6.12	4.56	5.63
C72	Spinal cord and other parts of the central nervous system	7	0.18	0.54	0.00	0.17	0.00	0.00	0.00	0.0												

Table 32 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C85	Other types of non-Hodgkin lymphoma, nos	130	1.09	0.36	0.35	0.50	1.70	1.11	0.93	2.01	2.98	2.88	5.01	7.30	12.32	10.22	11.18	26.11	33.67	48.98	2.45	3.24
C90	Multiple myeloma and malignant plasmacyte neoplasms	89	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.25	1.32	2.06	7.51	7.30	6.16	17.88	17.57	37.98	4.81	24.49	1.68	2.56
C91	Lymphoid leukemia	107	3.82	2.71	2.60	1.18	1.13	0.22	0.00	0.25	0.99	0.41	1.00	2.19	2.64	6.39	7.98	21.36	38.48	12.25	2.02	2.34
C92	Myeloid leukemia	119	0.91	1.08	0.69	1.01	0.76	1.77	3.02	2.77	3.64	2.06	2.50	9.49	5.28	5.11	9.58	16.62	9.62	18.37	2.24	2.63
C95	Unspecified cell leukemia	36	0.55	0.54	0.35	0.50	0.19	0.00	0.23	0.76	0.00	1.65	1.50	0.00	0.88	1.28	7.98	4.75	14.43	6.12	0.68	0.83
C96	Other malignant lymphatic tissue neoplasms and correlates	3	0.18	0.18	0.00	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.06
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.60	0.00	0.00	0.00	0.02	0.03
C00-96, D46	All invasive primary malignant neoplasms	8,708	13.82	11.20	14.19	14.46	21.72	24.78	32.01	55.40	106.50	195.69	320.52	633.46	899.66	1,436.91	1,780.52	2,447.36	3,131.61	3,195.98	164.26	244.63
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	7,271	13.82	11.20	13.84	13.79	20.02	21.24	27.60	43.31	84.67	161.49	252.41	528.37	752.65	1,226.16	1,478.71	2,079.43	2,621.70	2,571.48	137.15	204.57
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.00	0.00	1.60	0.00	0.00	6.12	0.06	0.09
D01	Carcinoma in situ of other organs of the gastrointestinal tract	3	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.25	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.05
D02	Carcinoma in situ of the middle ear and respiratory system	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.73	0.88	1.28	0.00	0.00	9.62	0.00	0.09	0.15
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.12	0.02	0.03
D04	Skin carcinoma in situ	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.00	1.46	3.52	2.55	3.19	2.37	9.62	12.25	0.30	0.49
D07	Carcinoma in situ of other sex organs and unspecified organs	4	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.25	0.00	0.00	0.50	0.00	0.00	0.00	0.00	2.37	0.00	0.00	0.08	0.08
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.60	0.00	4.81	0.00	0.04	0.06
C00-96, D00-09, D46	All primary malignant neoplasms	8,742	13.82	11.20	14.19	14.46	21.91	24.78	32.24	55.90	107.16	196.10	321.02	635.65	904.07	1,440.74	1,786.91	2,452.11	3,155.67	3,220.47	164.90	245.58

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 33 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C81	Hodgkin's disease	100	0.38	1.30	1.72	1.38	1.81	2.64	0.79	1.29	0.81	1.98	3.20	2.23	1.26	2.57	3.02	7.46	2.63	5.93	1.66	1.66
C82	Non-Hodgkin follicular lymphoma	17	0.00	0.00	0.00	0.00	0.16	0.00	0.20	0.22	0.00	0.66	0.40	1.11	0.00	4.29	2.01	0.00	5.26	0.00	0.28	0.34
C83	Non-Hodgkin diffuse lymphoma	71	0.38	0.19	0.17	0.15	0.33	0.38	0.40	0.65	1.08	1.32	3.60	2.78	6.28	4.29	10.07	5.97	2.63	14.82	1.18	1.38
C84	Peripheral and cutaneous T-cell lymphoma	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.40	0.00	0.00	0.00	0.00	4.48	2.63	2.96	0.12	0.11
C85	Other types of non-Hodgkin lymphoma, nos	137	0.19	0.56	0.17	0.61	0.16	0.94	0.59	1.51	1.35	1.98	6.40	8.90	8.17	11.15	13.09	16.42	26.29	26.68	2.27	2.59
C90	Multiple myeloma and malignant plasmacyte neoplasms	100	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	1.89	1.32	4.40	6.68	9.42	9.44	16.11	11.94	28.92	11.86	1.66	2.00
C91	Lymphoid leukemia	64	3.20	1.86	1.20	0.46	0.33	0.19	0.20	0.22	0.54	0.99	0.40	0.00	2.51	2.57	3.02	4.48	5.26	2.96	1.06	1.22
C92	Myeloid leukemia	117	0.75	0.37	0.69	0.92	1.15	0.94	0.79	1.94	3.24	2.31	2.00	3.34	6.28	7.72	7.05	14.93	10.52	17.79	1.94	2.09
C93	Monocytic leukemia	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C94	Other specified-type cell leukemias	2	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	0.00	0.00	0.03	0.03
C95	Unspecified cell leukemia	44	0.94	0.56	0.00	0.15	0.00	0.38	0.00	0.43	0.27	0.99	2.00	0.00	0.63	2.57	4.03	8.96	10.52	11.86	0.73	0.80
C96	Other lymphatic tissue malignant neoplasms and correlates	3	0.19	0.00	0.00	0.00	0.00	0.00	0.20	0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
C00-96, D46	All invasive primary malignant neoplasms	10,908	11.30	11.37	8.95	12.88	18.59	37.16	69.97	123.26	228.67	321.59	460.31	619.76	732.60	924.72	974.69	1,389.80	1,464.52	1,615.87	181.02	207.17
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	9,549	11.30	11.18	8.60	12.42	17.44	33.39	64.63	112.27	206.78	293.88	415.88	558.01	663.48	802.91	821.64	1,134.53	1,164.78	1,227.47	158.47	182.57
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.00	0.00	0.02	0.03
D01	Carcinoma in situ of other organs of the gastrointestinal tract	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	0.00	0.00	1.11	0.63	0.86	0.00	0.00	0.00	0.00	0.08	0.11
D02	Carcinoma in situ of the middle ear and respiratory system	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.00	0.00	0.86	0.00	0.00	0.00	0.00	0.03	0.05
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	0.00	0.00	0.02	0.02
D04	Skin carcinoma in situ	26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.43	0.27	1.32	0.40	2.23	0.63	0.86	2.01	4.48	10.52	5.93	0.43	0.45
D05	Breast carcinoma in situ	113	0.00	0.00	0.00	0.00	0.00	0.19	0.40	1.08	3.24	5.61	8.01	11.68	8.17	6.86	4.03	10.45	2.63	5.93	1.88	2.26
D06	Cervical carcinoma in situ	772	0.00	0.00	0.17	2.15	8.39	15.66	25.89	23.92	28.92	24.41	18.41	19.47	19.48	19.73	16.11	13.44	5.26	20.75	12.81	11.98
D07	Carcinoma in situ of other sex organs and unspecified organs	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.54	0.33	1.20	0.56	0.63	1.72	0.00	0.00	0.00	0.00	0.17	0.21
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00	0.00	1.49	0.00	0.00	0.03	0.04
C00-96, D00-09, D46	All primary malignant neoplasms	11,840	11.30	11.37	9.12	15.02	26.99	53.01	96.26	148.68	261.92	353.25	488.72	655.37	762.75	955.60	997.85	1,419.66	1,482.92	1,648.48	196.49	222.31

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Fortaleza - CE, 2000 - 2005

Male

Table 34

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	419	11.84	97.1	3.1	29.1
C15 Esophagus	239	7.14	91.2	13.0	74.1
C16 Stomach	660	19.12	87.1	17.7	73.3
C18-21 Large intestine, anal canal and anus	447	12.58	94.2	7.8	39.4
C22 Liver	30	2.76	93.3	0.0	433.3
C25 Pancreas	123	3.52	68.3	40.7	92.7
C32 Larynx	297	8.91	91.6	9.1	42.4
C33-34 Trachea, bronchus and lungs	778	23.14	79.7	25.3	79.2
C43 Skin melanoma	80	40.06	97.5	5.0	23.8
C61 Prostate	1.830	55.06	92.2	9.5	29.3
C70-72 Central Nervous System	190	5.91	94.7	23.2	107.4
C73 Thyroid	72	1.80	95.8	1.4	11.1
C91-95 Leukemia	262	5.79	86.3	27.1	63.4
C81-85, C96 Lymphoma	337	7.83	95.0	5.9	41.8
C00-96, D46 All primary invasive malignant Neoplasms	8,708	244.63	89.4	14.1	44.9
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	7,271	204.57	87.6	16.7	53.3

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 35

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	176	3.29	98.3	4.5	23.9
C15 Esophagus	123	2.48	91.1	17.9	60.2
C16 Stomach	447	8.62	84.1	21.0	60.9
C18-21 Large intestine, anal canal and anus	579	11.36	91.5	9.2	43.2
C22 Liver	22	2.01	95.5	0.0	713.6
C25 Pancreas	153	2.97	67.3	49.7	96.1
C32 Larynx	59	1.15	91.5	11.9	30.5
C33-34 Trachea, bronchus and lungs	588	11.92	81.3	25.3	73.5
C43 Skin melanoma	84	24.61	96.4	1.2	21.4
C50 Breast	2.781	53.59	97.7	2.8	24.2
C53 Cervix	1.228	23.27	98.0	2.2	23.3
C70-72 Central Nervous System	171	4.44	97.1	33.9	122.8
C73 Thyroid	420	7.64	95.5	1.7	9.3
C91-95 Leukemia	228	4.16	76.3	36.4	75.4
C81-85, C96 Lymphoma	335	6.12	92.5	8.7	34.9
C00-96, D46 All primary invasive malignant Neoplasms	10,908	207.17	91.2	12.4	38.4
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	9,549	182.57	90.1	14.1	43.6

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Male




Figure 27

Female




Figure 28

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Fortaleza - CE, 2000 - 2005

Table 36

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	74	44.01	44.91	90	39.54	40.86	52	31.53	33.34	62	26.94	29.28
Ia. Lymphoid leukemia	51	30.33	31.03	58	25.48	26.70	34	20.62	21.83	37	16.08	17.95
Ib. Acute myeloid leukemia	14	8.33	8.32	19	8.35	8.34	10	6.06	6.09	15	6.52	6.45
Ic. Myeloproliferative chronic diseases	0	0.00	0.00	1	0.44	0.38	0	0.00	0.00	1	0.43	0.34
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	0.59	0.70	1	0.44	0.54	0	0.00	0.00	0	0.00	0.00
Ie. Specified leukemias and other unspecified leukemias	8	4.76	4.86	11	4.83	4.90	8	4.85	5.42	9	3.91	4.54
II. Reticuloendothelial lymphomas and neoplasms	39	23.19	23.84	58	25.48	25.66	29	17.59	16.94	43	18.68	17.96
Ila. Hodgkin's lymphoma	16	9.52	9.28	28	12.30	11.73	19	11.52	10.65	28	12.17	11.36
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	15	8.92	9.18	21	9.23	9.39	7	4.25	4.13	12	5.21	4.92
Ilc. Burkitt's lymphoma	6	3.57	4.09	6	2.64	3.17	2	1.21	1.45	2	0.87	1.12
Ild. Miscellany of lymphoreticular neoplasms	2	1.19	1.29	3	1.32	1.37	1	0.61	0.72	1	0.43	0.56
III. CNS and misc. of intracranial and intraspinal neoplasms	33	19.63	18.78	43	18.89	18.34	25	15.16	14.99	33	14.34	14.37
Illa. Ependymoma and choroid plexus tumor	3	1.78	1.67	5	2.20	2.05	2	1.21	1.20	2	0.87	0.93
IIlb. Astrocytoma	6	3.57	3.26	7	3.08	2.90	4	2.43	2.32	5	2.17	2.15
IIlc. Intracranial and intraspinal embryonic tumors	11	6.54	6.33	14	6.15	6.04	7	4.25	4.26	9	3.91	3.99
IIId. Other gliomas	2	1.19	1.17	3	1.32	1.28	4	2.43	2.20	5	2.17	2.05
IIle. Other intracranial and intraspinal neoplasms	1	0.59	0.50	1	0.44	0.39	0	0.00	0.00	1	0.43	0.34
IIIf. Unspecified intracranial and intraspinal tumors	10	5.95	5.86	13	5.71	5.68	8	4.85	5.00	11	4.78	4.91
IV. Neuroblastoma and other peripheral nervous cell tumor	7	4.16	4.48	7	3.08	3.47	3	1.82	2.23	3	1.30	1.73
IVa. Neuroblastoma and ganglioneuroblastoma	5	2.97	3.39	5	2.20	2.63	3	1.82	2.23	3	1.30	1.73
IVb. Other peripheral nervous cell tumors	2	1.19	1.09	2	0.88	0.84	0	0.00	0.00	0	0.00	0.00
V. Retinoblastoma	8	4.76	5.51	8	3.51	4.27	4	2.43	2.92	4	1.74	2.26
VI. Renal tumors	8	4.76	4.87	9	3.95	4.15	10	6.06	6.77	12	5.21	5.94
VIa. Nephroblastoma and other renal non-epithelial tumors	7	4.16	4.37	7	3.08	3.38	9	5.46	6.05	11	4.78	5.38
VIb. Renal carcinomas	1	0.59	0.50	2	0.88	0.77	0	0.00	0.00	0	0.00	0.00
VIc. Unspecified malignant renal tumors	0	0.00	0.00	0	0.00	0.00	1	0.61	0.72	1	0.43	0.56
VII. Hepatic tumors	0	0.00	0.00	2	0.88	0.76	1	0.61	0.60	2	0.87	0.81
VIIa. Hepatoblastoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.43	0.34
VIIb. Hepatocellular carcinoma	0	0.00	0.00	1	0.44	0.38	0	0.00	0.00	0	0.00	0.00
VIIc. Unspecified malignant hepatic tumors	0	0.00	0.00	1	0.44	0.38	1	0.61	0.60	1	0.43	0.47
VIII. Malignant bone tumors	10	5.95	5.02	21	9.23	8.05	14	8.49	7.72	24	10.43	9.44
VIIIa. Osteosarcoma	9	5.35	4.52	19	8.35	7.29	8	4.85	4.20	16	6.95	6.01
VIIIc. Ewing's sarcoma and related bone sarcomas	1	0.59	0.50	2	0.88	0.77	4	2.43	2.32	6	2.61	2.49
VIIIe. Unspecified malignant bone tumors	0	0.00	0.00	0	0.00	0.00	2	1.21	1.20	2	0.87	0.93
IX. Soft-tissue and other extraosseous sarcomas	10	5.95	5.71	16	7.03	6.70	9	5.46	5.50	12	5.21	5.30
IXa. Rhabdomyosarcoma	6	3.57	3.49	8	3.51	3.46	3	1.82	1.93	3	1.30	1.49
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	2	1.19	1.21	4	1.76	1.70	1	0.61	0.72	2	0.87	0.91
IXd. Other unspecified soft-tissue sarcomas	1	0.59	0.50	3	1.32	1.15	2	1.21	1.00	3	1.30	1.12
IXe. Unspecified soft-tissue sarcomas	1	0.59	0.50	1	0.44	0.39	3	1.82	1.85	4	1.74	1.78
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	3	1.78	1.51	5	2.20	1.92	6	3.64	3.42	17	7.39	6.45
Xa. Intracranial and intraspinal germ cell tumors	1	0.59	0.50	1	0.44	0.39	1	0.61	0.72	2	0.87	0.91
Xb. Malignant intracranial and intraspinal germ cell tumors	1	0.59	0.50	1	0.44	0.39	0	0.00	0.00	1	0.43	0.34
Xc. Malignant gonadal germ cell tumors	1	0.59	0.50	3	1.32	1.15	4	2.43	2.20	9	3.91	3.43
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.43	0.34
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	0	0.00	0.00	1	0.61	0.50	4	1.74	1.42
XI. Other malignant epithelial neoplasms and melanomas	7	4.16	3.68	16	7.03	6.25	9	5.46	5.05	41	17.82	14.95
XIb. Thyroid carcinoma	0	0.00	0.00	2	0.88	0.76	3	1.82	1.70	11	4.78	4.08
XIc. Nasopharynx carcinoma	3	1.78	1.59	5	2.20	1.99	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	2	1.19	1.00	6	2.64	2.29	2	1.21	1.00	5	2.17	1.81
XIf. Other carcinomas and unspecified carcinomas	2	1.19	1.09	3	1.32	1.22	4	2.43	2.35	25	10.86	9.07
XII. Other malignant and unspecified neoplasms	21	12.49	12.44	31	13.62	13.42	12	7.28	7.32	19	8.26	8.09
XIIa. Other specified malignant tumors	0	0.00	0.00	0	0.00	0.00	1	0.61	0.60	1	0.43	0.47
XIIb. Other unspecified malignant tumors	21	12.49	12.44	31	13.62	13.42	11	6.67	6.72	18	7.82	7.62
All neoplasms	220	130.84	130.76	306	134.43	133.86	174	105.52	106.82	272	118.19	116.58

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação





Figure 29. Distribution of the population* in Goiania
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Goiania

Coordinator

José Carlos de Oliveira

Supervisor

Maria Paula Curado

Epidemiologist/biostatistician

Edesio Martins

Codifier

Carleane Maciel Bandeira e Silva

Registrars

Anderson Gomes de Oliveira

Elcivone Cirineu de Souza

Matinair Siqueira Mineiro

Diego Rodrigues M. e Silva

Advisory Committee

Antônio Gomes Tele

Élbio Cândido de Paula

Elecly Messias de Oliveira

Geraldo da Silva Queiroz

Nildes Ferreira Borges

Ruffo de Freitas Junior

Sormany Del Carmo

Infrastructure and Data Source

The Goiania PBCR was created in July 1986 by the Health Secretariat of the State of Goiás and installed as advised by the Ministry of Health, whereas the data collection started in 1988. In November 1994, through a partnership with the State Health Secretariat, it was transferred to the Goiás Cancer Combat Association (ACCG), where it carries out its activities under the ACCG's administration. It will be financially supported by the SHS/MHS, as per Ordinance No. 2,607; it is not yet due to political issues.




Figure 30. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand men, per tumor primary site and age group

Goiânia - GO, 2000 - 2005

Table 37

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	23	0.00	0.00	0.00	0.00	0.00	0.00	0.44	1.43	1.11	4.14	0.00	1.24	6.40	4.59	3.29	10.69	10.27	0.00	0.84	1.09
C01	Tongue base	31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.69	6.16	6.20	9.60	9.18	6.59	10.69	20.54	0.00	1.13	1.67
C02	Other parts of the tongue	71	0.00	0.00	0.00	0.00	0.00	0.77	0.44	1.43	1.11	7.59	16.72	11.17	14.39	11.47	13.18	10.69	30.81	13.61	2.59	3.49
C03	Gingiva	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	1.76	2.48	1.60	2.29	3.29	0.00	0.00	0.00	0.29	0.43
C04	Floor of the mouth	29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.23	3.45	2.64	4.96	8.00	4.59	9.88	10.69	10.27	0.00	1.06	1.48
C05	Palate	25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	2.23	1.38	2.64	6.20	1.60	4.59	9.88	10.69	10.27	13.61	0.91	1.25
C06	Other parts of the mouth	43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	3.90	5.52	8.80	6.20	6.40	0.00	13.18	21.39	0.00	0.00	1.57	2.02
C07	Parotid gland	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	1.11	2.07	1.76	2.48	9.60	2.29	0.00	10.69	10.27	0.00	0.77	1.05
C08	Other larger salivary glands	5	0.00	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	1.60	0.00	3.29	0.00	10.27	0.00	0.18	2.02
C09	Amygdala	26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	3.45	2.64	9.93	3.20	4.59	6.59	10.69	0.00	0.00	0.95	1.31
C10	Oropharynx	44	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.00	4.46	4.14	8.80	8.69	6.40	6.88	3.29	21.39	0.00	0.00	1.60	2.08
C11	Nasopharynx	32	0.00	0.00	0.77	0.33	0.65	0.77	0.87	0.48	0.56	1.38	2.64	1.24	8.00	11.47	0.00	16.04	10.27	13.61	1.17	1.54
C12	Pyrimor sinus	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	6.21	3.52	8.69	12.79	2.29	13.18	10.69	10.27	0.00	1.39	1.97
C13	Hypopharynx	28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.38	4.40	4.96	9.60	6.88	9.88	21.39	0.00	13.61	1.02	1.57
C14	Inaccurate locations of the lip, oral cavity and pharynx	4	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.29	3.29	5.35	0.00	0.00	0.15	0.21
C15	Esophagus	198	0.00	0.00	0.00	0.00	0.00	0.00	1.31	1.43	5.02	15.18	33.43	43.43	39.98	71.14	49.42	48.12	30.81	54.46	7.22	10.41
C16	Stomach	431	0.41	0.00	0.38	0.00	0.65	0.00	3.50	5.72	10.03	20.01	30.80	57.07	94.35	105.57	230.63	278.03	287.57	326.74	15.72	23.72
C17	Small intestine	20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.56	0.00	2.64	0.00	6.40	11.47	6.59	5.35	30.81	0.00	0.73	1.13
C18	Colon	320	0.00	0.00	0.00	0.67	1.30	1.16	3.50	7.62	10.03	24.84	28.16	40.94	41.58	105.57	148.26	144.36	143.79	122.53	11.67	16.63
C19	Rectosigmoid junction	36	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.48	0.00	1.38	2.64	7.44	9.60	9.18	23.06	21.39	10.27	13.61	1.31	2.02
C20	Rectum	166	0.00	0.00	0.00	0.65	0.77	1.31	4.29	3.90	7.59	17.60	22.33	27.19	59.67	69.19	90.89	92.43	54.46	6.05	8.82	
C21	Anus and anal canal	8	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.00	0.56	0.00	1.76	1.24	0.00	4.59	0.00	0.00	10.27	0.00	0.29	0.39
C22	Liver and intrahepatic biliary ducts	111	0.41	0.00	0.38	0.33	0.00	0.39	0.44	1.91	2.79	4.83	9.68	14.89	15.99	43.60	49.42	53.47	92.43	54.46	4.05	6.03
C23	Gallbladder	19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	1.38	0.00	4.96	3.20	11.47	0.00	10.69	20.54	13.61	0.69	1.06
C24	Other parts of the biliary ducts	37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	1.67	1.38	2.64	4.96	4.80	6.88	23.06	32.08	20.54	40.84	1.35	2.03
C25	Pancreas	81	0.00	0.00	0.00	0.33	0.00	0.00	0.87	0.48	2.79	3.45	5.28	9.93	27.19	25.24	26.36	42.77	51.35	54.46	2.95	4.48
C26	Inaccurate locations in the gastrointestinal tract	22	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.00	1.67	0.00	2.64	0.00	0.00	4.59	16.47	16.04	10.27	40.84	0.80	1.17
C30	Nasal cavity and middle ear	8	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.48	0.56	0.00	1.76	0.00	0.00	0.00	3.29	5.35	10.27	0.00	0.29	0.35
C31	Paranasal sinuses	8	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.48	0.00	0.00	0.88	0.00	1.60	2.29	6.59	5.35	0.00	0.00	0.29	0.42
C32	Larynx	163	0.00	0.00	0.00	0.00	0.39	0.87	0.00	5.57	9.66	20.24	33.50	35.18	43.80	85.66	48.12	61.62	54.46	5.95	8.84	
C33	Trachea	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.88	1.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.09
C34	Bronchus and lungs	492	0.00	0.00	0.00	0.00	0.39	1.31	1.91	6.13	16.56	39.59	83.13	124.74	195.07	253.69	278.03	318.38	190.60	17.95	28.13	
C37	Thymus	2	0.00	0.00	0.00	0.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.29	0.00	0.00	0.00	0.07	0.09
C38	Heart, mediastine and pleura	17	0.82	0.00	0.00	0.33	0.32	0.00	0.87	0.48	0.00	2.07	1.76	1.24	1.60	2.29	0.00	5.35	0.00	13.61	0.62	0.75
C40	Bones and limb joints	41	0.00	0.82	2.69	4.01	1.30	1.94	0.44	1.91	0.00	0.69	0.88	1.24	3.20	0.00	0.00	0.00	10.27	0.00	1.50	1.40
C41	Bones and joints of other locations	22	0.00	0.00	0.77	0.00	1.30	1.16	0.87	0.48	1.11	0.00	1.76	1.24	1.60	0.00	3.29	10.69	10.27	0.00	0.80	0.84
C43	Malignant skin melanoma	124	0.00	0.00	0.00	0.67	0.00	0.77	0.87	2.38	8.36	10.35	11.44	17.37	22.39	25.24	26.36	58.81	10.27	149.76	4.52	6.28
C44	Other malignant skin neoplasms	3,847	0.41	0.41	0.38	0.33	2.27	12.00	16.17	53.82	99.78	198.75	314.99	527.32	727.64	1,096.96	1,545.20	2,630.59	2,957.87	2,913.44	140.32	208.83
C45	Mesothelioma	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.88	0.00	1.60	0.00	0.00	0.00	0.00	0.00	0.11	0.14
C46	Kaposi's sarcoma	27	0.00	0.00	0.00	0.00	0.32	1.55	3.06	2.86	1.11	0.00	1.76	1.24	0.00	0.00	3.29	10.69	0.00	13.61	0.98	0.95
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.03
C48	Retropertoneum and peritoneum	20	0.41	0.41	0.00	0.33	0.00	0.00	0.87	0.48	0.56	0.00	1.76	0.00	0.00	4.59	16.47	5.35	20.54	13.61	0.73	1.01
C49	Connective tissue and other soft tissues	68	0.41	1.23	1.54	0.67	0.97	1.16	2.62	4.76	3.34	3.45	1.76	2.48	4.80	13.77	16.47	21.39	10.27	27.23	2.48	2.92
C50	Breast	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.88	1.24	6.40	4.59	6.59	5.35	0.00	0.00	0.47	0.74
C60	Penis	71	0.00	0.00	0.00	0.33	0.65	0.39	0.44	2.86	3.34	2.76	3.52	3.72	15.99	25.24	29.65	10.69	41.08	95.30	2.59	3.78
C61	Prostate	2,162	0.00	0.00	0.38	0.00	0.32	0.00	0.44	2.38	6.69	25.53	80.07	249.39	566.12	973.03	1,383.76	1,684.22	1,817.86	1,606.48	78.86	129.62
C62	Testicles	56	0.41	0.00	0.00	2.34	0.92	3.10	3.50	2.86	4.46	2.07	0.88	1.24	1.60	2.29	3.29	5.35	0.00	0.00	2.04	1.86
C63	Other male sex organs, nos	2	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.29	0.00	0.00	0.00	0.00	0.07	0.10
C64	Kidney	125	4.94	1.23	0.38	0.33	0.65	0.00	1.31	1.91	2.79	7.59	7.04	18.61	31.98	27.54	49.42	42.77	30.81	27.23	4.56	6.56
C65	Renal pelvis	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.59	0.00	0.00	0.00	0.00	0.07	0.14
C66	Ureters	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.29	0.00	0.00	0.00	0.04	0.07
C67	Bladder	267	0.00	0.00	0.00	0.00	0.00	0.77	0.87	0.00	5.02	4.83	11.44	37.22	49.58	87.21	148.26	219.22	297.84	272.28	9.74	15.37
C68	Other organs of the urinary system, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00	0.00	0.00	0.00	3.29	0.00	0.00	13.61	0.11	0.17
C69	Eyes and appendages	31	2.88	0.00	0.00	0.00	0.65	0.39	0.44	0.48	1.11	1.38	2.64	1.24	3.20	9.18	9.88	0.00	10.27	13.61	1.13	1.54
C70	Meninges	5	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.00	0.00	0.00	0.00	1.24	0.00	0.00	6.59	0.00	10.27	0.00	0.18	0.26
C71	Encephalon	210	4.53	3.70	1.92	3.67	3.57	5.03	9.18	7.14	6.69	8.97	14.08	16.13	33.58	36.72	29.65	48.12	20.54	27.23	7.66	9.13
C73	Thyroid gland	64	0.00</																			

Table 37 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
D02	Carcinoma in situ of the middle ear and respiratory system	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.24	0.00	2.29	0.00	0.00	10.27	0.00	0.11	0.17
D03	Melanoma in situ	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	1.11	2.07	0.00	1.24	0.00	2.29	0.00	5.35	10.27	0.00	0.36	0.44
D04	Skin carcinoma in situ	21	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.48	0.56	1.38	1.76	2.48	1.60	9.18	9.88	16.04	0.00	13.61	0.77	1.12
D07	Carcinoma in situ of other sex organs and unspecified organs	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.88	0.00	1.60	0.00	6.59	5.35	0.00	0.00	0.22	0.33
D09	Carcinoma in situ of other locations and unspecified locations	5	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.00	0.00	0.00	2.64	1.24	0.00	0.00	0.00	0.00	0.00	0.00	0.18	0.21
C00-96, D00-09, D46	All primary malignant neoplasms	10,637	26.75	25.11	17.30	23.70	30.51	45.69	78.68	138.12	247.50	465.81	786.60	1,380.96	2,163.73	3,300.06	4,675.14	6,400.04	6,963.32	6,575.67	387.99	576.63

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Goiânia - GO, 2000 - 2005

Table 38

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	4	0.00	0.00	0.00	0.00	0.30	0.00	0.00	0.00	0.47	0.00	0.00	1.07	0.00	1.75	0.00	0.00	0.00	0.00	0.13	0.15
C01	Tongue base	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.21	1.31	5.25	2.39	3.77	0.00	8.61	0.33	0.47
C02	Other parts of the tongue	18	0.00	0.00	0.00	0.00	0.30	0.00	0.39	0.00	0.47	1.76	0.76	1.07	2.63	3.50	2.39	15.07	0.00	8.61	0.60	0.71
C03	Gingiva	3	0.00	0.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.50	8.61	0.10	0.12
C04	Floor of the mouth	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.59	0.76	0.00	2.63	1.75	4.78	3.77	0.00	8.61	0.30	0.41
C05	Palate	15	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.47	0.00	1.53	4.28	1.31	1.75	2.39	3.77	13.00	8.61	0.50	0.60
C06	Other parts of the mouth	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.59	2.29	2.14	0.00	8.75	7.18	3.77	0.00	0.00	0.53	0.71
C07	Parotid gland	24	0.00	0.00	0.39	0.00	0.60	0.35	0.39	0.41	2.84	0.00	1.53	3.21	1.31	0.00	9.57	0.00	6.50	8.61	0.80	0.85
C08	Other larger salivary glands	4	0.00	0.00	0.00	0.00	0.00	0.00	1.16	0.00	0.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.10
C09	Amygdala	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.76	0.00	1.31	0.00	2.39	0.00	0.00	8.61	0.17	0.21
C10	Oropharynx	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.95	1.17	0.76	2.14	1.31	1.75	0.00	0.00	0.00	0.00	0.37	0.41
C11	Nasopharynx	18	0.00	0.42	0.78	0.31	0.30	0.00	0.00	0.41	0.95	2.34	0.76	1.07	1.31	0.00	4.78	0.00	6.50	0.00	0.60	0.65
C12	Piriform sinus	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.59	0.76	2.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.16
C13	Hypopharynx	5	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	0.00	2.39	3.77	6.50	0.00	0.17	0.18
C14	Inaccurate locations of the lip, oral cavity and pharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.39	0.00	0.00	0.00	0.03	0.05
C15	Esophagus	62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.47	2.34	7.64	9.84	19.71	15.75	7.18	22.60	13.00	8.61	2.06	2.72
C16	Stomach	279	0.00	0.00	0.00	0.00	1.49	2.80	3.47	5.73	5.20	8.21	17.57	23.56	47.31	52.49	88.51	109.24	129.98	163.68	9.27	11.32
C17	Small intestine	18	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.95	1.17	2.29	2.14	1.31	0.00	4.78	11.30	6.50	8.61	0.60	0.69
C18	Colon	364	0.00	0.00	0.00	0.00	0.60	0.35	3.47	5.32	13.23	14.07	27.50	34.26	67.02	80.48	93.29	139.38	149.48	180.91	12.10	14.99
C19	Rectosigmoid junction	37	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.95	1.17	1.53	5.35	6.57	7.00	21.53	15.07	0.00	17.23	1.23	1.61
C20	Rectum	185	0.00	0.00	0.00	0.00	0.30	1.05	1.93	3.68	5.20	8.21	16.80	20.34	35.48	40.24	40.66	86.64	26.00	60.30	6.15	7.64
C21	Anus and anal canal	27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.25	2.34	2.29	1.07	2.63	5.25	2.39	11.30	6.50	0.00	0.90	1.01
C22	Liver and intrahepatic biliary ducts	52	0.43	0.00	0.00	0.00	0.30	0.00	0.00	0.82	0.95	1.17	3.82	8.57	5.26	5.25	16.74	33.90	32.49	25.84	1.73	2.12
C23	Gallbladder	64	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.82	0.95	1.17	2.29	3.21	7.88	26.24	28.70	41.44	19.50	34.46	2.13	2.80
C24	Other parts of the biliary ducts	23	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00	0.00	1.53	2.14	3.94	8.75	9.57	3.77	19.50	17.23	0.76	1.02
C25	Pancreas	105	0.00	0.00	0.00	0.00	0.00	0.00	1.16	0.41	1.42	5.86	7.64	14.99	15.77	26.24	38.27	33.90	45.49	43.07	3.49	4.48
C26	Inaccurate locations in the gastrointestinal tract	26	0.00	0.00	0.00	0.00	0.30	0.00	0.39	0.41	0.47	0.00	0.76	4.28	2.63	5.25	4.78	18.84	13.00	25.84	0.86	1.05
C30	Nasal cavity and middle ear	12	0.00	0.00	0.00	0.31	0.00	0.00	0.39	0.00	0.47	0.00	0.76	3.21	0.00	1.75	0.00	7.53	6.50	8.61	0.40	0.45
C31	Paranasal sinuses	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	1.17	0.00	0.00	1.31	0.00	0.00	0.00	0.00	0.00	0.13	0.15
C32	Larynx	36	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.95	1.17	6.11	3.21	6.57	12.25	9.57	7.53	6.50	8.61	1.20	1.56
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02
C34	Bronchus and lungs	304	0.00	0.00	0.00	0.31	0.30	1.05	0.39	0.82	6.14	10.55	18.33	48.18	73.59	68.23	88.51	135.61	84.49	129.22	10.10	13.24
C37	Thymus	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.06
C38	Heart, mediastine and pleura	9	0.43	0.00	0.39	0.00	0.00	0.35	0.00	0.00	1.42	0.00	0.00	2.14	1.31	0.00	0.00	0.00	0.00	0.00	0.30	0.34
C40	Bones and limb joints	22	0.00	0.42	0.78	0.62	0.90	0.70	0.77	0.41	1.42	0.00	2.29	0.00	0.00	1.75	2.39	3.77	0.00	0.00	0.73	0.70
C41	Bones and joints of other locations	15	0.43	0.00	0.39	0.31	0.90	0.00	0.39	0.41	0.47	0.59	0.76	1.07	0.00	0.00	0.00	11.30	0.00	0.00	0.50	0.49
C43	Malignant skin melanoma	123	0.00	0.00	0.00	0.31	1.19	2.45	1.93	3.68	7.56	5.27	11.46	5.35	14.45	20.99	26.31	22.60	58.49	25.84	4.09	4.60
C44	Other malignant skin neoplasms	4,622	0.00	0.00	0.39	2.80	3.58	21.39	32.37	67.13	112.49	195.16	272.69	425.09	621.55	971.01	1,530.92	1,943.80	2,723.05	3,049.66	153.59	190.26
C45	Mesothelioma	6	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.47	0.00	0.00	2.14	1.31	0.00	0.00	3.77	0.00	0.00	0.20	0.23
C46	Kaposi's sarcoma	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.00	0.00	0.00	0.00	1.75	0.00	3.77	6.50	0.00	0.13	0.15
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04
C48	Retropertoneum and peritoneum	17	0.43	0.00	0.39	0.00	0.00	0.00	0.00	0.82	0.47	0.59	0.76	1.07	1.31	1.75	7.18	0.00	13.00	17.23	0.56	0.68
C49	Connective tissue and other soft tissues	60	2.13	0.42	0.39	1.56	1.19	0.70	0.77	1.23	2.36	4.69	2.29	3.21	11.83	5.25	4.78	15.07	0.00	0.00	1.99	2.29
C50	Breast	1,776	0.00	0.00	0.00	0.00	0.60	5.96	26.97	57.71	111.55	150.62	210.06	246.28	231.27	246.69	196.15	278.76	266.46	284.29	59.02	67.81
C51	Vulva	33	0.00	0.00	0.00	0.00	0.00	0.35	0.39	0.41	0.95	2.93	2.29	1.07	1.31	3.50	14.35	18.84	19.50	17.23	1.10	1.28
C52	Vagina	24	0.43	0.00	0.00	0.00	0.00	0.00	0.00	1.23	0.95	0.00	0.76	0.00	6.57	1.75	4.78	18.84	19.50	8.61	0.80	0.96
C53	Cervix	884	0.00	0.00	0.00	0.00	5.07	15.08	32.37	35.61	44.90	55.68	80.97	93.16	102.50	132.97	114.82	128.08	116.98	129.22	29.38	32.40
C54	Endometrium	186	0.00	0.00	0.00	0.00	0.00	0.35	0.39	3.68	5.20	7.62	17.57	32.12	43.36	33.24	52.63	52.74	19.50	34.46	6.18	7.79
C55	Uterus, nos	42	0.00	0.00	0.00	0.00	0.00	0.70	0.39	0.82	2.36	3.52	3.06	4.28	7.88	5.25	7.18	11.30	6.50	17.23	1.40	1.65
C56	Ovary	230	0.43	0.84	1.17	1.87	0.90	3.16	3.85	4.91	9.45	10.55	24.44	27.84	30.22	48.99	33.49	52.74	38.99	17.23	7.64	8.95
C57	Other female sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04
C58	Placenta	2	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.05
C64	Kidney	93	1.71	1.27	0.00	0.00	0.00	0.35	1.16	0.82	0.95	1.76	8.40	9.64	17.08	22.74	31.10	22.60	38.99	17.23	3.09	3.94
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.77	0.00	0.00	0.03	0.04
C67	Bladder	119	0.00	0.00	0.00	0.31	0.00	0.00	0.00	1.23	1.89	4.69	5.35	16.06	21.02	20.99	45.45	41.44	58.49	120.61	3.95	5.10
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.61	0.03	0.04
C69	Eyes and appendages	25	2.56	0.00	0.00	0.00	0.30															

Table 38 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C85	Other types of non-Hodgkin lymphoma, nos	45	0.00	0.00	0.00	0.31	0.60	0.70	0.39	2.05	2.84	1.76	3.82	1.07	6.57	10.50	7.18	3.77	13.00	17.23	1.50	1.70
C90	Multiple myeloma and malignant plasmacyte neoplasms	84	0.00	0.00	0.00	0.00	0.30	0.35	0.00	0.00	2.36	4.10	6.11	10.71	14.45	20.99	31.10	41.44	26.00	8.61	2.79	3.59
C91	Lymphoid leukemia	73	4.27	3.80	2.72	0.93	2.39	1.05	1.54	0.82	0.47	1.76	2.29	2.14	7.88	8.75	9.57	3.77	6.50	8.61	2.43	2.85
C92	Myeloid leukemia	125	1.28	1.27	2.33	0.93	2.09	3.51	2.31	2.87	4.25	8.21	3.82	11.78	13.14	10.50	31.10	15.07	32.49	25.84	4.15	4.65
C93	Monocytic leukemia	2	0.43	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.08
C94	Other specified-type cell leukemias	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	1.75	0.00	0.00	0.00	0.00	0.07	0.09
C95	Unspecified cell leukemia	33	1.28	0.42	0.78	0.62	0.60	0.35	0.77	0.41	0.95	2.34	3.06	0.00	2.63	3.50	4.78	3.77	6.50	8.61	1.10	1.24
D46	Myelodysplastic syndromes	35	0.00	0.00	0.00	0.31	0.30	0.35	0.00	0.82	1.42	0.59	1.53	4.28	6.57	3.50	7.18	22.60	19.50	8.61	1.16	1.37
C00-96, D46	All invasive primary malignant neoplasms	11,369	20.91	16.87	14.77	20.54	39.40	84.14	152.20	231.27	405.54	578.46	851.68	1,203.54	1,575.56	2,055.74	2,813.06	3,627.67	4,295.79	4,867.40	377.79	453.08
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	6,747	20.91	16.87	14.38	17.73	35.81	62.76	119.83	164.14	293.05	383.29	578.99	778.45	954.01	1,084.73	1,282.14	1,683.87	1,572.74	1,817.74	224.20	262.82
D01	Carcinoma in situ of other organs of the gastrointestinal tract	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.59	0.00	0.00	0.00	3.50	0.00	0.00	0.00	0.00	0.13	0.17
D03	Melanoma in situ	23	0.00	0.00	0.00	0.00	0.00	0.35	0.39	0.41	0.00	1.17	1.53	3.21	3.94	5.25	4.78	3.77	13.00	8.61	0.76	0.91
D04	Skin carcinoma in situ	109	0.00	0.00	0.00	0.00	0.30	0.35	0.39	1.64	2.36	3.52	4.58	5.35	17.08	29.74	33.49	56.51	64.99	94.76	3.62	4.58
D05	Breast carcinoma in situ	117	0.00	0.00	0.00	0.00	0.70	0.77	3.68	7.09	17.00	13.75	14.99	13.14	14.00	9.57	7.53	19.50	8.61	3.89	4.41	
D06	Cervical carcinoma in situ	1,364	0.00	0.00	0.00	6.22	42.68	91.50	94.40	79.82	77.99	65.05	46.59	53.54	44.68	52.49	62.19	48.97	19.50	34.46	45.33	40.17
D07	Carcinoma in situ of other sex organs and unspecified organs	57	0.00	0.00	0.00	0.93	2.09	1.75	0.39	3.27	3.31	4.10	3.06	3.21	1.31	5.25	7.18	3.77	13.00	17.23	1.89	1.88
D09	Carcinoma in situ of other locations and unspecified locations	5	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.95	0.00	0.76	0.00	0.00	0.00	0.00	0.00	0.00	8.61	0.17	0.16
C00-96, D00-09, D46	All primary malignant neoplasms	13,048	20.91	16.87	14.77	27.69	84.46	178.80	248.92	320.09	497.71	669.89	921.95	1,283.85	1,655.72	2,165.96	2,930.27	3,748.21	4,425.77	5,039.69	433.58	505.35

*World Standard Population, modified by Doll et al., (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Goiânia - GO, 2000 - 2005

Male

Table 39

Topography	No.	Adjusted	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	300	14.81	97.3	2.3	36.3
C15 Esophagus	198	10.41	88.9	9.1	63.1
C16 Stomach	431	23.72	91.0	6.5	47.3
C18-21 Large intestine, anal canal and anus	530	27.86	93.6	5.3	31.3
C22 Liver	111	6.03	62.2	28.8	99.1
C25 Pancreas	81	4.48	60.5	28.4	117.3
C32 Larynx	163	8.84	95.1	1.2	36.8
C33-34 Trachea, bronchus and lungs	494	28.22	78.3	11.1	71.9
C43 Skin melanoma	124	208.83	96.8	2.4	20.2
C61 Prostate	2.162	129.62	95.5	3.1	13.7
C70-72 Central Nervous System	215	9.39	83.3	11.6	59.1
C73 Thyroid	64	2.64	98.4	1.6	7.8
C91-95 Leukemia	223	10.05	78.9	18.8	50.7
C81-85, C96 Lymphoma	297	13.69	91.9	6.7	31.0
C00-96, D46 All primary invasive malignant Neoplasms	10,590	574.26	92.2	4.7	23.0
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	6,743	365.43	88.8	7.3	35.8

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 40

Topography	No.	Adjusted	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	91	3.77	93.4	3.3	33.0
C15 Esophagus	62	2.72	88.7	8.1	54.8
C16 Stomach	279	11.32	93.2	4.7	38.7
C18-21 Large intestine, anal canal and anus	613	25.26	94.1	4.6	31.3
C22 Liver	52	2.12	48.1	48.1	121.2
C25 Pancreas	105	4.48	59.1	32.4	96.2
C32 Larynx	36	1.56	97.2	0.0	33.3
C33-34 Trachea, bronchus and lungs	305	13.26	98.5	13.4	72.8
C43 Skin melanoma	123	190.26	99.2	0.0	13.8
C50 Breast	1.776	67.81	97.2	1.6	19.3
C53 Cervix	884	32.40	98.5	1.1	20.4
C70-72 Central Nervous System	156	5.75	81.4	14.1	73.7
C73 Thyroid	367	12.54	97.3	1.4	6.0
C91-95 Leukemia	235	8.90	86.0	13.6	43.0
C81-85, C96 Lymphoma	259	9.57	92.7	4.6	33.2
C00-96, D46 All primary invasive malignant Neoplasms	11,369	453.08	96.6	3.4	19.6
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	6,747	262.82	93.9	5.6	33.0

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Goiânia - GO, 2000 - 2005

Male




Figure 31

Female




Figure 32

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Goiânia - GO, 2000 - 2005

Table 41

PediaPediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	55	73.72	76.36	68	65.03	68.94	45	61.75	62.76	54	51.42	54.94
Ia. Lymphoid leukemia	39	52.27	54.18	47	44.95	48.00	24	32.93	33.89	27	25.71	28.37
Ib. Acute myeloid leukemia	6	8.04	8.33	8	7.65	7.96	12	16.47	15.82	13	12.38	12.96
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	1.34	1.33	2	1.91	1.78	0	0.00	0.00	1	0.95	0.70
Ie. Specified leukemias and other unspecified leukemias	9	12.06	12.52	11	10.52	11.21	9	12.35	13.05	13	12.38	12.91
II. Reticuloendothelial lymphomas and neoplasms	27	36.19	35.25	36	34.43	34.08	6	8.23	8.27	18	17.14	14.81
Ila. Hodgkin's lymphoma	15	20.10	18.70	19	18.17	17.49	2	2.74	2.49	9	8.57	6.83
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	5	6.70	7.42	8	7.65	8.01	3	4.12	4.42	6	5.71	5.52
Ilc. Burkitt's lymphoma	6	8.04	8.02	6	5.74	6.21	1	1.37	1.36	2	1.90	1.75
Ile. Unspecified lymphoma	1	1.34	1.12	3	2.87	2.37	0	0.00	0.00	1	0.95	0.70
III. CNS and misc. of intracranial and intraspinal neoplasms	24	32.17	33.46	35	33.47	34.19	22	30.19	29.52	28	26.66	27.08
Illa. Ependymoma and choroid plexus tumor	4	5.36	5.64	6	5.74	5.87	1	1.37	1.36	1	0.95	1.05
IIlb. Astrocytoma	12	16.08	16.85	16	15.30	16.07	15	20.58	19.91	19	18.09	18.23
IIlc. Intracranial and intraspinal embryonic tumors	3	4.02	3.98	6	5.74	5.34	3	4.12	3.85	3	2.86	2.98
IIId. Other gliomas	2	2.68	2.44	4	3.83	3.40	0	0.00	0.00	1	0.95	0.70
IIIf. Unspecified intracranial and intraspinal tumors	3	4.02	4.54	3	2.87	3.52	3	4.12	4.41	4	3.81	4.11
IV. Neuroblastoma and other peripheral nervous cell tumor	6	8.04	9.03	6	5.74	7.00	7	9.61	10.79	7	6.67	8.36
Iva. Neuroblastoma and ganglioneuroblastoma	6	8.04	9.03	6	5.74	7.00	7	9.61	10.79	7	6.67	8.36
V. Retinoblastoma	6	8.04	9.55	6	5.74	7.40	6	8.23	9.95	6	5.71	7.71
VI. Renal tumors	16	21.45	24.24	17	16.26	19.54	6	8.23	9.06	6	5.71	7.02
Vla. Nephroblastoma and other renal non-epithelial tumors	16	21.45	24.24	16	15.30	18.79	6	8.23	9.06	6	5.71	7.02
Vlb. Renal carcinomas	0	0.00	0.00	1	0.96	0.75	0	0.00	0.00	0	0.00	0.00
VIII. Malignant bone tumors	11	14.74	12.70	23	21.99	18.85	4	5.49	4.75	6	5.71	5.08
VIIla. Osteosarcoma	6	8.04	6.91	14	13.39	11.36	2	2.74	2.26	2	1.90	1.75
VIIlb. Chondrosarcoma	0	0.00	0.00	2	1.91	1.50	1	1.37	1.13	1	0.95	0.87
VIIlc. Ewing's sarcoma and related bone sarcomas	5	6.70	5.79	7	6.69	5.99	1	1.37	1.36	3	2.86	2.45
IX. Soft-tissue and other extraosseous sarcomas	9	12.06	11.41	11	10.52	10.35	14	19.21	20.69	23	21.90	22.34
IXa. Rhabdomyosarcoma	5	6.70	6.27	6	5.74	5.61	8	10.98	11.55	10	9.52	10.35
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	0	0.00	0.00	0	0.00	0.00	2	2.74	3.05	2	1.90	2.36
IXd. Other unspecified soft-tissue sarcomas	3	4.02	4.03	4	3.83	3.88	2	2.74	3.05	8	7.62	6.56
IXe. Unspecified soft-tissue sarcomas	1	1.34	1.12	1	0.96	0.86	2	2.74	3.05	3	2.86	3.06
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	4	5.36	5.94	13	12.43	11.36	6	8.23	8.31	13	12.38	11.34
Xa. Intracranial and intraspinal germ cell tumors	4	5.36	5.94	13	12.43	11.36	6	8.23	8.31	10	9.52	9.24
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	3	2.86	2.10
XI. Other malignant epithelial neoplasms and melanomas	3	4.02	3.35	6	5.74	4.85	4	5.49	4.75	12	11.43	9.28
XIb. Thyroid carcinoma	0	0.00	0.00	2	1.91	1.50	1	1.37	1.13	8	7.62	5.77
XIc. Nasopharynx carcinoma	2	2.68	2.23	3	2.87	2.48	2	2.74	2.26	3	2.86	2.45
XIf. Other carcinomas and unspecified carcinomas	1	1.34	1.12	1	0.96	0.86	1	1.37	1.36	1	0.95	1.05
XII. Other malignant and unspecified neoplasms	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.95	0.70
XIIb. Other unspecified malignant tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.95	0.70
All neoplasms	161	215.79	221.30	221	211.34	216.57	120	164.67	168.83	174	165.70	168.65

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Jaú - SP, 2000 - 2005




Figure 33. Distribution of the population* in Jaú
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Jaú

Medical coordinator

José Getúlio Martins Segalla

Technical coordinator

Rute Maria Martins Capra

Advisers/Registrars

Donaldo Botelho Veneziano

Claudia Luciana de Araújo Veneziano

Data Collector

Kartiane Patrícia Ferreira Souto

Data Entry Clerk

Thamires Isabel da Silva Santos

Advisory Committee

Augusto Alves Cunha

Batista de Oliveira Júnior

Francisco Alves Moraes Neto

Francisco Carlos Quevedo

Jayme Oliveira e Souza Júnior

José Carlos Berto

José Getúlio Martins Segalla

Mair Pedro de Souza

Infrastructure and Data Source

The Jaú PBCR was created in 2006, when a pact was signed with the Municipal Health Secretariat and the Amaral Carvalho Foundation. The data collection started in the same year, with the registry of the cases diagnosed as of January 2000. The Jaú PBCR is located in a space granted by the Amaral Carvalho Foundation and is connected to the Education and Research Management of the Amaral Carvalho Corporate University. It receives financial support from the MHS, as per Ordinance No. 2,607/GM, of December 28th, 2005, and it also has the financial/operational support of the Amaral Carvalho Foundation.




Figure 34. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand men, per tumor primary site and age group

Jaú - SP, 2000 - 2005

Table 42

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.41	11.12	7.00	9.93	21.87	13.01	32.94	81.68	0.00	0.00	5.49	5.26
C01	Tongue base	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.91	0.00	0.00	0.00	32.80	0.00	82.36	0.00	0.00	0.00	5.14	5.29
C02	Other parts of the tongue	16	0.00	0.00	0.00	0.00	0.00	4.12	0.00	8.71	4.60	16.68	13.99	9.93	21.87	0.00	49.42	27.23	0.00	0.00	5.49	5.36
C04	Floor of the mouth	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.35	9.21	0.00	0.00	39.71	0.00	0.00	0.00	0.00	0.00	0.00	2.40	2.40
C05	Palate	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	13.99	9.93	21.87	0.00	0.00	0.00	51.87	0.00	2.74	2.56
C06	Other parts of the mouth	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.21	11.12	13.99	0.00	10.93	13.01	16.47	27.23	0.00	0.00	3.43	3.35
C07	Parotid gland	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35
C08	Other larger salivary glands	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.01	0.00	0.00	0.00	0.00	0.34	0.39
C09	Amygdala	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	7.00	9.93	21.87	0.00	0.00	0.00	0.00	0.00	0.00	1.71	1.90
C10	Oropharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.68
C11	Nasopharynx	3	0.00	0.00	0.00	0.00	3.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.01	16.47	0.00	0.00	0.00	1.03	1.01
C12	Piriform sinus	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	7.00	0.00	0.00	13.01	16.47	0.00	0.00	0.00	1.37	1.40
C13	Hypopharynx	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	0.00	9.93	21.87	0.00	32.94	0.00	0.00	0.00	2.06	2.26
C14	Inaccurate locations of the lip, oral cavity and pharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	9.93	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.75
C15	Esophagus	46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.35	13.81	5.56	34.99	119.12	109.33	104.07	49.42	27.23	51.87	77.82	15.77	17.34
C16	Stomach	47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.79	27.99	39.71	76.53	104.07	98.83	136.13	207.47	311.28	16.11	16.77	
C18	Colon	38	0.00	0.00	0.00	0.00	0.00	4.12	4.45	4.35	9.21	16.68	7.00	39.71	54.66	78.05	82.36	81.68	207.47	155.64	13.03	13.16
C19	Rectosigmoid junction	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.21	0.00	20.99	0.00	65.60	13.01	49.42	27.23	51.87	0.00	5.83	6.14
C20	Rectum	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.35	4.60	16.68	27.99	0.00	10.93	39.03	16.47	0.00	0.00	77.82	5.14	5.26
C21	Anus and anal canal	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.26
C22	Liver and intrahepatic biliary ducts	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	0.00	0.00	0.00	0.00	26.02	32.94	0.00	0.00	0.00	1.71	1.72
C23	Gallbladder	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	0.00	0.00	0.00	0.00	0.00	27.23	0.00	0.00	0.69	0.61
C24	Other parts of the biliary ducts	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00	0.00	13.01	0.00	27.23	0.00	0.00	1.03	1.01
C25	Pancreas	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	9.93	43.73	65.04	32.94	81.68	51.87	77.82	6.17	6.57
C31	Paranasal sinuses	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.85	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.79
C32	Larynx	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.81	11.12	27.99	19.85	21.87	0.00	65.89	108.90	51.87	0.00	7.54	7.23
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35
C34	Bronchus and lungs	70	0.00	0.00	0.00	0.00	3.57	4.12	0.00	4.35	9.21	33.35	34.99	79.41	76.53	182.13	230.60	217.81	51.87	155.64	24.00	24.71
C40	Bones and limb joints	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.01	0.00	0.00	0.00	0.00	0.34	0.39
C41	Bones and joints of other locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.40
C43	Malignant skin melanoma	18	0.00	0.00	0.00	0.00	3.57	0.00	4.45	4.35	4.60	0.00	20.99	19.85	21.87	13.01	32.94	108.90	0.00	0.00	6.17	5.95
C44	Other malignant skin neoplasms	503	0.00	0.00	0.00	3.45	3.57	8.25	26.69	56.61	115.08	166.75	314.88	416.91	612.22	1,001.69	1,367.16	1,878.57	1,711.62	1,478.60	172.44	172.20
C46	Kaposi's sarcoma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	0.00	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.63
C48	Retroperitoneum and peritoneum	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.28
C49	Connective tissue and other soft tissues	7	0.00	0.00	3.90	0.00	3.57	4.12	4.45	0.00	0.00	0.00	0.00	9.93	0.00	0.00	0.00	54.45	0.00	0.00	2.40	2.18
C50	Breast	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.33
C60	Penis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.23	0.00	0.00	0.34	0.27
C61	Prostate	185	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.35	41.98	168.75	273.31	494.34	625.93	980.13	570.54	622.57	63.42	64.90	
C62	Testicles	5	0.00	0.00	0.00	0.00	0.00	8.25	8.90	0.00	4.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.71	1.47
C63	Other male sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16.47	0.00	0.00	0.00	0.34	0.33
C64	Kidney	15	0.00	0.00	0.00	0.00	0.00	0.00	4.45	4.35	4.60	11.12	13.99	9.93	32.80	13.01	0.00	27.23	103.73	0.00	5.14	5.06
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35
C67	Bladder	44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	7.00	79.41	21.87	91.06	115.30	163.35	363.07	389.11	15.08	15.17
C69	Eyes and appendages	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.93	13.01	0.00	0.00	0.00	0.00	0.34	0.44
C71	Encephalon	15	0.00	4.33	0.00	0.00	0.00	0.00	0.00	4.35	4.60	5.56	13.99	9.93	21.87	13.01	32.94	81.68	0.00	0.00	5.14	5.14
C72	Spinal cord and other parts of the central nervous system	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	0.00	0.00	0.00	0.00	0.00	27.23	0.00	0.00	0.69	0.61
C73	Thyroid gland	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.56	0.00	9.93	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.73
C80	Unknown primary site	30	0.00	0.00	0.00	0.00	0.00	0.00	8.90	0.00	9.21	16.68	20.99	29.78	54.66	39.03	49.42	108.90	103.73	0.00	10.28	10.28
C81	Hodgkin's disease	3	0.00	0.00	0.00	0.00	0.00	8.25	0.00	0.00	4.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	0.94
C82	Non-Hodgkin follicular lymphoma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35
C83	Non-Hodgkin diffuse lymphoma	12	4.46	4.33	3.90	3.45	0.00	4.12	8.90	0.00	0.00	0.00	0.00	0.00	21.87	26.02	0.00	0.00	0.00	77.82	4.11	4.54
C84	Peripheral and cutaneous T-cell lymphoma	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.35	0.00	0.00	0.00	0.00	0.00	0.00	16.47	27.23	0.00	0.00	1.03	0.86
C85	Other types of non-Hodgkin lymphoma, nos	12	0.00	4.33	0.00	3.45	0.00	0.00	0.00	0.00	0.00	5.56	7.00	9.93	21.87	0.00	16.47	108.90	0.00	0.00	4.11	4.12
C90	Multiple myeloma and malignant plasmacyte neoplasms	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	9.93	21.87	13.01	16.47	81.68	0.00	0.00	3.09	3.16
C91	Lymphoid leukemia	9	8.92	0.00	3.90	3.45	0.00	4.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.02	16.47	0.00	0.00	77.82	3.09	3.56
C92	Myeloid leukemia	8	0.00	4.33	0.00	0.00	0.00	0.00	0.00	4.35	9.21	0.00	0.00	19.85	0.00	13.01	0.00	0.00	0.00	77.82	2.74	2.82
C95	Unspecified cell leukemia	1	0.00	0.00	0.00	0.0																

Table 42 (continuation)

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
D04	Skin carcinoma in situ	22	0.00	0.00	0.00	0.00	0.00	0.00	4.45	0.00	0.00	5.56	7.00	29.78	32.80	52.04	65.89	27.23	155.60	77.82	7.54	7.77
D07	Carcinoma in situ of other sex organs and unspecified organs	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.93	0.00	0.00	27.23	0.00	0.00	0.69	0.71
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.93	0.00	0.00	16.47	0.00	0.00	0.00	0.69	0.73
C00-96, D00-09, D46	All primary malignant neoplasms	1,312	13.38	17.32	11.71	13.78	17.86	49.49	75.62	117.58	280.80	500.25	769.72	1,270.60	1,771.07	2,510.73	3,294.35	4,682.82	3,734.44	3,657.59	449.79	454.63

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Jaú - SP, 2000 - 2005

Table 43

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	10.50	13.40	20.89	0.00	0.00	1.34	1.15
C02	Other parts of the tongue	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.69	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.35
C05	Palate	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	9.65	0.00	0.00	0.00	0.00	0.00	0.67	0.74
C06	Other parts of the mouth	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.32
C07	Parotid gland	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.40	0.00	0.00	0.00	0.33	0.27
C08	Other larger salivary glands	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.35
C10	Oropharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.89	0.00	0.00	0.33	0.21
C11	Nasopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.35
C15	Esophagus	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.33	21.29	0.00	0.00	0.00	13.40	0.00	0.00	0.00	1.67	1.65
C16	Stomach	36	0.00	0.00	0.00	0.00	0.00	4.24	0.00	8.45	4.60	5.33	7.10	17.37	48.26	21.01	107.17	125.31	68.66	218.53	12.06	9.88
C17	Small intestine	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.50	13.40	0.00	34.33	43.71	1.34	0.97
C18	Colon	45	0.00	0.00	0.00	0.00	0.00	4.24	0.00	4.22	9.20	21.32	14.20	52.11	28.96	42.01	107.17	104.43	171.64	174.83	15.07	12.56
C19	Rectosigmoid junction	16	0.00	0.00	0.00	0.00	0.00	0.00	4.22	9.20	0.00	21.29	26.06	9.65	21.01	13.40	41.77	34.33	0.00	5.36	4.79	
C20	Rectum	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	5.33	7.10	0.00	9.65	0.00	13.40	20.89	171.64	0.00	3.68	2.67
C21	Anus and anal canal	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	9.65	0.00	13.40	20.89	34.33	0.00	1.67	1.39
C22	Liver and intrahepatic biliary ducts	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	0.00	0.00	0.00	0.00	10.50	13.40	20.89	0.00	0.00	1.34	1.07
C23	Gallbladder	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.20	8.69	9.65	0.00	26.79	20.89	34.33	43.71	3.35	2.58
C24	Other parts of the biliary ducts	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	0.00	26.79	0.00	34.33	43.71	1.67	1.28
C25	Pancreas	19	0.00	0.00	0.00	0.00	0.00	0.00	4.25	0.00	0.00	0.00	0.00	17.37	28.96	21.01	40.19	83.54	68.66	87.41	6.36	5.16
C31	Paranasal sinuses	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.35
C32	Larynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.33	0.00	8.69	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.67
C34	Bronchus and lungs	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	4.60	5.33	28.39	26.06	19.31	31.51	26.79	83.54	34.33	0.00	7.37	6.57
C43	Malignant skin melanoma	29	0.00	0.00	0.00	0.00	0.00	4.24	8.50	0.00	18.41	26.64	14.20	8.69	9.65	31.51	26.79	104.43	68.66	43.71	9.71	8.08
C44	Other malignant skin neoplasms	687	0.00	0.00	4.02	3.49	3.85	4.24	25.50	63.35	184.07	255.78	312.30	477.68	521.24	703.71	1,540.52	2,360.07	2,265.71	2,578.67	230.10	188.36
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	3.85	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.31
C48	Retroperitoneum and peritoneum	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	0.00	0.00	13.40	0.00	0.00	0.00	0.67	0.62
C49	Connective tissue and other soft tissues	3	0.00	0.00	0.00	0.00	0.00	0.00	4.25	0.00	0.00	0.00	0.00	8.69	0.00	0.00	13.40	0.00	0.00	0.00	1.00	0.87
C50	Breast	184	0.00	0.00	0.00	0.00	4.24	12.75	63.35	82.83	154.53	170.35	95.54	202.70	199.56	241.13	271.51	240.30	218.53	61.63	55.41	
C52	Vagina	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.66	7.10	0.00	0.00	0.00	0.00	0.00	34.33	43.71	1.67	1.38
C53	Cervix	34	0.00	0.00	0.00	0.00	3.85	4.24	8.50	12.67	9.20	10.66	42.59	26.06	38.61	31.51	13.40	62.66	68.66	43.71	11.39	10.23
C54	Endometrium	33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	5.33	35.49	52.11	38.61	63.02	40.19	62.66	102.99	43.71	11.05	10.05
C56	Ovary	23	0.00	0.00	4.02	0.00	0.00	4.24	4.25	8.45	13.81	10.66	14.20	26.06	9.65	21.01	40.19	20.89	34.33	0.00	7.70	6.88
C57	Other female sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.40	0.00	0.00	0.00	0.33	0.27
C64	Kidney	10	0.00	0.00	0.00	3.49	0.00	0.00	0.00	0.00	4.60	15.99	14.20	0.00	9.65	10.50	0.00	0.00	0.00	43.71	3.35	3.18
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.71	0.33	0.22
C67	Bladder	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	0.00	0.00	0.00	8.69	9.65	21.01	13.40	83.54	34.33	43.71	4.02	3.11
C69	Eyes and appendages	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.51
C71	Encephalon	13	4.58	0.00	4.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.10	0.00	19.31	42.01	26.79	20.89	0.00	43.71	4.35	4.26
C73	Thyroid gland	39	0.00	0.00	0.00	10.47	7.69	0.00	25.50	12.67	23.01	47.96	35.49	17.37	28.96	10.50	0.00	0.00	0.00	0.00	13.06	12.05
C75	Other endocrine glands and related structures	1	4.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.55
C76	Other inaccurate locations	6	4.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.65	10.50	0.00	20.89	0.00	87.41	2.01	1.90
C80	Unknown primary site	23	0.00	0.00	0.00	0.00	0.00	4.24	0.00	0.00	9.20	0.00	14.20	34.74	28.96	31.51	40.19	62.66	0.00	87.41	7.70	6.96
C81	Hodgkin's disease	4	0.00	4.35	0.00	0.00	7.69	0.00	0.00	0.00	0.00	5.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	1.37
C83	Non-Hodgkin diffuse lymphoma	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.33	0.00	8.69	9.65	0.00	13.40	20.89	0.00	43.71	2.01	1.75
C84	Peripheral and cutaneous T-cell lymphoma	1	0.00	0.00	0.00	0.00	0.00	0.00	4.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.26
C85	Other types of non-Hodgkin lymphoma, nos	7	0.00	0.00	0.00	0.00	0.00	0.00	4.25	4.22	4.60	0.00	0.00	0.00	0.00	10.50	0.00	0.00	68.66	43.71	2.34	1.66
C90	Multiple myeloma and malignant plasmacyte neoplasms	11	0.00	0.00	0.00	0.00	0.00	4.24	0.00	0.00	4.60	0.00	0.00	8.69	19.31	10.50	26.79	41.77	0.00	43.71	3.68	3.22
C91	Lymphoid leukemia	10	9.16	8.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.69	0.00	21.01	13.40	41.77	0.00	0.00	3.35	3.63
C92	Myeloid leukemia	11	0.00	0.00	4.02	0.00	0.00	4.24	0.00	4.22	4.60	0.00	7.10	0.00	19.31	10.50	26.79	20.89	0.00	0.00	3.68	3.42
C95	Unspecified cell leukemia	3	0.00	0.00	0.00	3.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.50	13.40	0.00	0.00	0.00	1.00	0.90

Table 43 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
D46	Myelodysplastic syndromes	2	0.00	4.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.71	0.67	0.65
C00-96, D46	All invasive primary malignant neoplasms	1,361	22.91	17.40	16.08	20.93	26.93	42.41	102.01	202.73	400.35	602.15	844.63	946.67	1,148.65	1,407.42	2,558.61	3,759.40	3,604.53	4,108.39	455.85	387.40	
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	674	22.91	17.40	12.06	17.44	23.08	38.17	76.51	139.38	216.28	346.37	532.33	468.99	627.41	703.71	1,018.08	1,399.33	1,338.83	1,529.72	225.75	199.04	
D03	Melanoma in situ	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	0.00	0.00	0.00	0.00	0.00	10.50	40.19	0.00	34.33	43.71	2.34	1.76	
D04	Skin carcinoma in situ	32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.60	5.33	7.10	26.06	48.26	21.01	53.58	146.20	240.30	0.00	10.72	8.29		
D05	Breast carcinoma in situ	18	0.00	0.00	0.00	0.00	0.00	0.00	4.25	4.22	9.20	5.33	21.29	17.37	28.96	10.50	26.79	41.77	0.00	0.00	6.03	5.57	
D06	Cervical carcinoma in situ	66	0.00	0.00	0.00	0.00	7.69	50.90	55.26	50.68	32.21	31.97	35.49	26.06	0.00	31.51	26.79	0.00	34.33	0.00	22.11	19.36	
C00-96, D00-09, D46	All primary malignant neoplasms	1,484	22.91	17.40	16.08	20.93	34.62	93.31	161.52	261.86	446.37	644.78	908.51	1,016.15	1,225.87	1,480.94	2,705.96	3,947.37	3,913.49	4,152.10	497.05	422.38	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Jaú - SP, 2000 - 2005

Male

Table 44

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	79	26.81	98.7	1.3	40.5
C15	Esophagus	46	17.34	100.0	0.0	76.1
C16	Stomach	47	16.77	97.9	2.1	83.0
C18-21	Large intestine, anal canal and anus	71	24.82	95.8	0.0	32.4
C22	Liver	5	1.72	60.0	0.0	160.0
C25	Pancreas	18	6.57	61.1	5.6	77.8
C32	Larynx	22	7.23	95.5	4.6	22.7
C33-34	Trachea, bronchus and lungs	71	25.06	90.1	4.2	77.5
C43	Skin melanoma	18	172.20	100.0	0.0	27.8
C61	Prostate	185	64.90	95.7	1.6	0.3
C70-72	Central Nervous System	17	5.75	76.5	5.9	76.5
C73	Thyroid	2	0.73	100.0	0.0	0.0
C91-95	Leukemia	18	6.65	100.0	0.0	27.8
C81-85, C96	Lymphoma	31	10.80	100.0	0.0	38.7
C00-96, D46	All primary invasive malignant Neoplasms	1,277	442.60	96.7	1.0	29.7
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	774	270.39	94.8	1.7	48.4

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 45

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	9	2.67	100.0	0.0	11.1
C15	Esophagus	5	1.68	100.0	0.0	120.0
C16	Stomach	36	9.88	97.2	0.0	55.6
C18-21	Large intestine, anal canal and anus	77	21.40	93.5	0.0	39.0
C22	Liver	4	1.07	50.0	25.0	150.0
C25	Pancreas	19	5.16	79.0	10.5	100.0
C32	Larynx	2	0.67	100.0	0.0	100.0
C33-34	Trachea, bronchus and lungs	22	6.57	81.8	4.5	90.9
C43	Skin melanoma	29	188.36	96.6	3.5	13.8
C50	Breast	184	55.41	99.5	0.5	25.5
C53	Cervix	34	10.23	100.0	0.0	32.4
C70-72	Central Nervous System	13	4.26	61.5	23.1	84.6
C73	Thyroid	39	12.05	100.0	0.0	2.6
C91-95	Leukemia	24	7.95	100.0	0.0	41.7
C81-85, C96	Lymphoma	18	5.04	100.0	0.0	33.3
C00-96, D46	All primary invasive malignant Neoplasms	1,361	387.40	96.5	1.1	20.4
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	674	199.04	94.1	2.1	40.8

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Jaú - SP, 2000 - 2005

Male




Figure 35

Female




Figure 36

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Jaú - SP, 2000 - 2005

Table 46

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	4	56.24	59.91	5	49.93	54.19	6	86.09	89.56	7	71.17	77.26
Ia. Lymphoid leukemia	3	42.18	45.94	4	39.94	43.36	4	57.40	63.85	4	40.67	49.49
Ib. Acute myeloid leukemia	1	14.06	13.97	1	9.99	10.83	1	14.35	11.67	1	10.17	9.05
Id. Myelodysplastic syndrome and myeloproliferative diseases	0	0.00	0.00	0	0.00	0.00	1	14.35	14.03	1	10.17	10.87
Ie. Specified leukemias and other unspecified leukemias	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	10.17	7.85
II. Reticuloendothelial lymphomas and neoplasms	4	56.24	56.58	6	59.92	59.36	1	14.35	14.03	1	10.17	10.87
Ila. Hodgkin's lymphoma	0	0.00	0.00	0	0.00	0.00	1	14.35	14.03	1	10.17	10.87
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	2	28.12	25.31	4	39.94	35.12	0	0.00	0.00	0	0.00	0.00
Ilc. Burkitt's lymphoma	2	28.12	31.27	2	19.97	24.24	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	1	14.06	13.97	1	9.99	10.83	3	43.05	46.69	3	30.50	36.18
IIIc. Intracranial and intraspinal embryonic tumors	1	14.06	13.97	1	9.99	10.83	2	28.70	28.79	2	20.33	22.31
IIIe. Other intracranial and intraspinal neoplasms	0	0.00	0.00	0	0.00	0.00	1	14.35	17.89	1	10.17	13.87
VI. Renal tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	10.17	7.85
Vla. Nephroblastoma and other renal non-epithelial tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	10.17	7.85
IX. Soft-tissue and other extraosseous sarcomas	1	14.06	11.34	2	19.97	16.54	0	0.00	0.00	0	0.00	0.00
IXa. Rhabdomyosarcoma	1	14.06	11.34	1	9.99	8.79	0	0.00	0.00	0	0.00	0.00
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	0	0.00	0.00	1	9.99	7.75	0	0.00	0.00	0	0.00	0.00
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	0	0.00	0.00	0	0.00	0.00	2	28.70	29.57	2	20.33	22.91
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	1	14.35	17.89	1	10.17	13.87
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	0	0.00	0.00	1	14.35	11.67	1	10.17	9.05
XI. Other malignant epithelial neoplasms and melanomas	0	0.00	0.00	0	0.00	0.00	1	14.35	11.67	4	40.67	32.60
XIb. Thyroid carcinoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	3	30.50	23.55
XIe. Skin carcinoma	0	0.00	0.00	0	0.00	0.00	1	14.35	11.67	1	10.17	9.05
XII. Other malignant and unspecified neoplasms	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	10.17	7.85
XIIb. Other unspecified malignant tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	10.17	7.85
All neoplasms	10	140.61	141.80	14	139.80	140.91	13	186.54	191.51	19	193.18	195.52

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

João Pessoa - PB, 2000 - 2005





Figure 37. Distribution of the population* in João Pessoa
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – João Pessoa

Coordinator

Josefa Ângela Pontes de Aquino

Registrars/Data Collectors/Data Entry Clerks

Helemário José Pacheco de França Filho
 Vanja Raquel Vasconcelos de Souza Lemos
 Osmaldo Barbosa de Miranda
 Naylana Soares Brandão Barreto

Technical Support

Luis Rodrigo Gomes Brandão

Advisory Committee

Lourdes de Fátima Sousa
 Josefa Ângela Pontes de Aquino
 Jória Viana Guerreiro
 João Aguiinaldo do Nascimento
 Ariadne Campos Nóbrega
 Luis Rodrigo Gomes Brandão
 Marta Rejane Montenegro Batista
 Osmaldo Barbosa de Miranda
 Alana Soares Brandão Barreto

Infrastructure and Data Source

This PBCR was created in 2000, whereas the data collection started in 1999. It is located in the Health Secretariat of the State of Paraíba (SES/PB), and financially supported by Ordinance No. 2,607, SVS/MS.




Figure 38. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted encc rates*,
per 100 thousand men, per tumor primary site and age group

João Pessoa - PB, 2000 - 2005

Table 47

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	1.40	3.44	0.00	0.00	4.47	11.49	0.00	0.00	0.00	0.47	0.69
C01	Tongue base	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.40	0.00	0.00	0.00	37.38	0.34	0.59
C02	Other parts of the tongue	39	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.90	3.37	7.02	13.75	12.12	15.03	13.40	11.49	30.38	0.00	37.38	2.64	3.62
C03	Gingiva	7	0.00	0.00	0.00	0.00	0.66	0.00	0.00	0.00	0.00	2.81	1.72	2.42	0.00	4.47	0.00	7.60	0.00	0.00	0.47	0.61
C04	Floor of the mouth	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.27	15.03	0.00	5.74	0.00	0.00	0.61	1.01
C05	Palate	30	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.00	3.37	5.61	5.16	4.85	15.03	17.87	11.49	7.60	51.98	18.69	2.03	2.84
C06	Other parts of the mouth	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.61	13.75	4.85	6.01	4.47	11.49	15.19	0.00	0.00	1.42	1.97
C07	Parotid gland	9	0.72	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.47	17.23	7.60	12.99	18.69	0.61	0.86
C08	Other larger salivary glands	6	0.00	0.00	0.00	0.00	0.66	0.00	0.00	0.90	0.00	0.00	0.00	0.00	4.85	3.01	0.00	0.00	7.60	0.00	0.41	0.50
C09	Amygdala	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	5.61	6.88	4.85	15.03	0.00	0.00	7.60	0.00	0.00	1.15	1.62
C10	Oropharynx	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.02	3.44	7.27	6.01	4.47	5.74	22.79	12.99	0.00	1.22	1.67
C11	Nasopharynx	6	0.00	0.00	0.64	0.00	0.00	0.80	0.00	0.00	2.24	1.40	0.00	0.00	3.01	0.00	0.00	0.00	0.00	0.00	0.41	0.46
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.47	0.00	0.00	0.00	0.00	0.07	0.13
C13	Hypopharynx	14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.90	1.12	2.81	3.44	12.12	0.00	8.93	0.00	7.60	0.00	0.00	0.95	1.29
C14	Inaccurate locations of the lip, oral cavity and pharynx	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	1.40	1.72	4.85	9.02	8.93	5.74	7.60	0.00	0.00	0.81	1.25
C15	Esophagus	49	0.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	1.40	8.60	24.23	27.05	22.34	40.21	53.17	38.98	0.00	3.32	4.92
C16	Stomach	143	0.00	0.00	0.00	0.00	0.00	1.60	4.17	3.61	10.10	14.04	18.91	43.62	60.10	75.94	126.39	83.55	129.94	74.77	9.70	13.80
C17	Small intestine	10	0.00	0.00	0.00	0.00	0.66	0.00	0.00	0.00	2.24	2.81	1.72	4.85	0.00	0.00	0.00	7.60	12.99	0.00	0.68	0.78
C18	Colon	54	0.72	0.00	0.00	0.00	0.66	0.00	1.67	2.70	7.85	15.44	3.44	9.69	12.02	22.34	51.70	7.60	51.98	0.00	3.66	4.88
C19	Rectosigmoid junction	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	0.00	0.00	7.27	6.01	4.47	11.49	0.00	0.00	0.61	0.96	
C20	Rectum	33	0.00	0.00	0.00	0.00	0.00	0.00	0.90	2.24	7.02	3.44	9.69	9.02	22.34	17.23	22.79	38.98	18.69	2.24	3.06	
C21	Anus and anal canal	5	0.00	0.00	0.00	0.00	0.00	0.00	1.80	0.00	0.00	0.00	3.44	0.00	0.00	0.00	5.74	0.00	0.00	0.34	0.39	
C22	Liver and intrahepatic biliary ducts	28	0.72	0.00	0.00	0.00	0.00	0.83	1.80	2.24	1.40	6.88	4.85	12.02	17.87	11.49	22.79	12.99	0.00	1.90	2.60	
C23	Gallbladder	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	1.40	0.00	0.00	3.01	0.00	5.74	0.00	12.99	18.69	0.41	0.55
C24	Other parts of the biliary ducts	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.42	0.00	0.00	0.00	25.99	0.00	0.20	0.23	
C25	Pancreas	27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.61	4.21	1.72	7.27	6.01	22.34	22.98	7.60	12.99	37.38	1.83	2.66
C26	Inaccurate locations in the gastrointestinal tract	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.27	3.01	4.47	22.98	0.00	38.98	18.69	0.88	1.29
C31	Paranasal sinuses	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	1.40	0.00	0.00	3.01	0.00	0.00	0.00	0.00	0.00	0.20	0.27
C32	Larynx	79	0.00	0.00	0.00	0.00	0.00	0.00	0.90	1.12	12.63	6.88	33.92	33.06	40.21	91.92	45.58	77.96	37.38	5.36	7.98	
C34	Bronchus and lungs	139	0.00	0.69	0.00	0.00	0.00	0.00	0.83	0.00	3.37	18.25	18.91	43.62	63.11	134.02	97.66	91.15	116.94	37.38	9.43	14.29
C38	Heart, mediastine and pleura	8	0.00	0.00	0.00	1.20	0.00	0.80	0.00	0.00	1.12	0.00	1.72	0.00	3.01	0.00	11.49	0.00	0.00	0.54	0.68	
C40	Bones and limb joints	16	0.72	0.69	1.28	3.60	1.32	0.80	0.00	0.90	1.12	0.00	0.00	2.42	0.00	0.00	0.00	0.00	0.00	0.00	1.09	0.98
C41	Bones and joints of other locations	18	0.00	0.69	1.28	1.20	0.66	0.00	1.67	0.00	1.12	1.40	0.00	0.00	9.02	8.93	0.00	7.60	12.99	18.69	1.22	1.46
C43	Malignant skin melanoma	23	0.00	0.00	0.00	0.00	0.00	0.80	1.67	1.80	4.49	1.40	3.44	0.00	6.01	4.47	11.49	22.79	12.99	37.38	1.56	1.88
C44	Other malignant skin neoplasms	180	0.00	0.00	0.00	0.00	0.00	1.60	4.17	9.91	14.59	9.83	22.35	55.73	54.09	89.35	114.90	136.73	207.90	242.99	12.21	16.55
C46	Kaposi's sarcoma	3	0.00	0.00	0.00	0.00	0.00	0.83	0.00	0.00	1.40	1.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22
C48	Retropertoneum and peritoneum	11	0.00	0.00	0.00	0.60	0.00	0.80	0.00	0.90	1.12	2.81	1.72	2.42	3.01	0.00	5.74	0.00	12.99	0.00	0.75	0.89
C49	Connective tissue and other soft tissues	23	2.86	1.38	0.00	0.00	1.32	1.60	0.83	0.00	1.12	1.40	1.72	2.42	9.02	4.47	0.00	15.19	0.00	37.38	1.56	1.93
C50	Breast	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.42	0.00	0.00	5.74	7.60	0.00	0.00	0.20	0.29
C60	Penis	19	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.90	2.24	2.42	12.02	13.40	11.49	7.60	25.99	18.69	1.29	1.83		
C61	Prostate	521	0.00	0.00	0.00	0.60	0.00	0.00	0.00	0.00	1.40	32.66	106.62	198.34	486.93	511.29	751.99	844.59	523.36	35.33	53.16	
C62	Testicles	8	0.00	0.00	0.00	1.80	0.66	2.39	0.00	0.00	0.00	0.00	1.72	0.00	0.00	0.00	0.00	0.00	0.00	0.54	0.49	
C63	Other male sex organs, nos	1	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.06
C64	Kidney	30	2.15	0.69	0.00	0.00	0.00	0.00	0.00	1.80	1.12	5.61	1.72	12.12	12.02	17.87	17.23	7.60	12.99	0.00	2.03	2.91
C65	Renal pelvis	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.40	3.44	0.00	0.00	0.00	5.74	0.00	12.99	0.00	0.34	0.44	
C66	Ureters	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.01	4.47	0.00	0.00	0.00	0.14	0.25	
C67	Bladder	55	0.00	0.00	0.00	0.00	0.00	0.80	0.00	0.90	0.00	5.61	6.88	12.12	24.04	58.07	40.21	37.98	64.97	37.38	3.73	5.68
C68	Other organs of the urinary system, nos	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.19	0.00	0.00	0.14	0.15
C69	Eyes and appendages	4	1.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.60	0.00	18.69	0.27	0.34
C70	Meninges	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.09
C71	Encephalon	42	3.58	1.38	0.00	0.60	0.66	2.39	0.83	3.61	3.37	5.61	5.16	7.27	9.02	17.87	5.74	15.19	25.99	0.00	2.85	3.51
C72	Spinal cord and other parts of the central nervous system	5	0.00	0.00	0.00	0.00	0.00	0.00	2.50	0.00	0.00	0.00	1.72	0.00	3.01	0.00	0.00	0.00	0.00	0.34	0.36	
C73	Thyroid gland	17	0.00	0.00	0.00	1.80	0.66	0.00	0.00	1.80	1.12	1.40	5.16	9.69	3.01	0.00	0.00	7.60	0.00	0.00	1.15	1.32
C74	Adrenal gland	1	0.00	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.07
C75	Other endocrine glands and related structures	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.42	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.10
C76	Other inaccurate locations	32	0.00	0.00	0.00	0.60	1.32	0.80	0.83	0.00	3.37	4.21	8.60	0.00	0.00	22.34	17.23	45.58	12.99	18.69	2.17	2.79
C80	Unknown primary site	39	0.72	0.00	0.00	0.00	0.00	0.00	0.83	0.00	2.24	8.42	6.88	12.12	12.02	31.27	22.98	22.79	12.99	18.69	2.64	3.87
C81	Hodgkin's disease	18	0.00	0.6																		

Table 47 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C96	Other malignant lymphatic tissue neoplasms and correlates	5	0.72	1.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.42	0.00	4.47	0.00	0.00	0.00	0.00	0.34	0.46
C00-96, D46	All invasive primary malignant neoplasms	2,098	24.34	13.15	8.30	22.20	17.79	19.95	35.87	46.87	98.74	192.30	273.33	535.52	766.32	1,286.58	1,418.97	1,640.71	2,027.03	1,457.94	142.28	198.97
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	1,918	24.34	13.15	8.30	22.20	17.79	18.35	31.70	36.95	84.16	182.47	250.98	479.79	712.23	1,197.23	1,304.07	1,503.99	1,819.13	1,214.95	130.08	182.43
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.07
D04	Skin carcinoma in situ	2	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.74	0.00	0.00	0.00	0.14	0.16
D07	Carcinoma in situ of other sex organs and unspecified organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.01	0.00	0.00	0.00	0.00	0.00	0.07	0.12
C00-96, D00-09, D46	All primary malignant neoplasm	2,102	24.34	13.15	8.30	22.20	17.79	19.95	36.70	46.87	99.87	192.30	273.33	535.52	769.32	1,286.58	1,424.71	1,640.71	2,027.03	1,457.94	142.55	199.33

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

João Pessoa - PB, 2000 - 2005

Table 48

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.74	0.00	2.86	3.38	0.00	7.44	0.00	0.30	0.34
C02	Other parts of the tongue	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	0.00	2.75	3.74	0.00	0.00	9.73	7.44	18.20	0.60	0.56
C03	Gingiva	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00	0.00	0.00	0.00	0.00	14.89	0.00	0.18	0.14
C04	Floor of the mouth	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	1.13	0.00	1.87	0.00	2.86	3.38	0.00	0.00	0.00	0.30	0.35
C05	Palate	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.37	0.00	2.09	8.57	0.00	7.44	9.10	0.42	0.49	
C06	Other parts of the mouth	10	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.00	3.74	8.34	0.00	0.00	14.59	0.00	0.00	0.60	0.67
C07	Parotid gland	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	1.37	0.00	0.00	0.00	0.00	0.00	0.00	9.10	0.18	0.16
C08	Other larger salivary glands	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.17	2.86	3.38	0.00	0.00	0.00	0.24	0.32	
C09	Amygdala	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.00	1.37	1.87	2.09	0.00	0.00	0.00	0.00	0.24	0.28	
C10	Oropharynx	2	0.00	0.00	0.00	0.00	0.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.86	0.00	0.00	0.00	0.00	0.12	0.14	
C11	Nasopharynx	5	0.00	0.00	0.00	0.00	0.59	0.00	0.00	0.00	0.00	0.00	0.00	3.74	0.00	2.86	0.00	0.00	9.10	0.30	0.33	
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.10	0.06	0.05
C13	Hypopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.04	
C14	Inaccurate locations of the lip, oral cavity and pharynx	3	0.00	0.00	0.00	0.00	0.68	0.00	0.00	0.00	0.00	0.00	1.87	0.00	0.00	3.38	0.00	0.00	0.00	0.18	0.20	
C15	Esophagus	26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.52	0.94	2.26	1.37	5.62	6.26	14.28	10.15	4.86	14.89	27.30	1.55	1.72
C16	Stomach	78	0.74	0.00	0.00	0.00	0.68	2.11	0.76	7.51	9.06	10.98	16.85	22.94	17.13	37.22	14.59	52.11	9.10	4.64	5.16	
C17	Small intestine	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.00	1.87	4.17	0.00	0.00	4.86	0.00	0.00	0.24	0.29	
C18	Colon	69	0.00	0.00	0.00	0.00	1.35	0.70	0.76	0.94	5.66	9.61	11.23	22.94	45.69	33.83	14.59	14.89	36.39	4.11	4.89	
C19	Rectosigmoid junction	8	0.00	0.00	0.00	0.00	1.35	0.00	0.00	0.00	1.13	0.00	1.87	2.09	2.86	0.00	0.00	0.00	18.20	0.48	0.51	
C20	Rectum	59	0.00	0.00	0.00	0.00	1.35	2.81	3.05	0.94	4.53	5.49	3.74	20.85	37.12	20.30	34.05	14.89	0.00	3.51	3.98	
C21	Anus and anal canal	31	0.00	0.00	0.00	0.00	0.00	1.41	0.76	1.88	0.00	4.12	5.62	14.60	8.57	10.15	19.46	7.44	18.20	1.85	2.04	
C22	Liver and intrahepatic biliary ducts	33	0.00	0.00	0.00	0.00	0.00	0.70	1.52	1.88	2.26	6.86	3.74	6.26	8.57	6.77	24.32	29.78	18.20	1.96	2.00	
C23	Gallbladder	26	0.00	0.00	0.00	0.00	0.00	0.70	1.52	0.00	1.13	4.12	3.74	2.09	17.13	16.92	19.46	7.44	0.00	1.55	1.72	
C24	Other parts of the biliary ducts	6	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	1.87	0.00	2.86	0.00	3.38	0.00	0.00	0.00	0.36	0.41	
C25	Pancreas	37	0.00	0.00	0.00	0.00	1.17	0.00	0.00	2.28	0.94	2.26	1.37	3.74	10.43	17.13	20.30	9.73	29.78	27.30	2.20	2.36
C26	Inaccurate locations in the gastrointestinal tract	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	2.75	0.00	2.09	2.86	3.38	4.86	0.00	0.00	0.42	0.49	
C31	Paranasal sinuses	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	1.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.12	0.14	
C32	Larynx	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.74	4.17	8.57	3.38	4.86	7.44	0.00	0.60	0.73
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.86	0.00	0.00	0.06	0.05	
C34	Bronchus and lungs	76	0.00	0.00	0.00	0.00	0.00	1.41	0.76	1.88	7.93	15.10	5.62	29.19	45.69	23.68	38.91	7.44	36.39	4.52	5.32	
C38	Heart, mediastine and pleura	7	0.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.87	4.17	2.86	0.00	9.73	0.00	0.00	0.42	0.51	
C40	Bones and limb joints	17	0.00	0.00	1.28	0.56	0.59	0.68	0.70	2.28	0.00	2.26	0.00	3.74	2.09	2.86	3.38	4.86	0.00	1.01	1.02	
C41	Bones and joints of other locations	8	0.00	0.00	0.00	1.69	0.00	0.68	0.00	0.00	0.00	0.00	0.00	4.17	0.00	0.00	0.00	7.44	9.10	0.48	0.46	
C43	Malignant skin melanoma	33	0.00	0.00	0.00	0.00	0.59	0.68	0.00	1.52	3.75	3.40	5.49	11.23	10.43	8.57	6.77	4.86	7.44	0.00	1.96	2.24
C44	Other malignant skin neoplasms	206	0.00	0.00	0.64	0.00	0.00	2.03	3.52	5.33	15.02	11.32	21.97	41.19	37.53	59.97	84.59	136.19	96.77	191.07	12.26	12.87
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.86	0.00	0.00	0.00	0.06	0.09	
C48	Retroperitoneum and peritoneum	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.88	1.13	2.75	3.74	4.17	5.71	3.38	0.00	14.89	9.10	0.89	0.99
C49	Connective tissue and other soft tissues	30	0.00	0.00	0.00	0.56	0.59	0.00	1.41	0.00	5.63	2.26	8.24	3.74	4.17	5.71	6.77	9.73	14.89	0.00	1.79	1.86
C50	Breast	954	0.00	0.00	0.00	0.56	2.93	4.06	14.77	45.69	98.55	160.79	185.34	228.44	210.59	214.18	226.69	267.51	230.76	254.75	56.78	62.69
C51	Vulva	13	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.94	1.13	0.00	3.74	0.00	2.86	3.38	14.59	7.44	18.20	0.77	0.74
C52	Vagina	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.26	1.37	5.62	2.09	2.86	6.77	0.00	7.44	9.10	0.71	0.82
C53	Cervix	406	0.00	0.00	0.00	1.12	2.93	10.14	21.81	23.61	44.11	63.41	43.93	86.13	64.64	108.52	77.82	111.87	119.10	81.89	24.16	25.49
C54	Endometrium	58	0.00	0.00	0.00	0.00	0.68	0.70	1.52	1.88	3.40	8.24	13.11	25.02	25.70	23.68	19.46	14.89	18.20	3.45	4.05	
C55	Uterus, nos	33	0.00	0.00	0.00	0.00	0.59	4.06	0.70	2.28	2.82	4.53	0.00	5.62	4.17	11.42	6.77	4.86	7.44	18.20	1.96	2.04
C56	Ovary	98	0.00	0.71	2.56	0.00	0.59	1.35	2.81	5.33	10.32	13.59	17.85	14.98	12.51	34.27	20.30	29.18	37.22	0.00	5.83	6.28
C57	Other female sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.06	
C64	Kidney	19	2.97	0.71	0.00	0.00	0.00	0.00	1.52	1.88	0.00	1.37	7.49	0.00	2.86	0.00	4.86	14.89	9.10	1.13	1.25	
C65	Renal pelvis	6	0.00	0.71	0.00	0.00	0.00	0.00	0.00	0.00	0.94	1.13	0.00	1.87	0.00	2.86	0.00	0.00	0.00	9.10	0.36	0.40
C67	Bladder	24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.40	0.00	5.62	2.09	8.57	16.92	19.46	29.78	9.10	1.43	1.50
C68	Other organs of the urinary system, nos	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.87	0.00	2.86	0.00	0.00	0.00	0.00	0.12	0.16	
C69	Eyes and appendages	5	0.00	0.71	0.00	0.00	0.00	0.00	0.00	1.52	0.00	1.13	0.00	0.00	0.00	0.00	0.00	4.86	0.00	0.30	0.28	
C70	Meninges	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.37	1.87	0.00	0.00	0.00	0.00	0.00	0.12	0.14	
C71	Encephalon	56	1.48	1.42	0.64	1.69	0.00	1.35	3.52	1.52	3.75	4.53	8.24	7.49	12.51	14.28	20.30	9.73	0.00	9.10	3.33	3.63
C72	Spinal cord and other parts of the central nervous system	2	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.87	0.00	0.00	0.00	0.00	0.00	0.12	0.13	
C73	Thyroid gland	88	0.00	0.00	0.64	0.00	4.11	1.35	3.52	6.09	12.20	13.59	9.61	14.98	10.43	14.28	20.30	14.59	22.33	18.20	5.24	5.30
C74	Adrenal gland	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.05	
C75	Other endocrine glands and related structures	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.10	0.06	0.05
C76	Other inaccurate locations	39	0.00	0.00	0.64	0.56	0.00	0.00	1.41	0.76	1.88	1.13	1.37	7.49	10.43	8.57	16.92	14.59	59.55	18.20	2.32	2.33
C80	Unknown primary site	49																				

Table 48 (continuation)

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C94	Other specified-type cell leukemias	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.07
C95	Unspecified cell leukemia	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.00	0.00	1.87	0.00	0.00	3.38	0.00	0.00	0.00	0.00	0.18	0.20
C96	Other lymphatic tissue malignant neoplasms and correlates	1	0.00	0.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.07
D46	Myelodysplastic syndromes	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.09	0.00	0.00	4.86	0.00	0.00	0.12	0.13	
C00-96, D46	All invasive primary malignant neoplasms	2,933	13.35	9.21	9.61	11.81	18.20	38.54	69.65	124.13	242.16	354.41	407.75	610.42	631.76	899.54	842.47	967.90	1,027.24	1,037.21	174.56	190.32	
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	2,727	13.35	9.21	8.97	11.81	18.20	36.51	66.13	118.80	227.14	343.09	385.79	569.22	594.23	839.57	757.88	831.71	930.47	846.15	162.30	177.45	
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.86	0.00	0.00	0.00	0.00	0.06	0.09	
D01	Carcinoma in situ of other organs of the gastrointestinal tract	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.09	0.00	0.00	0.00	0.00	0.00	0.06	0.08	
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.04	
D04	Skin carcinoma in situ	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00	0.00	2.86	0.00	0.00	0.00	0.00	0.12	0.15	
D05	Breast carcinoma in situ	32	0.74	0.00	0.00	0.00	0.00	0.68	0.70	0.76	2.82	3.40	6.86	7.49	14.60	8.57	6.77	4.86	0.00	0.00	1.90	2.27	
D06	Cervical carcinoma in situ	254	0.00	0.00	0.00	2.81	7.63	27.05	29.55	44.17	28.16	26.04	19.22	16.85	12.51	19.99	13.53	0.00	7.44	9.10	15.12	13.79	
D07	Carcinoma in situ of other sex organs and unspecified organs	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.76	0.00	0.00	0.00	1.87	0.00	0.00	3.38	0.00	0.00	0.00	0.18	0.19	
C00-96, D00-09, D46	All primary malignant neoplasms	3,227	14.09	9.21	9.61	14.62	25.83	66.26	100.60	169.82	273.14	384.98	433.84	636.63	660.95	933.81	866.15	972.76	1,034.69	1,046.31	192.06	206.94	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

João Pessoa - PB, 2000 - 2005

Male

Table 49

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	153	14.62	97.4	2.0	33.3
C15 Esophagus	49	4.92	95.9	4.1	83.7
C16 Stomach	143	13.80	97.2	2.1	71.3
C18-21 Large intestine, anal canal and anus	101	9.30	99.0	2.0	41.6
C22 Liver	28	2.60	92.9	3.6	175.0
C25 Pancreas	27	2.66	81.5	14.8	155.6
C32 Larynx	79	7.98	96.2	3.8	45.6
C33-34 Trachea, bronchus and lungs	139	14.29	93.5	7.2	107.9
C43 Skin melanoma	23	16.55	100.0	0.0	21.7
C61 Prostate	521	53.16	98.9	1.3	29.9
C70-72 Central Nervous System	48	3.96	97.9	2.1	81.3
C73 Thyroid	17	1.32	94.1	0.0	11.8
C91-95 Leukemia	94	7.87	95.7	1.1	62.8
C81-85, C96 Lymphoma	96	7.50	96.9	1.0	32.3
C00-96, D46 All primary invasive malignant Neoplasms	2,098	198.97	97.1	2.5	50.0
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	1,918	182.43	96.9	2.7	54.1

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 50

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	46	2.98	11.0	0.0	37.0
C15 Esophagus	26	1.72	92.3	11.5	42.3
C16 Stomach	78	5.16	94.9	3.9	85.9
C18-21 Large intestine, anal canal and anus	167	11.42	98.2	1.2	40.1
C22 Liver	33	2.00	87.9	12.1	154.5
C25 Pancreas	37	2.36	86.5	10.8	173.0
C32 Larynx	10	0.73	100.0	0.0	50.0
C33-34 Trachea, bronchus and lungs	77	5.37	92.2	5.2	113.0
C43 Skin melanoma	33	12.87	100.0	0.0	30.3
C50 Breast	954	62.69	98.3	1.7	19.7
C53 Cervix	406	25.49	98.8	1.2	20.9
C70-72 Central Nervous System	60	3.90	90.0	3.3	101.7
C73 Thyroid	88	5.30	97.7	2.3	9.1
C91-95 Leukemia	83	5.53	97.6	1.2	68.7
C81-85, C96 Lymphoma	96	6.08	99.0	1.0	37.5
C00-96, D46 All primary invasive malignant Neoplasms	2,933	190.32	97.2	2.2	39.9
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	2,727	177.45	97.0	2.4	42.6

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

João Pessoa - PB, 2000 - 2005

Male




Figure 39

Female




Figure 40

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

João Pessoa - PB, 2000 - 2005

Table 51

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	14	31.76	34.26	24	39.51	40.05	14	32.41	35.24	18	29.51	32.37
Ia. Lymphoid leukemia	11	24.95	27.03	18	29.63	30.40	9	20.83	22.06	13	21.32	22.16
Ib. Acute myeloid leukemia	1	2.27	2.23	4	6.58	5.78	4	9.26	10.31	4	6.56	7.99
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	2.27	2.23	1	1.65	1.73	1	2.31	2.87	1	1.64	2.22
Ie. Specified leukemias and other unspecified leukemias	1	2.27	2.77	1	1.65	2.14	0	0.00	0.00	0	0.00	0.00
II. Reticuloendothelial lymphomas and neoplasms	16	36.30	37.96	23	37.86	38.87	7	16.20	16.91	12	19.68	19.43
Ila. Hodgkin's lymphoma	5	11.34	9.65	8	13.17	11.53	2	4.63	4.73	6	9.84	8.73
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	7	15.88	18.83	10	16.46	18.65	3	6.94	8.03	4	6.56	7.49
Ilc. Burkitt's lymphoma	1	2.27	2.23	2	3.29	3.08	1	2.31	1.86	1	1.64	1.44
Ild. Miscellany of lymphoreticular neoplasms	3	6.81	7.25	3	4.94	5.62	1	2.31	2.29	1	1.64	1.77
III. CNS and misc. of intracranial and intraspinal neoplasms	7	15.88	18.32	8	13.17	15.55	6	13.89	14.03	9	14.76	14.67
IIIa. Ependymoma and choroid plexus tumor	1	2.27	2.79	1	1.65	2.16	0	0.00	0.00	0	0.00	0.00
IIIb. Astrocytoma	4	9.07	10.53	4	6.58	8.16	2	4.63	4.73	3	4.92	4.93
IIIc. Intracranial and intraspinal embryonic tumors	2	4.54	5.00	2	3.29	3.87	1	2.31	2.87	2	3.28	3.49
IIId. Other gliomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	1.64	1.26
IIIf. Unspecified intracranial and intraspinal tumors	0	0.00	0.00	1	1.65	1.35	3	6.94	6.43	3	4.92	4.99
IV. Neuroblastoma and other peripheral nervous cell tumor	2	4.54	5.00	2	3.29	3.87	1	2.31	2.87	1	1.64	2.22
IVa. Neuroblastoma and ganglioneuroblastoma	2	4.54	5.00	2	3.29	3.87	1	2.31	2.87	1	1.64	2.22
V. Retinoblastoma	2	4.54	5.53	2	3.29	4.29	0	0.00	0.00	0	0.00	0.00
VI. Renal tumors	4	9.07	10.53	4	6.58	8.16	5	11.57	13.77	5	8.20	10.67
VIa. Nephroblastoma and other renal non-epithelial tumors	4	9.07	10.53	4	6.58	8.16	5	11.57	13.77	5	8.20	10.67
VIII. Malignant bone tumors	9	20.42	19.13	17	27.98	25.63	2	4.63	3.72	6	9.84	7.94
VIIIa. Osteosarcoma	3	6.81	5.56	7	11.52	9.71	1	2.31	1.86	3	4.92	3.97
VIIIb. Chondrosarcoma	0	0.00	0.00	1	1.65	1.35	0	0.00	0.00	0	0.00	0.00
VIIIc. Ewing's sarcoma and related bone sarcomas	2	4.54	4.09	3	4.94	4.52	1	2.31	1.86	2	3.28	2.71
VIIId. Other specified malignant bone tumors	2	4.54	4.46	2	3.29	3.46	0	0.00	0.00	0	0.00	0.00
VIIIe. Unspecified malignant bone tumors	2	4.54	5.02	4	6.58	6.59	0	0.00	0.00	1	1.64	1.26
IX. Soft-tissue and other extraosseous sarcomas	6	13.61	14.77	8	13.17	14.15	1	2.31	2.29	2	3.28	3.04
IXa. Rhabdomyosarcoma	5	11.34	12.01	5	8.23	9.31	1	2.31	2.29	1	1.64	1.77
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	0	0.00	0.00	1	1.65	1.35	0	0.00	0.00	0	0.00	0.00
IXd. Other unspecified soft-tissue sarcomas	1	2.27	2.77	1	1.65	2.14	0	0.00	0.00	0	0.00	0.00
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	1	1.65	1.35	0	0.00	0.00	1	1.64	1.26
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	0	0.00	0.00	2	3.29	2.70	5	11.57	9.73	5	8.20	7.54
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	1	1.65	1.35	3	6.94	5.58	3	4.92	4.33
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	1	2.31	2.29	1	1.64	1.77
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	1	1.65	1.35	1	2.31	1.86	1	1.64	1.44
XI. Other malignant epithelial neoplasms and melanomas	4	9.07	9.62	9	14.82	14.21	5	11.57	11.32	13	21.32	18.89
XIb. Thyroid carcinoma	0	0.00	0.00	3	4.94	4.05	1	2.31	1.86	1	1.64	1.44
XIc. Nasopharynx carcinoma	1	2.27	1.85	1	1.65	1.44	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	0	0.00	0.00	0	0.00	0.00	1	2.31	1.86	1	1.64	1.44
XIf. Other carcinomas and unspecified carcinomas	3	6.81	7.77	5	8.23	8.72	3	6.94	7.60	11	18.04	16.01
XII. Other malignant and unspecified neoplasms	2	4.54	5.56	4	6.58	7.01	1	2.31	2.29	2	3.28	3.04
XIIb. Other unspecified malignant tumors	2	4.54	5.56	4	6.58	7.01	1	2.31	2.29	2	3.28	3.04
All neoplasms	66	149.72	160.69	103	169.55	174.48	47	108.80	112.16	73	119.70	119.81

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Manaus - AM, 2000 - 2004





Figure 41. Distribution of the population* in Manaus

*Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Manaus

Coordinator

Nayara Cabral Machado

Statistician

Anasselis Veiga de Lima

Informatics support

Rubens Marques Furtado

Supervisors/Registrars

Paulo Ewerton Silva de Araújo

Elizacarla Neves Cardoso

Data Collectors

Franciely Pimentel Nobre

Jéssica Geber de Azevedo

Advisory Committee

Marília Muniz Cavalcante de Oliveira (nurse)

Maria José Pinheiro (oncologist nurse)

Margareth Rieko Minami Sato (cytopathologist doctor)

Anasselis Veiga de Lima (statistician)

Manoel Jesus Pinheiro (oncologist doctor)

Luciano Afonso Teixeira Brandão (mastologist doctor)

Manuel Matias Pinto (urologist doctor)

Fábio Francesconi do Valle (dermatologist doctor)

Sidney Chalub (gastroendocrinologist doctor)

Aristóteles Comte de Alencar (cardiologist doctor)

Infrastructure and Data Source

This PBCR was created in 2001 and the data collection started in June of that same year. It is located in the Oncology Control Center Foundation of the State of Amazonas and receives financial support directly from the National Health Fund, as per Ordinance No. 2,607/GM, of December 28th, 2005.




Figure 42. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary site and age group

Manaus - AM, 2000 - 2004

Table 52

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.06
C01	Tongue base	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.95	4.30	0.00	2.70	7.41	0.00	0.00	15.69	0.25	0.56	
C02	Other parts of the tongue	43	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.40	3.01	6.69	5.67	4.30	9.42	8.09	14.82	5.70	0.00	47.07	1.19	2.29	
C03	Gingiva	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	0.00	0.00	0.00	0.00	0.00	0.03	0.08
C04	Floor of the mouth	16	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.40	0.00	1.34	0.00	7.17	0.00	0.00	3.70	22.81	0.00	15.69	0.44	0.79	
C05	Palate	22	0.00	0.00	0.00	0.00	0.30	0.00	0.00	0.00	2.68	2.84	7.17	1.88	8.09	7.41	5.70	11.33	0.00	0.61	1.19		
C06	Other parts of the mouth	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	1.34	0.95	2.87	0.00	0.00	3.70	5.70	0.00	15.69	0.28	0.48		
C07	Parotid gland	5	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.67	0.95	0.00	0.00	2.70	0.00	5.70	0.00	0.00	0.14	0.25		
C08	Other larger salivary glands	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.05	
C09	Amygdala	29	0.00	0.00	0.00	0.00	0.00	0.00	0.79	1.00	3.34	4.73	5.73	5.65	2.70	14.82	17.10	0.00	0.00	0.80	1.55		
C10	Oropharynx	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	2.84	2.87	7.54	0.00	3.70	11.40	22.66	0.00	0.41	0.90		
C11	Nasopharynx	16	0.00	0.00	0.00	0.48	0.25	0.30	0.00	0.79	0.00	0.00	2.84	1.43	5.65	0.00	3.70	5.70	11.33	0.00	0.44	0.75	
C12	Piriform sinus	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	3.77	8.09	0.00	0.00	0.00	0.00	0.17	0.43		
C13	Hypopharynx	7	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.67	0.00	1.43	5.65	0.00	0.00	5.70	0.00	0.19	0.40		
C14	Inaccurate locations of the lip, oral cavity and pharynx	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	0.00	1.43	0.00	5.39	14.82	5.70	22.66	0.00	0.36	0.77		
C15	Esophagus	84	0.00	0.00	0.00	0.00	0.00	0.00	1.19	2.00	6.02	6.62	17.20	22.62	32.36	40.75	34.21	33.99	47.07	2.32	5.01		
C16	Stomach	461	0.00	0.00	0.00	0.00	0.49	0.59	2.41	3.96	13.53	30.10	46.31	78.84	77.28	188.75	237.09	273.68	203.97	203.99	12.71	26.83	
C17	Small intestine	9	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.00	2.01	0.00	0.00	5.65	0.00	3.70	5.70	0.00	0.00	0.25	0.50		
C18	Colon	75	0.00	0.00	0.00	0.00	0.30	1.37	1.98	3.51	5.35	6.62	18.64	15.08	10.79	33.34	28.51	33.99	15.69	2.07	3.96		
C19	Rectosigmoid junction	12	0.00	0.00	0.00	0.00	0.30	0.00	0.40	2.00	0.67	0.00	1.43	0.00	2.70	7.41	0.00	0.00	15.69	0.33	0.57		
C20	Rectum	56	0.00	0.00	0.00	0.24	0.00	0.30	0.69	3.16	1.50	2.01	4.73	11.47	11.31	13.48	7.41	28.51	45.33	31.38	1.54	2.86	
C21	Anus and anal canal	10	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	2.01	0.95	0.00	1.88	2.70	0.00	5.70	0.00	0.00	0.28	0.43		
C22	Liver and intrahepatic biliary ducts	175	0.22	0.24	0.26	0.24	0.99	0.89	1.03	1.19	5.51	14.05	13.23	21.50	35.81	59.32	77.80	79.82	90.65	156.91	4.82	9.88	
C23	Gallbladder	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	0.95	0.00	1.34	0.95	0.00	7.54	5.39	0.00	0.00	0.28	0.65	
C24	Other parts of the biliary ducts	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.95	1.43	1.88	0.00	0.00	22.81	0.00	15.69	0.25	0.52		
C25	Pancreas	68	0.22	0.00	0.00	0.00	0.00	0.69	1.58	1.00	0.67	4.73	21.50	15.08	24.27	33.34	34.21	22.66	47.07	1.87	4.05		
C26	Inaccurate locations in the gastrointestinal tract	19	0.00	0.00	0.00	0.00	0.00	0.30	0.34	0.40	0.50	0.67	0.00	4.30	5.65	2.70	7.41	11.40	22.66	15.69	0.52	1.07	
C31	Paranasal sinuses	5	0.22	0.00	0.00	0.24	0.00	0.00	0.00	0.00	0.67	0.00	0.00	1.88	2.70	0.00	0.00	0.00	0.00	0.14	0.24		
C32	Larynx	133	0.00	0.00	0.00	0.00	0.00	0.00	0.69	1.19	2.51	4.68	11.34	30.10	43.35	53.93	51.86	91.23	79.32	31.38	3.67	8.17	
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	0.00	0.00	0.00	0.00	0.03	0.08	
C34	Bronchus and lungs	435	0.22	0.24	0.26	0.00	0.00	1.37	1.19	7.02	14.05	32.13	70.24	111.20	188.75	288.95	273.68	407.93	156.91	11.99	27.36		
C38	Heart, mediastine and pleura	19	0.22	0.00	0.00	0.24	0.49	0.00	0.34	0.00	3.51	0.00	0.00	0.00	1.88	2.70	11.11	0.00	0.00	31.38	0.52	0.85	
C40	Bones and limb joints	28	0.00	0.24	0.78	2.63	0.49	0.89	0.34	0.79	1.00	0.67	0.00	1.88	0.00	0.00	5.70	0.00	0.00	0.77	0.74		
C41	Bones and joints of other locations	27	0.00	0.00	0.52	0.48	0.49	0.89	0.34	0.40	1.00	0.00	2.84	7.17	0.00	10.79	0.00	0.00	31.38	0.74	1.21		
C43	Malignant skin melanoma	35	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.40	0.50	2.01	3.78	8.60	7.54	13.48	22.23	17.10	11.33	0.00	0.96	2.11	
C44	Other malignant skin neoplasms	677	0.22	0.00	0.26	0.48	1.73	2.96	7.22	9.10	22.05	36.12	55.76	98.91	143.24	226.49	314.88	347.80	396.60	392.28	18.66	37.93	
C46	Kaposi's sarcoma	6	0.00	0.00	0.00	0.00	0.49	0.30	0.69	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.14		
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02	
C48	Retroperitoneum and peritoneum	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.67	1.89	0.00	5.65	2.70	3.70	5.70	11.33	0.00	0.36	0.66		
C49	Connective tissue and other soft tissues	47	0.67	0.24	0.52	0.96	1.48	0.00	1.03	1.19	0.00	2.68	2.84	8.60	11.31	5.39	3.70	5.70	11.33	15.69	1.30	2.02	
C50	Breast	8	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.40	0.00	0.00	0.95	0.00	3.77	2.70	0.00	11.40	0.00	0.22	0.44		
C60	Penis	51	0.00	0.00	0.00	0.00	0.00	0.30	1.03	2.37	1.50	4.01	3.78	7.17	9.42	16.18	11.11	39.91	0.00	15.69	1.41	2.60	
C61	Prostate	531	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	6.02	15.12	63.07	113.09	229.19	433.43	513.14	657.22	549.19	14.64	34.90		
C62	Testicles	38	0.44	0.00	0.26	1.20	1.73	1.18	2.75	0.79	5.00	3.34	0.00	2.87	0.00	0.00	3.70	0.00	0.00	1.05	1.05		
C63	Other male sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.05	
C64	Kidney	53	2.22	0.00	0.00	0.00	0.30	0.34	0.00	3.01	2.01	7.56	8.60	11.31	5.39	11.11	17.10	11.33	0.00	1.46	2.40		
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04	
C67	Bladder	79	0.22	0.00	0.00	0.00	0.00	0.59	0.00	0.00	1.50	2.68	2.84	14.33	18.85	26.96	62.98	34.21	56.66	94.15	2.18	4.96	
C69	Eyes and appendages	27	2.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	2.00	0.67	0.95	2.87	3.77	8.09	3.70	11.40	0.00	15.69	0.74	1.24	
C70	Meninges	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.67	0.00	0.00	1.88	0.00	0.00	0.00	0.00	0.00	0.08	0.15		
C71	Encephalon	137	2.00	3.13	2.35	1.68	2.47	1.78	3.78	3.56	4.01	6.69	4.73	5.73	13.19	24.27	55.57	11.40	22.66	15.69	3.78	5.48	
C72	Spinal cord and other parts of the central nervous system	6	0.00	0.24	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.95	1.43	3.77	0.00	0.00	0.00	0.00	0.00	0.17	0.30		
C73	Thyroid gland	21	0.00	0.00	0.00	0.00	0.00	0.30	0.69	1.19	0.50	0.00	4.73	0.00	3.77	8.09	7.41	11.40	0.00	0.00	0.58	1.06	
C74	Adrenal gland	7	0.89	0.24	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.21		
C75	Other endocrine glands and related structures	2	0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.06	
C76	Other inaccurate locations	35	0.00	0.00	0.00	0.00	0.25	0.30	0.00	0.00	0.50	4.01	2.84	5.73	3.77	13.48	22.23	11.40	33.99	15.69	0.96	2.05	
C80	Unknown primary site																						

Table 52 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C96	Other malignant lymphatic tissue neoplasms and correlates	4	0.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.11
C00-96, D46	All invasive primary malignant neoplasms	4,190	23.54	13.97	13.05	16.77	18.52	19.53	36.42	51.03	108.24	197.31	300.54	602.06	823.64	1,356.27	1,978.22	2,178.00	2,402.27	2,149.69	115.51	230.38
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	3,513	23.32	13.97	12.79	16.29	16.79	16.57	29.20	41.93	86.19	161.20	244.78	503.15	680.40	1,129.78	1,663.33	1,830.21	2,005.67	1,757.41	96.85	192.45
D02	Carcinoma in situ of the middle ear and respiratory system	3	0.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	3.70	0.00	0.00	0.00	0.08	0.17
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02
D04	Skin carcinoma in situ	11	0.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.67	0.00	1.43	3.77	5.39	3.70	11.40	0.00	15.69	0.30	0.70
D07	Carcinoma in situ of other sex organs and unspecified organs	2	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.70	0.00	0.00	0.06	0.08
C00-96, D00-09, D46	All primary malignant neoplasms	4,207	23.54	13.97	13.05	16.77	19.01	19.53	36.76	51.43	108.24	197.98	300.54	603.50	827.41	1,364.36	1,985.63	2,195.11	2,402.27	2,165.39	115.98	231.35

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Manaus - AM, 2000 - 2004

Table 53

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C01	Tongue base	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.03
C02	Other parts of the tongue	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	4.72	4.12	2.75	12.61	14.93	0.00	0.31	0.62
C03	Gingiva	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.20	0.00	8.11	0.05	0.08
C04	Floor of the mouth	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.90	1.27	0.00	0.00	5.51	0.00	0.00	0.00	0.13	0.23
C05	Palate	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.57	2.06	2.75	8.40	14.93	0.00	0.18	0.34
C06	Other parts of the mouth	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.79	0.00	0.00	2.75	4.20	0.00	8.11	0.13	0.23
C07	Parotid gland	10	0.23	0.00	0.00	0.44	0.00	0.00	0.00	0.00	0.00	0.64	0.00	2.54	0.00	2.06	0.00	8.40	0.00	8.11	0.26	0.39
C08	Other larger salivary glands	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.48	0.00	0.90	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.10	0.16
C09	Amygdala	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.00	0.00	0.90	0.00	0.00	0.00	0.00	8.40	0.00	0.00	0.13	0.20
C10	Oropharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	1.27	1.57	0.00	0.00	0.00	0.00	0.00	0.08	0.14
C11	Nasopharynx	7	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.38	0.95	0.00	0.00	0.00	0.00	0.00	2.75	4.20	7.46	0.00	0.18	0.23
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04
C14	Inaccurate locations of the lip, oral cavity and pharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.06	2.75	0.00	7.46	0.00	0.08	0.15
C15	Esophagus	19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.90	1.27	3.14	4.12	8.26	12.61	22.39	24.33	0.50	0.91	
C16	Stomach	228	0.23	0.00	0.00	0.22	0.00	0.82	2.63	4.21	5.72	10.19	16.12	25.40	37.72	61.83	79.88	113.46	89.55	113.53	5.98	10.41
C17	Small intestine	5	0.00	0.00	0.00	0.00	0.00	0.27	0.33	0.00	0.00	0.00	0.00	1.27	0.00	2.06	0.00	0.00	7.46	0.00	0.13	0.19
C18	Colon	95	0.00	0.00	0.00	0.22	0.00	0.82	0.33	1.15	4.29	2.55	6.27	8.89	15.72	24.73	27.55	46.23	59.70	40.55	2.49	4.14
C19	Rectosigmoid junction	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	1.43	0.64	0.90	1.27	0.00	4.12	2.75	0.00	7.46	0.00	0.29	0.46
C20	Rectum	68	0.00	0.00	0.00	0.00	0.23	0.27	0.66	1.53	1.43	7.01	6.27	7.62	15.72	12.37	22.04	12.61	0.00	32.44	1.78	3.02
C21	Anus and anal canal	32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.95	1.27	7.17	2.54	9.43	4.12	8.26	12.61	14.93	8.11	0.84	1.52
C22	Liver and intrahepatic biliary ducts	115	0.23	0.00	0.00	0.00	0.27	1.31	0.38	1.91	3.82	2.69	16.51	22.00	39.16	35.81	46.23	97.01	89.21	3.02	5.45	
C23	Gallbladder	27	0.00	0.00	0.00	0.00	0.00	0.33	0.76	0.48	0.00	6.27	3.81	3.14	6.18	8.26	12.61	7.46	8.11	0.71	1.24	
C24	Other parts of the biliary ducts	18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	2.54	4.72	6.18	2.75	16.81	7.46	24.33	0.47	0.89	
C25	Pancreas	62	0.00	0.00	0.26	0.00	0.00	0.33	1.15	0.95	1.27	5.37	11.43	9.43	10.31	22.04	25.21	37.31	48.66	1.63	2.78	
C26	Inaccurate locations in the gastrointestinal tract	28	0.00	0.00	0.00	0.00	0.27	0.33	0.76	0.48	0.64	0.90	1.27	7.86	4.12	2.75	12.61	52.24	16.22	0.73	1.21	
C31	Paranasal sinuses	7	0.00	0.00	0.00	0.23	0.27	0.00	0.00	0.00	0.00	0.00	3.81	0.00	0.00	0.00	2.75	4.20	0.00	0.00	0.18	0.29
C32	Larynx	19	0.23	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.95	1.27	1.79	3.81	3.14	2.06	11.02	4.20	0.00	0.00	0.50	0.88
C34	Bronchus and lungs	249	0.00	0.00	0.00	0.22	0.46	0.27	0.66	0.76	6.20	12.10	19.71	34.29	73.87	78.32	66.11	105.06	67.16	129.75	6.53	12.28
C37	Thymus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.03	0.06
C38	Heart, mediastine and pleura	7	0.00	0.25	0.00	0.00	0.00	0.54	0.00	0.00	0.00	0.64	0.00	1.27	0.00	0.00	2.75	4.20	0.00	0.00	0.18	0.25
C40	Bones and limb joints	28	0.00	0.49	1.80	1.77	0.46	0.27	0.66	0.00	0.95	0.00	0.00	1.27	1.57	0.00	0.00	7.46	8.11	0.73	0.72	
C41	Bones and joints of other locations	11	0.00	0.00	0.00	0.44	0.23	0.00	0.00	0.38	0.48	0.00	0.00	1.57	6.18	5.51	0.00	0.00	0.00	0.29	0.47	
C43	Malignant skin melanoma	23	0.00	0.00	0.00	0.23	0.27	0.33	0.00	2.39	1.91	0.00	0.00	4.72	2.06	2.75	8.40	7.46	16.22	0.60	0.83	
C44	Other malignant skin neoplasms	614	0.00	0.25	0.00	0.00	0.46	1.36	5.58	10.32	18.13	33.76	35.83	68.58	111.59	166.95	212.10	243.74	246.27	340.60	16.11	27.86
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.03	0.06
C46	Kaposi's sarcoma	4	0.00	0.00	0.00	0.00	0.46	0.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.08
C47	Peripheral nerves and autonomic nervous system	1	0.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.03
C48	Retroperitoneum and peritoneum	25	0.00	0.00	0.00	0.00	0.27	0.33	0.76	1.91	0.64	1.79	3.81	3.14	10.31	2.75	4.20	7.46	8.11	0.66	1.09	
C49	Connective tissue and other soft tissues	41	0.23	0.74	0.00	1.11	1.37	0.54	0.66	0.38	2.86	1.27	0.90	2.54	1.57	6.18	5.51	8.40	7.46	0.00	1.08	1.29
C50	Breast	838	0.00	0.00	0.00	0.00	1.14	3.53	16.42	27.53	49.13	81.54	94.05	134.62	124.17	98.93	121.20	163.89	149.25	129.75	21.98	34.33
C51	Vulva	21	0.00	0.00	0.00	0.00	0.00	0.33	0.00	2.39	2.55	2.69	0.00	0.00	6.18	5.51	4.20	7.46	8.11	0.55	0.87	
C52	Vagina	8	0.00	0.00	0.00	0.00	0.00	0.33	0.38	0.00	1.27	0.90	1.27	0.00	0.00	2.75	4.20	0.00	0.00	0.21	0.31	
C53	Cervix	1,314	0.00	0.00	0.00	0.22	0.91	15.49	33.49	55.44	87.77	112.12	133.47	166.36	179.18	150.46	190.07	176.50	149.25	121.64	34.47	50.59
C54	Endometrium	56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	1.91	3.82	3.58	8.89	17.29	22.67	13.77	16.81	7.46	16.22	1.47	2.84
C55	Uterus, nos	46	0.00	0.00	0.00	0.00	0.00	0.33	1.15	1.91	3.19	3.58	10.16	7.86	12.37	11.02	16.81	7.46	8.11	1.21	2.13	
C56	Ovary	130	0.23	0.00	1.28	0.89	2.05	1.63	2.63	4.21	6.68	4.46	16.12	15.24	17.29	16.49	16.53	12.61	14.93	16.22	3.41	4.81
C57	Other female sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.03	0.06
C58	Placenta	6	0.00	0.00	0.00	0.22	0.23	0.54	0.33	0.00	0.00	0.00	0.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.15
C64	Kidney	39	1.83	0.25	0.00	0.22	0.23	0.27	0.33	0.76	0.48	3.82	0.90	1.27	6.29	6.18	13.77	4.20	7.46	0.00	1.02	1.52
C65	Renal pelvis	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.46	0.00	0.03	0.04
C67	Bladder	23	0.00	0.00	0.00	0.22	0.00	0.27	0.00	0.00	0.00	1.27	1.79	3.81	7.86	6.18	8.26	4.20	0.00	16.22	0.60	1.15
C69	Eyes and appendages	15	0.92	0.00	0.00	0.23	0.27	0.33	0.00	0.00	0.00	0.00	1.79	1.27	0.00	0.00	5.51	0.00	7.46	8.11	0.39	0.50
C71	Encephalon	105	1.37	1.97	0.26	1.77	0.91	1.63	1.64	3.06	3.82	7.64	9.85	7.62	3.14	18.55	19.28	4.20	7.46	16.22	2.75	3.74
C72	Spinal cord and other parts of the central nervous system	3	0.00	0.00	0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	4.20	0.00	0.00	0.08	0.10
C73	Thyroid gland	78	0.00	0.00	0.26	0.22	0.91	1.90	1.64	2.68	3.82	7.01	5.37	8.89	6.29	10.31	5.51	21.01	14.93	24.33	2.05	2.88
C74	Adrenal gland	10	1.14	0.00	0.26	0.00	0.23	0.27	0.00	0.00	0.00	0.64	0.00	1.27	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.29
C75	Other endocrine glands and related structures	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	

Table 53 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C85	Other types of non-Hodgkin lymphoma, nos	61	0.23	0.49	0.26	0.00	0.23	0.54	1.31	1.91	0.95	1.91	7.17	5.08	12.57	12.37	13.77	16.81	22.39	16.22	1.60	2.60	
C90	Multiple myeloma and malignant plasmacyte neoplasms	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.64	0.90	1.27	6.29	4.12	8.26	0.00	0.00	0.00	0.34	0.70	
C91	Lymphoid leukemia	102	6.63	4.18	3.34	1.55	1.59	0.82	0.33	1.15	1.43	2.55	2.69	2.54	7.86	0.00	5.51	4.20	7.46	0.00	2.68	2.91	
C92	Myeloid leukemia	89	0.69	1.48	1.28	0.22	1.82	2.45	2.63	1.53	1.43	4.46	8.96	5.08	9.43	12.37	13.77	12.61	7.46	0.00	2.33	3.15	
C94	Other specified-type cell leukemias	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04	
C95	Unspecified cell leukemia	14	0.23	0.00	0.77	0.00	0.00	0.27	0.00	0.00	0.48	0.00	0.00	1.27	0.00	2.06	2.75	4.20	14.93	16.22	0.37	0.51	
C96	Other lymphatic tissue malignant neoplasms and correlates	2	0.00	0.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
C00-96, D46	All invasive primary malignant neoplasms	5,006	14.87	12.55	13.35	11.31	16.39	37.78	79.78	130.38	223.71	324.90	430.85	615.93	773.29	900.72	1,055.01	1,302.74	1,276.12	1,394.86	131.31	206.73	
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	4,392	14.87	12.30	13.35	11.31	15.93	36.43	74.20	120.05	205.59	291.14	395.02	547.35	661.70	733.76	842.91	1,059.00	1,029.85	1,054.25	115.21	178.88	
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04	
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.05	
D04	Skin carcinoma in situ	9	0.00	0.00	0.00	0.00	0.46	0.00	0.00	0.00	0.48	0.64	0.00	1.27	0.00	0.00	5.51	0.00	14.93	0.00	0.24	0.34	
D05	Breast carcinoma in situ	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.27	2.69	1.27	3.14	0.00	0.00	4.20	0.00	0.00	0.26	0.43	
D06	Cervical carcinoma in situ	1,040	0.00	0.00	0.00	1.77	9.33	27.18	60.41	62.70	73.94	64.98	60.91	49.53	45.58	47.41	24.79	16.81	7.46	0.00	27.28	27.78	
D07	Carcinoma in situ of other sex organs and unspecified organs	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	1.43	1.91	0.90	0.00	0.00	0.00	0.00	4.20	7.46	0.00	0.29	0.35	
D09	Carcinoma in situ of other locations and unspecified locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.03	
C00-96, D00-09, D46	All primary malignant neoplasms	6,079	14.87	12.55	13.35	13.09	26.18	64.97	140.19	193.46	300.04	394.34	495.35	669.27	822.02	948.12	1,085.31	1,327.95	1,305.97	1,394.86	159.46	235.74	

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Manaus - AM, 2000 - 2004

Male

Table 54

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	148	7.91	92.6	6.1	42.6
C15 Esophagus	84	5.01	47.6	45.2	95.2
C16 Stomach	461	26.83	54.5	37.7	82.9
C18-21 Large intestine, anal canal and anus	153	7.82	66.7	29.4	62.1
C22 Liver	175	9.88	19.4	71.4	99.4
C25 Pancreas	68	4.05	22.1	63.2	111.8
C32 Larynx	133	8.17	71.4	24.8	69.9
C33-34 Trachea, bronchus and lungs	436	27.44	39.4	51.4	96.3
C43 Skin melanoma	35	37.93	91.4	8.6	28.6
C61 Prostate	531	34.90	71.2	24.7	43.7
C70-72 Central Nervous System	146	5.92	43.8	37.0	85.6
C73 Thyroid	21	1.06	61.9	33.3	42.9
C91-95 Leukemia	237	8.16	78.5	19.4	60.8
C81-85, C96 Lymphoma	176	6.86	80.1	18.2	54.5
C00-96, D46 All primary invasive malignant Neoplasms	4,190	230.38	66.6	28.4	57.9
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	3,513	192.45	60.5	33.6	68.5

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 55

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	40	1.88	90.0	10.0	40.0
C15 Esophagus	19	0.91	52.6	36.8	100.0
C16 Stomach	228	10.41	46.9	48.7	91.7
C18-21 Large intestine, anal canal and anus	206	9.15	68.0	30.1	58.7
C22 Liver	115	5.45	16.5	79.1	102.6
C25 Pancreas	62	2.78	19.4	75.8	100.0
C32 Larynx	19	0.88	73.7	21.1	47.4
C33-34 Trachea, bronchus and lungs	249	12.28	33.7	55.8	98.8
C43 Skin melanoma	23	27.86	87.0	13.0	30.4
C50 Breast	838	34.33	88.3	11.3	27.6
C53 Cervix	1,314	50.59	89.4	9.8	31.9
C70-72 Central Nervous System	108	3.85	51.9	40.7	91.7
C73 Thyroid	78	2.88	85.9	12.8	19.2
C91-95 Leukemia	206	6.61	78.6	18.0	52.9
C81-85, C96 Lymphoma	118	4.25	80.5	18.6	39.0
C00-96, D46 All primary invasive malignant Neoplasms	5,006	206.73	75.8	22.2	44.6
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	4,392	178.88	72.6	25.1	50.5

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Manaus - AM, 2000 - 2004

Male




Figure 43

Female




Figure 44

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Manaus - AM, 2000 - 2004

Table 56

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14		No.	0-19		No.	0-14		No.	0-19	
		Crude	Adjusted*		Crude	Adjusted*		Crude	Adjusted*		Crude	Adjusted*
I. Leukemia	95	76.09	77.54	111	66.62	68.72	73	59.20	59.93	81	48.10	50.44
Ia. Lymphoid leukemia	71	56.87	57.96	80	48.02	49.77	55	44.60	45.67	62	36.82	38.89
Ib. Acute myeloid leukemia	18	14.42	14.55	20	12.00	12.36	10	8.11	7.93	11	6.53	6.65
Ic. Myeloproliferative chronic diseases	1	0.80	0.76	5	3.00	2.74	3	2.43	2.41	3	1.78	1.87
Id. Myelodysplastic syndrome and myeloproliferative diseases	0	0.00	0.00	1	0.60	0.54	1	0.81	0.79	1	0.59	0.62
Ie. Specified leukemias and other unspecified leukemias	5	4.00	4.27	5	3.00	3.31	4	3.24	3.12	4	2.38	2.42
II. Reticuloendothelial lymphomas and neoplasms	30	24.03	24.01	45	27.01	26.69	25	20.27	19.31	28	16.63	16.46
Ila. Hodgkin's lymphoma	13	10.41	10.08	19	11.40	11.04	12	9.73	9.18	13	7.72	7.62
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	6	4.81	4.60	14	8.40	7.88	5	4.05	3.87	6	3.56	3.50
Ilc. Burkitt's lymphoma	3	2.40	2.51	3	1.80	1.94	6	4.87	4.66	7	4.16	4.11
Ild. Miscellany of lymphoreticular neoplasms	4	3.20	3.46	4	2.40	2.68	2	1.62	1.59	2	1.19	1.23
Ile. Unspecified lymphoma	4	3.20	3.36	5	3.00	3.14	0	0.00	0.00	0	0.00	0.00
III. CNS and misc. of intracranial and intraspinal neoplasms	32	25.63	25.43	39	23.41	23.48	13	10.54	10.60	21	12.47	12.21
IIla. Ependymoma and choroid plexus tumor	2	1.60	1.64	2	1.20	1.27	1	0.81	0.89	1	0.59	0.69
IIlb. Astrocytoma	10	8.01	7.80	12	7.20	7.12	4	3.24	3.27	10	5.94	5.53
IIlc. Intracranial and intraspinal embryonic tumors	5	4.00	3.89	6	3.60	3.55	3	2.43	2.38	4	2.38	2.34
IIld. Other gliomas	1	0.80	0.76	1	0.60	0.59	0	0.00	0.00	0	0.00	0.00
IIle. Other intracranial and intraspinal neoplasms	1	0.80	0.83	1	0.60	0.65	0	0.00	0.00	0	0.00	0.00
IIIf. Unspecified intracranial and intraspinal tumors	13	10.41	10.50	17	10.20	10.30	5	4.05	4.06	6	3.56	3.65
IV. Neuroblastoma and other peripheral nervous cell tumor	3	2.40	2.54	3	1.80	1.97	3	2.43	2.67	3	1.78	2.07
IVa. Neuroblastoma and ganglioneuroblastoma	3	2.40	2.54	3	1.80	1.97	3	2.43	2.67	3	1.78	2.07
V. Retinoblastoma	8	6.41	6.93	8	4.80	5.37	3	2.43	2.65	3	1.78	2.05
VI. Renal tumors	10	8.01	8.66	10	6.00	6.71	8	6.49	7.02	9	5.34	5.94
VIa. Nephroblastoma and other renal non-epithelial tumors	10	8.01	8.66	10	6.00	6.71	8	6.49	7.02	9	5.34	5.94
VII. Hepatic tumors	2	1.60	1.62	3	1.80	1.80	1	0.81	0.87	1	0.59	0.68
VIIa. Hepatoblastoma	2	1.60	1.62	2	1.20	1.26	1	0.81	0.87	1	0.59	0.68
VIIc. Unspecified malignant hepatic tumors	0	0.00	0.00	1	0.60	0.54	0	0.00	0.00	0	0.00	0.00
VIII. Malignant bone tumors	6	4.81	4.57	19	11.40	10.54	8	6.49	6.06	16	9.50	8.69
VIIIa. Osteosarcoma	3	2.40	2.27	10	6.00	5.53	7	5.68	5.31	11	6.53	6.11
VIIIb. Chondrosarcoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.59	0.50
VIIIc. Ewing's sarcoma and related bone sarcomas	2	1.60	1.53	5	3.00	2.81	1	0.81	0.75	4	2.38	2.07
VIIIe. Unspecified malignant bone tumors	1	0.80	0.76	4	2.40	2.20	0	0.00	0.00	0	0.00	0.00
IX. Soft-tissue and other extraosseous sarcomas	5	4.00	4.08	7	4.20	4.24	2	1.62	1.59	8	4.75	4.23
IXa. Rhabdomyosarcoma	1	0.80	0.87	2	1.20	1.21	0	0.00	0.00	1	0.59	0.50
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	2	1.60	1.70	2	1.20	1.32	1	0.81	0.79	1	0.59	0.62
IXd. Other unspecified soft-tissue sarcomas	2	1.60	1.52	3	1.80	1.71	1	0.81	0.79	4	2.38	2.11
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	1.19	1.00
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	3	2.40	2.49	8	4.80	4.62	6	4.87	4.60	10	5.94	5.56
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	1	0.81	0.87	2	1.19	1.18
Xc. Malignant gonadal germ cell tumors	3	2.40	2.49	7	4.20	4.09	5	4.05	3.73	8	4.75	4.38
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	1	0.60	0.54	0	0.00	0.00	0	0.00	0.00
XI. Other malignant epithelial neoplasms and melanomas	5	4.00	3.92	11	6.60	6.27	6	4.87	4.93	22	13.06	11.81
XIa. Adrenal cortex carcinoma	0	0.00	0.00	0	0.00	0.00	2	1.62	1.63	2	1.19	1.27
XIb. Thyroid carcinoma	0	0.00	0.00	0	0.00	0.00	1	0.81	0.75	2	1.19	1.08
XIc. Nasopharynx carcinoma	0	0.00	0.00	2	1.20	1.08	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	2	1.60	1.62	4	2.40	2.34	1	0.81	0.79	1	0.59	0.62
XIf. Other carcinomas and unspecified carcinomas	3	2.40	2.29	5	3.00	2.85	2	1.62	1.76	17	10.10	8.85
XII. Other malignant and unspecified neoplasms	15	12.01	12.32	20	12.00	12.25	20	16.22	16.66	25	14.85	15.41
XIIa. Other specified malignant tumors	0	0.00	0.00	0	0.00	0.00	1	0.81	0.79	1	0.59	0.62
XIIb. Other unspecified malignant tumors	15	12.01	12.32	20	12.00	12.25	19	15.41	15.87	24	14.25	14.79
All neoplasms	214	171.40	174.11	284	170.46	172.65	168	136.23	136.89	227	134.80	135.53

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Natal - RN, 2000 - 2004





Figure 45. Distribution of the population* in Natal
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Natal

Coordinator

Juliana Bruna de Araujo

Registrars

Sandra Patrícia Saraiva Cipriano

Gisonildo Pereira

Data Collectors/Data Entry Clerks

Maria Angélica Freitas da Silva

Natália Louise de Araújo Cabral

Advisory Committee

Severina Pereira de Oliveira

Josiel Mariano Cordeiro

Infrastructure and Data Source

The Natal PBCR was established in 1996, whereas the data collection started in 1997. It is located in the building of the Health Secretariat of the State of Rio Grande do Norte (SES/RN).




Figure 46. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary location and age group

Natal - RN, 2000 - 2004

Table 57 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C85	Other types of non-Hodgkin lymphoma, nos	37	0.00	2.35	0.00	0.00	0.57	1.42	0.72	2.31	1.90	1.22	1.45	4.25	0.00	15.61	14.29	18.43	11.33	45.16	2.15	2.23
C90	Multiple myeloma and malignant plasmacyte neoplasms	40	0.00	0.00	0.00	0.00	0.00	0.00	0.72	0.00	0.00	2.44	8.71	10.62	19.33	19.51	0.00	24.58	34.00	0.00	2.32	2.82
C91	Lymphoid leukemia	48	1.19	1.18	2.17	3.05	0.57	1.42	0.00	1.54	1.90	1.22	4.35	0.00	5.52	19.51	0.00	24.58	0.00	60.21	2.79	2.74
C92	Myeloid leukemia	34	1.78	0.00	0.00	0.51	0.00	0.71	0.72	0.77	0.95	7.31	2.90	2.12	8.29	3.90	19.05	12.29	11.33	15.05	1.97	2.22
C95	Unspecified cell leukemia	12	0.59	0.00	1.09	0.00	0.00	0.00	0.00	0.77	1.90	1.22	0.00	0.00	0.00	0.00	0.00	0.00	11.33	0.00	0.70	0.46
C96	Other malignant lymphatic tissue neoplasms and correlates	3	0.00	0.00	0.00	0.00	0.00	0.00	0.72	0.00	0.00	1.22	1.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.19
C00-96, D46	All invasive primary malignant neoplasms	4,032	14.28	10.58	9.77	15.26	15.93	30.48	39.69	89.27	157.76	252.22	422.38	682.09	1,226.21	1,833.79	2,247.73	2,856.97	3,808.23	3,597.77	234.13	304.09
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	3,132	14.28	10.58	9.77	14.75	15.36	23.39	27.42	58.49	105.49	174.24	322.23	522.73	963.85	1,439.72	1,823.90	2,261.00	2,912.84	2,739.73	181.87	236.13
D01	Carcinoma in situ of other organs of the gastrointestinal tract	3	0.00	0.00	0.00	0.00	0.00	0.00	0.72	0.00	0.95	0.00	0.00	0.00	2.76	0.00	0.00	0.00	0.00	0.00	0.17	0.21
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.76	0.00	0.00	0.06	0.10
D04	Skin carcinoma in situ	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.76	6.14	34.00	0.00	0.29	0.33
D05	Breast carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.12	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.08
D07	Carcinoma in situ of other sex organs and unspecified organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.76	0.00	0.00	0.00	0.00	0.00	0.06	0.11
D09	Carcinoma in situ of other locations and unspecified locations	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.45	0.00	0.00	3.90	0.00	0.00	0.00	0.00	0.12	0.19
C00-96, D00-09, D46	All primary malignant neoplasms	4,045	14.28	10.58	9.77	15.26	15.93	30.48	40.41	89.27	158.72	252.22	423.83	684.22	1,231.74	1,837.69	2,257.25	2,863.11	3,842.23	3,597.77	234.89	305.11

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Natal - RN, 2000 - 2004

Table 58

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	1.92	2.64	0.00	8.24	7.09	0.00	0.31	0.34	
C01	Tongue base	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.00
C02	Other parts of the tongue	18	0.00	0.00	0.00	0.00	1.04	0.00	0.00	0.65	0.00	1.98	2.30	1.63	1.92	2.64	5.90	0.00	21.28	7.71	0.92	0.84	0.84
C03	Gingiva	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.09	0.00	0.05	0.04	0.04
C04	Floor of the mouth	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.76	2.64	0.00	4.12	7.09	15.42	0.41	0.46	0.46
C05	Palate	18	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	0.99	1.15	0.00	0.00	2.64	8.85	16.47	28.37	23.13	0.92	0.84	0.84
C06	Other parts of the mouth	24	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.00	0.00	1.15	8.16	3.84	2.64	8.85	12.36	35.47	15.42	1.23	1.21	1.21
C07	Parotid gland	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	0.00	0.00	0.00	0.00	5.90	4.12	0.00	0.00	0.21	0.21	0.21
C08	Other larger salivary glands	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.95	0.00	0.00	0.00	0.00	0.05	0.06
C09	Amygdala	4	0.00	0.00	0.53	0.00	0.00	0.00	0.00	0.65	0.00	0.00	0.00	1.63	0.00	0.00	2.95	0.00	0.00	0.00	0.21	0.21	0.21
C10	Oropharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.64	2.95	4.12	0.00	0.00	0.15	0.18	0.18
C11	Nasopharynx	2	0.00	0.00	0.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.95	0.00	0.00	0.00	0.10	0.11	0.11
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.07	0.07
C13	Hypopharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.65	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.09	0.09
C14	Inaccurate locations of the lip, oral cavity and pharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.92	0.00	0.00	0.00	0.00	0.00	0.05	0.08	0.08
C15	Esophagus	28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.65	0.00	2.97	2.30	4.89	7.68	2.64	8.85	16.47	14.19	23.13	1.44	1.44	1.44
C16	Stomach	188	0.00	0.00	0.00	0.00	0.52	1.22	1.87	2.58	8.66	18.80	13.79	26.10	28.81	47.46	64.91	86.49	92.22	123.35	9.66	9.61	9.61
C17	Small intestine	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.15	1.63	0.00	0.00	0.00	12.36	0.00	7.71	0.36	0.28	0.28
C18	Colon	143	0.00	0.00	0.00	0.00	0.00	0.61	0.00	3.88	4.73	4.95	17.24	24.47	42.25	42.19	38.36	53.54	92.22	69.39	7.35	7.77	7.77
C19	Rectosigmoid junction	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.36	1.98	1.15	3.26	3.84	0.00	0.00	8.24	7.09	23.13	0.87	0.84	0.84
C20	Rectum	78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.58	3.15	4.95	6.89	9.79	26.89	13.18	11.80	32.95	56.75	46.26	4.01	3.93	3.93
C21	Anus and anal canal	31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.65	5.51	0.99	2.30	3.26	5.76	13.18	5.90	12.36	7.09	30.84	1.59	1.73	1.73
C22	Liver and intrahepatic biliary ducts	39	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.98	9.19	4.89	5.76	7.91	5.90	24.71	14.19	30.84	2.00	1.91	1.91
C23	Gallbladder	55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.58	3.96	3.45	8.16	11.52	15.82	26.56	37.07	14.19	46.26	2.83	2.97	2.97
C24	Other parts of the biliary ducts	32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.99	0.00	4.89	3.84	13.18	11.80	20.59	35.47	7.71	1.64	1.51	1.51
C25	Pancreas	88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.98	8.04	14.68	9.60	18.46	26.56	65.90	70.94	77.10	4.52	3.98	3.98
C26	Inaccurate locations in the gastrointestinal tract	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	1.92	0.00	0.00	4.12	7.09	0.00	0.26	0.22	0.22
C30	Nasal cavity and middle ear	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.92	0.00	0.00	0.00	0.00	0.05	0.08	0.08
C31	Paranasal sinuses	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	0.00	2.95	4.12	0.00	0.00	0.15	0.16	0.16
C32	Larynx	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	3.45	6.53	3.84	2.64	2.95	8.24	0.00	7.71	0.77	0.91	0.91
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.00	0.00
C34	Bronchus and lungs	154	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.58	5.51	20.78	14.94	34.26	42.25	52.73	47.21	49.42	28.37	53.97	7.91	8.97	8.97
C38	Heart, mediastine and pleura	13	0.00	0.00	0.00	0.00	0.00	1.22	0.62	0.00	0.00	0.00	2.30	3.26	0.00	2.64	5.90	4.12	7.09	0.00	0.67	0.65	0.65
C40	Bones and limb joints	7	0.00	1.81	1.07	0.00	0.00	0.00	0.00	0.65	0.00	0.00	0.00	0.00	1.92	0.00	0.00	0.00	0.00	0.00	0.36	0.39	0.39
C41	Bones and joints of other locations	21	0.00	1.21	0.00	0.96	0.52	0.61	0.00	0.00	1.58	0.99	2.30	4.89	1.92	0.00	5.90	0.00	14.19	7.71	1.08	1.07	1.07
C43	Malignant skin melanoma	45	0.00	0.00	0.00	0.96	0.52	0.61	2.50	1.29	3.15	5.94	8.04	4.89	3.84	5.27	5.90	12.36	7.09	7.71	2.31	2.17	2.17
C44	Other malignant skin neoplasms	819	0.00	0.00	0.00	0.48	2.08	6.70	13.11	24.56	37.02	56.41	56.31	123.98	153.64	216.20	206.54	358.32	524.93	578.21	42.07	42.25	42.25
C46	Kaposi's sarcoma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.10	0.10
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.92	0.00	0.00	0.00	0.00	0.05	0.08	0.08
C48	Retroperitoneum and peritoneum	49	1.24	0.60	0.00	0.00	0.00	0.00	1.25	1.29	1.58	0.00	9.19	4.89	1.92	18.46	23.61	24.71	14.19	15.42	2.52	2.61	2.61
C49	Connective tissue and other soft tissues	29	0.62	0.60	0.00	1.43	0.00	1.83	0.00	0.65	1.58	4.95	0.00	1.63	1.92	2.64	8.85	8.24	14.19	7.71	1.49	1.43	1.43
C50	Breast	1,025	0.00	0.00	0.00	0.48	0.52	3.05	17.49	35.54	77.98	147.45	150.53	172.92	190.13	205.65	239.00	230.64	312.12	254.41	52.65	55.17	55.17
C51	Vulva	20	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.79	0.00	2.30	1.63	0.00	5.27	17.70	16.47	14.19	7.71	1.03	1.05	1.05
C52	Vagina	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	1.15	0.00	3.84	0.00	0.00	12.36	0.00	0.00	0.36	0.39	0.39
C53	Cervix	377	0.00	0.00	0.00	0.48	3.64	7.92	13.11	16.80	28.36	31.67	42.52	63.62	63.38	84.37	94.42	78.25	85.12	53.97	19.37	19.47	19.47
C54	Endometrium	83	0.00	0.00	0.00	0.00	0.52	0.00	1.94	2.36	6.93	5.75	19.58	21.13	23.73	32.46	28.83	35.47	23.13	4.26	4.61	4.61	4.61
C55	Uterus, nos	93	0.00	0.00	0.00	0.00	1.04	3.66	0.62	3.23	3.94	12.86	13.79	13.05	15.36	10.55	26.56	16.47	21.28	30.84	4.78	4.71	4.71
C56	Ovary, nos	145	0.62	0.00	1.60	1.43	1.04	0.61	1.87	4.52	6.30	10.89	14.94	29.36	23.05	39.55	35.41	45.30	35.47	23.13	7.45	7.38	7.38
C57	Other female sex organs, nos	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	1.98	0.00	1.63	0.00	0.00	2.95	0.00	0.00	7.71	0.31	0.33	0.33
C58	Placenta	1	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.04	0.04
C64	Kidney	50	1.24	0.60	0.00	0.00	0.52	0.00	1.25	1.94	2.36	6.93	3.45	8.16	1.92	5.27	2.95	32.95	14.19	38.55	2.57	2.39	2.39
C67	Bladder	47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	1.98	3.45	6.53	3.84	18.46	23.61	20.59	21.28	53.97	2.41	2.36	2.36
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	0.00	0.00	0.00	0.00	0.00	0.05	0.07	0.07
C69	Eyes and appendages	5	1.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	1.92	0.00	0.00	0.00	0.00	0.00	0.26	0.29	0.29
C70	Meninges	2	0.00	0.00	0.00	0.00																	

Table 58 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C90	Multiple myeloma and malignant plasmacyte neoplasms	37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.29	0.00	0.00	3.45	8.16	7.68	29.00	8.85	8.24	14.19	23.13	1.90	2.20
C91	Lymphoid leukemia	38	2.47	0.60	1.07	1.43	2.08	0.00	0.00	0.00	0.00	0.99	1.15	3.26	7.68	10.55	5.90	16.47	14.19	7.71	1.95	2.01
C92	Myeloid leukemia	41	1.24	0.60	1.07	0.96	2.08	0.61	0.00	4.52	1.58	0.99	3.45	1.63	0.00	10.55	8.85	8.24	21.28	7.71	2.11	1.99
C95	Unspecified cell leukemia	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	2.64	0.00	12.36	14.19	7.71	0.51	0.37
C96	Other lymphatic tissue malignant neoplasms and correlates	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.06
C00-96, D46	All invasive primary malignant neoplasms	4,683	14.23	10.28	9.06	15.29	28.10	46.31	81.80	138.93	244.96	425.52	484.93	743.87	829.64	1,088.91	1,189.11	1,643.33	2,000.43	2,004.47	240.56	244.45
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	3,864	14.23	10.28	9.06	14.81	26.02	39.60	68.69	114.38	207.94	369.12	428.62	619.89	676.00	872.71	982.56	1,285.01	1,475.49	1,426.26	198.49	202.20
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
D04	Skin carcinoma in situ	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.92	2.64	2.95	0.00	0.00	0.00	0.15	0.21
D05	Breast carcinoma in situ	91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.88	11.03	16.82	12.64	17.94	7.68	29.00	23.61	4.12	7.09	0.00	4.67	4.98
D06	Cervical carcinoma in situ	363	0.00	0.00	0.00	1.91	14.05	38.39	41.21	43.29	29.93	23.75	13.79	24.47	19.20	15.82	17.70	8.24	7.09	23.13	18.65	16.16
D07	Carcinoma in situ of other sex organs and unspecified organs	6	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.65	0.79	0.00	0.00	3.26	1.92	0.00	0.00	0.00	0.00	0.00	0.31	0.37
D09	Carcinoma in situ of other locations and unspecified locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.64	0.00	0.00	0.00	0.00	0.05	0.08
C00-96, D00-09, D46	All primary malignant neoplasms	5,149	14.85	10.28	9.06	17.20	42.16	84.69	123.02	186.75	288.28	466.10	511.36	789.55	860.36	1,139.00	1,233.37	1,655.68	2,014.61	2,027.60	264.50	266.34

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Natal - RN, 2000 - 2004

Male

Table 59

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	141	11.10	63.8	28.4	41.8
C15 Esophagus	82	5.74	57.3	32.9	59.8
C16 Stomach	270	21.56	49.3	36.3	53.3
C18-21 Large intestine, anal canal and anus	192	14.83	66.1	24.5	32.3
C22 Liver	34	2.17	26.5	50.0	132.4
C25 Pancreas	76	5.38	18.4	44.7	60.5
C32 Larynx	107	8.34	55.1	37.4	43.0
C33-34 Trachea, bronchus and lungs	304	24.11	42.8	40.5	70.4
C43 Skin melanoma	46	67.96	87.0	13.0	17.4
C61 Prostate	884	69.46	72.6	19.1	20.6
C70-72 Central Nervous System	78	5.34	48.7	33.3	57.7
C73 Thyroid	39	2.98	94.9	2.6	7.7
C91-95 Leukemia	94	5.42	53.2	37.2	72.3
C81-85, C96 Lymphoma	116	7.40	72.4	19.0	41.4
C00-96, D46 All primary invasive malignant Neoplasms	4,033	304.09	67.7	22.4	34.1
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	3,133	236.13	59.6	28.3	43.4

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 60

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	83	4.12	62.7	33.7	42.2
C15 Esophagus	28	1.44	53.6	39.3	53.6
C16 Stomach	188	9.61	54.8	36.2	51.6
C18-21 Large intestine, anal canal and anus	269	14.26	64.7	24.2	29.0
C22 Liver	39	1.91	20.5	43.6	182.1
C25 Pancreas	88	3.98	26.1	50.0	68.2
C32 Larynx	15	0.91	73.3	20.0	33.3
C33-34 Trachea, bronchus and lungs	155	8.97	42.6	42.6	80.6
C43 Skin melanoma	45	42.25	84.4	13.33	13.3
C50 Breast	1,025	55.17	74.8	20.0	19.9
C53 Cervix	377	19.47	76.4	20.7	31.3
C70-72 Central Nervous System	74	3.95	35.1	51.4	100.0
C73 Thyroid	305	16.22	92.1	4.6	3.9
C91-95 Leukemia	89	4.37	41.6	44.9	75.3
C81-85, C96 Lymphoma	135	6.48	64.4	28.1	48.9
C00-96, D46 All primary invasive malignant Neoplasms	4,683	244.45	69.9	22.1	31.7
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	3,864	202.20	64.5	26.4	38.1

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Natal - RN, 2000 - 2004

Male




Figure 47

Female




Figure 48

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Natal - RN, 2000 - 2004

Table 61

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	14	26.81	27.09	21	29.21	29.01	12	23.32	24.45	17	23.48	24.33
Ia. Lymphoid leukemia	8	15.32	14.71	14	19.47	18.27	7	13.60	14.60	10	13.81	14.54
Ib. Acute myeloid leukemia	2	3.83	4.61	3	4.17	4.72	5	9.71	9.85	7	9.67	9.78
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	1.91	2.31	1	1.39	1.79	0	0.00	0.00	0	0.00	0.00
Ie. Specified leukemias and other unspecified leukemias	3	5.74	5.46	3	4.17	4.23	0	0.00	0.00	0	0.00	0.00
II. Reticuloendothelial lymphomas and neoplasms	13	24.89	24.93	14	19.47	20.46	6	11.66	11.37	8	11.05	10.96
Ila. Hodgkin's lymphoma	5	9.57	8.93	6	8.35	8.07	1	1.94	1.95	2	2.76	2.59
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	1	1.91	1.90	1	1.39	1.47	2	3.89	3.09	2	2.76	2.40
Ilc. Burkitt's lymphoma	5	9.57	10.30	5	6.95	7.99	0	0.00	0.00	0	0.00	0.00
Ile. Unspecified lymphoma	2	3.83	3.79	2	2.78	2.94	3	5.83	6.32	4	5.53	5.98
III. CNS and misc. of intracranial and intraspinal neoplasms	9	17.23	15.24	13	18.08	16.39	6	11.66	12.62	7	9.67	10.85
IIla. Ependymoma and choroid plexus tumor	0	0.00	0.00	1	1.39	1.14	0	0.00	0.00	0	0.00	0.00
IIlb. Astrocytoma	2	3.83	3.88	2	2.78	3.01	0	0.00	0.00	0	0.00	0.00
IIlc. Intracranial and intraspinal embryonic tumors	4	7.66	6.31	4	5.56	4.89	2	3.89	3.50	2	2.76	2.71
IIld. Other gliomas	1	1.91	1.58	1	1.39	1.22	2	3.89	4.78	2	2.76	3.70
IIlf. Unspecified intracranial and intraspinal tumors	2	3.83	3.47	5	6.95	6.12	2	3.89	4.34	3	4.14	4.44
IV. Neuroblastoma and other peripheral nervous cell tumor	2	3.83	3.79	2	2.78	2.94	5	9.71	11.51	5	6.91	8.92
Iva. Neuroblastoma and ganglioneuroblastoma	2	3.83	3.79	2	2.78	2.94	5	9.71	11.51	5	6.91	8.92
V. Retinoblastoma	11	21.06	24.20	11	15.30	18.75	2	3.89	4.78	2	2.76	3.70
VI. Renal tumors	2	3.83	4.20	2	2.78	3.26	3	5.83	6.73	3	4.14	5.22
Via. Nephroblastoma and other renal non-epithelial tumors	1	1.91	2.31	1	1.39	1.79	3	5.83	6.73	3	4.14	5.22
Vib. Renal carcinomas	1	1.91	1.90	1	1.39	1.47	0	0.00	0.00	0	0.00	0.00
VII. Hepatic tumors	0	0.00	0.00	0	0.00	0.00	1	1.94	2.42	1	1.38	1.87
VIIa. Hepatoblastoma	0	0.00	0.00	0	0.00	0.00	1	1.94	2.42	1	1.38	1.87
VIII. Malignant bone tumors	2	3.83	3.79	5	6.95	6.37	7	13.60	12.85	9	12.43	12.11
VIIIa. Osteosarcoma	1	1.91	1.90	2	2.78	2.61	3	5.83	5.45	4	5.53	5.30
VIIIc. Ewing's sarcoma and related bone sarcomas	0	0.00	0.00	2	2.78	2.29	2	3.89	3.50	3	4.14	3.79
VIIIe. Unspecified malignant bone tumors	1	1.91	1.90	1	1.39	1.47	2	3.89	3.90	2	2.76	3.02
IX. Soft-tissue and other extraosseous sarcomas	0	0.00	0.00	0	0.00	0.00	2	3.89	3.90	4	5.53	5.17
IXa. Rhabdomyosarcoma	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	2.76	2.15
IXd. Other unspecified soft-tissue sarcomas	0	0.00	0.00	0	0.00	0.00	1	1.94	1.95	1	1.38	1.51
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	0	0.00	0.00	1	1.94	1.95	1	1.38	1.51
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	2	3.83	4.61	4	5.56	5.86	4	7.77	7.06	8	11.05	9.77
Xa. Intracranial and intraspinal germ cell tumors	0	0.00	0.00	2	2.78	2.29	0	0.00	0.00	0	0.00	0.00
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	1.38	1.07
Xc. Malignant gonadal germ cell tumors	1	1.91	2.31	1	1.39	1.79	2	3.89	3.09	4	5.53	4.55
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	1	1.91	2.31	1	1.39	1.79	2	3.89	3.96	3	4.14	4.15
XI. Other malignant epithelial neoplasms and melanomas	1	1.91	2.31	10	13.91	12.08	5	9.71	8.98	24	33.15	27.38
XIb. Thyroid carcinoma	0	0.00	0.00	2	2.78	2.29	3	5.83	5.04	12	16.58	13.58
XIc. Nasopharynx carcinoma	0	0.00	0.00	2	2.78	2.29	1	1.94	1.55	1	1.38	1.20
XId. Malignant melanoma	0	0.00	0.00	4	5.56	4.58	0	0.00	0.00	2	2.76	2.15
XIe. Skin carcinoma	0	0.00	0.00	1	1.39	1.14	0	0.00	0.00	1	1.38	1.07
XIf. Other carcinomas and unspecified carcinomas	1	1.91	2.31	1	1.39	1.79	1	1.94	2.39	8	11.05	9.38
XII. Other malignant and unspecified neoplasms	3	5.74	5.76	7	9.74	9.04	5	9.71	10.26	6	8.29	9.02
XIIb. Other unspecified malignant tumors	3	5.74	5.76	7	9.74	9.04	5	9.71	10.26	6	8.29	9.02
All neoplasms	59	112.97	115.93	89	123.80	124.17	58	112.69	116.92	94	129.84	129.31

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação





Figure 49. Distribution of the population* in Palmas

*Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Palmas

Coordinator

Antonia Otilia Monteiro Koop

Registrar/Data Collector/Data Entry Clerk

Ozirene de Sena C. Pereira

Infrastructure and Data Source

This PBCR was created in 2000, whereas the data collection started in 2001. It is located in SESAU, at the Coordination of Oncology Control and Risk Factors, and is financially supported by SES/SMS, as per Ordinance No. 2,607.




Figure 50. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary site and age group

Palmas - TO, 2000 - 2004

Table 62

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
C01	Tongue base	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.62	0.00	0.00	0.00	0.00	0.00	0.50	1.54
C05	Palate	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.48	0.00	0.00	0.00	0.00	0.00	259.74	0.74	2.36
C06	Other parts of the mouth	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.77
C10	Oropharynx	2	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	13.24	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.70
C11	Nasopharynx	1	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.17
C12	Piriform sinus	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	0.00	0.00	32.26	0.00	0.00	0.00	0.00	0.50	1.39
C13	Hypopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.77
C14	Inaccurate locations of the lip, oral cavity and pharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.85	0.00	13.24	19.31	0.00	0.00	0.00	0.00	0.00	0.74	1.65
C15	Esophagus	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.55	0.00	0.00	57.93	32.26	61.46	0.00	0.00	259.74	2.98	6.87
C16	Stomach	24	0.00	0.00	0.00	2.27	0.00	0.00	0.00	0.00	8.74	5.85	16.95	26.48	77.23	96.77	184.39	188.50	211.86	519.48	5.96	18.21
C17	Small intestine	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.24	19.31	0.00	0.00	0.00	0.00	0.00	0.50	1.30
C18	Colon	6	0.00	0.00	0.00	0.00	0.00	0.00	2.80	0.00	0.00	0.00	0.00	0.00	0.00	32.26	61.46	188.50	0.00	0.00	1.49	4.25
C19	Rectosigmoid junction	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.37	0.00	0.00	0.00	0.00	32.26	0.00	0.00	0.00	0.00	0.50	1.23
C20	Rectum	4	0.00	0.00	0.00	0.00	0.00	0.00	5.60	0.00	0.00	5.85	8.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	1.11
C21	Anus and anal canal	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.42
C22	Liver and intrahepatic biliary ducts	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	64.52	0.00	0.00	0.00	0.00	1.49	2.71
C25	Pancreas	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	0.00	0.00	0.00	0.00	188.50	0.00	259.74	1.24	3.61
C31	Paranasal sinuses	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	94.25	0.00	0.00	0.00	0.25	0.94
C32	Larynx	7	0.00	0.00	0.00	0.00	0.00	0.00	2.80	3.38	0.00	0.00	8.47	0.00	0.00	64.52	122.93	0.00	0.00	0.00	1.74	5.19
C34	Bronchus and lungs	25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	39.72	77.23	96.77	245.85	377.00	635.59	0.00	6.21	19.87	
C38	Heart, mediastine and pleura	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	0.00	0.00	0.00	61.46	0.00	0.00	0.00	0.00	0.50	1.65
C41	Bones and joints of other locations	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.74	5.85	0.00	0.00	0.00	0.00	94.25	0.00	0.00	0.00	0.99	1.82
C43	Malignant skin melanoma	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.75	0.00	5.85	16.95	0.00	19.31	0.00	0.00	0.00	0.00	519.48	1.99	4.97
C44	Other malignant skin neoplasms	46	0.00	0.00	0.00	0.00	2.10	2.42	0.00	3.38	13.11	29.24	25.42	52.97	135.16	258.06	307.31	0.00	211.86	519.48	11.42	29.45
C48	Retroperitoneum and peritoneum	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.50	0.77
C49	Connective tissue and other soft tissues	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.38	4.37	0.00	0.00	13.24	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.99
C60	Penis	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.37	11.70	0.00	13.24	0.00	32.26	0.00	0.00	0.00	0.00	1.74	2.46
C61	Prostate	119	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.85	8.47	119.17	405.48	645.16	1,352.18	1,413.76	2,330.51	2,337.66	29.55	105.64
C62	Testicles	5	0.00	0.00	0.00	2.27	4.20	0.00	0.00	3.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.24	0.74
C64	Kidney	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.42	0.00	0.00	32.26	0.00	0.00	211.86	0.00	1.24	3.30
C67	Bladder	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.85	0.00	13.24	38.62	64.52	122.93	0.00	0.00	0.00	1.99	6.82
C69	Eyes and appendages	3	2.03	0.00	0.00	0.00	0.00	0.00	2.80	0.00	0.00	0.00	8.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.84
C71	Encephalon	3	2.03	0.00	2.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.74	1.24
C73	Thyroid gland	1	0.00	0.00	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.17
C76	Other inaccurate locations	4	0.00	0.00	0.00	0.00	0.00	2.42	0.00	0.00	4.37	0.00	0.00	0.00	0.00	0.00	188.50	0.00	0.00	0.00	0.99	2.34
C80	Unknown primary site	12	2.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.24	38.62	0.00	184.39	0.00	635.59	519.48	2.98	11.78
C81	Hodgkin's disease	5	0.00	2.31	0.00	0.00	2.10	0.00	5.60	3.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.24	0.94
C83	Non-Hodgkin diffuse lymphoma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.26
C85	Other types of non-Hodgkin lymphoma, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.25	0.77
C90	Multiple myeloma and malignant plasmacyte neoplasms	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.85	0.00	0.00	0.00	0.00	0.00	282.75	0.00	0.00	0.99	3.18
C91	Lymphoid leukemia	3	0.00	2.31	0.00	0.00	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	61.46	0.00	0.00	0.00	0.74	1.63
C92	Myeloid leukemia	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.38	0.00	0.00	8.47	13.24	19.31	32.26	0.00	0.00	211.86	0.00	1.49	3.96
C93	Monocytic leukemia Leucemia monocitica	1	0.00	2.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.23
C96	Other malignant lymphatic tissue neoplasms and correlates	1	0.00	0.00	0.00	0.00	0.00	2.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.19
D46	Myelodisplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.25	0.77
C00-96, D46	All invasive primary malignant neoplasms	366	6.10	6.92	2.46	4.54	16.80	7.26	19.60	27.00	52.45	105.28	169.46	370.76	1,081.29	1,516.13	2,765.83	3,016.02	4,449.15	5,194.81	90.89	261.97
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	320	6.10	6.92	2.46	4.54	14.70	4.84	19.60	23.63	39.34	76.04	144.04	317.80	946.13	1,258.06	2,458.51	3,016.02	4,237.29	4,675.32	79.46	232.53
D04	Skin carcinoma in situ	2	0.00	0.00	0.00	0.00	0.00	0.00	2.80	0.00	0.00	0.00	0.00	0.00	19.31	0.00	0.00	0.00	0.00	0.00	0.50	0.94
C00-96, D00-09, D46	All primary malignant neoplasms	368	6.10	6.92	2.46	4.54	16.80	7.26	22.40	27.00	52.45	105.28	169.46	370.76	1,100.60	1,516.13	2,765.83	3,016.02	4,449.15	5,194.81	91.38	262.91

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand women, per tumor primary site and age group

Palmas - TO, 2000 - 2004

Table 63

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.59
C01	Tongue base	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.00
C02	Other parts of the tongue	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.90	0.00	0.00	0.00	0.00	0.00	0.00	104.17	0.00	0.00	0.50	1.34
C03	Gingiva	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	61.12	0.00	0.00	0.00	0.25	1.22
C04	Floor of the mouth	1	0.00	0.00	0.00	0.00	0.00	0.00	2.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.17
C05	Palate	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	84.28	0.00	104.17	0.00	0.00	0.75	3.57
C06	Other parts of the mouth	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	0.00	0.00	104.17	0.00	0.00	0.75	1.62
C08	Other larger salivary glands	2	0.00	0.00	0.00	0.00	0.00	2.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.14	0.00	0.00	0.00	0.00	0.50	1.45
C13	Hypopharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.63	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.71
C14	Inaccurate locations of the lip, oral cavity and pharynx	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	0.00	0.00	0.00	158.48	0.00	0.75	1.37
C15	Esophagus	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.90	0.00	0.00	0.00	0.00	84.28	61.12	208.33	0.00	0.00	1.49	6.13
C16	Stomach	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.59	7.30	34.75	0.00	51.02	42.14	0.00	104.17	158.48	218.34	3.98	9.58
C17	Small intestine	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.51	0.00	0.00	0.00	0.00	0.00	0.00	0.25	1.02
C18	Colon	12	0.00	0.00	0.00	0.00	1.88	2.31	2.83	0.00	0.00	7.30	0.00	0.00	25.51	84.28	122.25	0.00	158.48	0.00	2.98	7.73
C19	Rectosigmoid junction	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.00
C20	Rectum	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.48	0.00	0.00	0.00	17.63	0.00	0.00	61.12	0.00	0.00	0.00	0.75	2.14
C21	Anus and anal canal	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.14	0.00	0.00	0.00	0.00	0.25	1.26
C22	Liver and intrahepatic biliary ducts	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.30	0.00	0.00	25.51	42.14	244.50	0.00	158.48	0.00	2.24	8.41
C23	Gallbladder	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	17.63	0.00	0.00	0.00	0.00	0.00	0.00	0.75	1.28
C24	Other parts of the biliary ducts	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	0.00	0.00	104.17	0.00	0.00	0.50	1.62
C25	Pancreas	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.60	11.58	0.00	0.00	84.28	61.12	104.17	0.00	0.00	1.99	6.25
C26	Inaccurate locations in the gastrointestinal tract	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.90	0.00	11.58	0.00	25.51	42.14	0.00	104.17	0.00	0.00	1.49	4.20
C32	Larynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.29
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.14	0.00	0.00	0.00	0.00	0.25	1.26
C34	Bronchus and lungs	11	0.00	0.00	0.00	0.00	0.00	0.00	8.48	0.00	4.90	0.00	0.00	0.00	102.04	42.14	61.12	0.00	0.00	0.00	2.74	7.37
C41	Bones and joints of other locations	1	0.00	0.00	0.00	0.00	0.00	2.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.18
C43	Malignant skin melanoma	8	0.00	0.00	0.00	0.00	0.00	0.00	2.83	0.00	0.00	0.00	0.00	11.58	0.00	168.56	61.12	0.00	0.00	218.34	1.99	8.12
C44	Other malignant skin neoplasms	79	0.00	0.00	0.00	0.00	3.76	11.55	19.79	13.90	34.29	43.81	69.49	88.17	178.57	126.42	489.00	0.00	475.44	2,183.41	19.65	48.94
C48	Retropertoneum and peritoneum	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.51	0.00	0.00	0.00	0.00	0.00	0.25	1.02
C49	Connective tissue and other soft tissues	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.48	4.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50
C50	Breast	90	0.00	0.00	0.00	0.00	1.88	4.62	8.48	31.29	58.77	65.71	150.57	176.34	127.55	168.56	550.12	104.17	158.48	436.68	22.39	50.14
C53	Cervix	109	0.00	0.00	0.00	0.00	3.76	18.48	33.92	45.19	73.47	73.01	92.66	123.44	255.10	168.56	305.62	312.50	0.00	0.00	27.11	49.38
C54	Endometrium	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.30	0.00	0.00	0.00	84.28	0.00	0.00	0.00	0.00	1.24	2.97
C55	Uterus, nos	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.95	4.90	0.00	11.58	0.00	25.51	0.00	61.12	0.00	158.48	0.00	1.99	4.33
C56	Ovary	13	0.00	0.00	0.00	0.00	0.00	2.31	2.83	10.43	0.00	21.90	0.00	52.90	25.51	0.00	0.00	104.17	0.00	0.00	3.23	6.47
C64	Kidney	4	0.00	0.00	0.00	0.00	1.88	0.00	0.00	0.00	0.00	7.30	0.00	35.27	0.00	0.00	0.00	0.00	0.00	0.00	0.99	2.00
C67	Bladder	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.14	0.00	0.00	0.00	0.00	0.25	1.26
C71	Encephalon	8	0.00	0.00	0.00	0.00	1.88	4.62	2.83	3.48	4.90	7.30	0.00	0.00	25.51	0.00	0.00	0.00	0.00	0.00	1.99	2.65
C73	Thyroid gland	11	0.00	0.00	0.00	0.00	1.88	2.31	0.00	0.00	19.59	7.30	0.00	0.00	51.02	84.28	0.00	0.00	0.00	0.00	2.74	6.52
C76	Other inaccurate locations	7	0.00	0.00	2.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	35.27	25.51	0.00	0.00	312.50	0.00	0.00	1.74	5.77
C80	Unknown primary site	8	0.00	0.00	0.00	0.00	0.00	2.31	0.00	3.48	0.00	7.30	11.58	0.00	25.51	42.14	61.12	0.00	158.48	0.00	1.99	5.71
C81	Hodgkin's disease	1	0.00	0.00	0.00	1.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.17
C83	Non-Hodgkin diffuse lymphoma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.21
C85	Other types of non-Hodgkin lymphoma, nos	3	0.00	0.00	0.00	0.00	0.00	2.31	0.00	3.48	0.00	0.00	0.00	0.00	25.51	0.00	0.00	0.00	0.00	0.00	0.75	1.41
C91	Lymphoid leukemia	4	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.60	0.00	0.00	0.00	42.14	0.00	0.00	0.00	0.00	0.99	2.39
C92	Myeloid leukemia	5	0.00	0.00	0.00	0.00	0.00	0.00	2.83	3.48	0.00	0.00	0.00	17.63	25.51	0.00	0.00	104.17	0.00	0.00	1.24	3.15
C95	Unspecified cell leukemia	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	61.12	0.00	0.00	0.00	0.25	1.22
C96	Other lymphatic tissue malignant neoplasms and correlates	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	61.12	0.00	0.00	0.00	0.25	1.22
C00-96, D46	All invasive primary malignant neoplasms	472	2.10	0.00	2.37	1.94	16.93	55.44	87.63	132.10	254.69	292.06	451.70	581.91	1,071.43	1,559.21	2,322.74	1,875.00	1,584.79	3,056.77	117.40	276.32
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	393	2.10	0.00	2.37	1.94	13.17	43.89	67.84	118.19	220.40	248.25	382.21	493.74	892.86	1,432.79	1,833.74	1,875.00	1,109.35	873.36	97.75	227.38
D04	Skin carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.58
D06	Cervical carcinoma in situ	62	0.00	0.00	0.00	0.00	1.88	20.79	45.23	24.33	39.18	87.62	11.58	0.00	51.02	84.28	0.00	0.00	0.00	0.00	15.42	18.74
D07	Carcinoma in situ of other sex organs and unspecified organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25	0.58
C00-96, D00-09, D46	All primary malignant neoplasms	536	2.10	0.00	2.37	1.94	18.81	76.23	132.86	156.43	293.87	379.67	486.45	581.91	1,122.45	1,643.49	2,322.74	1,875.00	1,584.79	3,056.77	133.32	296.23

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA

Palmas - TO, 2000 - 2004

Male

Table 64

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	8	5.37	75.0	25.0	37.5
C15 Esophagus	12	6.87	58.3	41.7	66.7
C16 Stomach	24	6.87	62.5	37.5	45.8
C18-21 Large intestine, anal canal and anus	13	18.21	53.8	46.2	38.5
C22 Liver	6	7.01	83.3	33.3	50.0
C25 Pancreas	5	3.61	0.0	80.0	140.0
C32 Larynx	7	5.19	85.7	0.0	42.9
C33-34 Trachea, bronchus and lungs	25	19.87	36.0	84.0	84.0
C43 Skin melanoma	8	29.45	100.0	0.0	0.0
C61 Prostate	119	105.64	83.2	16.8	21.8
C70-72 Central Nervous System	3	1.24	33.3	66.7	300.0
C73 Thyroid	1	0.17	100.0	0.0	0.0
C91-95 Leukemia	10	5.81	60.0	10.0	80.0
C81-85, C96 Lymphoma	9	2.17	66.7	22.2	55.6
C00-96, D46 All primary invasive malignant Neoplasms	366	261.97	70.5	28.1	39.9
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	320	232.53	67.8	31.9	45.0

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 65

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	13	8.51	84.6	7.7	7.7
C15 Esophagus	6	6.13	66.7	66.7	83.3
C16 Stomach	16	9.58	68.8	31.3	68.8
C18-21 Large intestine, anal canal and anus	17	11.13	76.5	23.5	41.2
C22 Liver	9	8.41	44.4	66.7	55.6
C25 Pancreas	8	6.25	12.5	100.0	100.0
C32 Larynx	1	0.29	0.0	0.0	100.0
C33-34 Trachea, bronchus and lungs	12	8.64	33.3	58.3	66.7
C43 Skin melanoma	8	48.94	62.5	0.0	0.0
C50 Breast	90	50.14	76.7	11.1	20.0
C53 Cervix	109	49.38	92.7	3.7	10.1
C70-72 Central Nervous System	8	2.65	12.5	100.0	112.5
C73 Thyroid	11	6.52	63.6	9.1	27.3
C91-95 Leukemia	10	6.76	40.0	10.0	60.0
C81-85, C96 Lymphoma	6	3.02	50.0	16.7	33.3
C00-96, D46 All primary invasive malignant Neoplasms	472	276.32	71.8	19.7	28.8
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	393	227.38	70.0	23.7	34.4

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Palmas - TO, 2000 - 2004

Male




Figure 51

Female




Figure 52

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Palmas - TO, 2000 - 2004

Table 66

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I.Leukemia	2	15.01	14.87	2	11.28	11.53	1	7.60	8.09	1	5.46	6.27
Ia.Lymphoid leukemia	1	7.51	7.44	1	5.64	5.76	1	7.60	8.09	1	5.46	6.27
Ib.Acute myeloid leukemia	1	7.51	7.44	1	5.64	5.76	0	0.00	0.00	0	0.00	0.00
II.Reticuloendothelial lymphomas and neoplasms	1	7.51	7.44	1	5.64	5.76	0	0.00	0.00	1	5.46	4.37
Ila.Hodgkin's lymphoma	1	7.51	7.44	1	5.64	5.76	0	0.00	0.00	1	5.46	4.37
III.CNS and misc. of intracranial and intraspinal neoplasms	2	15.01	15.01	2	11.28	11.63	0	0.00	0.00	0	0.00	0.00
IIlc.Intracranial and intraspinal embryonic tumors	1	7.51	7.87	1	5.64	6.10	0	0.00	0.00	0	0.00	0.00
IIIf.Unspecified intracranial and intraspinal tumors	1	7.51	7.13	1	5.64	5.53	0	0.00	0.00	0	0.00	0.00
X.Germ cell tumors, trophoblastic tumors and gonadal neoplasms	0	0.00	0.00	1	5.64	5.11	1	7.60	6.87	1	5.46	5.33
Xb.Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	1	7.60	6.87	1	5.46	5.33
Xc.Malignant gonadal germ cell tumors	0	0.00	0.00	1	5.64	5.11	0	0.00	0.00	0	0.00	0.00
XI.Other malignant epithelial neoplasms and melanomas	0	0.00	0.00	1	5.64	5.11	0	0.00	0.00	0	0.00	0.00
XIf.Other carcinomas and unspecified carcinomas	0	0.00	0.00	1	5.64	5.11	0	0.00	0.00	0	0.00	0.00
XII.Other malignant and unspecified neoplasms	2	15.01	15.75	2	11.28	12.20	0	0.00	0.00	0	0.00	0.00
XIIb.Other unspecified malignant tumors	2	15.01	15.75	2	11.28	12.20	0	0.00	0.00	0	0.00	0.00
All neoplasms	7	52.54	53.06	9	50.77	51.33	2	15.21	14.96	3	16.39	15.96

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Porto Alegre - RS, 2000 - 2004




Figure 53. Distribution of the population* in Porto Alegre
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Porto Alegre

Coordinator

Paulo Recena Grassi (in memoriam)

Registrars/Data Entry Clerks

Berenice D'Avila Salazar

Cristina Schlöttgen

Data Collectors

Adriana Vier Azevedo

Fausto Nunes Steckel

Flávio Aranovich

Mariana H. Pereira de Mello

Priscila Allem C. dos Santos

Infrastructure and Data Source

This PBCR was created in 1973, whereas the data collection started in 1979. It is located in the SHS/RS and financially supported by Ordinance No. 2,607. In turn, the managerial and operational support originate entirely from the SHS/RS, more specifically from the Health Information Center.




Figure 54. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*, per 100 thousand men, per tumor primary site and age group

Porto Alegre - RS, 2000 - 2004

Table 67

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	34	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.39	0.42	0.49	3.00	4.04	4.06	4.99	10.09	2.73	11.28	0.00	1.05	1.04
C01	Tongue base	64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.11	3.43	7.81	10.52	11.16	6.23	10.09	2.73	16.92	0.00	1.98	2.09
C02	Other parts of the tongue	101	0.00	0.00	0.00	0.00	0.00	0.00	0.42	1.57	1.69	4.91	10.81	24.27	14.20	11.22	6.73	13.64	11.28	0.00	3.13	3.26
C03	Gingiva	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.42	0.00	0.00	0.00	0.00	1.25	0.00	0.00	0.00	0.00	0.09	0.09
C04	Floor of the mouth	43	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.39	1.69	1.96	3.60	3.24	9.13	8.73	8.41	2.73	5.64	0.00	1.33	1.45
C05	Palate	41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.42	4.42	3.60	8.09	3.04	7.48	3.36	5.46	5.64	0.00	1.27	1.31
C06	Other parts of the mouth	80	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.39	2.11	4.42	9.01	11.32	10.14	16.21	11.77	5.46	5.64	0.00	2.48	2.55
C07	Parotid gland	31	0.00	0.38	0.00	0.00	0.32	0.00	0.42	0.79	0.84	0.49	3.00	4.85	5.07	1.25	1.68	8.18	11.28	0.00	0.96	0.97
C08	Other larger salivary glands	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.43	2.03	0.00	1.68	0.00	0.00	0.00	0.19	0.21
C09	Amygdala	35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.84	1.96	5.41	4.04	8.11	2.49	5.04	0.00	0.00	0.00	1.08	1.12
C10	Oropharynx	71	0.00	0.00	0.00	0.00	0.00	0.00	0.39	4.22	5.89	6.61	11.32	6.09	7.48	1.68	16.37	16.92	9.21	2.20	2.21	
C11	Nasopharynx	27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.18	1.27	0.49	5.41	1.62	4.06	3.74	0.00	5.46	0.00	0.00	0.84	0.84
C12	Piriform sinus	39	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.42	0.49	4.20	5.66	7.10	8.73	6.73	10.91	0.00	0.00	0.00	1.21	1.31
C13	Hypopharynx	45	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.79	0.84	1.47	4.20	4.85	6.09	3.74	18.49	2.73	16.92	0.00	1.39	1.45
C14	Inaccurate locations of the lip, oral cavity and pharynx	23	0.00	0.00	0.00	0.00	0.00	0.38	0.83	0.39	0.00	1.47	3.00	2.43	1.01	2.49	3.36	5.46	0.00	9.21	0.71	0.72
C15	Esophagus	546	0.00	0.00	0.00	0.00	0.00	0.00	0.42	3.93	13.10	22.08	40.85	62.29	93.31	110.94	95.83	100.92	112.81	147.36	16.89	18.19
C16	Stomach	549	0.00	0.00	0.00	0.00	0.65	1.14	0.42	2.36	11.41	17.66	37.24	46.92	71.00	89.75	132.82	166.38	208.70	248.66	16.99	17.93
C17	Small intestine	34	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.42	0.98	3.00	3.24	2.03	7.48	8.41	10.91	5.64	27.63	1.05	1.14	
C18	Colon	622	0.00	0.00	0.36	0.31	0.32	2.28	2.49	3.15	9.72	12.76	30.03	46.92	85.20	109.70	144.59	218.20	310.23	396.02	19.25	20.64
C19	Rectosigmoid junction	117	0.00	0.00	0.00	0.00	0.32	0.00	1.25	1.18	0.84	1.47	6.01	9.71	16.23	29.92	23.54	43.64	56.40	18.42	3.62	3.83
C20	Rectum	289	0.00	0.00	0.00	0.00	0.32	0.76	1.66	3.93	4.65	13.74	13.82	27.50	45.64	48.62	77.34	73.64	67.69	55.26	8.94	9.50
C21	Anus and anal canal	32	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.39	0.84	1.47	3.60	2.43	1.01	1.25	11.77	13.64	0.00	18.42	0.99	1.01
C22	Liver and intrahepatic biliary ducts	364	0.37	0.00	0.00	0.00	0.00	0.38	0.00	0.39	5.91	12.27	30.63	40.45	52.74	69.81	70.61	106.37	124.09	64.47	11.26	11.96
C23	Gallbladder	28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.60	2.43	4.06	8.73	11.77	10.91	5.64	9.21	0.87	0.97	
C24	Other parts of the biliary ducts	70	0.00	0.00	0.00	0.00	0.00	0.00	0.42	2.94	3.00	7.28	7.10	16.21	21.86	19.09	28.20	27.63	2.17	2.32		
C25	Pancreas	230	0.00	0.00	0.00	0.00	0.65	0.00	0.42	1.97	2.11	5.89	12.61	18.61	19.27	43.63	75.66	84.55	107.17	110.52	7.12	7.58
C26	Inaccurate locations in the gastrointestinal tract	41	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.39	0.84	0.00	1.20	3.24	3.04	11.22	10.09	10.91	39.48	18.42	1.27	1.35
C30	Nasal cavity and middle ear	11	0.37	0.00	0.00	0.00	0.00	0.00	0.42	0.00	0.42	0.49	0.60	0.81	1.01	2.49	0.00	2.73	5.64	0.00	0.34	0.36
C31	Paranasal sinuses	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.42	1.96	1.20	1.62	2.03	2.49	0.00	0.00	5.64	18.42	0.53	0.57
C32	Larynx	349	0.00	0.00	0.00	0.00	0.00	0.00	0.42	2.75	7.60	13.74	32.44	42.06	52.74	69.81	75.66	49.10	50.76	82.89	10.80	11.65
C33	Trachea	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.00	0.60	0.81	2.03	2.49	6.73	0.00	0.00	0.00	0.34	0.38	
C34	Bronchus and lungs	1,989	0.37	0.76	0.00	0.31	0.32	0.38	2.08	4.72	20.70	46.12	91.90	169.06	321.51	463.72	578.37	679.16	535.85	488.12	61.54	66.23
C37	Thymus	5	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.62	0.00	0.00	0.00	2.73	5.64	0.00	0.15	0.15
C38	Heart, mediastine and pleura	77	0.37	0.00	0.36	0.00	0.97	0.76	0.83	0.79	0.00	2.94	1.80	10.52	10.14	11.22	13.45	24.55	39.48	9.21	2.38	2.50
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	0.00	0.00	2.73	5.64	0.00	0.09	0.09
C40	Bones and limb joints	33	0.74	0.38	2.88	1.25	1.62	0.76	0.00	0.39	0.84	0.49	0.00	0.81	1.01	2.49	0.00	2.73	11.28	0.00	1.02	1.02
C41	Bones and joints of other locations	44	0.37	0.00	0.36	1.25	1.30	0.38	0.83	0.39	0.42	0.49	4.81	4.04	4.06	3.74	3.36	2.73	11.28	9.21	1.36	1.33
C43	Malignant skin melanoma	252	0.00	0.00	0.36	0.31	1.95	3.42	3.74	7.86	6.34	10.79	15.62	23.46	27.38	29.92	47.08	38.19	45.12	46.05	7.80	7.71
C44	Other malignant skin neoplasms	2,089	0.00	0.76	0.72	0.94	4.94	9.98	23.20	42.67	64.28	96.11	177.15	244.43	320.36	490.94	706.43	857.35	709.15	64.64	65.10	
C45	Mesothelioma	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.42	0.00	0.60	0.81	1.01	2.49	3.36	0.00	0.00	9.21	0.31	0.34
C46	Kaposi's sarcoma	45	0.00	0.00	0.36	0.31	0.65	2.28	2.49	4.33	0.84	1.47	1.20	0.81	3.04	1.25	0.00	8.18	11.28	0.00	1.39	1.23
C47	Peripheral nerves and autonomic nervous system	5	0.00	0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.00	1.25	0.00	0.00	0.00	0.00	0.15	0.11
C48	Retroperitoneum and peritoneum	24	0.00	0.00	0.36	0.00	0.00	0.00	0.42	0.39	0.42	0.98	2.40	1.62	2.03	0.00	8.41	5.46	5.64	18.42	0.74	0.77
C49	Connective tissue and other soft tissues	61	0.37	0.00	0.36	0.31	2.60	1.52	1.66	2.36	0.84	0.49	1.80	6.47	7.10	4.99	10.09	13.64	0.00	0.00	1.89	1.88
C50	Breast	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49	2.40	0.00	3.04	3.74	1.68	16.37	5.64	9.21	0.65	0.66
C60	Penis	33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.18	0.42	0.49	0.00	2.43	6.09	6.23	8.41	10.91	16.92	9.21	1.02	1.06
C61	Prostate	2,963	0.00	0.00	0.00	0.00	0.00	0.00	0.42	1.97	4.65	25.02	77.49	233.78	448.29	695.58	1,012.14	1,221.94	1,280.39	1,215.69	91.68	98.89
C62	Testicles	177	0.37	0.00	0.36	3.13	8.11	15.20	12.47	11.80	6.34	6.38	1.80	2.43	1.01	3.74	1.68	0.00	5.64	0.00	5.48	4.84
C63	Other male sex organs, nos	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	0.00	2.73	0.00	9.21	0.09	0.11	
C64	Kidney	351	1.85	1.13	1.08	0.31	0.65	0.76	0.83	2.36	3.38	12.27	24.03	29.93	52.74	64.82	67.25	106.37	84.61	138.15	10.86	11.68
C65	Renal pelvis	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49	0.00	0.00	1.01	0.00	0.00	2.73	0.00	9.21	0.12	0.14	
C66	Ureters	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.74	0.00	5.46	0.00	0.00	0.15	0.17
C67	Bladder	473	0.00	0.00	0.00	0.63	0.00	0.38	0.00	0.79	2.96	5.89	12.01	33.17	58.83	92.25	144.59	218.20	293.30	267.08	14.64	15.59
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.68	0.00	0.00	0.00	0.03	0.03
C69	Eyes and appendages	25	2.59	0.00	0.36	0.00	0.32	0.00	0.00	0.00	0.00	0.49	0.60	2.43	0.00	3.74	3.36	13.64	5.64	0.00	0.77	0.87
C70	Meninges	3	0.00	0.00	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.60	0.00	0.00	0.00	1.68	0.00	0.00	0.00	0.09	0.10
C71	Encephalon	273	4.45	2.27	3.60	1.88	3.25	3.42														

Table 67 (continuation)

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C84	Peripheral and cutaneous T-cell lymphoma	18	0.00	0.00	0.00	0.00	0.32	0.00	0.42	0.79	0.42	1.47	0.60	0.00	4.06	1.25	1.68	5.46	0.00	9.21	0.56	0.58
C85	Other types of non-Hodgkin lymphoma, nos	269	0.74	0.38	0.36	0.94	2.60	3.04	6.65	3.54	10.56	10.79	15.62	17.80	30.43	32.41	43.71	54.55	84.61	73.68	8.32	8.48
C88	Malignant immunoproliferative diseases	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.60	0.00	1.01	0.00	0.00	0.00	11.28	9.21	0.15	0.17
C90	Multiple myeloma and malignant plasmacyte neoplasms	122	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.39	2.11	4.42	4.20	12.13	17.24	31.16	13.45	51.82	50.76	36.84	3.77	4.01
C91	Lymphoid leukemia	102	6.30	3.40	4.32	1.57	1.95	0.76	2.08	1.18	0.42	1.47	2.40	2.43	4.06	7.48	13.45	16.37	16.92	46.05	3.16	3.50
C92	Myeloid leukemia	148	1.48	1.51	0.72	1.57	0.97	1.14	1.66	1.57	3.80	4.42	8.41	7.28	9.13	9.97	20.18	24.55	45.12	82.89	4.58	4.06
C94	Other specified-type cell leukemias	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.00	0.00	0.00	0.00	0.03	0.04
C95	Unspecified cell leukemia	33	0.37	0.00	1.44	0.31	0.00	0.38	0.00	0.00	0.84	0.49	1.20	0.81	0.00	7.48	6.73	5.46	22.56	27.63	1.02	1.07
C96	Other malignant lymphatic tissue neoplasms and correlates	8	0.00	0.00	0.00	0.00	0.32	0.38	0.00	1.18	0.00	0.00	0.00	0.00	1.01	0.00	1.68	0.00	0.00	0.00	0.25	0.20
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.21	0.03	0.05
C00-96, D46	All invasive primary malignant neoplasms	14,448	26.32	15.50	21.22	22.86	40.24	54.35	73.58	123.46	209.96	380.77	722.00	1,248.16	1,919.94	2,665.14	3,539.12	4,429.53	4,918.50	4,660.16	447.03	469.26
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	12,359	26.32	14.75	20.50	21.92	39.27	49.41	63.61	100.26	167.29	316.49	625.89	1,071.01	1,675.51	2,344.77	3,048.19	3,723.10	4,061.14	3,951.00	382.40	404.16
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.60	0.81	0.00	1.25	1.68	0.00	5.64	0.00	0.22	0.19
D02	Carcinoma in situ of the middle ear and respiratory system	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49	0.00	0.00	2.03	0.00	0.00	0.00	0.00	0.00	0.09	0.11
D03	Melanoma in situ	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.98	0.60	0.81	1.01	2.49	1.68	0.00	16.92	0.00	0.37	0.38
D04	Skin carcinoma in situ	24	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.79	0.42	0.00	2.40	1.62	0.00	8.73	0.00	8.18	11.28	18.42	0.74	0.77
D05	Breast carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	0.00	0.00	0.00	0.00	0.03	0.04
D07	Carcinoma in situ of other sex organs and unspecified organs	41	0.00	0.00	0.00	0.31	0.00	0.00	0.42	0.00	0.00	0.00	3.60	4.85	4.06	12.47	6.73	5.46	11.28	9.21	1.27	1.26
D09	Carcinoma in situ of other locations and unspecified locations	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	1.68	2.73	0.00	0.00	0.09	0.10
C00-96, D00-09, D46	All primary malignant neoplasms	14,539	26.32	15.50	21.22	23.17	40.24	54.35	74.42	124.64	210.80	382.24	729.20	1,256.25	1,929.06	2,690.07	3,550.89	4,445.90	4,963.62	4,687.79	449.85	472.11

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Porto Alegre - RS, 2000 - 2004

Table 68

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	7	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.35	0.00	0.00	0.00	0.00	0.81	0.97	1.43	4.70	0.00	0.19	0.13
C01	Tongue base	19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	1.06	1.18	0.47	1.85	0.00	1.61	0.97	1.43	9.40	0.00	0.52	0.38
C02	Other parts of the tongue	35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.39	1.41	1.23	4.30	2.42	5.81	5.73	7.05	17.94	0.95	0.71
C04	Floor of the mouth	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	1.41	0.62	0.00	0.81	0.97	0.00	0.00	2.99	0.24	0.20
C05	Palate	14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.18	0.00	1.23	1.43	1.61	0.00	2.86	2.35	2.99	0.38	0.28
C06	Other parts of the mouth	25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	2.82	1.23	1.43	3.23	0.00	4.30	9.40	5.98	0.68	0.51
C07	Parotid gland	29	0.00	0.39	0.00	0.00	0.31	0.36	0.37	0.34	0.70	1.58	1.88	2.47	1.43	2.42	2.91	0.00	4.70	0.00	0.79	0.68
C08	Other larger salivary glands	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.39	0.47	0.00	1.43	0.00	0.97	0.00	0.00	0.00	0.16	0.14
C09	Amygdala	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.94	0.62	0.00	0.00	0.97	1.43	0.00	2.99	0.00	0.18
C10	Oropharynx	8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.39	0.94	0.62	0.72	0.00	0.97	1.43	0.00	0.00	0.22	0.18
C11	Nasopharynx	9	0.00	0.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.47	0.62	0.72	1.61	0.00	2.86	0.00	0.00	0.24	0.22
C12	Piriform sinus	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05
C13	Hypopharynx	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.47	0.00	0.72	1.61	0.97	0.00	2.35	0.00	0.19	0.16
C14	Inaccurate locations of the lip, oral cavity and pharynx	6	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	1.43	0.81	0.00	0.00	4.70	0.00	0.16	0.13
C15	Esophagus	199	0.00	0.00	0.00	0.00	0.00	0.36	0.37	0.34	1.06	3.15	8.93	19.76	20.78	25.03	26.15	22.91	30.55	47.85	5.40	4.29
C16	Stomach	399	0.00	0.00	0.00	0.00	0.31	0.72	1.12	5.40	3.52	9.46	10.33	18.52	26.51	38.75	56.18	78.77	98.69	137.56	10.83	7.83
C17	Small intestine	28	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.68	0.35	0.79	0.94	2.47	2.15	2.42	3.87	7.16	2.35	0.00	0.76	0.56
C18	Colon	812	0.39	0.00	0.37	0.00	0.62	2.53	1.12	4.73	8.11	18.13	33.82	40.75	46.57	71.85	122.04	168.99	220.87	227.27	22.04	15.97
C19	Rectosigmoid junction	133	0.00	0.00	0.00	0.00	0.00	0.72	0.00	1.35	1.76	4.73	7.05	8.64	12.18	5.65	19.37	20.05	23.50	32.89	3.61	2.75
C20	Rectum	289	0.00	0.00	0.00	0.00	0.00	0.36	1.87	2.36	4.93	8.67	14.56	20.37	20.06	27.45	32.93	40.10	63.44	65.79	7.84	5.97
C21	Anus and anal canal	101	0.00	0.00	0.00	0.00	0.00	0.36	0.00	0.00	1.41	2.36	1.41	7.41	14.33	9.69	14.53	15.75	23.50	14.95	2.74	2.13
C22	Liver and intrahepatic biliary ducts	211	0.39	0.00	0.00	0.00	0.00	0.36	1.12	0.00	2.11	2.36	9.40	11.11	19.34	31.49	30.03	40.10	30.55	50.84	5.73	4.45
C23	Gallbladder	129	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35	1.97	1.88	7.41	10.75	16.15	23.25	35.80	25.85	32.89	3.50	2.58
C24	Other parts of the biliary ducts	81	0.00	0.00	0.00	0.00	0.00	0.36	0.00	0.34	0.00	1.58	3.29	1.85	5.02	9.69	12.59	15.75	30.55	26.91	2.20	1.57
C25	Pancreas	291	0.00	0.00	0.00	0.00	0.00	0.36	1.12	0.34	0.70	1.58	9.86	13.58	21.49	24.22	49.40	68.74	96.34	107.65	7.90	5.57
C26	Inaccurate locations in the gastrointestinal tract	45	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.39	0.47	1.85	2.87	2.42	4.84	11.46	16.45	35.88	1.22	0.80
C30	Nasal cavity and middle ear	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.47	0.62	2.15	0.81	0.97	2.86	0.00	0.00	0.30	0.25
C31	Paranasal sinuses	8	0.00	0.00	0.00	0.00	0.00	0.72	0.00	0.34	0.00	0.39	0.94	0.00	0.00	0.00	0.00	0.00	4.70	0.00	0.22	0.17
C32	Larynx	71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.70	1.58	3.76	6.79	8.60	4.04	9.69	8.59	18.80	8.97	1.93	1.48
C33	Trachea	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.41	0.00	0.72	0.81	1.94	0.00	0.00	0.00	0.19	0.16
C34	Bronchus and lungs	1,070	0.00	0.39	0.37	0.32	0.62	0.72	2.62	7.09	15.86	27.59	40.87	82.11	117.50	134.02	140.44	153.24	112.78	161.48	29.04	23.16
C37	Thymus	11	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.68	0.35	0.39	0.00	0.62	0.72	0.81	0.00	1.43	4.70	0.00	0.30	0.23
C38	Heart, mediastine and pleura	76	0.00	0.00	0.37	0.00	0.31	0.36	1.50	0.34	1.76	2.36	6.11	6.79	2.87	3.23	11.62	8.59	7.05	5.98	2.06	1.62
C39	Inaccurate locations in the respiratory system and intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.97	0.00	0.00	0.00	0.03	0.02
C40	Bones and limb joints	17	0.39	0.78	1.87	0.63	0.00	0.00	0.37	0.00	0.35	0.79	0.94	0.00	0.00	0.81	0.00	0.00	0.00	0.00	0.46	0.51
C41	Bones and joints of other locations	32	0.39	0.39	0.75	0.95	0.62	0.00	0.75	0.00	0.35	1.18	1.88	0.62	0.72	0.81	5.81	4.30	2.35	0.00	0.87	0.77
C43	Malignant skin melanoma	312	0.77	0.00	0.00	0.95	4.67	4.70	7.12	10.13	9.87	11.82	9.40	17.29	19.34	16.15	21.31	30.08	35.25	38.87	8.47	6.78
C44	Other malignant skin neoplasms	2,063	0.39	0.00	0.00	0.63	4.05	6.15	13.50	20.59	40.53	63.45	79.39	98.78	141.85	174.39	250.86	370.93	413.54	397.72	56.00	40.81
C45	Mesothelioma	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.47	0.00	0.72	0.81	0.00	0.00	0.00	0.00	0.11	0.10
C46	Kaposi's sarcoma	11	0.00	0.00	0.00	0.00	0.00	0.00	0.75	0.34	0.35	0.39	1.41	0.00	0.00	0.81	0.97	0.00	0.00	2.99	0.30	0.24
C47	Peripheral nerves and autonomic nervous system	1	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.03
C48	Retroperitoneum and peritoneum	52	0.39	0.39	0.37	0.00	0.62	0.00	0.00	0.00	1.41	0.79	2.82	3.09	4.30	5.65	5.81	5.73	7.05	5.98	1.41	1.15
C49	Connective tissue and other soft tissues	107	0.77	0.00	1.12	1.26	1.56	1.81	2.25	3.04	1.06	2.76	4.70	1.85	3.58	12.92	4.84	11.46	23.50	11.96	2.90	2.35
C50	Breast	4,200	0.00	0.00	0.37	0.00	1.56	12.65	19.50	63.13	134.29	206.51	252.26	317.32	323.11	365.73	366.12	442.53	451.14	400.71	114.00	91.79
C51	Vulva	65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.68	1.06	0.39	3.29	1.23	2.87	7.27	10.65	21.48	7.05	23.92	1.76	1.26
C52	Vagina	40	0.00	0.00	0.00	0.00	0.31	0.00	0.00	0.00	0.70	0.39	2.35	2.47	3.58	4.84	4.84	5.73	4.70	8.97	1.09	0.82
C53	Cervix	891	0.00	0.00	0.00	0.00	2.18	14.82	21.37	33.76	35.25	44.93	51.67	60.50	45.14	63.78	49.40	52.99	30.55	35.88	24.18	20.05
C54	Endometrium	367	0.00	0.00	0.00	0.00	0.00	0.00	0.37	1.69	5.29	8.28	15.03	32.10	37.25	58.94	40.68	57.29	49.34	26.91	9.96	8.00
C55	Uterus, nos	139	0.00	0.00	0.00	0.00	0.00	1.81	1.12	2.03	3.52	3.55	4.23	6.17	11.46	17.76	14.53	21.48	11.75	38.87	3.77	2.97
C56	Ovary	559	0.00	0.00	1.12	0.63	0.31	2.17	1.50	6.41	7.75	16.55	22.08	39.51	53.02	71.85	68.77	74.47	91.64	44.86	15.17	12.05
C57	Other female sex organs, nos	15	0.00	0.00	0.00	0.00	0.00	0.36	0.00	0.68	0.00	0.79	0.47	0.62	2.87	0.00	0.00	2.86	2.35	2.99	0.41	0.33
C58	Placenta	3	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.35	0.00	0.00	0.00	0.00	0.00	0.00	1.43	0.00	0.00	0.08	0.06
C64	Kidney	248	1.93	0.39	0.00	0.00	0.00	0.72	1.12	1.35	2.82	7.49	10.33	17.29	17.91	29.87	33.90	37.24	44.64	38.87	6.73	5.38
C65	Renal pelvis	3	0.00	0.00	0.00	0.00	0.00	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.72	0.00	0.00	1.43	0.00	0.00	0.08	0.07
C66	Ureters	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.72	0.00	0.97	0.00	0.00	0.00	0.08	0.07
C67	Bladder	196	0.00	0.00	0.00	0.00	0.31	0.00	0.75	0.34	0.35	2.76	3.29	11.73	13.61	17.76	32.93	42.96	58.74	71.77	5.32	3.73
C68	Other organs of the urinary system, nos	6	0.00	0.00																		

Table 68 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C76	Other inaccurate locations	140	0.77	0.78	0.00	0.32	0.31	1.45	0.75	1.35	2.11	3.15	7.05	8.64	5.02	10.50	14.53	20.05	30.55	56.82	3.80	2.92
C80	Unknown primary site	372	0.00	0.39	0.00	0.95	0.00	0.72	0.75	1.69	3.88	11.03	14.09	22.22	27.22	42.79	46.49	52.99	61.09	131.58	10.10	7.61
C81	Hodgkin's disease	85	0.00	0.00	1.87	1.58	6.23	2.89	2.62	2.36	2.11	1.97	1.41	1.23	2.15	3.23	2.91	5.73	0.00	5.98	2.31	2.03
C82	Non-Hodgkin follicular lymphoma	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.35	0.39	0.94	1.85	2.15	0.81	0.00	1.43	4.70	0.00	0.46	0.37
C83	Non-Hodgkin diffuse lymphoma	84	1.16	1.18	0.00	0.32	0.93	0.36	1.12	1.01	1.06	1.97	0.94	6.79	5.73	8.07	8.72	14.32	11.75	11.96	2.28	1.92
C84	Peripheral and cutaneous T-cell lymphoma	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.47	0.62	0.72	0.81	1.94	1.43	0.00	2.99	0.24	0.19
C85	Other types of non-Hodgkin lymphoma, nos	243	0.77	0.39	0.75	0.63	1.56	2.89	3.00	3.04	3.17	4.73	6.11	12.35	16.48	33.10	28.09	45.83	32.90	29.90	6.60	5.23
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.43	0.00	0.00	0.03	0.01
C90	Multiple myeloma and malignant plasmacyte neoplasms	112	0.00	0.00	0.00	0.00	0.00	0.36	0.00	0.00	0.00	2.36	3.29	6.79	11.46	13.72	19.37	20.05	23.50	29.90	3.04	2.33
C91	Lymphoid leukemia	73	2.70	2.35	2.24	1.58	0.31	1.08	0.37	0.34	0.00	0.39	0.47	2.47	5.02	5.65	7.75	7.16	16.45	8.97	1.98	1.93
C92	Myeloid leukemia	126	0.39	0.39	1.50	1.26	0.93	0.72	1.50	1.35	1.06	2.36	3.76	3.70	9.31	8.07	10.65	27.21	9.40	17.94	3.42	2.42
C93	Monocytic leukemia	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.99	0.03	0.01
C94	Other specified-type cell leukemias	3	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.98	0.08	0.06
C95	Unspecified cell leukemia	23	0.39	0.00	0.00	0.63	0.00	0.00	0.37	0.68	0.35	1.18	0.47	0.62	1.43	0.00	0.97	7.16	2.35	5.98	0.62	0.50
C96	Other lymphatic tissue malignant neoplasms and correlates	3	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.00	0.00	0.97	0.00	0.00	0.00	0.08	0.08
D46	Myelodysplastic syndromes	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02
C00-96, D46	All invasive primary malignant neoplasms	15,412	17.36	14.10	15.70	16.73	34.27	70.51	103.47	195.47	328.84	521.40	708.87	972.34	1,155.61	1,443.53	1,671.77	2,165.41	2,352.03	2,508.90	418.33	327.01
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	13,349	16.97	14.10	15.70	16.10	30.22	64.36	89.98	174.88	288.31	457.95	629.48	873.56	1,013.76	1,269.14	1,420.91	1,794.49	1,938.49	2,111.18	362.34	286.19
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.72	0.00	0.00	0.00	2.35	0.00	0.08	0.06
D01	Carcinoma in situ of other organs of the gastrointestinal tract	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.39	0.00	0.00	0.72	0.00	0.00	0.00	2.35	0.00	0.08	0.06
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.97	0.00	0.00	0.00	0.03	0.02
D03	Melanoma in situ	26	0.00	0.00	0.00	0.00	0.31	0.36	0.37	0.34	1.06	0.39	0.94	0.62	2.87	1.61	3.87	2.86	0.00	5.98	0.71	0.55
D04	Skin carcinoma in situ	32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.35	0.39	0.94	1.85	1.43	1.61	6.78	4.30	14.10	8.97	0.87	0.59
D05	Breast carcinoma in situ	350	0.00	0.00	0.00	0.00	0.00	0.36	1.87	5.74	15.86	22.86	22.08	32.72	31.52	25.83	24.21	15.75	9.40	11.96	9.50	8.01
D06	Cervical carcinoma in situ	431	0.00	0.00	0.00	0.95	6.23	24.95	29.62	23.29	23.97	12.61	12.68	12.35	6.45	8.88	7.75	7.16	2.35	2.99	11.70	9.85
D07	Carcinoma in situ of other sex organs and unspecified organs	31	0.00	0.00	0.00	0.00	0.31	0.72	0.37	1.01	2.11	1.18	1.88	1.85	0.00	1.61	0.97	4.30	0.00	2.99	0.84	0.66
D09	Carcinoma in situ of other locations and unspecified locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.97	0.00	0.00	0.00	0.03	0.02
C00-96, D00-09, D46	All primary malignant neoplasms	16,290	17.36	14.10	15.70	17.68	41.12	96.90	135.72	226.19	372.19	559.62	747.39	1,021.73	1,199.31	1,483.09	1,717.29	2,199.79	2,382.57	2,541.79	442.16	346.83

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Porto Alegre - RS, 2000 - 2004

Male

Table 69

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	472	15.12	89.4	8.9	33.1
C15 Esophagus	546	18.19	68.3	26.0	61.0
C16 Stomach	549	17.93	71.4	24.8	60.1
C18-21 Large intestine, anal canal and anus	1,060	34.97	77.7	18.5	45.9
C22 Liver	364	11.96	38.2	51.4	76.1
C25 Pancreas	230	7.58	40.9	45.2	94.3
C32 Larynx	349	11.65	80.5	15.2	43.0
C33-34 Trachea, bronchus and lungs	2,000	66.61	70.6	23.8	64.3
C43 Skin melanoma	252	65.10	88.9	7.1	26.2
C61 Prostate	2,963	98.89	87.2	9.6	21.0
C70-72 Central Nervous System	302	9.50	51.0	32.5	56.3
C73 Thyroid	72	2.14	72.2	2.8	16.7
C91-95 Leukemia	284	8.67	61.3	31.3	68.3
C81-85, C96 Lymphoma	493	15.33	75.3	19.1	41.4
C00-96, D46 All primary invasive malignant Neoplasms	14,448	469.26	78.2	17.1	38.6
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	12,359	404.16	74.7	20.0	45.0

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 70

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	126	2.57	90.5	6.3	31.7
C15 Esophagus	199	4.29	70.9	26.1	54.8
C16 Stomach	399	7.83	64.4	31.1	61.2
C18-21 Large intestine, anal canal and anus	1,335	26.82	76.1	18.7	43.8
C22 Liver	211	4.45	40.8	51.2	74.4
C25 Pancreas	291	5.57	32.3	54.3	92.4
C32 Larynx	71	1.48	78.9	16.9	35.2
C33-34 Trachea, bronchus and lungs	1,077	23.32	73.1	20.8	54.4
C43 Skin melanoma	312	40.81	85.6	10.9	21.5
C50 Breast	4,200	91.79	88.9	8.5	23.7
C53 Cervix	891	20.05	86.6	11.1	31.5
C70-72 Central Nervous System	298	6.83	42.3	42.3	56.0
C73 Thyroid	287	6.47	80.1	3.1	7.3
C91-95 Leukemia	226	4.92	53.6	43.8	61.1
C81-85, C96 Lymphoma	441	9.83	78.5	17.0	43.5
C00-96, D46 All primary invasive malignant Neoplasms	15,412	327.01	79.4	16.1	34.6
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	13,349	286.19	76.4	18.6	39.8

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Porto Alegre - RS, 2000 - 2004

Male




Figure 55

Female




Figure 56

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Porto Alegre - RS, 2000 - 2004

Table 71

Pediatric Tumors - ICC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	53	65.25	66.34	64	56.55	59.16	27	34.52	34.27	38	34.58	34.38
Ia. Lymphoid leukemia	38	46.78	48.02	43	38.00	40.73	19	24.30	24.59	24	21.84	22.61
Ib. Acute myeloid leukemia	8	9.85	10.61	13	11.49	11.75	7	8.95	8.19	9	8.19	7.77
Ic. Myeloproliferative chronic diseases	2	2.46	2.09	2	1.77	1.62	0	0.00	0.00	1	0.91	0.71
Id. Myelodysplastic syndrome and myeloproliferative diseases	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.91	0.71
Ie. Specified leukemias and other unspecified leukemias	5	6.16	5.62	6	5.30	5.06	1	1.28	1.50	3	2.73	2.58
II. Reticuloendothelial lymphomas and neoplasms	16	19.70	19.53	36	31.81	29.22	16	20.46	20.15	24	21.84	21.30
Ila. Hodgkin's lymphoma	7	8.62	8.23	19	16.79	14.83	5	6.39	5.43	10	9.10	7.76
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	5	6.16	5.75	12	10.60	9.39	5	6.39	6.61	8	7.28	7.25
Ilc. Burkitt's lymphoma	2	2.46	2.66	2	1.77	2.06	4	5.11	5.52	4	3.64	4.28
Ile. Unspecified lymphoma	2	2.46	2.88	3	2.65	2.94	2	2.56	2.58	2	1.82	2.00
III. CNS and misc. of intracranial and intraspinal neoplasms	27	33.24	33.38	34	30.04	30.80	21	26.85	28.42	25	22.75	24.86
Illa. Ependymoma and choroid plexus tumor	0	0.00	0.00	0	0.00	0.00	2	2.56	3.00	3	2.73	3.03
IIlb. Astrocytoma	6	7.39	6.66	7	6.19	5.87	5	6.39	6.79	7	6.37	6.68
IIlc. Intracranial and intraspinal embryonic tumors	9	11.08	11.92	12	10.60	11.36	10	12.79	13.11	10	9.10	10.16
IIId. Other gliomas	2	2.46	2.44	2	1.77	1.89	0	0.00	0.00	1	0.91	0.71
IIle. Other intracranial and intraspinal neoplasms	10	12.31	12.35	13	11.49	11.68	1	1.28	1.26	1	0.91	0.98
IIIf. Unspecified intracranial and intraspinal tumors	0	0.00	0.00	0	0.00	0.00	3	3.84	4.26	3	2.73	3.30
IV. Neuroblastoma and other peripheral nervous cell tumor	9	11.08	12.07	9	7.95	9.35	7	8.95	9.02	7	6.37	6.99
IVa. Neuroblastoma and ganglioneuroblastoma	9	11.08	12.07	9	7.95	9.35	7	8.95	9.02	7	6.37	6.99
V. Retinoblastoma	7	8.62	10.06	7	6.19	7.80	3	3.84	4.50	3	2.73	3.48
VI. Renal tumors	11	13.54	14.00	12	10.60	11.55	6	7.67	8.73	6	5.46	6.77
VIa. Nephroblastoma and other renal non-epithelial tumors	6	7.39	8.43	7	6.19	7.24	6	7.67	8.73	6	5.46	6.77
VIb. Renal carcinomas	4	4.92	4.35	4	3.53	3.37	0	0.00	0.00	0	0.00	0.00
VIc. Unspecified malignant renal tumors	1	1.23	1.22	1	0.88	0.95	0	0.00	0.00	0	0.00	0.00
VII. Hepatic tumors	1	1.23	1.44	1	0.88	1.12	1	1.28	1.47	1	0.91	1.14
VIIa. Hepatoblastoma	1	1.23	1.44	1	0.88	1.12	1	1.28	1.47	1	0.91	1.14
VIII. Malignant bone tumors	12	14.77	13.47	17	15.02	13.96	12	15.34	14.36	17	15.47	14.68
VIIIa. Osteosarcoma	8	9.85	9.12	12	10.60	9.88	6	7.67	6.87	9	8.19	7.45
VIIIb. Chondrosarcoma	0	0.00	0.00	1	0.88	0.70	0	0.00	0.00	0	0.00	0.00
VIIIc. Ewing's sarcoma and related bone sarcomas	4	4.92	4.35	4	3.53	3.37	4	5.11	4.93	5	4.55	4.53
VIIIe. Unspecified malignant bone tumors	0	0.00	0.00	0	0.00	0.00	2	2.56	2.56	3	2.73	2.69
IX. Soft-tissue and other extraosseous sarcomas	9	11.08	10.77	13	11.49	11.16	8	10.23	10.10	15	13.65	12.80
IXa. Rhabdomyosarcoma	5	6.16	6.41	6	5.30	5.67	5	6.39	6.85	8	7.28	7.44
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	2	2.46	2.26	2	1.77	1.75	2	2.56	2.17	3	2.73	2.39
Ixc. Kaposi's sarcoma	1	1.23	1.04	2	1.77	1.51	0	0.00	0.00	0	0.00	0.00
IXd. Other unspecified soft-tissue sarcomas	1	1.23	1.04	2	1.77	1.51	0	0.00	0.00	2	1.82	1.42
IXe. Unspecified soft-tissue sarcomas	0	0.00	0.00	1	0.88	0.70	1	1.28	1.09	2	1.82	1.55
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	2	2.46	2.45	16	14.14	11.76	5	6.39	5.84	7	6.37	5.95
Xa. Intracranial and intraspinal germ cell tumors	1	1.23	1.04	2	1.77	1.51	1	1.28	1.09	1	0.91	0.84
Xb. Malignant intracranial and intraspinal germ cell tumors	0	0.00	0.00	3	2.65	2.11	1	1.28	1.50	1	0.91	1.16
Xc. Malignant gonadal germ cell tumors	1	1.23	1.41	10	8.84	7.43	1	1.28	1.09	2	1.82	1.55
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	2	2.56	2.17	3	2.73	2.39
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	1	0.88	0.70	0	0.00	0.00	0	0.00	0.00
XI. Other malignant epithelial neoplasms and melanomas	11	13.54	13.52	23	20.32	18.93	10	12.79	12.81	25	22.75	20.58
XIb. Thyroid carcinoma	1	1.23	1.22	3	2.65	2.35	2	2.56	2.35	8	7.28	6.08
XIc. Nasopharynx carcinoma	0	0.00	0.00	0	0.00	0.00	1	1.28	1.26	1	0.91	0.98
XId. Malignant melanoma	1	1.23	1.04	2	1.77	1.51	2	2.56	3.00	5	4.55	4.45
XIe. Skin carcinoma	4	4.92	4.53	7	6.19	5.62	1	1.28	1.50	3	2.73	2.58
XIf. Other carcinomas and unspecified carcinomas	5	6.16	6.73	11	9.72	9.44	4	5.11	4.70	8	7.28	6.48
XII. Other malignant and unspecified neoplasms	13	16.00	16.63	13	11.49	12.89	7	8.95	8.78	11	10.01	9.65
XIIa. Other specified malignant tumors	1	1.23	1.22	1	0.88	0.95	0	0.00	0.00	0	0.00	0.00
XIIb. Other unspecified malignant tumors	12	14.77	15.41	12	10.60	11.94	7	8.95	8.78	11	10.01	9.65
All neoplasms	171	210.52	213.64	245	216.49	217.70	123	157.28	158.44	179	162.91	162.57

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação




Figure 57. Distribution of the population* in Recife

*Demographic Census of 2000 – IBGE

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Recife

Coordinator

Claudia Cristina Lima de Castro

Registrars

Alzeni Virgílio de Vasconcelos
 Érica Fernanda Ferreira Costa Selva
 Kátia Oliveira Lima
 Marta Verônica Batista Cabral
 Tiago Sales Faria

Data Collectors

Alzeni Virgílio de Vasconcelos
 Kátia Oliveira Lima
 Marta Verônica Batista Cabral
 Tiago Sales Faria

Data Entry Clerks

Érica Fernanda Ferreira Costa Selva
 Evelin Cristina de Albuquerque Cardoso
 Henrique Landim Santos
 Tiago Sales Faria

Address codifier

Antonio Ricardo de Abreu Neto

Advisory Committee

Andréa Maria Ferreira Barbosa
 Terezinha Aquino
 Paula Albuquerque

Infrastructure and Data Source

This PBCR was created in 1996, year when the data collection started. It is located in the Recife Health Secretariat and financially supported by the Ministry of Health.




Figure 58. Proportion of new cases, compared to the year of highest frequency

Sources: Data from Population-Based Cancer Registry

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Table 72 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C91	Lymphoid leukemia	55	4.92	3.19	3.32	2.07	0.73	0.42	0.46	0.00	0.58	0.74	1.81	1.28	1.53	4.09	5.19	11.57	0.00	11.38	2.05	2.20	
C92	Myeloid leukemia	54	1.64	1.20	2.21	0.69	2.20	2.09	0.93	1.48	1.16	2.22	0.91	3.85	1.53	8.18	12.98	7.71	15.13	0.00	2.01	2.19	
C95	Unspecified cell leukemia	14	0.00	0.40	1.11	0.34	0.00	0.00	0.46	0.00	0.00	0.74	0.00	1.28	1.53	2.05	0.00	7.71	7.57	11.38	0.52	0.59	
C96	Other malignant lymphatic tissue neoplasms and correlates	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49	0.00	0.00	2.72	1.28	1.53	2.05	0.00	15.43	7.57	11.38	0.48	0.59	
D46	Myelodysplastic syndromes	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.28	1.53	2.05	2.60	0.00	0.00	11.38	0.19	0.28	
C00-96, D46	All invasive primary malignant neoplasms	4,505	19.68	15.14	13.29	15.85	22.39	30.10	31.01	59.04	97.50	184.72	308.37	530.75	741.13	1,180.13	1,497.77	2,125.28	2,814.98	2,514.51	167.88	212.59	
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	4,031	19.27	14.75	13.29	15.50	19.82	27.59	27.77	52.15	81.25	158.86	271.19	466.65	661.50	1,075.82	1,344.62	1,909.28	2,527.43	2,252.82	150.22	190.22	
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.58	0.00	0.00	2.56	0.00	4.09	0.00	0.00	0.00	0.00	0.19	0.26	
D01	Carcinoma in situ of other organs of the gastrointestinal tract	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.05	0.00	0.00	0.00	0.00	0.04	0.06	
D02	Carcinoma in situ of the middle ear and respiratory system	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.91	1.28	0.00	2.05	0.00	0.00	0.00	7.57	0.00	0.15	0.20
D04	Skin carcinoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.05	0.00	0.00	0.00	0.00	0.04	0.06	
D05	Breast carcinoma in situ	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.28	1.53	0.00	2.60	0.00	0.00	0.00	0.11	0.16	
D07	Carcinoma in situ of other sex organs and unspecified organs	9	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.00	2.56	0.00	6.14	0.00	3.86	15.13	0.00	0.34	0.45	
D09	Carcinoma in situ of other locations and unspecified locations	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.03	
C00-96, D00-09, D46	All primary malignant neoplasms	4,529	19.68	15.14	13.29	15.85	22.39	30.10	31.01	59.04	98.66	185.45	309.28	538.44	742.66	1,196.49	1,500.36	2,129.14	2,837.68	2,514.51	168.77	213.81	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Recife - PE, 2000 - 2003

Table 73

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	12	0.00	0.00	0.00	0.33	0.34	0.00	0.00	0.00	0.00	0.00	0.69	0.90	0.00	5.02	0.00	4.47	0.00	9.11	0.39	0.37	
C01	Tongue base	3	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.00	0.00	0.00	0.00	0.90	0.00	0.00	1.49	0.00	0.00	0.00	0.10	0.09	
C02	Other parts of the tongue	34	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.41	0.48	0.57	1.37	0.90	6.96	3.77	10.43	11.19	14.89	0.00	1.10	1.00	
C04	Floor of the mouth	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.90	0.00	1.26	0.00	4.47	3.72	4.55	0.19	0.16	
C05	Palate	18	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.41	0.00	1.13	0.69	0.00	0.99	2.51	2.98	8.95	11.17	4.55	0.58	0.49	
C06	Other parts of the mouth	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.69	0.00	2.98	0.00	2.98	2.24	7.44	13.66	0.42	0.37	
C07	Parotid gland	21	0.00	0.00	0.00	0.33	0.00	0.00	0.40	0.41	1.91	0.00	0.69	3.58	0.99	0.00	1.49	8.95	3.72	9.11	0.68	0.59	
C08	Other larger salivary glands	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.99	0.00	0.00	0.00	0.00	0.00	0.06	0.07	
C09	Amygdala	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.69	0.90	0.00	0.00	1.49	4.47	0.00	4.55	0.23	0.20	
C10	Oropharynx	3	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.57	0.00	0.00	0.00	0.00	0.00	2.24	0.00	0.00	0.10	0.09	
C11	Nasopharynx	4	0.00	0.00	0.00	0.33	0.00	0.00	0.00	0.41	0.00	0.00	0.00	0.90	0.00	1.26	0.00	0.00	0.00	0.00	0.13	0.13	
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.49	0.00	0.00	0.00	0.03	0.03	
C13	Hypopharynx	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.26	0.00	0.00	0.00	0.00	0.03	0.04	
C14	Inaccurate locations of the lip, oral cavity and pharynx	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.57	0.00	0.00	0.00	0.00	0.00	0.00	3.72	0.00	0.06	0.05	
C15	Esophagus	55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.83	1.43	1.70	2.74	1.79	8.95	10.05	11.92	6.71	18.61	22.76	1.78	1.62	
C16	Stomach	215	0.00	0.00	0.00	0.00	0.34	1.11	3.96	2.89	4.77	7.37	10.97	11.64	24.85	27.63	46.17	60.41	44.67	109.27	6.96	6.39	
C17	Small intestine	21	0.00	0.00	0.00	0.00	0.68	0.00	0.79	0.00	0.48	0.57	0.69	1.79	2.98	5.02	2.98	2.24	7.44	4.55	0.68	0.65	
C18	Colon	186	0.00	0.00	0.00	0.00	1.02	0.74	2.38	2.89	4.77	6.24	4.80	15.23	16.90	32.65	23.83	69.36	70.72	59.19	6.03	5.44	
C19	Rectosigmoid junction	21	0.00	0.00	0.00	0.00	0.74	0.00	0.00	0.00	0.00	0.57	2.06	0.00	0.99	2.51	2.98	4.47	11.17	18.21	0.68	0.56	
C20	Rectum	134	0.00	0.00	0.00	0.00	0.00	1.11	0.79	0.83	6.20	3.97	4.80	13.44	12.92	16.32	29.79	29.09	48.39	59.19	4.64	4.00	
C21	Anus and anal canal	61	0.00	0.00	0.00	0.00	0.37	0.00	0.83	3.34	1.70	4.11	3.58	9.94	10.05	8.94	6.71	26.06	13.66	1.98	1.87		
C22	Liver and intrahepatic biliary ducts	180	0.00	0.00	0.37	0.33	0.34	0.37	0.40	1.24	1.91	5.67	8.23	15.23	13.92	30.14	43.20	53.70	63.28	95.61	5.83	5.35	
C23	Gallbladder	80	0.00	0.00	0.00	0.00	0.34	0.74	0.00	0.41	1.43	1.70	5.49	11.64	12.92	6.28	16.38	17.90	29.78	13.66	2.59	2.47	
C24	Other parts of the biliary ducts	66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	1.13	2.74	11.64	4.97	11.30	19.36	24.61	0.00	31.87	2.14	2.06	
C25	Pancreas	117	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.83	2.86	0.57	7.54	10.75	8.95	15.07	40.22	29.09	48.39	36.42	3.79	3.42	
C26	Inaccurate locations in the gastrointestinal tract	33	0.00	0.41	0.00	0.00	0.00	0.00	0.79	0.00	0.00	2.83	0.00	1.79	0.99	3.77	7.45	8.95	11.17	31.87	1.07	0.94	
C30	Nasal cavity and middle ear	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.99	1.26	0.00	0.00	0.00	0.00	0.13	0.11	
C31	Paranasal sinuses	6	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.00	0.00	0.00	0.69	0.90	0.00	0.00	0.00	4.47	3.72	0.00	0.19	0.16	
C32	Larynx	28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.83	0.48	1.13	2.06	3.58	4.97	5.02	1.49	6.71	7.44	4.55	0.91	0.90	
C34	Bronchus and lungs	265	0.00	0.41	0.00	0.67	0.00	0.37	1.98	3.31	3.81	10.77	16.46	29.56	42.75	33.91	58.09	67.12	52.11	45.53	8.58	8.38	
C37	Thymus	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.57	0.00	0.00	0.00	1.26	0.00	0.00	0.00	0.00	0.10	0.10	
C38	Heart, mediastine and pleura	23	0.00	0.41	0.00	0.00	0.34	0.37	0.00	0.00	1.43	1.13	1.37	2.69	1.99	1.26	1.49	4.47	3.72	9.11	0.75	0.68	
C40	Bones and limb joints	25	0.00	0.00	1.87	0.67	0.68	0.00	0.00	0.41	0.00	1.70	1.37	0.90	0.99	2.51	4.47	4.47	0.00	0.00	0.81	0.76	
C41	Bones and joints of other locations	34	0.00	0.41	0.00	0.33	0.34	0.37	0.00	0.41	1.43	1.70	2.06	3.58	0.00	5.02	4.47	8.95	7.44	9.11	1.10	1.00	
C43	Malignant skin melanoma	32	0.00	0.00	0.00	0.00	0.00	0.37	0.00	1.24	0.48	1.13	0.69	4.48	1.99	6.28	4.47	6.71	7.44	18.21	1.04	0.97	
C44	Other malignant skin neoplasms	507	0.00	0.41	0.00	0.67	0.68	1.11	4.75	5.79	10.97	19.84	23.31	46.58	52.69	59.02	101.29	149.90	174.95	177.56	16.42	14.92	
C45	Mesothelioma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	3.72	0.00	0.06	0.06	
C46	Kaposi's sarcoma	3	0.00	0.00	0.00	0.00	0.00	0.74	0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.08	
C47	Peripheral nerves and autonomic nervous system	3	0.00	0.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	1.49	0.00	0.00	0.00	0.10	0.11	
C48	Retropertoneum and peritoneum	37	0.85	0.00	0.37	0.00	0.00	0.00	0.40	0.83	0.95	1.13	2.74	3.58	6.96	6.28	4.47	0.00	7.44	0.00	1.20	1.21	
C49	Connective tissue and other soft tissues	33	0.85	0.41	0.37	0.33	0.68	0.37	0.79	0.00	1.43	1.13	0.69	4.48	0.99	2.51	2.98	8.95	7.44	4.55	1.07	1.03	
C50	Breast	1,814	0.00	0.00	0.00	0.33	2.38	8.13	21.78	41.74	88.21	128.11	159.77	186.31	194.86	227.29	205.55	241.63	301.51	218.54	58.76	56.84	
C51	Vulva	43	0.00	0.00	0.00	0.00	0.00	0.74	1.19	0.83	0.48	0.57	0.69	2.69	3.98	5.02	4.47	15.66	26.06	22.76	1.39	1.18	
C52	Vagina	13	0.00	0.00	0.00	0.00	0.00	0.37	0.40	0.00	0.00	0.00	0.69	1.79	1.99	2.51	0.00	0.00	3.72	9.11	0.42	0.38	
C53	Cervix	623	0.00	0.00	0.00	1.00	2.38	6.28	13.07	20.25	33.38	44.21	64.46	49.26	60.64	50.23	68.52	49.22	81.89	63.74	20.18	19.15	
C54	Endometrium	149	0.00	0.00	0.00	0.00	0.00	0.00	0.40	3.31	5.24	7.37	10.97	10.75	24.85	32.65	16.38	29.09	22.33	31.87	4.83	4.82	
C55	Uterus, nos	75	0.00	0.00	0.00	0.00	0.34	0.74	0.40	2.07	2.38	3.97	8.23	6.27	3.98	11.30	5.96	20.14	18.61	9.11	2.43	2.23	
C56	Ovary	241	0.43	1.24	0.75	0.33	0.68	1.48	1.98	4.55	12.40	14.17	15.09	15.23	28.83	48.97	40.22	29.09	22.33	22.76	7.81	7.74	
C57	Other female sex organs, nos	14	0.00	0.00	0.00	0.00	0.34	0.00	0.00	0.41	0.48	0.00	1.37	1.79	0.99	1.26	0.00	2.24	7.44	4.55	0.45	0.38	
C58	Placenta	2	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.05	
C64	Kidney	60	1.70	2.07	0.37	0.33	0.00	1.48	0.40	0.41	1.91	0.57	2.74	1.79	4.97	3.77	16.38	11.19	14.89	13.66	1.94	1.89	
C66	Ureters	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.72	4.55	0.06	0.04
C67	Bladder	62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.65	0.48	1.13	3.43	5.37	3.98	13.81	8.94	13.42	18.61	50.08	2.01	1.81	
C68	Other organs of the urinary system, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.49	0.00	0.00	0.00	0.03	0.03	
C69	Eyes and appendages	17	1.70	0.00	1.12	0.00	0.34	0.37	0.00	0.00	0.00	1.70	0.69	0.00	0.99	0.00	2.98	2.24	0.00	0.00	0.55	0.62	
C70	Meninges	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.90	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.04	
C71	Encephalon	160	5.54	2.07	2.62	2.00	0.68	0.74	1.58	6.61	4.77	5.67	6.17										

Table 73 (continuation)

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C80	Unknown primary site	104	0.85	0.00	0.00	0.00	0.00	0.00	1.98	1.65	3.34	5.10	3.43	13.44	6.96	8.79	25.32	13.42	37.22	40.98	3.37	3.11	
C81	Hodgkin's disease	32	0.00	0.41	1.12	3.33	1.36	1.48	2.38	0.41	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.55	1.04	0.92
C82	Non-Hodgkin follicular lymphoma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.06	
C83	Non-Hodgkin diffuse lymphoma	33	1.28	0.00	0.00	0.00	0.00	0.37	0.00	0.83	1.43	1.13	0.69	2.69	5.96	5.02	1.49	11.19	3.72	0.00	1.07	1.08	
C84	Peripheral and cutaneous T-cell lymphoma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.00	0.00	1.49	0.00	0.00	0.00	0.06	0.06	
C85	Other types of non-Hodgkin lymphoma, nos	86	0.43	0.83	0.00	0.00	0.68	0.74	3.96	2.48	1.43	3.40	4.11	6.27	3.98	15.07	14.89	13.42	14.89	22.76	2.79	2.61	
C90	Multiple myeloma and malignant plasmacyte neoplasms	46	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.41	0.95	2.83	3.43	3.58	3.98	6.28	7.45	8.95	7.44	18.21	1.49	1.33	
C91	Lymphoid leukemia	68	7.66	4.14	1.87	2.00	1.02	0.37	0.79	0.83	1.43	1.70	0.69	0.90	2.98	1.26	5.96	2.24	3.72	13.66	2.20	2.53	
C92	Myeloid leukemia	58	0.85	0.41	0.37	1.33	0.68	0.37	0.79	2.48	1.43	1.70	4.80	1.79	0.99	3.77	8.94	13.42	7.44	13.66	1.88	1.65	
C95	Unspecified cell leukemia	19	0.00	0.00	0.37	0.00	1.36	0.00	1.19	0.41	0.00	0.57	0.69	0.00	0.99	2.51	1.49	0.00	7.44	9.11	0.62	0.53	
C96	Other lymphatic tissue malignant neoplasms and correlates	19	0.00	0.00	0.00	0.33	0.00	0.74	0.40	0.41	0.00	0.00	0.00	0.90	1.99	0.00	8.94	11.19	0.00	0.00	0.62	0.54	
D46	Myelodysplastic syndromes	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.90	0.99	0.00	1.49	6.71	7.44	4.55	0.32	0.27	
C00-96, D46	All invasive primary malignant neoplasms	6,361	24.27	15.32	12.33	18.34	21.80	37.31	79.59	124.80	224.57	316.30	423.77	555.35	648.20	801.18	977.11	1,176.84	1,369.81	1,466.04	206.05	195.50	
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	5,854	24.27	14.91	12.33	17.67	21.12	36.20	74.84	119.02	213.60	296.46	400.45	508.77	595.50	742.15	875.82	1,026.94	1,194.86	1,288.47	189.63	180.59	
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.00	0.00	0.00	0.99	0.00	1.49	0.00	0.00	4.55	0.13	0.12	
D01	Carcinoma in situ of other organs of the gastrointestinal tract	7	0.00	0.00	0.00	0.00	0.00	0.37	0.40	0.00	0.00	0.00	0.00	0.90	1.99	0.00	1.49	0.00	3.72	0.00	0.23	0.22	
D03	Melanoma in situ	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02	
D04	Skin carcinoma in situ	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.90	0.00	1.26	0.00	0.00	3.72	0.00	0.16	0.13	
D05	Breast carcinoma in situ	56	0.00	0.00	0.00	0.00	0.00	0.74	0.40	2.07	1.43	3.97	5.49	7.17	7.95	5.02	5.96	6.71	3.72	4.55	1.81	1.79	
D06	Cervical carcinoma in situ	354	0.00	0.00	0.00	0.00	6.47	16.25	18.21	37.19	26.70	18.71	12.34	14.33	13.92	5.02	5.96	6.71	7.44	0.00	11.47	9.99	
D07	Carcinoma in situ of other sex organs and unspecified organs	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.65	0.95	1.70	1.37	1.79	0.00	1.26	2.98	0.00	0.00	0.00	0.52	0.50	
D09	Carcinoma in situ of other locations and unspecified locations	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.00	0.00	0.00	1.26	0.00	2.24	0.00	0.00	0.10	0.08	
C00-96, D00-09, D46	All primary malignant neoplasms	6,807	24.27	15.32	12.33	18.34	28.28	54.67	98.60	166.54	254.13	340.67	443.65	580.43	673.05	814.99	994.98	1,192.50	1,388.42	1,475.14	220.50	208.35	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Recife - PE, 2000 - 2003

Male

Table 74

Topography	No.	Adjusted*	MV(%)	DCQ(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	204	99.3	86.8	5.4	59.3
C15 Esophagus	119	5.78	68.1	18.5	85.7
C16 Stomach	248	11.83	55.7	33.1	84.7
C18-21 Large intestine, anal canal and anus	201	9.35	69.7	16.9	54.7
C22 Liver	148	7.42	34.5	50.0	103.4
C25 Pancreas	97	4.67	39.2	43.3	111.3
C32 Larynx	180	8.98	83.3	11.7	58.3
C33-34 Trachea, bronchus and lungs	492	24.50	59.1	26.8	95.9
C43 Skin melanoma	42	22.37	71.4	19.1	66.7
C61 Prostate	1,028	50.01	79.2	13.2	41.1
C70-72 Central Nervous System	141	5.89	42.6	35.6	90.8
C73 Thyroid	24	0.92	91.7	12.5	33.3
C91-95 Leukemia	123	4.97	77.2	13.0	78.0
C81-85, C96 Lymphoma	161	7.07	67.7	23.6	59.6
C00-96, D46 All primary invasive malignant Neoplasms	4,505	212.59	71.3	18.6	60.0
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	4,031	190.22	68.6	20.6	66.4

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 75

Topography	No.	Adjusted*	MV(%)	DCQ(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	96	2.76	86.5	6.3	24.0
C15 Esophagus	55	1.62	70.9	14.6	63.6
C16 Stomach	215	6.39	53.0	33.5	75.8
C18-21 Large intestine, anal canal and anus	402	11.88	66.4	20.9	56.0
C22 Liver	180	5.35	38.9	41.1	95.6
C25 Pancreas	117	3.42	23.9	63.3	115.4
C32 Larynx	28	0.90	89.3	3.6	32.1
C33-34 Trachea, bronchus and lungs	265	8.38	56.6	26.8	83.4
C43 Skin melanoma	32	14.92	75.0	12.5	40.6
C50 Breast	1,814	56.84	81.3	5.8	29.9
C53 Cervix	623	19.15	89.3	5.9	35.3
C70-72 Central Nervous System	169	5.65	47.3	30.2	71.6
C73 Thyroid	156	4.73	90.4	2.6	10.3
C91-95 Leukemia	145	4.72	71.0	17.9	83.4
C81-85, C96 Lymphoma	174	5.27	67.8	21.8	45.4
C00-96, D46 All primary invasive malignant Neoplasms	6,361	195.50	73.4	15.0	47.3
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	5,854	180.59	71.4	16.2	51.0

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Recife - PE, 2000 - 2003

Male




Figure 59

Female




Figure 60

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Recife - PE, 2000 - 2003

Table 76

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	46	60.08	60.08	55	52.08	53.53	38	51.08	55.27	48	45.99	50.34
Ia. Lymphoid leukemia	29	37.87	38.94	35	33.14	34.83	33	44.36	48.46	39	37.36	42.06
Ib. Acute myeloid leukemia	10	13.06	13.00	12	11.36	11.62	4	5.38	5.72	6	5.75	5.94
Ic. Myeloproliferative chronic diseases	1	1.31	1.29	1	0.95	1.00	0	0.00	0.00	1	0.96	0.75
Id. Myelodysplastic syndrome and myeloproliferative diseases	2	2.61	2.36	2	1.89	1.83	0	0.00	0.00	1	0.96	0.75
Ie. Specified leukemias and other unspecified leukemias	4	5.22	4.50	5	4.73	4.26	1	1.34	1.09	1	0.96	0.84
II. Reticuloendothelial lymphomas and neoplasms	13	16.98	16.16	21	19.89	18.72	10	13.44	13.87	20	18.16	18.25
Ila. Hodgkin's lymphoma	6	7.84	7.29	9	8.52	7.97	4	5.38	4.59	14	13.41	11.06
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	4	5.22	5.23	6	5.68	5.60	3	4.03	4.32	3	2.87	3.35
Ilc. Burkitt's lymphoma	1	1.31	1.29	4	3.79	3.32	2	2.69	3.30	2	1.92	2.56
Ile. Unspecified lymphoma	2	2.61	2.36	2	1.89	1.83	1	1.34	1.65	1	0.96	1.28
III. CNS and misc. of intracranial and intraspinal neoplasms	16	20.90	21.22	20	18.94	19.55	26	34.95	37.06	32	30.66	33.23
Illa. Ependymoma and choroid plexus tumor	2	2.61	2.36	2	1.89	1.83	3	4.03	4.39	3	2.87	3.40
Illb. Astrocytoma	3	3.92	4.16	4	3.79	4.00	9	12.10	12.83	10	9.58	10.70
Illc. Intracranial and intraspinal embryonic tumors	1	1.31	1.07	2	1.89	1.61	3	4.03	4.95	4	3.83	4.59
Illf. Unspecified intracranial and intraspinal tumors	10	13.06	13.64	12	11.36	12.12	11	14.79	14.89	15	14.37	14.54
IV. Neuroblastoma and other peripheral nervous cell tumor	5	6.53	7.96	5	4.73	6.17	4	5.38	5.41	4	3.83	4.19
Iva. Neuroblastoma and ganglioneuroblastoma	5	6.53	7.96	5	4.73	6.17	4	5.38	5.41	4	3.83	4.19
V. Retinoblastoma	6	7.84	8.69	6	5.68	6.74	4	5.38	6.59	4	3.83	5.11
VI. Renal tumors	9	11.75	13.40	9	8.52	10.38	9	12.10	12.70	10	9.58	10.59
Via. Nephroblastoma and other renal non-epithelial tumors	8	10.45	11.79	8	7.58	9.14	8	10.75	11.62	8	7.66	9.00
Vic. Unspecified malignant renal tumors	1	1.31	1.60	1	0.95	1.24	1	1.34	1.09	2	1.92	1.59
VII. Hepatic tumors	1	1.31	1.60	1	0.95	1.24	1	1.34	1.09	2	1.92	1.59
VIIa. Hepatoblastoma	0	0.00	0.00	0	0.00	0.00	1	1.34	1.09	1	0.96	0.84
VIIc. Unspecified malignant hepatic tumors	1	1.31	1.60	1	0.95	1.24	0	0.00	0.00	1	0.96	0.75
VIII. Malignant bone tumors	6	7.84	7.37	13	12.31	11.14	6	8.07	6.76	9	8.62	7.49
VIIIa. Osteosarcoma	3	3.92	3.73	7	6.63	5.99	5	6.72	5.43	5	4.79	4.20
VIIIc. Ewing's sarcoma and related bone sarcomas	2	2.61	2.36	4	3.79	3.38	1	1.34	1.34	3	2.87	2.54
VIIIe. Unspecified malignant bone tumors	1	1.31	1.29	2	1.89	1.77	0	0.00	0.00	1	0.96	0.75
IX. Soft-tissue and other extrasosseous sarcomas	5	6.53	5.79	11	10.42	9.13	7	9.41	9.55	9	8.62	8.90
IXa. Rhabdomyosarcoma	1	1.31	1.07	4	3.79	3.16	4	5.38	5.16	4	3.83	4.00
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	1	1.31	1.07	1	0.95	0.83	0	0.00	0.00	1	0.96	0.75
IXd. Other unspecified soft-tissue sarcomas	1	1.31	1.29	1	0.95	1.00	1	1.34	1.65	1	0.96	1.28
IXe. Unspecified soft-tissue sarcomas	2	2.61	2.36	5	4.73	4.15	2	2.69	2.74	3	2.87	2.87
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	1	1.31	1.60	2	1.89	2.02	8	10.75	10.80	9	8.62	9.12
Xb. Malignant intracranial and intraspinal germ cell tumors	1	1.31	1.60	1	0.95	1.24	2	2.69	2.97	2	1.92	2.30
Xc. Malignant gonadal germ cell tumors	0	0.00	0.00	1	0.95	0.78	4	5.38	5.41	4	3.83	4.19
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	1	1.34	1.34	2	1.92	1.79
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	0	0.00	0.00	0	0.00	0.00	1	1.34	1.09	1	0.96	0.84
XI. Other malignant epithelial neoplasms and melanomas	6	7.84	9.24	13	12.31	12.59	6	8.07	8.18	24	22.99	19.84
XIb. Thyroid carcinoma	0	0.00	0.00	1	0.95	0.78	0	0.00	0.00	10	9.58	7.50
XIc. Nasopharynx carcinoma	1	1.31	1.60	1	0.95	1.24	0	0.00	0.00	1	0.96	0.75
XId. Malignant melanoma	0	0.00	0.00	1	0.95	0.78	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	2	2.61	2.87	3	2.84	3.00	0	0.00	0.00	1	0.96	0.75
XIf. Other carcinomas and unspecified carcinomas	3	3.92	4.77	7	6.63	6.80	6	8.07	8.18	12	11.50	10.84
XII. Other malignant and unspecified neoplasms	8	10.45	10.56	12	11.36	11.28	8	10.75	11.88	11	10.54	11.46
XIIb. Other unspecified malignant tumors	8	10.45	10.56	12	11.36	11.28	8	10.75	11.88	11	10.54	11.46
All neoplasms	122	159.33	163.65	168	159.09	162.48	127	170.72	179.15	182	174.36	180.11

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Salvador - BA, 2000 - 2004




Figure 61. Distribution of the population* in Salvador
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – Salvador

Coordinator

Elmando Sampaio Silva

Supervisor

Dermeval Nunes dos Santos

Registrars

Ana Cristina de Santana

Daniele Rodrigues da Conceição

Data Entry Clerks

Mário José Guimarães Filho

Edgleice Oliveira Souza Machado da Silva

Advisory Committee

Maria de Lurdes V. Froes (clinical oncologist)

Luiz Carlos Calmon Teixeira (radiotherapist)

Robson Moura Freitas (general surgeon)

Helenemarie S. Barbosa (pathologist)

Maria José Amorim Nascimento (gynecologist)

Infrastructure and Data Source

This PBCR was created in 1996, whereas the data collection started in 1997. It is located in the Bahia League Against Cancer/Aristides Maltez Hospital, at avenida D. João VI, 332, Brotas, Salvador, and financially supported by the SES/SMS, as per Ordinance No. 2,607.




Figure 62. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand men, per tumor primary site and age group

Salvador - BA, 2000 - 2004

Table 77

CID-10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	14	0.00	0.00	0.00	0.00	0.00	0.18	0.20	0.22	0.51	0.66	0.88	0.67	0.00	0.00	3.54	0.00	0.00	14.01	0.24	0.32
C01	Tongue base	24	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.51	0.00	0.88	5.39	0.87	3.73	3.54	5.64	5.48	0.00	0.40	0.61
C02	Other parts of the tongue	128	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22	1.02	6.31	13.58	16.18	12.98	18.67	14.15	11.27	16.45	14.01	2.16	3.42
C03	Gingiva	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.33	1.31	1.35	0.87	2.49	3.54	0.00	0.00	7.00	0.22	0.37
C04	Floor of the mouth	34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.51	1.99	2.19	5.39	2.60	7.47	1.77	0.00	0.00	0.00	0.57	0.87
C05	Palate	53	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.22	2.04	1.66	1.75	4.05	9.52	7.47	7.07	14.09	0.00	7.00	0.89	1.42
C06	Other parts of the mouth	86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	1.53	3.65	5.69	5.39	6.92	16.18	17.68	14.09	21.93	35.02	1.45	2.38
C07	Parotid gland	27	0.00	0.00	0.35	0.00	0.30	0.00	0.20	0.22	0.26	0.00	0.44	2.02	1.73	3.73	5.30	8.45	16.45	14.01	0.46	0.72
C08	Other larger salivary glands	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	2.02	0.67	0.87	0.00	0.00	10.97	0.00	0.10	0.15
C09	Amygdala	56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	1.53	2.66	6.13	4.05	4.33	6.22	8.84	11.27	0.00	7.00	0.94	1.43
C10	Oropharynx	78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.56	2.32	7.01	10.11	10.38	9.96	7.07	8.45	5.48	7.00	1.32	2.05
C11	Nasopharynx	39	0.00	0.00	0.52	0.14	0.60	0.18	0.00	0.22	0.51	2.32	1.75	0.67	2.60	6.22	3.54	2.82	5.48	14.01	0.66	0.91
C12	Piriform sinus	18	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.26	0.66	0.44	1.35	2.60	3.73	5.30	2.82	0.00	0.00	0.30	0.51	
C13	Hypopharynx	41	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.51	1.33	4.82	4.72	1.73	9.96	5.30	2.82	10.97	0.00	0.69	1.11
C14	Inaccurate locations of the lip, oral cavity and pharynx	36	0.00	0.00	0.17	0.14	0.15	0.18	0.00	0.44	1.02	1.00	1.75	3.37	1.73	4.98	3.54	8.45	0.00	14.01	0.61	0.87
C15	Esophagus	281	0.00	0.00	0.00	0.00	0.00	0.00	0.20	1.54	2.30	10.63	15.33	29.00	29.42	53.52	45.97	59.17	60.31	42.02	4.74	7.61
C16	Stomach	564	0.00	0.00	0.00	0.42	0.15	0.37	1.01	3.96	7.67	15.94	22.77	40.46	65.75	74.68	157.36	149.33	120.62	203.10	9.51	15.68
C17	Small intestine	28	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.22	0.51	0.33	3.50	1.35	2.60	6.22	1.77	5.64	10.97	0.00	0.47	0.74
C18	Colon	241	0.18	0.00	0.17	0.14	0.15	0.18	0.40	0.88	1.79	5.65	7.01	18.88	26.82	37.34	60.12	101.43	71.28	84.04	4.06	6.89
C19	Rectosigmoid junction	21	0.00	0.00	0.00	0.14	0.60	0.00	0.20	0.66	0.26	0.66	0.00	1.35	1.73	3.73	7.07	2.82	5.48	0.00	0.35	0.55
C20	Rectum	162	0.00	0.00	0.00	0.14	0.15	0.18	1.61	1.32	1.53	2.32	7.01	10.79	21.63	27.38	37.13	39.45	65.79	35.02	2.73	4.56
C21	Anus and anal canal	24	0.18	0.00	0.00	0.00	0.15	0.00	0.20	0.44	0.51	0.66	0.88	2.70	2.60	3.73	1.77	2.82	0.00	0.00	0.40	0.57
C22	Liver and intrahepatic biliary ducts	237	0.91	0.37	0.17	0.00	0.15	1.10	0.81	0.88	2.56	5.98	11.82	16.18	35.47	41.08	42.44	50.72	60.31	35.02	4.00	6.60
C23	Gallbladder	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.02	0.33	0.88	2.70	0.87	1.24	8.84	8.45	0.00	7.00	0.37	0.60
C24	Other parts of the biliary ducts	44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.51	1.00	2.19	2.70	4.33	8.71	8.84	14.09	21.93	28.01	0.74	1.31
C25	Pancreas	145	0.18	0.00	0.17	0.00	0.15	0.00	0.60	0.66	1.53	3.98	7.44	3.37	14.71	31.12	21.22	59.17	65.79	56.03	2.44	4.11
C26	Inaccurate locations in the gastrointestinal tract	22	0.00	0.00	0.00	0.00	0.15	0.00	0.20	0.00	0.51	0.00	0.00	0.00	5.19	4.98	7.07	5.64	5.48	7.00	0.37	0.67
C30	Nasal cavity and middle ear	8	0.00	0.00	0.00	0.00	0.15	0.00	0.00	0.00	0.00	0.00	0.44	0.67	1.73	0.00	0.00	5.64	5.48	0.00	0.13	0.21
C31	Paranasal sinuses	14	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22	0.26	1.33	0.44	1.35	0.00	2.49	0.00	2.82	5.48	0.00	0.24	0.33
C32	Larynx	279	0.00	0.00	0.00	0.00	0.00	0.18	0.20	0.44	2.56	8.97	15.33	24.95	40.66	56.01	49.51	61.99	54.83	56.03	4.70	7.98
C33	Trachea	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.00	0.87	1.24	0.00	0.00	5.48	7.00	0.08	0.15
C34	Bronchus and lungs	704	0.00	0.19	0.00	0.00	0.30	0.18	0.40	1.54	4.86	13.95	34.16	38.44	91.71	149.37	166.20	262.03	219.31	175.08	11.87	20.61
C37	Thymus	3	0.00	0.00	0.00	0.14	0.00	0.00	0.00	0.00	0.26	0.00	0.00	0.00	0.00	1.24	0.00	0.00	0.00	0.00	0.05	0.07
C38	Heart, mediastine and pleura	55	0.18	0.19	0.00	0.00	0.00	0.18	0.20	0.44	0.26	1.33	3.07	6.74	6.06	1.24	10.61	16.91	16.45	7.00	0.93	1.39
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.77	0.00	0.00	0.00	0.02	0.04
C40	Bones and limb joints	51	0.00	0.19	1.90	1.27	0.75	1.10	1.01	0.66	0.26	0.33	0.44	1.35	0.00	2.49	0.00	2.82	0.00	0.00	0.86	0.77
C41	Bones and joints of other locations	42	0.00	0.00	0.00	0.14	0.15	0.55	0.40	0.44	0.77	0.33	2.19	3.37	2.60	2.49	8.84	8.45	27.41	7.00	0.71	1.04
C43	Malignant skin melanoma	107	0.18	0.00	0.00	0.00	0.30	0.55	0.60	0.66	3.07	5.31	5.69	4.05	7.79	12.45	21.22	16.91	21.93	28.01	1.80	2.64
C44	Other malignant skin neoplasms	1,523	0.00	0.74	0.52	0.28	1.64	3.84	1.81	9.25	18.40	42.17	54.74	77.55	122.85	247.70	334.18	473.35	696.31	763.36	25.68	41.78
C45	Mesothelioma	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
C46	Kaposi's sarcoma	17	0.00	0.00	0.00	0.14	0.00	0.73	0.40	0.00	0.51	0.66	0.00	0.67	1.73	2.49	0.00	0.00	5.48	0.00	0.29	0.36
C47	Peripheral nerves and autonomic nervous system	5	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.67	0.87	0.00	0.00	0.00	0.00	0.00	0.08	0.11
C48	Retroperitoneum and peritoneum	50	0.55	0.00	0.00	0.00	0.30	0.00	0.60	0.44	1.02	0.66	2.19	2.02	6.06	4.98	7.07	8.45	21.93	14.01	0.84	1.24
C49	Connective tissue and other soft tissues	117	1.09	0.74	0.17	0.99	0.75	1.10	1.61	1.32	2.81	1.99	3.50	10.79	6.06	13.69	8.84	5.64	21.93	7.00	1.97	2.56
C50	Breast	26	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22	0.26	0.66	1.75	2.02	1.73	2.49	3.54	8.45	10.97	21.01	0.44	0.71
C60	Penis	82	0.00	0.00	0.00	0.00	0.15	0.18	0.60	0.66	2.30	1.66	4.38	4.05	7.79	9.96	15.91	11.27	27.41	42.02	1.38	2.11
C61	Prostate	2,961	0.00	0.00	0.00	0.00	0.15	0.00	1.41	0.88	1.53	10.63	52.11	175.32	357.32	678.38	1,083.86	1,329.88	1,463.90	1,260.59	49.92	93.74
C62	Testicles	30	0.73	0.00	0.00	0.28	0.60	0.55	0.20	0.66	1.02	0.66	1.31	0.00	0.87	0.00	0.00	0.00	7.00	0.51	0.49	
C63	Other male sex organs, nos	1	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01
C64	Kidney	128	2.73	0.74	0.00	0.00	0.00	0.55	0.40	0.88	1.53	2.99	5.25	10.11	16.44	14.94	22.99	11.27	27.41	28.01	2.16	3.42
C65	Renal pelvis	7	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.33	0.44	0.00	0.87	1.24	1.77	0.00	5.48	0.00	0.12	0.19
C66	Ureters	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.02	0.04
C67	Bladder	297	0.00	0.00	0.00	0.14	0.15	0.00	0.40	0.22	1.53	1.00	5.69	19.56	32.88	51.03	109.62	126.79	153.52	154.07	5.01	9.13
C68	Other organs of the urinary system, nos	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.00	0.00	0.00	1.24	0.00	0.00	0.00	0.00	0.03	0.05
C69	Eyes and appendages	31	1.64	0.19	0.17	0.00	0.15	0.18	0.81	1.10	0.51	0.33	0.00	0.00	3.46	1.24	1.77	0.00	0.00	0.00	0.52	0.63
C70	Meninges	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.77	0.00	0.00	0.00	0.02	0.04
C71	Encephalon	261	2.55	2.22	2.94	1.56	1.64	2.56	3.22	3												

Table 77 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C81	Hodgkin's disease	60	0.00	0.74	0.69	1.41	1.20	1.10	0.60	0.44	1.02	0.66	1.75	2.70	1.73	1.24	3.54	5.64	5.48	0.00	1.01	1.07
C82	Non-Hodgkin follicular lymphoma	6	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.22	0.00	0.33	0.00	0.67	0.87	0.00	0.00	2.82	0.00	0.00	0.10	0.13
C83	Non-Hodgkin diffuse lymphoma	96	0.00	0.74	0.52	0.85	0.60	0.55	1.21	0.44	2.30	1.00	1.31	3.37	6.06	11.20	14.15	25.36	27.41	21.01	1.62	2.14
C84	Peripheral and cutaneous T-cell lymphoma	20	0.00	0.00	0.00	0.00	0.15	0.00	0.20	0.22	1.02	0.33	1.31	2.02	0.87	2.49	0.00	2.82	0.00	14.01	0.34	0.47
C85	Other types of non-Hodgkin lymphoma, nos	174	0.36	0.37	0.17	0.99	1.20	1.46	1.61	3.08	3.07	5.31	6.57	8.09	11.25	21.16	14.15	36.63	71.28	14.01	2.93	3.99
C88	Malignant immunoproliferative diseases	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
C90	Multiple myeloma and malignant plasmacyte neoplasms	68	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.44	1.02	1.99	0.88	6.07	9.52	8.71	21.22	14.09	16.45	21.01	1.15	1.90
C91	Lymphoid leukemia	92	3.10	3.89	1.04	0.71	0.30	0.00	0.81	0.66	0.77	0.66	0.88	3.37	3.46	9.96	7.07	5.64	16.45	0.00	1.55	2.01
C92	Myeloid leukemia	88	0.73	0.93	0.52	0.99	1.05	0.91	1.41	0.88	1.02	1.00	3.07	2.70	3.46	2.49	8.84	19.72	16.45	42.02	1.48	1.87
C95	Unspecified cell leukemia	37	0.00	0.00	0.35	0.42	0.15	0.37	0.40	0.66	0.00	1.00	2.19	2.02	4.33	2.49	3.54	5.64	5.48	7.00	0.62	0.86
C96	Other malignant lymphatic tissue neoplasms and correlates	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	0.00	5.48	0.00	0.03	0.05
D46	Myelodysplastic syndromes	5	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.00	0.00	1.24	3.54	0.00	5.48	0.00	0.08	0.15
C00-96, D46	All invasive primary malignant neoplasms	10,400	17.12	13.34	11.05	12.44	14.80	21.22	30.80	48.66	100.95	201.90	369.60	647.35	1,081.46	1,818.54	2,510.74	3,237.35	3,673.45	3,550.67	175.34	292.22
C00-96, D46/ C44	All invasive primary malignant neoplasms, except for skin	8,877	17.12	12.60	10.53	12.16	13.16	17.38	28.99	39.42	82.55	159.73	314.86	569.80	958.61	1,570.84	2,176.57	2,764.00	2,977.14	2,787.31	149.66	250.44
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.67	0.00	3.73	0.00	0.00	0.00	0.00	0.08	0.16
D01	Carcinoma in situ of other organs of the gastrointestinal tract	4	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.22	0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.05
D02	Carcinoma in situ of the middle ear and respiratory system	7	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.26	0.33	0.00	0.67	0.00	0.00	0.00	5.64	5.48	0.00	0.12	0.16
D03	Melanoma in situ	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	1.24	0.00	2.82	0.00	7.00	0.07	0.13
D04	Skin carcinoma in situ	26	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.51	1.00	1.75	0.67	0.87	9.96	8.84	2.82	0.00	0.00	0.44	0.76
D07	Carcinoma in situ of other sex organs and unspecified organs	4	0.00	0.00	0.00	0.00	0.15	0.00	0.00	0.22	0.26	0.00	0.00	0.00	0.00	1.24	0.00	0.00	0.00	0.00	0.07	0.08
D09	Carcinoma in situ of other locations and unspecified locations	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.00	0.00	1.24	0.00	0.00	0.00	0.00	0.05	0.06
C00-96, D00-09, D46	All primary malignant neoplasms	10,453	17.12	13.34	11.05	12.44	14.95	21.22	31.61	49.10	102.23	203.56	371.79	650.04	1,082.33	1,835.97	2,519.58	3,248.62	3,678.93	3,557.67	176.23	293.61

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

Salvador - BA, 2000 - 2004

Table 78

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	7	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.79	0.00	4.60	2.53	0.00	0.11	0.11
C01	Tongue base	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.37	0.00	0.00	0.00	0.00	1.53	0.00	0.00	0.05	0.05
C02	Other parts of the tongue	34	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.00	0.44	0.28	0.74	2.59	2.48	3.95	6.00	4.60	7.60	5.28	0.51	0.64
C03	Gingiva	4	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	1.53	2.53	0.00	0.06	0.06
C04	Floor of the mouth	6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.52	0.00	0.79	1.00	1.53	2.53	0.00	0.09	0.10
C05	Palate	23	0.00	0.00	0.00	0.00	0.13	0.00	0.17	0.00	0.22	0.56	0.37	0.52	1.86	2.37	2.00	7.67	2.53	5.28	0.35	0.41
C06	Other parts of the mouth	34	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.38	0.22	0.28	1.11	1.04	4.34	0.79	9.00	3.07	5.07	7.92	0.51	0.63
C07	Parotid gland	19	0.00	0.00	0.00	0.00	0.13	0.00	0.35	0.38	0.00	0.28	0.37	0.52	0.62	2.37	1.00	1.53	5.07	5.28	0.29	0.29
C08	Other larger salivary glands	10	0.00	0.00	0.00	0.13	0.00	0.00	0.17	0.38	0.22	0.00	1.11	0.52	0.00	0.79	0.00	0.00	0.00	0.00	0.15	0.16
C09	Amygdala	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.74	0.52	3.10	1.58	2.00	0.00	2.53	2.64	0.23	0.31
C10	Oropharynx	13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.37	0.52	0.62	2.37	2.00	3.07	5.07	0.00	0.20	0.24
C11	Nasopharynx	14	0.00	0.00	0.17	0.00	0.27	0.00	0.35	0.00	0.22	0.28	0.74	0.52	0.62	0.79	0.00	3.07	0.00	0.00	0.21	0.22
C12	Piriform sinus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.53	0.00	0.00	0.02	0.02
C13	Hypopharynx	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.22	0.28	0.00	0.52	0.62	0.79	0.00	0.00	2.53	0.00	0.11	0.12
C14	Inaccurate locations of the lip, oral cavity and pharynx	10	0.00	0.00	0.00	0.00	0.13	0.16	0.00	0.00	0.22	0.00	0.00	0.52	0.62	1.58	1.00	0.00	0.00	2.64	0.15	0.16
C15	Esophagus	89	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.00	1.09	1.68	2.95	4.15	5.58	9.47	11.00	15.33	12.67	26.41	1.34	1.58
C16	Stomach	421	0.00	0.00	0.00	0.00	0.40	0.80	2.61	3.38	5.91	7.27	9.59	20.21	27.91	39.45	50.01	65.93	86.17	81.87	6.32	7.33
C17	Small intestine	23	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.19	0.22	0.56	0.37	1.04	2.48	1.58	5.00	3.07	5.07	0.00	0.35	0.43
C18	Colon	389	0.00	0.00	0.00	0.13	0.13	0.32	0.87	2.26	3.28	5.60	17.33	16.59	26.67	30.77	52.01	73.60	76.03	84.51	5.84	6.87
C19	Rectosigmoid junction	32	0.00	0.00	0.00	0.00	0.00	0.16	0.17	0.56	0.66	0.28	1.11	3.11	1.86	2.37	3.00	4.60	2.53	2.64	0.48	0.57
C20	Rectum	204	0.00	0.00	0.00	0.00	0.40	0.48	0.87	1.50	2.19	4.76	4.42	11.92	13.02	17.36	27.00	24.53	40.55	34.33	3.06	3.53
C21	Anus and anal canal	62	0.00	0.00	0.00	0.00	0.13	0.16	0.00	0.56	0.22	1.68	1.11	2.59	3.10	7.89	11.00	9.20	2.53	18.49	0.93	1.11
C22	Liver and intrahepatic biliary ducts	190	0.00	0.38	0.00	0.00	0.00	0.48	0.69	0.38	1.75	2.52	6.27	9.85	13.64	14.99	23.00	33.73	58.29	36.97	2.85	3.37
C23	Gallbladder	98	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.88	2.80	3.69	4.66	5.58	11.84	14.00	21.47	12.67	13.21	1.47	1.81
C24	Other parts of the biliary ducts	74	0.00	0.00	0.00	0.00	0.13	0.00	0.17	0.38	0.66	0.84	1.47	2.59	1.86	9.47	15.00	13.80	17.74	23.77	1.11	1.31
C25	Pancreas	174	0.00	0.00	0.00	0.13	0.13	0.00	0.17	0.19	1.09	2.52	5.90	8.29	8.68	20.51	34.01	30.67	38.02	36.97	2.61	3.21
C26	Inaccurate locations in the gastrointestinal tract	34	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.74	1.55	1.24	0.79	6.00	0.00	15.21	34.33	0.51	0.55
C30	Nasal cavity and middle ear	7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	0.28	0.37	0.52	0.00	0.00	1.00	0.00	0.00	5.28	0.11	0.12
C31	Paranasal sinuses	9	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.19	0.22	0.56	0.00	0.00	0.00	1.58	0.00	0.00	0.00	2.64	0.14	0.14
C32	Larynx	39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.84	2.95	2.07	3.72	1.58	6.00	4.60	5.07	2.64	0.59	0.71
C33	Trachea	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
C34	Bronchus and lungs	404	0.19	0.00	0.00	0.27	0.13	0.16	0.69	1.50	3.06	9.51	11.06	23.32	33.49	48.13	62.01	65.93	60.83	34.33	6.06	7.60
C37	Thymus	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01
C38	Heart, mediastine and pleura	46	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.19	0.88	1.68	2.21	2.59	4.34	2.37	3.00	3.07	2.53	7.92	0.69	0.78
C39	Inaccurate locations in the respiratory system and intrathoracic organs	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01
C40	Bones and limb joints	31	0.19	0.00	0.87	0.94	0.40	0.16	0.52	0.00	0.22	0.00	1.11	1.04	1.24	0.79	1.00	0.00	0.00	2.64	0.47	0.48
C41	Bones and joints of other locations	35	0.19	0.19	0.35	0.40	0.27	0.00	0.17	0.19	0.44	1.12	0.37	0.52	2.48	0.79	2.00	3.07	10.14	2.64	0.53	0.54
C43	Malignant skin melanoma	109	0.00	0.00	0.00	0.00	0.13	0.48	0.69	2.07	1.09	4.06	5.18	10.54	7.89	9.00	13.80	20.28	13.21	1.64	1.92	
C44	Other malignant skin neoplasms	1,565	0.57	0.00	0.17	0.13	1.60	3.03	4.17	7.71	16.64	35.53	46.08	67.90	104.18	124.66	170.03	283.67	321.87	338.05	23.48	26.77
C45	Mesothelioma	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.53	0.00	0.00	0.03	0.04
C46	Kaposi's sarcoma	4	0.00	0.00	0.00	0.00	0.00	0.16	0.17	0.00	0.00	0.28	0.00	0.52	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.06
C47	Peripheral nerves and autonomic nervous system	6	0.00	0.38	0.00	0.13	0.00	0.00	0.17	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	2.53	0.00	0.09	0.09
C48	Retropertitoneum and peritoneum	77	0.76	0.00	0.00	0.13	0.00	0.00	0.17	0.56	1.31	0.84	2.58	2.59	8.68	4.73	13.00	7.67	12.67	7.92	1.16	1.44
C49	Connective tissue and other soft tissues	104	0.76	0.19	0.00	0.67	1.06	0.64	1.04	0.94	2.19	1.68	2.21	3.11	5.58	9.47	6.00	10.73	10.14	7.92	1.56	1.72
C50	Breast	3,171	0.00	0.00	0.00	0.13	1.60	7.49	17.89	38.16	76.84	121.98	158.52	164.82	206.50	209.88	238.04	280.61	286.39	264.10	47.57	55.43
C51	Vulva	49	0.00	0.00	0.00	0.13	0.00	0.16	0.00	0.56	0.22	1.12	0.74	2.59	1.24	4.73	5.00	9.20	7.60	18.49	0.74	0.79
C52	Vagina	38	0.00	0.00	0.00	0.00	0.00	0.32	0.17	0.00	0.00	0.56	1.47	2.07	3.72	2.37	7.00	3.07	2.53	10.56	0.57	0.68
C53	Cervix	940	0.00	0.00	0.00	0.00	1.20	3.51	10.07	17.86	24.74	31.61	30.60	48.72	55.19	59.96	76.01	76.67	76.03	58.10	14.10	15.88
C54	Endometrium	293	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.56	3.28	3.92	10.69	15.55	26.67	35.51	38.01	59.80	45.62	26.41	4.40	5.50
C55	Uterus, nos	52	0.00	0.00	0.00	0.13	0.00	0.16	0.52	0.56	1.09	1.40	2.21	3.63	2.48	3.16	3.00	6.13	10.14	2.64	0.78	0.87
C56	Ovary	396	0.38	0.57	0.52	1.47	1.60	1.43	2.78	3.76	5.47	10.35	16.22	15.55	24.18	34.72	36.01	46.00	45.62	23.77	5.94	6.84
C57	Other female sex organs, nos	9	0.00	0.00	0.00	0.00	0.27	0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.00	3.07	0.00	2.64	0.14	0.14
C58	Placenta	7	0.00	0.00	0.00	0.27	0.16	0.16	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.08
C64	Kidney	108	2.47	0.19	0.00	0.13	0.40	0.16	0.52	1.13	0.66	1.40	2.58	3.63	8.68	8.68	13.00	6.13	20.28	10.56	1.62	1.95
C65	Renal pelvis	4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00	0.79	0.00	3.07	0.00	0.00	0.06	0.08
C66	Ureters	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.62	0.79	0.00	0.00	0.00	0.00	0.03	0.05
C67	Bladder	145	0.00	0.00	0.00	0.00	0.00	0.32	0.35	1.13	0.88	2.24	3.32	6.74	8							

Salvador - BA, 2000 - 2004

Table 78 (continuation)

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C73	Thyroid gland	305	0.00	0.00	0.52	0.94	1.73	3.35	4.52	6.39	8.98	12.59	8.85	11.92	11.16	17.36	7.00	13.80	5.07	10.56	4.58	4.73
C74	Adrenal gland	8	0.57	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.22	0.00	0.00	0.52	0.00	1.58	0.00	0.00	0.00	0.00	0.12	0.16
C75	Other endocrine glands and related structures	8	0.00	0.19	0.00	0.13	0.00	0.16	0.17	0.00	0.22	0.00	0.00	0.00	0.62	0.00	0.00	3.07	0.00	0.00	0.12	0.12
C76	Other inaccurate locations	109	0.38	0.19	0.00	0.27	0.53	0.80	1.04	0.94	0.66	1.68	3.69	4.66	6.20	8.68	14.00	10.73	20.28	15.85	1.64	1.90
C80	Unknown primary site	402	0.19	0.00	0.17	0.13	0.80	1.28	1.74	2.26	6.13	5.88	13.27	17.10	24.80	32.35	64.01	56.73	70.96	66.03	6.03	7.02
C81	Hodgkin's disease	60	0.00	0.76	0.52	0.80	1.20	0.80	0.17	0.94	0.44	0.84	1.47	2.07	1.24	2.37	1.00	7.67	2.53	2.64	0.90	0.90
C82	Non-Hodgkin follicular lymphoma	10	0.00	0.00	0.17	0.00	0.00	0.00	0.00	0.00	0.22	0.84	0.37	0.52	0.62	0.79	0.00	0.00	0.00	0.00	0.15	0.17
C83	Non-Hodgkin diffuse lymphoma	97	0.19	0.38	0.35	0.40	0.40	0.16	1.22	0.56	0.66	1.40	2.58	5.70	6.20	8.68	10.00	7.67	17.74	13.21	1.46	1.70
C84	Peripheral and cutaneous T-cell lymphoma	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.56	0.74	0.00	0.62	0.79	1.00	0.00	0.00	0.00	0.15	0.17
C85	Other types of non-Hodgkin lymphoma, nos	153	0.00	0.00	0.35	0.27	0.00	0.96	1.56	0.56	1.97	3.08	4.42	7.26	7.44	18.15	20.00	16.87	20.28	21.13	2.30	2.69
C88	Malignant immunoproliferative diseases	2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00	0.00	0.00	2.64	0.03	0.03
C90	Multiple myeloma and malignant plasmacyte neoplasms	128	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.38	0.66	3.08	5.53	12.44	10.54	12.62	16.00	18.40	12.67	15.85	1.92	2.47
C91	Lymphoid leukemia	72	2.66	1.53	1.22	0.00	0.27	0.00	0.17	0.94	0.22	0.28	0.74	2.07	1.86	3.95	6.00	6.13	15.21	5.28	1.08	1.30
C92	Myeloid leukemia	107	1.14	0.57	0.70	0.27	0.93	0.96	1.04	0.56	1.53	1.68	4.42	3.11	5.58	5.52	10.00	7.67	5.07	10.56	1.61	1.81
C95	Unspecified cell leukemia	49	0.76	0.57	0.17	0.40	0.40	0.00	0.00	0.00	0.66	0.56	3.32	0.52	2.48	3.16	2.00	3.07	10.14	10.56	0.74	0.86
C96	Other lymphatic tissue malignant neoplasms and correlates	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.52	0.62	0.00	2.00	0.00	0.00	0.00	0.08	0.10
D46	Myelodysplastic syndromes	6	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.00	0.52	0.00	0.00	0.00	1.53	5.07	2.64	0.09	0.09
C00-96, D46	All invasive primary malignant neoplasms	11,431	14.46	7.44	8.18	9.51	18.22	32.20	62.70	105.65	186.73	297.67	418.06	547.33	731.12	895.52	1,164.17	1,412.23	1,578.93	1,513.31	171.47	199.04
C00-96, D00-09, D46/ C44	All invasive primary malignant neoplasms, except for skin	9,866	13.89	7.44	8.00	9.38	16.63	29.17	58.53	97.94	170.09	262.14	371.98	479.43	626.94	770.86	994.15	1,128.56	1,257.06	1,175.26	147.99	172.27
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00	1.58	0.00	0.00	0.00	0.00	0.05	0.07
D01	Carcinoma in situ of other organs of the gastrointestinal tract	5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.22	0.00	0.00	0.00	0.00	0.79	2.00	0.00	0.00	0.00	0.08	0.09
D02	Carcinoma in situ of the middle ear and respiratory system	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01
D03	Melanoma in situ	5	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.22	0.00	0.00	0.52	0.00	0.00	0.00	3.07	0.00	0.00	0.08	0.08
D04	Skin carcinoma in situ	35	0.00	0.00	0.00	0.00	0.13	0.16	0.00	0.00	0.00	1.12	1.11	1.55	2.48	2.37	5.00	7.67	7.60	7.92	0.53	0.63
D05	Breast carcinoma in situ	173	0.00	0.00	0.00	0.00	0.13	0.48	0.52	2.07	3.94	7.55	9.22	10.88	14.88	7.89	14.00	12.27	7.60	7.92	2.60	3.10
D06	Cervical carcinoma in situ	901	0.00	0.00	0.00	1.21	8.11	19.44	30.05	32.33	26.27	23.50	15.48	12.96	16.12	14.99	17.00	10.73	15.21	7.92	13.52	11.99
D07	Carcinoma in situ of other sex organs and unspecified organs	24	0.00	0.00	0.00	0.00	0.00	0.64	0.17	0.19	0.44	0.84	1.84	1.04	0.00	2.37	0.00	3.07	0.00	0.00	0.36	0.38
D09	Carcinoma in situ of other locations and unspecified locations	6	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.22	0.28	0.37	0.52	0.62	0.00	0.00	0.00	0.00	0.00	0.09	0.11
C00-96, D00-09, D46	All primary malignant neoplasms	12,584	14.46	7.44	8.18	10.71	26.61	53.23	93.44	140.61	218.03	330.97	446.08	575.32	765.22	925.50	1,202.18	1,449.03	1,609.35	1,537.08	188.76	215.51

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Salvador - BA, 2000 - 2004

Male

Table 79

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	486	12.87	86.2	9.7	57.4
C15 Esophagus	281	7.61	70.8	21.0	73.7
C16 Stomach	564	15.68	76.6	14.4	65.4
C18-21 Large intestine, anal canal and anus	448	12.57	77.7	10.9	46.0
C22 Liver	237	6.60	39.7	39.2	88.6
C25 Pancreas	145	4.11	38.6	38.6	104.8
C32 Larynx	279	7.98	83.5	9.7	49.8
C33-34 Trachea, bronchus and lungs	709	20.77	61.5	21.9	89.3
C43 Skin melanoma	107	41.78	89.7	2.8	17.8
C61 Prostate	2,961	91.74	74.1	5.8	20.9
C70-72 Central Nervous System	276	6.10	50.4	24.6	75.7
C73 Thyroid	49	0.97	87.8	2.0	14.3
C91-95 Leukemia	217	4.74	44.2	28.6	77.0
C81-85, C96 Lymphoma	358	7.86	81.6	9.2	45.5
C00-96, D46 All primary invasive malignant Neoplasms	10,400	292.22	77.3	12.2	42.0
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	8,877	250.44	74.1	14.3	48.9

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 80

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)
C00-10/C07-08 Lip, tongue, oral cavity and oropharynx	139	2.57	84.9	10.1	55.4
C15 Esophagus	89	1.58	61.8	25.8	84.3
C16 Stomach	421	7.33	72.2	16.9	61.5
C18-21 Large intestine, anal canal and anus	687	12.07	79.0	11.6	46.1
C22 Liver	190	3.37	29.5	46.8	97.9
C25 Pancreas	174	3.21	36.8	39.1	100.0
C32 Larynx	39	0.71	79.5	15.4	48.7
C33-34 Trachea, bronchus and lungs	405	7.62	58.8	23.7	86.2
C43 Skin melanoma	109	26.77	83.5	1.8	10.1
C50 Breast	3,171	55.43	86.2	5.5	24.5
C53 Cervix	940	15.88	82.6	13.6	41.0
C70-72 Central Nervous System	224	3.72	42.4	33.5	92.4
C73 Thyroid	305	4.73	86.6	3.9	9.5
C91-95 Leukemia	228	3.97	29.4	37.3	68.4
C81-85, C96 Lymphoma	335	5.73	77.9	11.6	43.6
C00-96, D46 All primary invasive malignant Neoplasms	11,431	199.04	76.7	13.0	40.0
C00-96, D46/ C44 All primary invasive malignant Neoplasms, except for skin	9,866	172.27	73.4	15.0	46.1

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM

MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Salvador - BA, 2000 - 2004

Male




Figure 63

Female




Figure 64

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Salvador - BA, 2000 - 2004

Table 81

Pediatric Tumors - ICCC	Boys						Girls					
	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*	No.	0-14 Crude	Adjusted*	No.	0-19 Crude	Adjusted*
I. Leukemia	58	34.77	35.87	73	30.73	32.57	50	30.78	32.35	55	23.20	26.58
Ia. Lymphoid leukemia	44	26.38	27.56	49	20.63	22.95	29	17.85	18.78	29	12.23	14.55
Ib. Acute myeloid leukemia	10	5.99	6.01	13	5.47	5.61	8	4.93	5.19	9	3.80	4.32
Ic. Myeloproliferative chronic diseases	0	0.00	0.00	4	1.68	1.27	4	2.46	2.36	5	2.11	2.13
Id. Myelodysplastic syndrome and myeloproliferative diseases	2	1.20	1.30	2	0.84	1.01	1	0.62	0.73	1	0.42	0.57
Ie. Specified leukemias and other unspecified leukemias	2	1.20	1.00	5	2.10	1.73	8	4.93	5.29	11	4.64	5.01
II. Reticuloendothelial lymphomas and neoplasms	20	11.99	11.40	43	18.10	16.15	15	9.24	8.47	26	10.97	9.88
Ila. Hodgkin's lymphoma	8	4.80	4.40	18	7.58	6.59	7	4.31	3.98	13	5.48	4.89
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	9	5.40	5.10	19	8.00	7.14	7	4.31	3.88	11	4.64	4.21
Ilc. Burkitt's lymphoma	1	0.60	0.60	1	0.42	0.46	1	0.62	0.62	1	0.42	0.48
Ile. Unspecified lymphoma	2	1.20	1.30	5	2.10	1.96	0	0.00	0.00	1	0.42	0.30
III. CNS and misc. of intracranial and intraspinal neoplasms	44	26.38	26.16	57	24.00	24.41	21	12.93	12.44	25	10.54	10.85
Illa. Ependymoma and choroid plexus tumor	7	4.20	4.32	7	2.95	3.35	1	0.62	0.74	1	0.42	0.57
IIlb. Astrocytoma	12	7.19	6.91	16	6.74	6.62	5	3.08	2.76	7	2.95	2.74
IIlc. Intracranial and intraspinal embryonic tumors	10	5.99	6.20	13	5.47	5.76	3	1.85	1.52	3	1.27	1.17
IIId. Other gliomas	1	0.60	0.50	1	0.42	0.39	0	0.00	0.00	0	0.00	0.00
IIIf. Unspecified intracranial and intraspinal tumors	14	8.39	8.23	20	8.42	8.29	12	7.39	7.43	14	5.91	6.36
IV. Neuroblastoma and other peripheral nervous cell tumor	10	5.99	6.83	10	4.21	5.29	7	4.31	5.03	7	2.95	3.90
IVa. Neuroblastoma and ganglioneuroblastoma	9	5.40	6.13	9	3.79	4.75	7	4.31	5.03	7	2.95	3.90
IVb. Other peripheral nervous cell tumors	1	0.60	0.71	1	0.42	0.55	0	0.00	0.00	0	0.00	0.00
V. Retinoblastoma	10	5.99	6.95	10	4.21	5.38	9	5.54	6.51	9	3.80	5.05
VI. Renal tumors	19	11.39	12.97	19	8.00	10.05	14	8.62	10.19	15	6.33	8.20
VIa. Nephroblastoma and other renal non-epithelial tumors	19	11.39	12.97	19	8.00	10.05	11	6.77	7.98	11	4.64	6.19
VIb. Renal carcinomas	0	0.00	0.00	0	0.00	0.00	1	0.62	0.74	1	0.42	0.57
VIc. Unspecified malignant renal tumors	0	0.00	0.00	0	0.00	0.00	2	1.23	1.47	3	1.27	1.44
VII. Hepatic tumors	8	4.80	5.22	8	3.37	4.05	1	0.62	0.62	1	0.42	0.48
VIIa. Hepatoblastoma	6	3.60	4.01	6	2.53	3.11	0	0.00	0.00	0	0.00	0.00
VIIb. Hepatocellular carcinoma	1	0.60	0.50	1	0.42	0.39	0	0.00	0.00	0	0.00	0.00
VIIc. Unspecified malignant hepatic tumors	1	0.60	0.71	1	0.42	0.55	1	0.62	0.62	1	0.42	0.48
VIII. Malignant bone tumors	12	7.19	6.11	21	8.84	7.60	8	4.93	4.38	18	7.59	6.41
VIIIa. Osteosarcoma	11	6.59	5.61	18	7.58	6.58	2	1.23	1.01	6	2.53	1.99
VIIIb. Chondrosarcoma	1	0.60	0.50	3	1.26	1.02	1	0.62	0.51	2	0.84	0.69
VIIIc. Ewing's sarcoma and related bone sarcomas	0	0.00	0.00	0	0.00	0.00	2	1.23	1.24	6	2.53	2.17
VIIIe. Unspecified malignant bone tumors	0	0.00	0.00	0	0.00	0.00	3	1.85	1.63	4	1.69	1.56
IX. Soft-tissue and other extraosseous sarcomas	13	7.79	8.13	21	8.84	8.85	9	5.54	5.92	17	7.17	7.00
IXa. Rhabdomyosarcoma	3	1.80	1.71	5	2.10	1.96	5	3.08	3.44	7	2.95	3.27
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	6	3.60	3.71	10	4.21	4.15	1	0.62	0.51	3	1.27	0.99
IXc. Kaposi's sarcoma	0	0.00	0.00	1	0.42	0.32	0	0.00	0.00	0	0.00	0.00
IXd. Other unspecified soft-tissue sarcomas	1	0.60	0.71	2	0.84	0.87	1	0.62	0.51	2	0.84	0.69
IXe. Unspecified soft-tissue sarcomas	3	1.80	2.01	3	1.26	1.56	2	1.23	1.47	5	2.11	2.04
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	6	3.60	4.23	7	2.95	3.60	9	5.54	5.45	22	9.28	8.14
Xa. Intracranial and intraspinal germ cell tumors	0	0.00	0.00	0	0.00	0.00	1	0.62	0.62	2	0.84	0.78
Xb. Malignant intracranial and intraspinal germ cell tumors	3	1.80	2.11	3	1.26	1.64	2	1.23	1.47	4	1.69	1.74
Xc. Malignant gonadal germ cell tumors	2	1.20	1.41	3	1.26	1.41	5	3.08	2.86	13	5.48	4.63
Xd. Gonadal carcinomas	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	0.84	0.60
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	1	0.60	0.71	1	0.42	0.55	1	0.62	0.51	1	0.42	0.39
XI. Other malignant epithelial neoplasms and melanomas	16	9.59	9.11	29	12.21	11.20	7	4.31	4.23	29	12.23	9.91
XIb. Thyroid carcinoma	1	0.60	0.60	4	1.68	1.42	2	1.23	1.01	9	3.80	2.89
XIc. Nasopharynx carcinoma	2	1.20	1.00	3	1.26	1.10	0	0.00	0.00	0	0.00	0.00
XId. Malignant melanoma	1	0.60	0.71	1	0.42	0.55	0	0.00	0.00	0	0.00	0.00
XIe. Skin carcinoma	5	3.00	2.80	6	2.53	2.48	3	1.85	1.98	4	1.69	1.83
XIf. Other carcinomas and unspecified carcinomas	7	4.20	4.01	15	6.31	5.65	2	1.23	1.24	16	6.75	5.18
XII. Other malignant and unspecified neoplasms	14	8.39	8.41	20	8.42	8.43	12	7.39	8.12	18	7.59	8.10
XIIa. Other specified malignant tumors	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.42	0.30
XIIb. Other unspecified malignant tumors	14	8.39	8.41	20	8.42	8.43	12	7.39	8.12	17	7.17	7.80
All neoplasms	230	137.88	141.39	318	133.88	137.57	162	99.74	103.72	242	102.07	104.49

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

São Paulo - SP, 2001 - 2005




Figure 65. Distribution of the population* in São Paulo
 *Demographic Census of 2000 – IBGE
 Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE

PBCR Team – São Paulo

Coordinator

Fernanda Alessandra Silva Michels

Vice coordinator

Aryane Simon

Database coordinator

Iza Alzira Cavalheri Sconza

Data Entry Clerks

Maria Lucinda Telles Mascaro
 Maria Nazaré Marques da Silva
 Maria Rita de Cássia Gomes dos Santos
 Sofia de Fátima da Silva Barbosa de Oliveira
 Thamires de Souza Correia

Data source coordinator

Ivani Márica Fedoryszyn

Registrars/Data Collectors

Ângela Cristina Lipparelli
 Eglair Longo
 Lea Fernandes da Silva Soares
 Maria Aparecida Jorge

Information System Analyst

Donaldo Botelho Veneziano

Scientific advisement

Antonio Pedro Mirra
 Carlos Marigo
 José Maria Pacheco de Souza
 Maria do Rosario Dias de Oliveira Latorre
 Maria Lucia Lebrão
 Sabina Léa Davidson Gotlieb

Advisory technical Committee

Mauro Taniguchi (Municipal Health Secretariat)
 Ruy Paulo D'elia Nunes (Health Surveillance Coordination - COVISA)
 Carmen Helena Seoane Leal (COVISA)
 Margarida M. T. de Azevedo Lira (Municipal Health Secretariat)
 Marina de Freitas (Municipal Health Secretariat)
 Victor Wunsch Filho (Public Health University)
 Maria do Rosario Dias de Oliveira Latorre (Public Health University)
 Valeria Lombardo (São Paulo Oncocentro Foundation)

Infrastructure and Data Source

This PBCR was created in 1969, year when the data collection started (however, the uninterrupted collection started only in 1997). It is located in the Municipal Health Secretariat and financially supported by the MHS/SHS (as per Ordinance No. 1,344).




Figure 66. Proportion of new cases, compared to the year of highest frequency
 Sources: Data from Population-Based Cancer Registry
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand men, per tumor primary site and age group

São Paulo - SP, 2001 - 2005

Table 82

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*	
C00	Lip	259	0.00	0.09	0.04	0.04	0.20	0.17	0.28	0.50	0.91	1.17	2.76	2.76	4.00	5.82	8.30	7.94	6.86	7.72	1.02	1.12	
C01	Tongue base	291	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.45	1.60	2.81	5.52	3.60	4.75	6.41	7.55	5.01	1.72	1.29	1.14	1.32	
C02	Other parts of the tongue	973	0.00	0.00	0.00	0.04	0.35	0.26	0.28	1.76	3.99	8.43	13.88	16.57	19.58	17.47	17.36	15.88	16.30	9.01	3.82	4.22	
C03	Gingiva	133	0.04	0.00	0.04	0.00	0.08	0.00	0.09	0.05	0.46	0.89	1.81	1.80	2.08	2.33	3.52	4.60	6.01	0.00	0.52	0.57	
C04	Floor of the mouth	323	0.00	0.05	0.00	0.00	0.00	0.17	0.05	0.35	1.43	3.56	4.22	6.01	6.82	5.44	5.03	4.60	5.15	5.15	1.27	1.43	
C05	Palate	354	0.00	0.05	0.13	0.00	0.16	0.21	0.28	0.20	2.00	2.40	4.31	6.97	7.56	5.63	5.79	9.19	2.57	5.15	1.39	1.55	
C06	Other parts of the mouth	635	0.26	0.19	0.04	0.28	0.35	0.43	0.51	0.95	2.28	5.07	8.28	10.21	9.49	13.78	10.57	10.44	12.87	12.87	2.49	2.73	
C07	Parotid gland	167	0.04	0.05	0.00	0.12	0.12	0.09	0.42	0.30	0.57	0.96	0.60	2.40	3.41	2.14	4.53	5.85	8.58	6.43	0.66	0.72	
C08	Other larger salivary glands	57	0.00	0.05	0.00	0.12	0.20	0.09	0.18	0.25	0.17	0.27	0.17	0.60	0.89	0.58	0.75	0.84	2.57	2.57	0.22	0.23	
C09	Amygdala	371	0.74	0.56	0.13	0.12	0.20	0.21	0.28	0.25	1.43	3.36	5.26	6.13	6.53	5.05	4.78	5.01	3.43	3.86	1.46	1.62	
C10	Oropharynx	508	0.00	0.00	0.00	0.08	0.08	0.13	0.18	0.45	1.65	5.62	7.33	9.61	10.23	10.68	12.83	4.18	6.01	1.29	1.99	2.31	
C11	Nasopharynx	206	0.04	0.05	0.18	0.48	0.24	0.04	0.28	0.30	0.86	1.44	1.81	2.28	4.30	4.27	4.03	4.60	0.86	3.86	0.81	0.90	
C12	Piriform sinus	189	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	0.74	1.17	2.85	3.24	4.60	4.46	4.28	5.01	2.57	0.00	0.74	0.86	
C13	Hypopharynx	217	0.00	0.00	0.00	0.04	0.04	0.00	0.09	0.25	0.57	1.10	3.10	4.08	5.49	4.66	5.28	7.94	1.72	2.57	0.85	1.01	
C14	Inaccurate locations of the lip, oral cavity and pharynx	232	0.00	0.05	0.00	0.08	0.20	0.04	0.14	0.25	1.03	1.85	3.71	3.72	4.15	3.49	5.53	5.01	3.43	1.29	0.91	1.02	
C15	Esophagus	2,435	0.00	0.00	0.00	0.00	0.04	0.55	0.74	1.56	6.90	17.14	29.57	40.72	54.29	58.04	62.89	70.61	75.49	64.34	9.56	11.31	
C16	Stomach	5,401	0.00	0.05	0.00	0.12	0.47	1.15	2.44	5.73	11.00	21.32	38.36	64.62	97.30	144.04	185.15	254.44	344.87	341.01	21.20	24.97	
C17	Small intestine	327	0.00	0.00	0.00	0.00	0.04	0.21	0.32	0.45	1.14	2.40	1.64	4.80	5.34	7.96	9.56	12.95	12.01	10.29	1.28	1.44	
C18	Colon	4,042	0.00	0.00	0.00	0.04	0.59	1.32	2.58	4.77	7.70	12.27	25.69	49.48	68.38	102.31	133.08	219.34	256.51	263.80	15.87	18.32	
C19	Rectosigmoid junction	461	0.00	0.00	0.00	0.00	0.04	0.09	0.55	1.31	1.78	3.62	6.73	8.16	11.65	14.34	23.40	24.88	25.74	1.81	2.13		
C20	Rectum	2,278	0.00	0.00	0.00	0.08	0.24	0.94	1.29	2.46	5.25	7.88	16.21	26.90	39.01	65.62	70.94	110.30	130.40	122.25	8.94	10.31	
C21	Anus and anal canal	234	0.00	0.00	0.00	0.00	0.20	0.13	0.28	0.60	1.08	1.37	2.67	2.76	3.56	3.49	6.79	8.36	8.58	2.57	0.92	0.99	
C22	Liver and intrahepatic biliary ducts	642	0.61	0.19	0.00	0.04	0.16	0.17	0.37	0.60	1.03	3.08	6.47	10.93	12.46	16.89	18.36	21.31	18.87	23.16	2.52	2.98	
C23	Gallbladder	216	0.00	0.00	0.00	0.00	0.04	0.04	0.00	0.14	0.20	0.23	0.75	1.21	2.64	2.82	6.79	9.56	11.28	15.44	15.44	0.85	1.02
C24	Other parts of the biliary ducts	257	0.00	0.00	0.00	0.00	0.00	0.00	0.14	0.40	0.46	0.89	2.59	1.80	4.00	6.21	9.31	13.37	19.73	21.88	1.01	1.19	
C25	Pancreas	1,284	0.00	0.00	0.00	0.00	0.08	0.21	0.46	0.95	3.14	5.55	10.78	18.02	22.84	30.48	49.56	58.49	88.36	69.49	5.04	6.08	
C26	Inaccurate locations in the gastrointestinal tract	242	0.00	0.00	0.04	0.00	0.08	0.09	0.18	0.20	0.57	0.89	1.38	2.16	3.71	4.66	9.56	12.12	24.02	20.59	0.95	1.11	
C30	Nasal cavity and middle ear	44	0.00	0.09	0.13	0.00	0.04	0.09	0.18	0.10	0.11	0.41	0.09	0.60	0.30	0.78	0.75	0.84	0.86	3.86	0.17	0.19	
C31	Paranasal sinuses	146	0.17	0.14	0.18	0.16	0.39	0.34	0.46	0.30	0.63	0.62	0.86	1.20	1.48	2.52	2.52	1.67	0.86	7.72	0.57	0.58	
C32	Larynx	2,413	0.17	0.09	0.00	0.08	0.16	0.17	0.51	1.16	4.79	15.70	30.00	42.04	53.25	62.90	67.92	66.01	82.36	54.05	9.47	11.29	
C33	Trachea	39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.06	0.21	0.60	0.96	0.44	0.97	1.01	0.84	0.00	0.00	0.15	0.16	
C34	Bronchus and lungs	5,991	0.00	0.00	0.00	0.04	0.32	0.89	1.66	3.06	7.93	21.80	42.68	76.99	122.97	189.28	243.51	301.65	327.71	283.10	23.52	28.92	
C37	Thymus	11	0.00	0.00	0.00	0.00	0.04	0.04	0.05	0.05	0.00	0.21	0.09	0.00	0.15	0.19	0.25	0.00	0.00	0.00	0.04	0.05	
C38	Heart, mediastine and pleura	183	0.17	0.05	0.00	0.20	0.20	0.51	0.42	0.05	0.29	0.62	2.24	1.20	1.78	2.91	7.04	8.36	3.43	5.15	0.72	0.77	
C39	Inaccurate locations of the respiratory system and the intrathoracic organs	69	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.05	0.11	0.27	0.43	0.96	1.04	2.14	1.76	4.18	4.29	2.57	0.27	0.31	
C40	Bones and limb joints	226	0.09	0.93	1.14	2.25	0.99	0.55	0.46	0.30	0.34	0.96	0.69	0.84	0.89	0.78	1.26	2.09	0.86	1.29	0.89	0.84	
C41	Bones and joints of other locations	356	0.22	1.02	1.32	1.69	1.22	1.19	0.74	1.10	0.86	1.65	1.38	2.76	2.52	3.88	2.77	6.68	4.29	7.72	1.40	1.43	
C43	Malignant skin melanoma	1,186	0.00	0.05	0.09	0.32	0.79	0.64	1.48	2.76	2.79	5.21	8.19	9.97	13.20	19.02	24.65	43.03	46.33	52.76	4.66	4.22	
C44	Other malignant skin neoplasms	18,095	0.04	0.37	0.53	0.52	1.38	4.09	9.45	17.13	30.90	54.77	89.14	144.85	226.20	316.24	484.26	768.33	1,004.58	1,019.17	71.03	63.58	
C45	Mesothelioma	36	0.00	0.00	0.00	0.00	0.08	0.00	0.00	0.10	0.00	0.34	0.09	0.36	0.59	0.58	1.26	2.51	1.72	1.29	0.14	0.16	
C46	Kaposi's sarcoma	267	0.00	0.05	0.00	0.16	0.39	0.94	1.89	1.91	1.60	1.71	1.29	1.32	0.44	1.16	1.01	2.09	0.86	9.01	1.05	0.81	
C47	Peripheral nerves and autonomic nervous system	33	0.04	0.05	0.00	0.04	0.16	0.21	0.09	0.05	0.11	0.34	0.09	0.00	0.30	0.58	0.75	0.00	0.00	0.00	0.13	0.13	
C48	Retroperitoneum and peritoneum	57	0.22	0.09	0.00	0.04	0.12	0.09	0.09	0.10	0.06	0.21	0.34	0.24	0.44	1.94	1.51	2.92	1.72	1.29	0.22	0.26	
C49	Connective tissue and other soft tissues	685	1.49	1.16	1.19	1.48	1.26	0.94	1.80	2.26	2.17	3.08	3.62	5.89	5.19	7.96	10.06	12.53	23.16	20.59	2.69	2.68	
C50	Breast	275	0.00	0.00	0.00	0.00	0.20	0.04	0.23	0.60	0.80	1.23	2.50	3.72	5.34	4.46	8.30	9.61	16.30	11.58	1.08	1.21	
C60	Penis	378	0.09	0.05	0.09	0.24	1.02	0.85	0.92	1.56	1.77	1.99	2.59	3.84	3.26	5.63	6.54	7.10	12.87	12.87	1.48	1.48	
C61	Prostate	16,797	0.00	0.00	0.00	0.08	0.16	0.09	0.51	1.10	3.99	18.44	67.68	167.55	337.01	556.37	753.44	1,016.93	1,137.56	1,080.94	65.93	78.06	
C62	Testicles	805	1.57	1.40	1.14	2.17	4.41	6.98	4.89	3.52	3.76	2.26	1.47	0.84	1.93	2.52	2.26	5.01	6.01	5.15	3.16	2.81	
C63	Other male sex organs, nos	69	0.04	0.05	0.09	0.12	0.24	0.26	0.14	0.25	0.40	0.21	0.43	1.08	0.15	0.39	1.76	0.84	0.00	1.29	0.27	0.26	
C64	Kidney	1,385	1.79	0.93	0.31	0.08	0.35	0.47	1.25	1.66	3.59	8.57	12.24	20.42	26.70	30.48	36.23	40.94	37.75	39.89	5.44	6.25	
C65	Renal pelvis	20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.26	0.24	0.30	0.39	1.51	0.42	1.72	0.00	0.08	0.09	
C66	Ureters	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.07	0.00	0.48	0.30	0.39	1.51	0.84	2.57	0.00	0.09	0.11	
C67	Bladder	2,880	0.09	0.00	0.13	0.12	0.12	0.34	0.42	1.26	3.42	7.06	13.88	32.43	43.16	73.77	112.20	179.24	244.50	256.08	11.30	13.27	
C68	Other organs of the urinary system, nos	56	0.00	0.00	0.04	0.00	0.20	0.04	0.14	0.05	0.11	0.14	0.34	0.48	0.89	0.78	2.26	2.09	2.57	3.86	0.22	0.24	
C69	Eyes and appendages	262	2.27	0.42	0.04	0.20	0.28	0.17	0.18	0.40	0.97	0.89	1.47	2.28	3.41	2.33	5.53	6.68	6.86	3.86	1.03	1.12	
C70	Meninges	76	0.31	0.37	0.18	0.20	0.24	0.17	0.28	0.05	0.17	0.41	0.52	0.36	0.59	0.19	0.75	1.67	0.00	0.00	0.30</		

Table 82 (continuation)

CID -10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C76	Other inaccurate locations	412	0.26	0.23	0.13	0.32	0.51	0.38	1.01	1.16	0.86	2.06	3.10	6.85	6.53	6.99	9.56	10.86	12.01	7.72	1.62	1.77
C80	Unknown primary site	3,714	0.96	0.56	0.53	1.40	1.77	2.13	2.95	5.07	9.35	15.15	31.21	46.00	64.23	89.11	111.44	147.90	148.41	156.99	14.58	16.49
C81	Hodgkin's disease	595	0.22	1.40	1.54	2.81	2.52	2.51	2.12	1.91	3.02	2.19	2.33	2.28	3.56	2.52	4.78	7.52	4.29	7.72	2.34	2.17
C82	Non-Hodgkin follicular lymphoma	154	0.00	0.00	0.00	0.16	0.12	0.04	0.28	0.35	0.86	1.10	1.12	1.92	3.26	2.52	2.77	4.60	4.29	5.15	0.60	0.67
C83	Non-Hodgkin diffuse lymphoma	512	0.96	0.88	0.53	0.72	0.83	0.72	0.55	1.21	1.31	2.47	3.88	4.44	5.93	9.90	14.34	10.86	20.59	12.87	2.01	2.24
C84	Peripheral and cutaneous T-cell lymphoma	144	0.04	0.00	0.00	0.28	0.28	0.21	0.37	0.40	0.86	0.69	0.60	1.92	1.48	1.94	2.01	1.67	6.01	2.57	0.57	0.53
C85	Other types of non-Hodgkin lymphoma, nos	1,651	0.74	1.30	1.10	1.89	2.05	2.51	3.37	4.67	6.78	7.47	11.98	17.30	21.21	31.45	37.73	43.03	54.90	61.77	6.48	7.04
C88	Malignant immunoproliferative diseases	11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.14	0.00	0.24	0.15	0.39	0.00	0.42	1.72	0.00	0.04	0.05
C90	Multiple myeloma and malignant plasmacyte neoplasms	760	0.00	0.09	0.00	0.04	0.08	0.30	0.55	1.10	2.34	4.11	6.90	13.21	13.50	17.28	25.91	29.25	30.88	25.74	2.98	3.55
C91	Lymphoid leukemia	694	4.67	3.21	2.55	1.93	1.26	0.94	0.74	1.00	1.14	1.30	2.85	4.20	4.45	7.18	11.07	15.46	29.17	32.17	2.72	3.10
C92	Myeloid leukemia	884	1.49	0.93	0.79	1.69	1.58	1.83	2.08	2.86	3.42	3.77	4.83	5.28	9.34	15.14	18.11	31.33	32.60	38.60	3.47	3.81
C93	Monocytic leukemia Leucemia monocitica	3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.39	0.00	0.00	0.00	0.00	0.01	0.02
C94	Other specified-type cell leukemias	21	0.00	0.00	0.00	0.00	0.00	0.04	0.05	0.05	0.11	0.00	0.17	0.60	0.30	0.19	0.50	0.84	0.86	1.29	0.08	0.10
C95	Unspecified cell leukemia	223	0.48	0.56	0.40	0.32	0.63	0.43	0.46	0.70	0.46	0.89	1.21	1.56	2.08	1.75	4.78	8.77	11.15	5.15	0.88	0.94
C96	Other malignant lymphatic tissue neoplasms and correlates	31	0.26	0.28	0.13	0.00	0.00	0.13	0.05	0.10	0.00	0.07	0.00	0.12	0.00	0.00	0.75	1.25	0.00	0.00	0.12	0.13
D46	Myelodysplastic syndromes	7	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.39	0.00	0.42	0.86	1.29	0.03	0.03
C00-96, D46	All invasive primary malignant neoplasms	88,283	25.51	21.00	17.39	26.24	34.37	44.58	62.49	97.58	173.21	324.96	585.91	973.81	1,438.65	2,064.37	2,748.34	3,775.66	4,483.31	4,327.61	346.53	379.40
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	70,188	25.47	20.63	16.86	25.72	32.99	40.49	53.04	80.46	142.31	270.20	496.76	828.96	1,212.45	1,748.13	2,264.08	3,007.32	3,478.73	3,308.44	275.50	315.82
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.06	0.48	0.86	1.08	1.19	0.97	1.26	2.51	2.57	0.00	0.23	0.26
D01	Carcinoma in situ of other organs of the gastrointestinal tract	53	0.00	0.00	0.00	0.00	0.04	0.00	0.14	0.05	0.17	0.41	0.52	0.60	0.59	0.78	0.75	1.67	6.01	1.29	0.21	0.21
D02	Carcinoma in situ of the middle ear and respiratory system	59	0.00	0.00	0.00	0.00	0.00	0.04	0.05	0.05	0.00	0.41	0.60	1.32	1.19	0.97	1.51	2.09	2.57	2.57	0.23	0.27
D03	Melanoma in situ	140	0.00	0.00	0.00	0.00	0.04	0.13	0.18	0.10	0.34	0.41	0.26	0.96	1.33	1.36	1.51	3.34	3.43	2.57	0.55	0.31
D04	Skin carcinoma in situ	505	0.00	0.00	0.00	0.04	0.04	0.00	0.18	0.15	0.68	0.96	1.81	3.48	4.30	11.07	14.84	22.98	37.75	33.46	1.98	1.74
D05	Breast carcinoma in situ	17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.17	0.24	0.30	0.78	0.50	0.00	1.72	0.00	0.07	0.08
D07	Carcinoma in situ of other sex organs and unspecified organs	131	0.00	0.00	0.04	0.16	0.28	0.26	0.28	0.30	0.34	0.69	0.69	1.32	2.37	3.11	3.52	4.18	3.43	0.00	0.51	0.56
D09	Carcinoma in situ of other locations and unspecified locations	70	0.00	0.00	0.00	0.00	0.04	0.09	0.09	0.00	0.11	0.27	0.43	0.72	1.04	2.72	2.52	1.67	6.01	0.00	0.27	0.31
C00-96, D00-09, D46	All primary malignant neoplasms	89,317	25.51	21.00	17.44	26.44	34.80	45.09	63.42	98.34	174.92	328.66	591.25	983.54	1,450.97	2,086.11	2,774.76	3,814.10	4,546.80	4,367.50	350.58	383.16

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 100 thousand women, per tumor primary site and age group

São Paulo - SP, 2001 - 2005

Table 83

CID - 10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C00	Lip	118	0.05	0.05	0.18	0.08	0.15	0.36	0.21	0.23	0.15	0.41	0.36	0.69	0.69	1.56	1.85	2.33	4.88	3.38	0.42	0.36
C01	Tongue base	54	0.00	0.00	0.00	0.00	0.04	0.00	0.09	0.05	0.05	0.41	0.66	0.89	0.23	0.71	0.67	1.29	1.33	2.26	0.19	0.18
C02	Other parts of the tongue	350	0.05	0.10	0.04	0.15	0.22	0.32	0.26	0.95	0.70	1.82	2.55	2.76	2.87	5.52	7.24	5.94	9.31	11.28	1.25	1.12
C03	Gingiva	81	0.14	0.00	0.04	0.00	0.04	0.04	0.09	0.09	0.10	0.06	0.51	0.79	1.15	1.42	1.01	2.07	2.22	4.51	0.29	0.27
C04	Floor of the mouth	86	0.09	0.00	0.00	0.00	0.07	0.04	0.00	0.14	0.30	0.47	0.58	1.28	1.38	1.42	0.51	1.29	1.33	2.82	0.31	0.30
C05	Palate	164	0.00	0.00	0.09	0.04	0.18	0.12	0.26	0.50	0.65	0.82	1.09	1.38	2.07	1.84	3.03	3.36	3.99	1.69	0.59	0.54
C06	Other parts of the mouth	263	0.18	0.05	0.13	0.08	0.30	0.36	0.60	0.50	0.40	1.17	1.46	2.17	2.18	2.97	4.21	3.88	11.97	8.46	0.94	0.82
C07	Parotid gland	210	0.00	0.05	0.09	0.19	0.22	0.36	0.34	0.50	0.85	1.05	1.24	1.77	2.18	2.55	2.19	3.10	4.88	6.20	0.75	0.67
C08	Other larger salivary glands	68	0.05	0.00	0.04	0.00	0.18	0.08	0.34	0.23	0.35	0.41	0.36	0.59	0.46	0.28	0.84	1.55	0.89	0.56	0.24	0.21
C09	Amygdala	112	0.32	0.24	0.31	0.19	0.33	0.28	0.21	0.23	0.05	0.70	0.36	0.69	1.38	1.13	1.68	0.78	0.89	0.00	0.40	0.41
C10	Oropharynx	97	0.05	0.05	0.04	0.00	0.04	0.04	0.04	0.14	0.45	0.47	0.29	1.18	1.49	1.13	1.85	2.07	2.22	3.38	0.35	0.33
C11	Nasopharynx	94	0.05	0.00	0.09	0.08	0.22	0.20	0.17	0.23	0.65	0.35	0.29	0.89	0.92	1.42	1.35	0.52	2.66	1.13	0.34	0.32
C12	Pitiform sinus	23	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.05	0.05	0.23	0.22	0.20	0.34	0.14	0.34	0.00	0.00	0.56	0.08	0.07
C13	Hypopharynx	35	0.00	0.00	0.00	0.00	0.07	0.00	0.04	0.00	0.10	0.06	0.58	0.20	0.69	0.57	0.84	0.52	0.44	0.56	0.13	0.13
C14	Inaccurate locations of the lip, oral cavity and pharynx	68	0.00	0.00	0.00	0.00	0.07	0.16	0.00	0.23	0.20	0.41	0.29	0.79	0.69	0.71	0.67	1.55	1.77	2.26	0.24	0.21
C15	Esophagus	661	0.00	0.00	0.00	0.00	0.07	0.20	0.26	0.45	0.95	2.29	4.08	7.87	10.57	10.47	12.29	19.38	20.39	27.64	2.36	2.19
C16	Stomach	3,490	0.05	0.10	0.00	0.19	0.63	1.48	3.18	4.05	7.42	12.37	17.63	26.77	40.11	51.38	71.21	110.61	144.04	168.66	12.47	11.01
C17	Small intestine	322	0.00	0.00	0.04	0.00	0.04	0.28	0.34	0.41	0.75	0.88	2.33	3.25	3.10	6.09	6.57	9.30	10.19	6.20	1.15	1.03
C18	Colon	4,819	0.00	0.00	0.00	0.04	0.78	1.04	2.88	4.82	9.26	17.93	25.20	38.58	51.95	72.48	102.35	157.38	197.67	223.38	17.22	15.02
C19	Rectosigmoid junction	494	0.05	0.00	0.00	0.04	0.04	0.24	0.13	0.41	1.15	1.88	2.33	5.91	6.78	8.07	11.45	10.60	16.84	14.67	1.77	1.60
C20	Rectum	2,168	0.05	0.00	0.00	0.00	0.33	0.68	1.50	2.52	4.83	7.74	15.95	19.39	26.55	32.70	43.60	61.77	69.14	85.18	7.75	6.96
C21	Anus and anal canal	362	0.00	0.00	0.00	0.00	0.07	0.16	0.21	0.54	1.00	2.05	2.99	3.54	4.71	4.67	5.72	10.60	10.64	6.77	1.29	1.17
C22	Liver and intrahepatic biliary ducts	353	0.23	0.00	0.09	0.15	0.11	0.16	0.30	0.41	0.75	1.41	1.97	3.44	4.25	6.94	7.24	6.72	13.30	9.59	1.26	1.18
C23	Gallbladder	449	0.00	0.00	0.00	0.04	0.11	0.12	0.04	0.36	0.70	1.64	2.77	3.25	5.86	9.20	9.26	14.21	16.40	22.00	1.60	1.48
C24	Other parts of the biliary ducts	348	0.00	0.00	0.00	0.00	0.07	0.08	0.04	0.18	0.70	0.88	2.11	2.26	3.22	6.09	7.91	13.18	14.63	26.51	1.24	1.12
C25	Pancreas	1,540	0.00	0.00	0.00	0.00	0.18	0.12	0.69	1.17	1.74	3.81	6.41	12.40	19.65	25.76	37.37	55.56	80.66	92.51	5.50	5.01
C26	Inaccurate locations in the gastrointestinal tract	282	0.14	0.05	0.04	0.08	0.04	0.16	0.13	0.23	0.50	0.82	0.87	2.26	2.41	3.54	4.88	9.05	15.07	26.51	1.01	0.88
C30	Nasal cavity and middle ear	71	0.00	0.05	0.09	0.08	0.04	0.04	0.26	0.14	0.20	0.35	0.44	0.89	0.46	0.28	0.51	1.81	2.22	1.69	0.25	0.21
C31	Paranasal sinuses	123	0.09	0.00	0.09	0.12	0.11	0.12	0.34	0.45	0.55	0.53	0.80	1.28	0.69	0.57	2.36	0.52	1.77	4.51	0.44	0.38
C32	Larynx	477	0.18	0.10	0.00	0.04	0.11	0.20	0.39	0.63	1.05	2.70	3.86	6.99	6.78	9.91	6.73	6.46	7.09	5.64	1.70	1.65
C33	Trachea	18	0.00	0.00	0.00	0.00	0.00	0.08	0.00	0.05	0.10	0.12	0.07	0.30	0.23	0.14	0.17	0.26	0.44	0.00	0.06	0.06
C34	Bronchus and lungs	3,392	0.00	0.00	0.04	0.04	0.22	0.76	1.72	3.65	6.87	14.77	23.02	34.25	45.86	62.42	75.58	93.55	113.46	96.46	12.12	11.43
C37	Thymus	29	0.00	0.00	0.00	0.04	0.04	0.00	0.09	0.00	0.10	0.06	0.51	1.20	0.11	0.28	0.34	0.52	0.89	0.56	0.10	0.09
C38	Heart, mediastine and pleura	173	0.27	0.00	0.18	0.12	0.18	0.24	0.13	0.23	0.45	0.82	0.95	1.67	1.72	1.98	2.19	2.84	4.43	5.08	0.62	0.55
C39	Inaccurate locations in the respiratory system and intrathoracic organs	92	0.05	0.05	0.00	0.00	0.04	0.04	0.00	0.00	0.20	0.35	0.87	0.98	1.15	1.56	2.02	1.81	0.89	4.51	0.33	0.31
C40	Bones and limb joints	190	0.18	0.91	1.68	0.96	0.63	0.48	0.21	0.32	0.60	0.35	0.22	0.98	1.15	0.14	0.51	1.03	0.89	1.13	0.68	0.66
C41	Bones and joints of other locations	336	0.23	0.91	1.28	1.04	0.92	0.80	0.47	1.08	0.75	1.35	1.53	1.38	2.64	2.41	1.68	3.88	3.99	5.08	1.20	1.11
C43	Malignant skin melanoma	1,433	0.00	0.05	0.13	0.12	0.59	1.76	1.89	2.39	3.88	6.04	7.87	9.94	10.00	13.16	18.52	24.03	28.81	40.05	5.12	3.61
C44	Other malignant skin neoplasms	19,873	0.18	0.48	0.40	0.73	2.37	4.72	10.83	15.62	32.71	48.58	76.62	114.08	161.36	228.89	337.51	514.80	651.51	749.66	71.02	47.82
C45	Mesothelioma	25	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.05	0.00	0.06	0.00	0.30	0.23	0.99	0.51	0.52	0.89	0.56	0.09	0.08
C46	Kaposi's sarcoma	55	0.00	0.00	0.00	0.04	0.07	0.20	0.26	0.14	0.25	0.12	0.15	0.10	0.34	0.28	0.51	1.29	0.89	2.82	0.20	0.15
C47	Peripheral nerves and autonomic nervous system	48	0.09	0.14	0.09	0.15	0.11	0.08	0.09	0.09	0.10	0.12	0.29	0.30	0.46	0.28	0.84	0.78	0.00	0.56	0.17	0.17
C48	Retroperitoneum and peritoneum	85	0.32	0.05	0.04	0.04	0.07	0.08	0.09	0.23	0.15	0.23	0.51	0.79	0.80	1.42	1.68	0.78	2.22	2.82	0.30	0.30
C49	Connective tissue and other soft tissues	697	1.04	0.91	0.84	0.85	1.11	0.88	1.16	1.89	2.74	2.29	4.15	5.22	5.17	6.37	7.41	10.34	14.63	10.72	2.49	2.20
C50	Breast	21,450	0.00	0.00	0.00	0.23	2.07	7.72	20.89	50.23	100.96	152.84	196.73	233.47	236.99	286.93	275.57	350.17	356.34	348.04	76.66	70.10
C51	Vulva	461	0.18	0.10	0.04	0.27	0.41	0.44	0.69	0.77	1.15	1.52	1.89	1.67	4.83	7.36	8.08	13.44	17.29	20.87	1.65	1.44
C52	Vagina	281	0.05	0.00	0.00	0.12	0.18	0.24	0.34	0.32	0.80	1.17	1.17	1.48	1.61	2.83	3.87	4.39	4.88	2.26	1.00	0.63
C53	Cervix	5,144	0.00	0.00	0.00	0.85	3.48	8.35	14.01	19.80	27.68	34.40	39.70	49.71	47.47	54.36	53.36	54.53	56.73	58.10	18.38	16.47
C54	Endometrium	2,140	0.00	0.05	0.00	0.00	0.30	0.48	1.12	1.98	3.53	6.80	14.49	22.24	33.21	45.44	46.63	58.41	60.28	39.49	7.65	7.19
C55	Uterus, nos	963	0.00	0.00	0.00	0.08	0.11	0.56	1.16	1.35	3.29	5.10	5.90	9.65	12.76	12.88	15.49	20.93	21.27	22.56	3.44	3.03
C56	Ovary	2,844	0.41	0.19	0.80	1.20	1.52	2.48	2.88	4.73	10.60	13.95	23.23	31.30	36.20	43.17	44.10	56.34	41.66	42.31	10.16	9.52
C57	Other female sex organs, nos	136	0.00	0.00	0.00	0.08	0.11	0.40	0.64	0.68	0.55	0.82	0.58	0.59	1.03	1.27	2.02	1.55	2.22	2.26	0.49	0.42
C58	Placenta	29	0.00	0.00	0.09	0.15	0.26	0.04	0.17	0.18	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.10	0.08
C64	Kidney	913	2.21	1.05	0.22	0.19	0.48	0.40	0.34	1.35	2.14	3.34	5.90	7.97	10.46	13.45	16.16	19.90	21.72	20.31	3.26	3.08
C65	Renal pelvis	15	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.12	0.15	0.39	0.23	0.14	0.00	0.00	0.44	0.56	0.05	0.05
C66	Ureters	14	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.10	0.00	0.00	0.20	0.11	0.14	0.51	0.52	0.44	0.00	0.05	0.04
C67	Bladder	1,312	0.09																			

Table 83 (continuation)

CID-10th revision	Primary site	No.	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude	Adjusted*
C72	Spinal cord and other parts of the central nervous system	109	0.32	0.05	0.13	0.12	0.07	0.16	0.21	0.45	0.20	0.53	0.51	0.59	1.03	1.13	2.02	2.07	1.77	2.82	0.39	0.38
C73	Thyroid gland	5,896	0.00	0.14	0.53	2.54	8.06	14.63	23.95	27.99	35.30	43.25	52.15	48.43	37.01	33.12	26.09	32.82	23.49	21.44	21.07	18.03
C74	Adrenal gland	118	1.89	0.57	0.04	0.31	0.11	0.04	0.04	0.18	0.25	0.35	0.07	0.79	0.34	1.56	0.17	0.78	0.89	1.13	0.42	0.49
C75	Other endocrine glands and related structures	82	0.09	0.05	0.13	0.12	0.15	0.12	0.26	0.23	0.40	0.59	0.36	0.49	0.57	0.71	1.01	0.52	1.33	1.69	0.29	0.27
C76	Other inaccurate locations	584	0.23	0.14	0.22	0.42	0.48	0.68	1.03	1.80	1.69	2.75	3.06	3.25	6.55	6.23	8.75	11.89	16.84	20.87	2.09	1.84
C80	Unknown primary site	3,838	0.45	0.96	0.62	0.96	1.44	2.64	3.70	5.94	9.16	14.36	22.43	35.34	35.63	57.47	73.90	97.69	123.21	125.23	13.72	11.99
C81	Hodgkin's disease	524	0.18	0.43	0.84	2.31	2.55	3.08	2.54	1.71	1.24	1.05	1.75	1.77	2.07	2.12	2.53	4.13	2.66	2.82	1.87	1.62
C82	Non-Hodgkin follicular lymphoma	165	0.00	0.00	0.00	0.08	0.18	0.16	0.21	0.32	0.45	1.00	1.31	1.97	2.07	1.84	3.37	2.33	2.66	1.69	0.59	0.55
C83	Non-Hodgkin diffuse lymphoma	493	0.45	0.33	0.40	0.58	0.41	0.80	0.52	0.86	0.90	1.82	1.82	3.25	6.09	7.36	9.26	10.60	15.51	9.59	1.76	1.62
C84	Peripheral and cutaneous T-cell lymphoma	113	0.05	0.00	0.00	0.08	0.15	0.24	0.04	0.14	0.50	0.47	0.66	0.59	1.03	0.99	1.52	1.81	1.77	3.95	0.40	0.32
C85	Other types of non-Hodgkin lymphoma, nos	1,500	0.50	0.67	0.35	0.93	1.63	2.00	1.98	2.34	3.68	4.63	8.96	13.19	15.17	24.21	25.08	39.28	36.79	40.05	5.36	4.88
C88	Malignant immunoproliferative diseases	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00	0.00	0.23	0.00	0.17	1.03	0.89	0.00	0.04	0.03
C90	Multiple myeloma and malignant plasmacyte neoplasms	838	0.00	0.00	0.04	0.00	0.04	0.16	0.43	0.36	2.04	3.16	5.83	8.46	13.22	18.12	17.68	26.36	23.49	18.61	2.99	2.91
C91	Lymphoid leukemia	571	3.47	3.11	1.86	1.12	0.85	0.48	0.64	0.81	0.95	1.17	1.89	2.56	3.10	5.52	4.71	11.89	6.65	20.87	2.04	2.15
C92	Myeloid leukemia	839	1.08	0.81	0.93	1.31	1.78	1.56	1.98	2.25	2.09	3.34	4.88	5.02	6.55	7.93	10.77	14.47	20.83	28.77	3.00	2.81
C93	Monocytic leukemia	2	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.01	0.01
C94	Other specified-type cell leukemias	10	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.12	0.15	0.10	0.00	0.28	0.34	0.00	0.00	0.00	0.04	0.04
C95	Unspecified cell leukemia	213	0.32	0.38	0.27	0.42	0.48	0.68	0.17	0.27	0.50	0.64	0.80	0.89	1.84	2.12	2.19	3.36	6.20	13.54	0.76	0.71
C96	Other lymphatic tissue malignant neoplasms and correlates	22	0.18	0.05	0.04	0.00	0.04	0.00	0.00	0.14	0.00	0.06	0.07	0.10	0.23	0.14	0.00	0.00	0.44	0.00	0.08	0.07
D46	Myelodysplastic syndromes	22	0.00	0.00	0.04	0.00	0.00	0.00	0.09	0.05	0.15	0.06	0.07	0.00	0.00	0.42	0.17	0.78	1.33	1.13	0.08	0.06
C00-96, D46	All invasive primary malignant neoplasms	97,765	21.65	16.78	16.22	22.09	40.58	69.44	114.09	179.08	303.38	453.29	631.13	837.33	982.31	1,269.87	1,514.18	2,092.78	2,449.60	2,676.56	349.39	298.80
C00-96, D46/C44	All invasive primary malignant neoplasms, except for skin	77,892	21.47	16.31	15.83	21.36	38.21	64.72	103.26	163.47	270.67	404.71	554.50	723.25	820.95	1,040.98	1,176.67	1,577.98	1,798.09	1,926.90	278.37	250.98
D00	Carcinoma in situ of the oral cavity, esophagus and stomach	29	0.00	0.00	0.00	0.00	0.00	0.08	0.04	0.05	0.10	0.18	0.29	0.30	0.23	0.28	0.34	0.26	0.44	0.56	0.10	0.09
D01	Carcinoma in situ of other organs of the gastrointestinal tract	54	0.00	0.00	0.04	0.00	0.00	0.04	0.04	0.09	0.15	0.12	0.22	0.59	0.46	0.42	1.68	1.81	1.77	0.56	0.19	0.16
D02	Carcinoma in situ of the middle ear and respiratory system	19	0.00	0.00	0.04	0.00	0.04	0.04	0.09	0.05	0.15	0.12	0.00	0.20	0.11	0.28	0.34	0.00	0.00	0.00	0.07	0.06
D03	Melanoma in situ	192	0.00	0.00	0.00	0.15	0.00	0.24	0.26	0.23	0.40	0.41	0.58	1.08	0.92	1.70	2.86	1.29	1.77	1.69	0.69	0.36
D04	Skin carcinoma in situ	705	0.05	0.05	0.00	0.00	0.18	0.16	0.09	0.09	0.35	0.94	2.11	2.76	5.17	7.79	13.97	21.97	29.25	26.51	2.52	1.56
D05	Breast carcinoma in situ	1,138	0.00	0.00	0.00	0.00	0.04	0.08	0.56	2.75	8.16	10.84	11.07	14.76	12.53	12.74	9.76	11.63	10.19	6.20	4.07	3.77
D06	Cervical carcinoma in situ	4,278	0.00	0.00	0.00	1.31	8.66	20.51	28.80	28.04	28.48	24.50	20.39	20.08	16.78	14.58	14.31	14.21	7.53	9.59	15.29	12.49
D07	Carcinoma in situ of other sex organs and unspecified organs	135	0.00	0.05	0.00	0.04	0.22	0.36	0.30	0.63	0.50	0.76	0.66	0.89	1.03	1.70	1.35	1.81	0.44	2.82	0.48	0.41
D09	Carcinoma in situ of other locations and unspecified locations	98	0.00	0.00	0.04	0.08	0.18	0.16	0.30	0.32	0.35	0.41	0.58	0.30	0.92	1.27	1.18	1.55	2.66	2.82	0.35	0.30
C00-96, D00-09, D46	All primary malignant neoplasms	104,413	21.70	16.88	16.36	23.68	49.90	91.10	144.57	211.31	342.01	491.56	667.03	878.27	1,020.47	1,310.64	1,559.97	2,147.31	2,503.67	2,727.33	373.15	317.99

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

São Paulo - SP, 2001 - 2005

Male

Table 84

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	3,847	16.86	81.8	6.4	38.4
C15	Esophagus	2,435	11.31	73.3	13.9	61.2
C16	Stomach	5,401	24.97	74.9	12.3	52.5
C18-21	Large intestine, anal canal and anus	7,015	31.75	80.7	7.1	34.4
C22	Liver	642	2.98	69.5	26.2	63.1
C25	Pancreas	1,284	6.08	36.1	29.0	78.1
C32	Larynx	2,413	11.29	79.5	10.3	41.3
C33-34	Trachea, bronchus and lungs	6,030	29.08	62.4	18.2	69.8
C43	Skin melanoma	1,186	63.58	95.7	4.0	19.6
C61	Prostate	16,797	78.06	83.7	5.5	17.9
C70-72	Central Nervous System	1,624	6.96	48.8	15.8	52.2
C73	Thyroid	1,137	4.25	83.5	1.4	6.2
C91-95	Leukemia	1,825	7.95	73.2	26.8	55.7
C81-85, C96	Lymphoma	3,087	12.75	88.4	11.6	32.8
C00-96, D46	All primary invasive malignant Neoplasms	88,283	379.40	79.5	8.7	31.0
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	70,188	315.82	74.3	10.9	37.9

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 85

Topography	No.	Adjusted*	MV(%)	DCO(%)	M/I(%)	
C00-10/C07-08	Lip, tongue, oral cavity and oropharynx	1,325	4.32	70.3	3.7	23.2
C15	Esophagus	661	2.19	71.3	13.8	54.5
C16	Stomach	3,490	11.01	74.6	11.8	48.4
C18-21	Large intestine, anal canal and anus	7,843	24.76	79.3	7.9	35.5
C22	Liver	353	1.18	65.7	26.3	69.7
C25	Pancreas	1,540	5.01	32.8	28.4	77.7
C32	Larynx	477	1.65	74.4	6.9	29.1
C33-34	Trachea, bronchus and lungs	3,410	11.49	63.6	16.5	63.5
C43	Skin melanoma	1,433	49.82	97.7	2.3	12.6
C50	Breast	21,450	70.10	82.4	4.2	18.4
C53	Cervix	5,144	16.47	86.4	4.7	26.7
C70-72	Central Nervous System	1,681	5.77	43.6	17.4	51.1
C73	Thyroid	5,896	18.03	83.9	0.6	2.6
C91-95	Leukemia	1,635	5.73	72.5	27.5	55.1
C81-85, C96	Lymphoma	2,817	9.04	88.5	11.5	30.7
C00-96, D46	All primary invasive malignant Neoplasms	97,765	298.80	80.1	6.9	24.9
C00-96, D46/ C44	All primary invasive malignant Neoplasms, except for skin	77,892	250.98	75.0	8.6	30.5

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry
MS/SVS/DASIS/CGIAE/Sistema de Informação sobre Mortalidade – SIM
MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

São Paulo - SP, 2001 - 2005

Male




Figure 67

Female




Figure 68

*World Standard Population, modified by Doll et al. (1966)
 Sources: Data from Population-Based Cancer Registry
 MP/Fundação Instituto Brasileiro de Geografia e Estatística – IBGE
 MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Specific, crude and age-adjusted incidence rates*,
per 1 million male and female children and adolescents

São Paulo - SP, 2001 - 2005

Table 86

Pediatric Tumors - ICCC	Boys						Girls						
	0-14		0-19		No.	Crude	0-14		0-19		No.	Crude	Adjusted*
	No.	Crude	Adjusted*	No.			Crude	Adjusted*	No.	Crude			
I. Leukemia	419	62.41	64.05	541	58.77	60.66	337	51.29	52.55	424	46.27	48.27	
Ia. Lymphoid leukemia	286	42.60	43.72	341	37.04	38.85	229	34.85	35.99	266	29.03	31.10	
Ib. Acute myeloid leukemia	69	10.28	10.52	108	11.73	11.68	67	10.20	10.22	102	11.13	10.95	
Ic. Myeloproliferative chronic diseases	10	1.49	1.55	19	2.06	2.01	6	0.91	0.91	9	0.98	0.97	
Id. Myelodysplastic syndrome and myeloproliferative diseases	1	0.15	0.15	2	0.22	0.21	2	0.30	0.30	2	0.22	0.23	
Ie. Specified leukemias and other unspecified leukemias	53	7.89	8.12	71	7.71	7.91	33	5.02	5.12	45	4.91	5.01	
II. Reticuloendothelial lymphomas and neoplasms	254	37.83	37.12	423	45.95	44.02	121	18.42	18.26	245	26.74	24.91	
Ila. Hodgkin's lymphoma	88	13.11	12.38	170	18.47	17.00	40	6.09	5.71	113	12.33	10.76	
Ilb. Non-Hodgkin lymphoma (except for Burkitt's lymphoma)	84	12.51	12.17	148	16.08	15.21	48	7.31	7.27	88	9.60	9.11	
Ilc. Burkitt's lymphoma	43	6.40	6.67	48	5.21	5.62	17	2.59	2.70	18	1.96	2.18	
Ild. Miscellany of lymphoreticular neoplasms	16	2.38	2.43	16	1.74	1.88	7	1.07	1.11	7	0.76	0.86	
Ile. Unspecified lymphoma	23	3.43	3.47	41	4.45	4.31	9	1.37	1.46	19	2.07	2.00	
III. CNS and misc. of intracranial and intraspinal neoplasms	240	35.75	36.15	307	33.35	34.07	232	35.31	35.72	283	30.88	32.11	
Illa. Ependymoma and choroid plexus tumor	20	2.98	3.12	25	2.72	2.87	19	2.89	2.96	22	2.40	2.56	
IIlb. Astrocytoma	35	5.21	5.11	50	5.43	5.32	52	7.91	7.82	64	6.98	7.10	
IIlc. Intracranial and intraspinal embryonic tumors	57	8.49	8.42	69	7.50	7.61	40	6.09	6.12	44	4.80	5.09	
IIId. Other gliomas	16	2.38	2.26	20	2.17	2.11	16	2.44	2.30	21	2.29	2.22	
IIle. Other intracranial and intraspinal neoplasms	0	0.00	0.00	1	0.11	0.09	1	0.15	0.17	2	0.22	0.22	
IIIf. Unspecified intracranial and intraspinal tumors	112	16.68	17.25	142	15.43	16.07	104	15.83	16.35	130	14.19	14.92	
IV. Neuroblastoma and other peripheral nervous cell tumor	59	8.79	9.66	60	6.52	7.58	66	10.05	11.16	70	7.64	9.00	
IVa. Neuroblastoma and ganglioneuroblastoma	58	8.64	9.49	58	6.30	7.36	65	9.89	10.99	68	7.42	8.78	
IVb. Other peripheral nervous cell tumors	1	0.15	0.17	2	0.22	0.22	1	0.15	0.17	2	0.22	0.22	
V. Retinoblastoma	55	8.19	9.24	55	5.97	7.16	48	7.31	8.34	48	5.24	6.46	
VI. Renal tumors	78	11.62	12.39	81	8.80	9.87	89	13.55	14.75	96	10.48	12.04	
VIa. Nephroblastoma and other renal non-epithelial tumors	61	9.09	9.85	61	6.63	7.63	74	11.26	12.44	76	8.29	9.82	
VIb. Renal carcinomas	3	0.45	0.41	6	0.65	0.58	3	0.46	0.44	8	0.87	0.77	
VIc. Unspecified malignant renal tumors	14	2.09	2.13	14	1.52	1.65	12	1.83	1.88	12	1.31	1.45	
VII. Hepatic tumors	19	2.83	3.14	20	2.17	2.52	8	1.22	1.24	12	1.31	1.31	
VIIa. Hepatoblastoma	17	2.53	2.84	17	1.85	2.20	3	0.46	0.52	3	0.33	0.41	
VIIb. Hepatocellular carcinoma	1	0.15	0.15	2	0.22	0.21	4	0.61	0.54	8	0.87	0.76	
VIIc. Unspecified malignant hepatic tumors	1	0.15	0.15	1	0.11	0.12	1	0.15	0.17	1	0.11	0.14	
VIII. Malignant bone tumors	124	18.47	17.29	251	27.27	24.87	136	20.70	19.03	194	21.17	19.78	
VIIIa. Osteosarcoma	54	8.04	7.25	121	13.14	11.67	62	9.44	8.42	87	9.49	8.70	
VIIIb. Chondrosarcoma	1	0.15	0.13	9	0.98	0.82	2	0.30	0.26	7	0.76	0.63	
VIIIc. Ewing's sarcoma and related bone sarcomas	25	3.72	3.52	48	5.21	4.81	35	5.33	4.94	46	5.02	4.78	
VIIIId. Other specified malignant bone tumors	3	0.45	0.42	5	0.54	0.51	0	0.00	0.00	2	0.22	0.17	
VIIIe. Unspecified malignant bone tumors	41	6.11	5.97	68	7.39	7.06	37	5.63	5.41	52	5.67	5.49	
IX. Soft-tissue and other extraosseous sarcomas	95	14.15	14.27	142	15.43	15.30	69	10.50	10.62	111	12.11	11.88	
IXa. Rhabdomyosarcoma	47	7.00	7.26	62	6.73	6.98	29	4.41	4.68	40	4.37	4.58	
IXb. Fibrosarcoma, peripheral nerve sheath tumor and other neoplasms	7	1.04	1.06	8	0.87	0.91	11	1.67	1.62	21	2.29	2.13	
IXc. Kaposi's sarcoma	1	0.15	0.15	5	0.54	0.48	1	0.15	0.13	2	0.22	0.19	
IXd. Other unspecified soft-tissue sarcomas	22	3.28	3.15	34	3.69	3.53	14	2.13	2.16	28	3.06	2.89	
IXe. Unspecified soft-tissue sarcomas	18	2.68	2.65	33	3.58	3.41	14	2.13	2.04	20	2.18	2.10	
X. Germ cell tumors, trophoblastic tumors and gonadal neoplasms	97	14.45	14.65	163	17.71	17.31	48	7.31	7.13	86	9.38	8.82	
Xa. Intracranial and intraspinal germ cell tumors	0	0.00	0.00	2	0.22	0.18	1	0.15	0.13	1	0.11	0.10	
Xb. Malignant intracranial and intraspinal germ cell tumors	2	0.30	0.34	6	0.65	0.62	10	1.52	1.59	11	1.20	1.32	
Xc. Malignant gonadal germ cell tumors	20	2.98	2.95	64	6.95	6.26	30	4.57	4.38	44	4.80	4.61	
Xd. Gonadal carcinomas	3	0.45	0.42	6	0.65	0.60	1	0.15	0.13	5	0.55	0.45	
Xe. Other malignant gonadal tumors and unspecified gonadal tumors	72	10.72	10.94	85	9.23	9.65	6	0.91	0.91	25	2.73	2.35	
XI. Other malignant epithelial neoplasms and melanomas	68	10.13	9.43	167	18.14	16.25	91	13.85	12.92	311	33.94	29.10	
XIa. Adrenal cortex carcinoma	1	0.15	0.17	1	0.11	0.13	3	0.46	0.52	4	0.44	0.49	
XIb. Thyroid carcinoma	5	0.74	0.70	24	2.61	2.26	13	1.98	1.75	89	9.71	7.95	
XIc. Nasopharynx carcinoma	6	0.89	0.79	16	1.74	1.51	4	0.61	0.56	7	0.76	0.69	
XId. Malignant melanoma	5	0.74	0.68	16	1.74	1.52	6	0.91	0.84	17	1.86	1.61	
XIe. Skin carcinoma	20	2.98	2.73	33	3.58	3.29	24	3.65	3.50	48	5.24	4.79	
XIf. Other carcinomas and unspecified carcinomas	31	4.62	4.36	77	8.36	7.54	41	6.24	5.75	146	15.93	13.56	
XII. Other malignant and unspecified neoplasms	195	29.05	30.45	276	29.98	30.92	170	25.87	26.51	266	29.03	28.87	
XIIb. Other unspecified malignant tumors	195	29.05	30.45	276	29.98	30.92	170	25.87	26.51	266	29.03	28.87	
All neoplasms	1,703	253.67	257.86	2,486	270.05	270.53	1,415	215.36	218.23	2,146	234.18	232.55	

*World Standard Population, modified by Doll et al. (1966)

Sources: Data from Population-Based Cancer Registry

MP/Fundação Instituto Brasileiro de Geografia e Estatística - IBGE
MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Below, the ten most frequent primary sites at the PBCRs are represented in charts, per gender. For purposes of comparability, the graphic analysis considered the PBCRs classified in Group A, according to the quality criteria explained in the methodology.

All neoplasms (C00-C96, D46 except for non-melanoma skin cancer - C44)




Figure 69

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Non-Melanoma Skin Cancer (C44)




Figure 70

Esophagus Cancer (C15)




Figure 71

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Stomach Cancer (C16)




Figure 72

Colorectal Cancer (C18-C20)




Figure 73

Cancer of the Liver and Intrahepatic Biliary Ducts (C22)




Figure 74

Larynx Cancer (C32)




Figure 75

Trachea, Bronchus and Lung Cancer (C33-C34)




Figure 76

Female Breast Cancer (C50)




Figure 77

Cervical Uteri Cancer (C53)




Figure 78

Endometrial Cancer (C54)




Figure 79

Ovary Cancer (C56)




Figure 80

Prostate Cancer (C61)




Figure 81

Bladder Cancer (C67)




Figure 82

Cancer of the Central Nervous System (C70-C72)




Figure 83

Thyroid Cancer (C73)




Figure 84

Cervical Carcinoma in situ (D06)




Figure 85



The most recent international estimates point to the incidence of over 13 million new cases of cancer in the world. For men, the cancer incidence¹ is higher in North America (334 per 100 thousand), Australia/New Zealand (356.8 per 100 thousand) and Northern and Western Europe (303 and 337.4 per 100 thousand, respectively). For women, the profile is very similar, with the highest incidence rates being in North America (274.4 per 100 thousand), Australia/New Zealand (276.4 per 100 thousand) and Northern and Western Europe (249.4 and 250.9 per 100 thousand, respectively).

The lowest incidence rates for men are found in Central/Western Africa and Central/Southern Africa. For women, these rates are found in Central/Northern Africa (incidence rates lower than 100 per 100 thousand). Most cancer cases that occur in the developed countries are associated with longer survival (prostate, breast and colorectal cancer), while in the developing countries, the most common types of cancer are the ones with the worst prognoses (liver, stomach and esophagus).

In Brazil, the incidence rates, for most PBCRs, have intermediate values, both for men and women. Nevertheless, some places present incidence rates similar to the developed countries, like Porto Alegre, Goiânia, São Paulo and Belo Horizonte. The highest adjusted incidence rates in men were found in Porto Alegre (404.16 per 100 thousand), Goiânia (365.43 per 100 thousand) and São Paulo (315.82 per 100 thousand). The same profile was observed in women, with the highest rates being found in Porto Alegre (286.18 per 100 thousand); Goiânia (262.82 per 100 thousand) and São Paulo (250.98 per 100 thousand). The lowest incidence rates were found in Fortaleza (204.57 per 100 thousand men; 182.57 per 100 thousand women), Recife (190.22 per 100 thousand men; 180.59 per 100 thousand women); and João Pessoa (182.42 per 100 thousand men; 177.45 per 100 thousand women).

Non-melanoma skin cancer

The non-melanoma skin cancer is the most common type of cancer in the world and its incidence continues to increase. It rarely produces metastases and generally has a good prognosis. However, if not correctly diagnosed and followed, it may destroy the local skin, soft tissues, cartilage and bone.

The non-melanoma skin cancer has two more common histological types: basal cell carcinoma and squamous-cell carcinoma. The first reaches among 75% to 80% of the non-melanoma skin cancers, while the second reaches among 25%, at most. In Brazil, skin cancer is the most common for both genders. The exact number of individuals with basal cell or squamous-cell carcinoma is unknown since most countries do not report these neoplasms in their cancer registries.

The number of cases may be underrated for different reasons, such as the fact that these tumors are not specified in the death certificate notification, or even because many cases are treated without histological analysis.

The most important risk factor for the development of non-melanoma skin cancer is exposure to the ultraviolet (UV) radiation (received in the initial stages of life) combined with the patient's type of skin. The genetic susceptibility to develop it is related to the quantity of melanin and the skin response to the UV radiation. As a result, the incidence is higher in Caucasians compared to non-white people. There, it is recommended that people protect themselves from the solar rays through sunscreens, clothes and hats, thus, contributing to the prevention of non-melanoma skin cancer, especially if the exposure is avoided since the initial stages of life. In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Aracaju (211.3), Goiânia (208.8) and Jaú (172.2). Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Goiânia (190.3), Jaú (188.4) and Aracaju (134.9). The lowest rates were found in the cities of João Pessoa- 16.5 for men - and Belém – 9.7 for women.

Esophagus cancer

Every year, 460 thousand new cases of esophagus cancer are registered in the world. In terms of incidence, it is the ninth most common type of cancer for both genders, worldwide. In Brazil, it is the eighth most common type of cancer.

Esophagus cancer can be divided into two histological subtypes: squamous-cell carcinoma and adenocarcinoma. The first is the most common type and occurs mostly in men aged 50 or older, inflicting mainly the middle and lower thirds of

¹ Estimate of the age-adjusted incidence rates for the world standard population

the esophagus. The adenocarcinoma inflicts the distal part of the esophagus, in the presence of gastric reflux and gastric metaplasia of the epithelium (Barrett's esophagus).

The risk factors related to the squamous-cell carcinoma are age, family history and external factors, such as alcohol, smoking, oral infections caused by fungi, infectious agents (human papillomavirus), riboflavin and vitamin A deficiency and excessive ingestion of mate tea. However, these factors are not related to the increased risk of developing adenocarcinoma. The gastroesophageal reflux disease injures the Barrett's esophagus, an important precursor of the adenocarcinoma. The excessive ingestion of calories, fat, animal protein and the lack of fibers may be associated with the increased risk of adenocarcinoma.

It is interesting to emphasize that the mortality rates are nearly as high as the incidence rates due to the high lethality of this neoplasia. In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre, Jaú and Belo Horizonte, with 18.2, 17.3 and 12.0, respectively. Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were observed in Palmas, 6.1, Porto Alegre, 4.3, and Belo Horizonte, 3.2. The lowest rates were observed in the city of Belém for both genders, 3.4 per 100 thousand men and 0.4 per 100 thousand women.

Stomach cancer

Stomach cancer is one of the main malignant neoplasms in the world, being the fourth most common and the second most lethal type. Its magnitude is twice as high in the developing countries, being more common in men compared to women. It is age-related, reaching its apex in people ranging from fifty to sixty years of age. Countries such as Japan, China, and the ones in Eastern Europe and Latin America present the highest incidence rates. Brazil presents an intermediate stomach cancer incidence rate when compared to the international values, for both genders.

Regarding the histological type, the adenocarcinomas represent its majority. The main risk factor of stomach cancer is the infection caused by the *Helicobacter pylori* (*H. pylori*) bacteria.

Smoking and family history are also important risk factors. Nearly 18% of the gastric cancer incidence can be assigned to smoking (and around 10% - 15% of cases present a family history of stomach cancer). The most important actions for its prevention are: reducing the prevalence of the *H. pylori* by improving sanitation and changing the population's lifestyle, concerning eating habits (ingestion of fruits and vegetables, decreased use of salt and smoked foods and especially food preservation), decreased tobacco use and maintenance of an adequate body weight.

Worldwide, the relative survival five years after the diagnosis of stomach cancer is very low for both genders: it is no higher than 35% for men and 15% for women. In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in São Paulo (25.0), Goiânia (23.7) and Curitiba (21.6). Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Goiânia (11.3), São Paulo (11.01) and Jaú (9.9). The lowest rates were found in the cities of Recife – 11.8 for men – and João Pessoa – 5.2 for women.

Colorectal cancer

Colorectal cancer is the second most prevalent type of cancer in the world, in addition to being the third in terms of incidence. Its incidence is higher in the developed countries. In Brazil, colorectal cancer is among the five most frequent types of cancer, being the fourth most common for men and the third for women. As the colorectal cancer is the predominant disease of the elderly population (its incidence is higher for people aged between 50 and 70 years old), it has been increasing gradually and is expected to increase even more given the higher life expectancy. Despite this, it also affects the younger population, aged under 40 years old, in a more aggressive way, decreasing the possibility of cure.

The development of this type of cancer is slow and may take years. There are multiple factors involved with its appearance, the most important being family history and genetic predisposition to the development of chronic bowel diseases. Others, such as smoking, excessive alcohol consumption, obesity, overweight and eating habits favoring saturated fats may contribute to an increased risk of developing it.

Regarding the histology of these tumors, the adenocarcinomas represent over 95% of the total number of diagnoses of colorectal cancer (tumors that originate in glandular tissue). A study conducted in two Brazilian capitals (Fortaleza and Porto Alegre) showed that both presented a trend towards increased incidence rates from 1990 to 1999. This increase may be due to early cancer detection strategies and changes in people's lifestyles and age structure.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre (34.0), São Paulo (30.8) and Goiânia (27.5). Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Porto Alegre (24.7), Goiânia (24.2) and São Paulo (23.6). The lowest rates were found in the cities of Recife – 8.8 for men – and João Pessoa – 9.4 for women.

Liver cancer

Liver cancer is the fifth most common type of cancer in the world, with approximately 550 thousand new cases every year. Due to its poor prognosis, the number of deaths is not very different from the number of cases, making it the third most lethal cancer worldwide.

In diseases like liver cancer, characterized by the high lethality and short survival after diagnosis, the mortality rates are close to the incidence rates. Thus, the mortality rate is a good indicator of the disease's incidence in the population. The liver cancer known as hepatocellular carcinoma is the most common type of primary liver cancer. There are also the cholangiocarcinoma (which may attack the bile ducts inside the liver), the angiosarcoma (a tumor of the blood vessels) and, in children, the hepatoblastoma. What is unusual in the diagnosis of liver cancer is its short evolution period, that is, the patient usually presents with a very advanced-stage disease when the diagnosis is made. Survival is mostly associated with tumor size, depending on whether the diagnosis was made prior to its causing liver failure and/or metastases.

Some risk factors for the development of liver cancer are already known, such as advanced age, hepatic cirrhosis, family history and sex steroids. The aflatoxin (toxin produced

by a fungus that grows in cereals and other foods in hot and humid areas) is associated with liver cancer. Chronic viral infections caused by Hepatitis B and C are considered strong risk factors for its development. The main measures of control and prevention are based on the control of hepatitis B and C, the inspection of food infection by aflatoxins, the control of alcohol consumption and the fight against smoking.

In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre, Manaus and Recife, with 12.0, 9.9 and 7.4, respectively. Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Palmas, 8.4, Manaus, 5.5, and Recife, 5.3. The lowest rates were found in the city of Jaú, for both genders, 1.7 per 100 thousand men and 1.1 per 100 thousand women.

Larynx cancer

From the several types of head and neck cancers, the larynx cancer is the most frequent and the second most common cancer of the respiratory system in the world, accounting for 25% of the malignant tumors of the head and neck and 2% of the total number of malignant neoplasms. Its incidence is different for each gender, presenting a higher number of cases in men. The larynx cancer incidence has increased significantly since the 1980s in Europe. In Brazil, the cities of São Paulo (SP) and Porto Alegre (RS) are mentioned among the ones with the highest incidence of larynx cancer in the world.

Among the risk factors for larynx cancer, the most remarkable is smoking, a relationship that has been known since the 1950s, when the first epidemiological studies about this neoplasia were published. Other risk factors, such as diets with few nutrients, unfavorable socioeconomic condition, chronic larynx inflammation caused by gastroesophageal reflux and the participation of the Human Papillomavirus as an etiological agent, were identified as factors that contribute to the development of larynx cancer. Since 1980, the larynx cancer treatment involves different therapeutic modalities (surgery, radiotherapy, associated with chemotherapy or not). It is a tumor that offers high rates of cure, regardless of the type of treatment (radiotherapy, surgery or both), ranging from 80% to 100%, as long as it is diagnosed early.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre (11.7), São Paulo (11.3) and Aracaju (10.7). Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in São Paulo, Cuiabá and Goiânia – 1.6 in both registries. The lowest rates were observed in the cities of Belém – 4.6 for men – and Palmas – 0.3 for women.

Lung cancer

Lung cancer has been the most common type of cancer in the world since the 1920s, excluding the non-melanoma skin cancer. The age group ranging from 50 to 70 years of age presents the highest incidence. Generally, it attacks men more often than women, though this profile has been changing in the past few years, as it has become more common among the women.

In the past 50 years, tobacco smoking was considered the main cause of lung cancer. The risk of developing lung cancer increases with the quantity and duration of tobacco consumption: the individuals who started smoking in adolescence are more likely to develop lung cancer than those who started smoking after turning 25. The environmental or occupational exposure to tobacco smoke, radon, asbestos and the air pollution are also associated with an increased risk of developing lung cancer.

Lung cancer is considered to be an aggressive disease, of late diagnosis, and the presence of symptoms usually is the sign of a worse prognosis, which decreases the chances of cure. Over 85% of patients die in the first five years after the diagnosis. Studies made clear that a diet rich in fruits, vegetables, cereals, meats, milk and eggs provides substances that protect against lung cancer, particularly the cruciferous vegetables (cauliflower, broccoli, cabbage) and foods containing betacarotene.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre, 66.6, São Paulo, 29.1, and Goiânia 28.2. Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Porto Alegre, 23.3, Goiânia, 13.3,

and Fortaleza, 11.9. The lowest rates were found in the city of João Pessoa, for both genders, 14.3 per 100 thousand men and 5.4 per 100 thousand women.

Female breast cancer

Breast cancer is an important public health problem in Brazil and in the world, as it is the second most frequent type of cancer in the population and the most common in women. In Brazil, its incidence rates have an intermediate magnitude compared to the rest of the world. Breast cancer is related to society's urbanization process, as it becomes clear there is a greater risk of developing the disease for women with high socioeconomic status. It is more common in women living in big cities than in those living in rural areas.

The etiology of breast cancer is multifactorial and involves individual, environmental, reproductive, hormonal and genetic factors. Age is one of the most important risk factors, because, although it is relatively rare to develop it before the 35 years of age, the chances increase quickly up to the 50 years of age. After this, however, the increase slows down.

The risk factors are related to a woman's reproductive life (early menarche, nulliparity, age of first preterm pregnancy after the 30 years of age, number of children, use of oral contraceptives, late menopause and hormone replacement therapy), among others. Breastfeeding is considered to be a protection factor and is associated with a decreased risk of developing this type of cancer. Although heredity accounts for only 10% of the total number of breast cancer cases, women with a family history of this neoplasia, especially those having one or more immediate relatives (mother, sisters, daughters) who developed the disease before turning 50, present a higher risk of developing the disease. In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Porto Alegre (91.8), Belo Horizonte (72.7) and São Paulo (29.1). The lowest rates were found in the city of Cuiabá (49.6).

Cervical Uteri cancer

Cervical uteri cancer is the third most common type of cancer among the women, with an estimate of 529 thousand new cases in 2008, worldwide. Over 85% of these cases, and

over 50% of the total number of deaths, occur in developing countries. The regions considered to be of high risk are the following: East Africa and West Africa (standardized incidence rates above 30 per 100 thousand), South Africa (26.8 per 100 thousand), South of Central Asia (24.6 per 100 thousand), South America (standardized incidence rates of 23.9 per 100 thousand). The values are considered lower in Western Asia, North America and Australia/New Zealand (standardized incidence rates below 6 per 100 thousand). Generally, cervical uteri cancer was responsible for 275 thousand deaths in 2008, around 88% of them in developing countries: 53 thousand in Africa, 31,700 in Latin America and Caribbean, and 159,800 in Asia. In Brazil, 18,430 new cases of cervical uteri cancer were estimated for 2010, with an estimated risk of nearly 18 cases for every 100 thousand women. Its incidence is the highest in women aging between 45 and 49 years old and it is estimated that the early and systematic population-based screening, as well as the treatment of the precursor lesions, can reduce the disease's mortality in up to 80%.

Cervical uteri cancer is a disease of slow evolution, presenting preinvasive stages. Therefore, the evolution period of an initial cervical lesion to the invasive form is approximately 20 years. This considerably long period opens up for efficient preventive actions that may change the disease's evolutive process. It is known that nearly 100% of cervical squamous-cell tumors present the DNA (deoxyribonucleic acid) of the human papillomavirus (HPV) (BOULET et al., 2008). The oncogenic role of the high-risk HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) is recognized and, at present, the infection caused by these viruses is considered a necessary cause for the development of cervical uteri cancer.

Epidemiologic studies show that the persistence of the high-risk HPV infection may increase the chances of developing low- and high-grade intraepithelial lesions, whereas the high-grade ones may evolve into cervical uteri cancer, when not diagnosed and treated, which constitutes the main risk factor for this type of cancer. Cofactors such as smoking, prolonged use of oral contraceptives, multiparity, infectious agents like the Chlamydia Trachomatis and the human immunodeficiency virus (HIV), have been consistently associated with the development of this type of cancer.

In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Cuiabá (35.6), Goiânia (32.4) and Aracaju (29.1). The lowest rate was observed in the city of Jaú (10.2).

Endometrial cancer

Endometrial cancer is the sixth most frequent type of cancer among the women, with around 287 thousand new cases in 2008, worldwide. Its incidence is more evident in the age group over 50 years of age, its average age of diagnosis being at 61 years old. The incidence is rare in women under 50 years old.

In the cases of this type of cancer, survival depends on the stage in which the disease is detected. In the initial stage, five-year survival may reach 80% to 90% of cases. In more advanced stages, survival is significantly lower. In the developed countries, there has been a decrease in the mortality rate, ascribed to the fact the disease has been detected ever earlier. There are many factors that increase the risk of endometrial cancer, including age, heredity, natural hormonal metabolism, hormone replacement therapy, obesity and history of breast or bowel cancer.

The prevention or early diagnosis of endometrial cancer is usually not an easy task. In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Jaú, Porto Alegre and Goiânia, 10.1, 8.0 and 7.8, respectively. The lowest rate was observed in the city of Belém, with 2.3 per 100 thousand women.

Ovary cancer

Worldwide, 225 thousand new cases of ovary cancer were estimated for 2008. Its incidence is common in developed countries, being the seventh most common neoplasia. The highest incidence rates can be found in the USA, Europe and Israel, whereas the lowest rates can be found in Japan and the developing countries.

Ovary cancer is the most lethal gynecologic cancer in the world. The absence of signs and symptoms and the lack of screening strategies contribute to the late diagnosis of the disease, in an advanced stage for most patients, resulting in low rates of cure.

The survival rate in the initial stage is 85% to 95% in five years. However, only a third of the cases is diagnosed in this stage. Among the women with the advanced-stage tumor, the survival rate is much lower (around 10% to 30%). The family history of ovary, breast and colorectal cancer is an important risk factor for the development of ovary cancer. Nonetheless, only 5% to 10% of ovary cancer cases are hereditary.

It is believed that the use of certain oral contraceptives reduces the risk of developing it, which can be reduced even further the longer the duration of the use, and that this protective effect lasts even after the use is interrupted. Low parity and late menopause increase the risk, while pregnancy and lactation seem to have a protective effect. This protective effect of pregnancy seems to be associated with the decreased ovulation which is, in turn, associated with high levels of progesterone. There are divergences as to the role of tobacco, hormone replacement therapy and dietetic factors (alcohol, meats, fats, milk and dairy products) in the carcinogenesis of this tumor. Recent studies have reported that obesity is a potential risk factor for ovary cancer.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand women, were found in Porto Alegre (12.1), São Paulo (9.5) and Goiânia (9.0). The lowest rate was observed in the city of João Pessoa (6.3).

Prostate cancer

Prostate cancer is the most prevalent in men and the sixth most frequent type of cancer in the world. The age-adjusted incidence rates are six times higher in the developed countries compared to the developing countries. After the introduction of the PSA (Prostate-Specific Antigen) test in some developed countries, such as the USA, Canada and Australia, a rapid increase in the prostate cancer incidence rates was observed, followed by a subsequent decrease in these rates. The PSA test used in some countries has some limitations, notably the low specificity. High levels of PSA may reflect the presence of benign prostatic hyperplasia and chronic infection and inflammation, leading to a false positive result.

In Brazil, a risk of 54 new cases is estimated for every 100 thousand men. It is the most frequent type of cancer in all regions of the country and, throughout the years, there has been a trend towards an increase in the incidence. It

is believed that this increase is related to the evolution of the diagnostic methods, the increase in the population's life expectancy and the improved quality of the country's information systems. Age is an established risk factor for prostate cancer. It is known that, after the 50 years of age, the prostate cancer incidence rates increase steadily. There is strong evidence that family history also acts as a risk factor in the carcinogenesis of this tumor.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Goiânia (129.6), Aracaju (116.0) and Belo Horizonte (107.1). The lowest rate was observed in the city of Recife (50.0).

Bladder cancer

The Mediterranean countries and Egypt have the highest incidence rates for bladder cancer. The Italian cities of Naples (1998-2002), Genoa (1998-2000) and Sondrio (1998-2002) have the highest average incidence rates for men. For every 100 thousand men, the rates are 47.2, 40.4 and 38.8, respectively. The most important risk factor for the development of bladder cancer is tobacco smoking, as it accounts for 66% of the new cases in men and 30% in women. Other potential risk factors for the development of bladder cancer are the occupational exposure to aromatic amines, the infection caused by the *Schistosoma Haematobium* parasite, family history and genetic predisposition.

Generally, bladder cancer is 3 to 4 times more common in men than it is in women. On the other hand, the survival rate for this tumor is lower in women. The most common histological type is the urothelial or transitional-cell carcinoma. In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre (15.6), Goiânia (15.4) and Jaú (15.2). Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Goiânia (5.1), São Paulo (4.1) and Porto Alegre (4.3). The lowest rates were found in the cities of Belém – 3.8 for men and 0.5 for women.

Cancer of the central nervous system

The central nervous system (CNS) is formed by the encephalon and the spinal cord. Worldwide, 239 thousand new cases of cancer of the CNS were estimated for 2008, 8,461 being in Brazil. The mortality/incidence ratio for this type of cancer is high: 73% for the world and 92% for Brazil. The histological type and predominant location of the tumors of the CNS vary considerably with age and gender. The frequency in men is higher than in women for the gliomas, for example. However, the opposite happens for the meningiomas.

In children, the medulloblastomas and astrocytomas are predominant. In adults, the most common types are the gliomas and meningiomas, accounting for 60% and 20% of all the primary tumors in this age group, respectively. Unlike the case of adults, 70% of the tumors in children are infratentorial. The etiological factors that led to the increased incidence of brain tumors in all age groups are not well defined. Most tumors are not associated with risk factors; they simply develop with no apparent reason. Among the few associated risk factors, there is the more well established environmental risk: radiation exposure.

In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand men, were found in Porto Alegre with 9.5, Goiânia with 9.4 and Curitiba with 7.5. Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in Porto Alegre, 6.8, Cuiabá, 6.6 and São Paulo, 5.8. The lowest rates, per 100 thousand, were observed in the cities of Palmas, 1.2 for men, and Belém, 1.4 for women.

Thyroid cancer

Thyroid cancer is a relatively rare neoplasia worldwide, accounting for 1% to 5% of all neoplasms in women and less than 2% in men. According to data from the latest volume of the publication *Cancer Incidence in Five Continents*, from 1973 to 2002, the incidence rates increased more than five times for most populations analyzed. This variation was assigned mainly to the papillary carcinoma. A possible explanation for this trend is the higher detection of subclinical diseases through the use of ultrasound and image-guided biopsy procedures. An increase in the thyroid neoplasms larger than 4 cm and those presenting distant metastasis has also been observed, which suggests an actual increase in

the incidence of the disease due to other reasons, including environmental, dietetic and genetic factors that need to be explored.

Among the risk factors, radiation is the best established, whether by exposure in the treatment of benign and malignant diseases or environmental exposure. In the past 50 years, knowledge has been accumulated regarding the effect of the external radiation exposure of the thyroid associated with hypothyroidism, nodules and cancer.

In contrast, a dietetic pattern involving fish and cooked vegetables led to a higher risk of follicular cancer. Studies reported a correlation between the increased incidence of thyroid cancer and the increased consumption of iodine in the diet. Thyroid cancer is the most frequent among women, attacking three women for every man in the international comparisons. Possible explanations for this disparity could be the biological differences between the genders, different screening patterns or the differences in behavior specific to each gender. Patients with Hashimoto's thyroiditis are three times more likely to develop thyroid cancer, whereas this is also a disease strongly associated with the female gender.

In Brazil, for the PBCRs analyzed, the highest yearly average incidence rates, adjusted by age per 100 thousand men, were found in São Paulo, 4.2, Aracaju, 3.3 and Natal, 3.0. Regarding the women, the highest yearly average incidence rates, adjusted by age per 100 thousand women, were found in São Paulo, 18.0, Natal, 16.2 and Aracaju, 15.7. The lowest rates, per 100 thousand, were observed in the cities of Palmas, 0.2 for men, and Belém, 1.3 for women.



Leukemia (Group I)




Figure 86

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Lymphoma (Group II)




Figure 87

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Tumors of the Central Nervous System (Group III)




Figure 88

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Malignant Bone Tumors (Group VIII)




Figure 89

*Rates per 100 thousand/ World Standard Population, modified by Doll et al (1966)

Comments

Cancers that inflict children and adolescents, up to 19 years old, are considered rare compared to the tumors that affect the adults. Around 1% to 3% of all malignant tumors in the populations attack children and adolescents. Worldwide, the most common pediatric tumor is the leukemia, accounting for 25% to 35% of all tumors in children. It is known that, in developed countries, the tumors of the CNS represent the second most common diagnosis, accounting for about 17% to 25% of the neoplasms in children. Lymphomas occupy the third place, representing 7% to 18% of the pediatric neoplasms. In the developing countries, in turn, the order of the lymphomas and tumors of the CNS is inverse, as the first are the second most common diagnosis and the second are the third.

The cancer in children and adolescents must be studied apart from the cancer in adults for presenting differences in the primary sites, different histological origins and clinical behaviors. They generally present smaller latency periods, growing more quickly and being more invasive; however, they have a better response to treatment and are considered to have a good prognosis. Besides, the association between cancer in children and adolescents and risk factors is not well established yet, differently from some environmental and behavioral risk factors – such as smoking, alcohol consumption, nourishment, sun exposure, among others – already well described in the literature as being associated with several tumors in the adult population. Therefore, the classifications used for the pediatric tumors are different from those used for the tumors in adults, morphology being the main aspect taken into account.

It is estimated that there will be 10 thousand new cases of cancer in children and adolescents up to 18 years old in Brazil, in 2010.

In Brazil, for the PBCRs analyzed, the highest values of the yearly average incidence rates, adjusted by age per one million children and adolescents, for leukemia in men, were found in Goiânia; Manaus and Cuiabá, with 68.9, 68.7 and 61.7, respectively. Regarding the women, the highest yearly average incidence rates, adjusted by age per one million children and adolescents, were found in Jaú, 77.3, Goiânia, 54.9, and Manaus, 50.4. The lowest rates were observed in the city of Aracaju, for both genders, with 26.3 per one million male children and adolescents and 14.4 per one million female children and adolescents.

For the lymphomas, the highest yearly average incidence rates, adjusted by age per one million male children and adolescents, were found in Jaú, 59.4, São Paulo, 44.0, and João Pessoa, 38.9. Regarding the women, the highest yearly average incidence rates, adjusted by age per one million children and adolescents, were found in São Paulo, 24.9, Porto Alegre, 21.3 and João Pessoa, 19.4. The lowest rates were observed in the city of Salvador, for males, with 16.2 per one million children and adolescents and Belém, for females, with 6.9 per one million children and adolescents.

For the Central Nervous System, the highest yearly average incidence rates, adjusted by age per one million male children and adolescents, were found in Aracaju, 37.9, Goiânia, 34.2, and São Paulo, 34.1. Regarding the women, the highest yearly average incidence rates, adjusted by age per one million children and adolescents, were found in Jaú, 36.2, Recife, 33.2 and São Paulo, 32.1. The lowest rates were observed in the city of Belém, for both genders, with 5.8 per one million male children and adolescents and 4.5 per one million female children and adolescents.

For the malignant bone tumors, the highest yearly average incidence rates, adjusted by age per one million male children and adolescents, were found in João Pessoa, 25.6, São Paulo, 24.9, and Goiânia, 18.9. Regarding the women, the highest yearly average incidence rates, adjusted by age per one million children and adolescents, were found in São Paulo, 19.8, Cuiabá, 16.7, and Porto Alegre, 14.7. The lowest rates were observed in the city of Belém, for both genders, with 2.4 per one million male children and adolescents and 4.0 per one million female children and adolescents.

- Acartürk TO, Edington H. Nonmelanoma skin cancer. *Clin Plast Surg* 2005; 32 (2): 237-48.
- Agarwal G, Ramakant P, Sánchez Forgach ER, Rendon JC, Chaparro JM, Sa´nchez Basurto C, et al. Breast cancer care in developing countries. *World J Surg* 2009; 33(10): 2069-76.
- Ajani JA. Future developments in esophageal câncer research. *Gastroenterol Clin North Am* 2009; 38 (1): 183-8.
- Alba LMD, Castro FMR. Factores de riesgo de desarrollo de câncer de laringe en la poblaci3n adulta del Hospital Espaol de M3xico. *Acta Otorrinolaringol Esp* 2008; 59 (8): 367-70.
- Aletti DG, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. *Mayo Clin Proc* 2007; 82 (6): 751-70.
- American Cancer Society. Disponvel em: <http://www.cancer.org/index>.
- Arab M, Khayamzadeh M, Tehranian A, Tabatabaefar M, Hosseini M, Anbiaee R, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. *Indian J Cancer* 2010; 47(3): 322-7.
- Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. *Mol Nutr Food Res* 2009; 53 (2): 171-84.
- Baker SR, Bhatti WA. The thyroid cancer epidemic: Is it the dark side of the CT revolution? *Eur J Radiol* 2006; 60 (1): 67-9.
- Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer—aetiology and pathogenesis. *Best Pract Res Clin Gastroenterol* 2006; 20 (4): 721–34.
- Barros JA, Valladares G, Faria AR, Fugita EM, Ruiz AP, Vianna AGD et al. Diagn3stico precoce do câncer de pulm3o: o grande desafio. Vari3veis epidemiol3gicas e clnicas, estadiamento e tratamento. *J Bras Pneumol* 2006; 32(3): 221-7.
- Bashash M, Shah A., Hislop G, Brooks-Wilson A., Nhu Le, Bajdik C. Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999. *Can J Gastroenterol* 2008; 22 (2): 143-8.
- Bosetti C. Trends in laryngeal cancer mortality in Europe. *Int J Cancer* 2006; 119 (3): 673–81.
- Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. *Cancer Epidemiol Biomarkers Prev* 2008; 17(4): 810-7.
- Boyle P, Levin B. World Health Organization World Cancer Report 2008. Lyon: IARC; 2008.
- Braga PE, Latorre MRD, Curado MP. Câncer na inf3ncia: an3lise comparativa da incid3ncia, mortalidade e sobrevida em Goi3nia (Brasil) e outros pases. *Cad Saude Pblica* 2002; 18 (1): 33-44.
- Brenner H, Rothenbacher D, Arndt V. Epidemiology of Stomach Cancer. *Methods Mol Biol* 2009; 472: 467-77. doi: 10.1007/978-1-60327-492-0 467.
- Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. *Thyroid* 2006; 16 (1): 47–53.
- Bustamante-Teixeira MT, Faerstein E, Mariotto A, de Britto AV, Moreira Filho DC, Latorre MRDO. Sobrevida em pacientes com cancer g3strico em Campinas, S3o Paulo, Brasil. *Cad Saude Publica* 2006; 22 (8): 1611-8.

Cabrera R, Nelson R. Review article: the management of hepatocellular carcinoma. *Aliment Pharmacol Ther* [serial online] 2010; 31: [16 screens]. Disponível em: URL:<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04200.x/pdf> Acesso em: set 2010.

Carew J. Advances in multimodality therapy for laryngeal cancer. *CA Cancer J Clin* 1998; 48 (4): 211- 28

Carneiro J, Barreto J, Freitas N, Queiroz M. Câncer colorretal: características clínicas e anatomopatológicas em pacientes com idade inferior a 40 anos. *Rev Bras Coloproct* 2006; 26 (4): 430-5.

Castro MSM, Vieira VA, Assunção RM. Padrões espaço-temporais da mortalidade por câncer de pulmão no Sul do Brasil. *Rev Bras Epidemiol* 2004; 7 (2): 131-43.

Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Cutsem EV. Gastric cancer. *Crit Rev Oncol Hematol* 2009; 71 (2): 127-64.

Chen AY, Jemal, A, Ward, EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. *Cancer* 2009; 115 (16): 3801-7.

Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA Era. *Prostate* 2008; 68 (14): 1582-91.

Cho YA, Kim J, Park K-S, Lim S-Y, Shin A, Sung M-K. Effect of dietary soy intake on breast cancer risk according to menopause and hormone receptor status. *Eur J Clin Nutr* 2010; 64 (9): 924-32.

Chuang S, Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. *Cancer Lett* 2009; 286 (1): 9-14.

Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). *Eur J Cancer* 2007; 43 (5): 891–900.

Conte VP. Carcinoma hepatocelular. *Arq Gastroenterol* 2000; 37 (1): 58-68.

Cravero MEB, Araya FS, Alonso FT. Análisis de la mortalidad por cáncer laríngeo en Chile (1990-2004). *Acta Otorrinolaringol Esp* 2007; 58(8): 336-40.

Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. *Urology* 2009; 73 Suppl 5A: 4-10.

Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol* 2006; 12(3): 354-62.

Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, et al. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr* 2008; 87 (5): 1405–13.

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al, editors. Cancer incidence in five continents [monograph on the internet]. Lyon: IARC; 2007. vol. IX . Disponível em: <http://ci5.iarc.fr/CI5i-ix/ci5i-ix.htm>

Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR et al. Active surveillance for prostate cancer. *Cancer* 2008; 112(12): 2664-70.

Dann RB, Kelley JL, Zorn KK. Strategies for ovarian cancer prevention. *Obstet Gynecol Clin North Am* 2007; 34 (4): 667–86.

DASIS - Sistema de Informações sobre Mortalidade – SIM, Secretaria de Vigilância Saúde. Ministério da Saúde. Disponível em: <http://www.datasus.gov.br>. Acesso em: set 2010.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. *JAMA* 2006; 295 (18): 2164–7.

Dijkstra B, Prichard RS, Lee A, Kelly LM, Smyth PPA, Crotty T, et al. Changing patterns of thyroid carcinoma. *Ir J Med Sci* 2007; 176 (2): 87-90.

Dufloth RM, Carvalho S, Heinrich JK, Shinzato JY, dos Santos CC, Zeferino L, et al. Analisis of BRCA1 And BRCA2 mutations in Brazilian breast cancer patients positive family history. *Sao Paulo Med J* 2005; 123 (4): 192-7.

Egeberg R, Halkjaer J, Rottmann N, Hansen L, Holten I. Social inequality and incidence of and survival form cancer of the colon and rectum in a population- based study in Denmark, 1994-2003. *European Journal of Cancer and clinical Oncology* 2008; 44 (14): 1978-88.

Eisenberg ALA, Koifaman S. Sobrevida de cinco anos em pacientes com carcinoma ductal infiltrante de mama com linfonodos axilares negativos, 1992-1996, Rio de Janeiro, Brasil. *Rev Bras Med* 2006; 63:152-63.

Eslick GD. Epidemiology of esophageal cancer. *Gastroenterol Clin North Am* 2009; 38 (1): 17–25.

Faivre J, Forman D, Estève J, Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. *Eur J Cancer* 1998; 34 (14): 2167-75.

Farhoud S, Bromberg S, Barreto E, Godoy A. Variáveis clínicas e macroscópicas que influenciam o prognóstico do carcinoma colorretal. *Arq Gastroenterol* 2002;39 (3): 163-72.

Fattaneh A, Tavassoli MD, Vincenzo Eusebi MD. Tumors of the mammary gland. In: *AFIP Atlas of tumor pathology*. Washington, DC: The American Registry of Pathology, Armed Forces Institute of Pathology, 2009. p. 67-100; 123- 148; Fourth series; Fascicle 10.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. In press 2010.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [internet]. Lyon, France: International Agency for Research on Cancer, 2010. Disponível em: <http://globocan.iarc.fr>. Acesso em: set 2010.

Ferlito A, Rinaldo A, Silver CE, Robbins KT, Medina JE, Rodrigo JP, et al. Neck dissection for laryngeal cancer. *J Am Coll Surg* 2008; 207 (4): 587-93.

Ferreira FR, Nascimento LFC. Câncer cutâneo em Taubaté(SP) – Brasil, de 2001 a 2005: um estudo de prevalência. *An Bras Dermatol*. 2008; 83(4):317-22.

Flowers A. Brain tumors in the older person. *Cancer control*. 2000; 7(6): 523-38.

Fillmore KM, Chikritzhs T, Stockwell T, Bostrom A, Pascal R. Alcohol use and prostate cancer: a meta-analysis. *Mol*

Nutr Food Res 2009; 53: 240-55.

Freitas CAF, Luza AC, Sales SC, Silva EG, Perrony JS. Tratamento cirúrgico de neoplasia maligna de pele não melanoma. Estudo de 100 casos tratados em Campo Grande. Revista Brasileira de cirurgia da cabeça e pescoço 2009; 38 (3): 190-3.

Gama A. Câncer coloretal – a importância de sua prevenção. Arq Gastroenterol 2005; 42 (1): 2-3.

Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a metaanalysis. J Natl Cancer Inst 2005; 97 (23): 1768–77.

Gatta G, Capocaccia, R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A, et al. Toward a comparison of survival in American and European cancer patients. Cancer 2000; 89 (4): 893-900.

Gek-Hsiang Lim, Chia-Siong Wong, Khuan-Yew Chow, Vineta Bhalla, Kee-Seng Chia. Trends in Long-term Cancer Survival in Singapore: 1968-2002. Ann Acad Med Singapore 2009; 38 (2): 99-105.

Georgakilas AG, Aziz K, Ziech D, Georgakila S, Panayiotidis MI. BRCA1 involvement in toxicological responses and human cancer etiology. Toxicol Lett 2009; 188(2): 77-83.

Gomes MC, Costa MM, Borojevic R, Monteiro NA, Vieira R, Koifman S. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007; 103 (3): 349-53.

Gomes R, Rebello LMEF, de Araújo FC, do Nascimento EF. A prevenção do câncer de próstata: uma revisão da literatura. Cien Saude Colet 2008; 13(1): 235-46.

Gondos A, Bray F, Hakulinen T, Brenner H, the EUNICE Survival Working Group. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2008; 20 (3): 564-73.

Gondos A, Holleccek B, Arndt V, Stegmaier C, Ziegler C, Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol 2007; 18 (7): 1253–9.

Guerra MR, Gallo CVM, Mendonça GAS. Risco de câncer no Brasil: tendência e estudos epidemiológicos recentes. Revista brasileira de cancerologia 2005; 51(3): 227-34.

Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies Can J Urol 2008; 15 (1): 3866-71.

Haas P, Anton A, Francisco A. Câncer colo retal no Brasil: consumo de grãos integrais como prevenção. Revista brasileira de análises clínicas 2007; 39(3): 231-5.

Henry MACA, Lercio MM, Oliveira WK. Câncer do esôfago em paciente com megaesôfago chagásico. Arq Gastroenterol 2007; 44 (2): 151-5.

Hochhegger B, Haygert CJP, Antunes PSP, Moraes E, Gazzoni F, Andrade RGF, et al. Estadiamento local das neoplasias malignas esofágicas na tomografia computadorizada: testando um protocolo de avaliação. Revista da imagem 2007; 29(2): 43-6.

Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17 (1): 2-9.

Holschneider CH , Berek JS. Ovarian Cancer: epidemiology, biology, and prognostic factors. *Semin Surg Oncol* 2000; 19 (1): 3–10.

How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. *CMAJ* 2007; 177 (11): 1383-4.

Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. *Epidemiol Ver* 1986; 8:1–27.

Instituto Nacional de Câncer (Brasil). Atlas de mortalidade por câncer no Brasil: série temporal das taxas de mortalidade, brutas e ajustadas por idade pelas populações mundial e brasileira, para topografias selecionadas, entre 1979 e 2007. Disponível em: <http://www1.inca.gov.br/vigilancia/mortalidade.html>. Acesso em: set 2010.

Instituto Nacional de Câncer (Brasil). Câncer na criança e no adolescente no Brasil: dados dos registros de base populacional e de mortalidade. Rio de Janeiro: INCA; 2008.

Intituto Nacional de Câncer (Brasil). Câncer no Brasil. Dados dos registros de base populacional, vol. 2. Rio de Janeiro: INCA; 1995.

Instituto Nacional de Câncer (Brasil). Estimativas 2010: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2009.

International Agency of Cancer Research. IARC monographs on the evaluation of carcinogenic risks to humans. Human Papilomaviruses. Lyon, France: WHO; 2005; 90.

International Agency for Research on Cancer. Schistosomes, liver flukes and helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 61. Lyon: IARC; 1994.

International Agency for Research on Cancer. Section of cancer information Globocan. Lyon: IARC; 2008. Disponível em: <http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno>. Acesso em: set 2010.

Irigaray P, Newby J, Clapp R, Hardell L, Howard, Montagnier L, et al. Lifestyle-related factors and environmental agents causing cancer: An overview. *Biomed Pharmacother* 2007; 61 (10): 640-58.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. *CA Cancer J Clin* 2010 Sep-Oct; 60(5):277-300. Disponível em: <http://caonline.amcancersoc.org/cgi/content/abstract/60/5/277>. Acesso em: set 2010.

Jemal A, Ward E, Thun M. Declining Death Rates Reflect Progress against Cancer. *PLoS One* 2010; 5(3): e9584.

Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. *Br J Cancer* 2001; 84 (3): 400-5.

Kelsey JL. Breast cancer epidemiology: summary and future directions. *Epidemiol Rev* 1993; 15 (1): 256-63.

Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. *Epidemiol Rev* 1993; 15 (1): 7-16.

Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. *CMAJ* 2007; 177 (11):1357–61.

Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control* 2009; 20(5): 525-31.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. *Urology* 2005; 66 (6 Suppl 1): 4-34.

Kiviat NB. Papillomaviruses in non-melanoma skin cancer: epidemiological aspects. *Semin Cancer Biol* 1999; 9 (6): 397-403.

Knobel M, Medeiros-Neto G. Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. *Arq Bras Endocrinol Metab* 2007 Jul; 51(5): 701-12. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302007000500007&lng=en&nrm=iso&tlng=en doi: 10.1590/S0004-27302007000500007.

Kristal AR, Arnold KB, Neuhauser ML, Goodman P, Platz EA, Albanes D, et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. *Am J Epidemiol* 2010;172 (5): 566–77.

Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? *Best Pract Res Clin Gastroenterol* 2006; 20 (5): 803-12.

Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. *J Am Coll Surg* 2007; 204 (5): 764-73.

Lee DA, Miller SJ. Nonmelanoma Skin. *Câncer Facial Plast Surg Clin North Am* 2009; 17 (3): 309-24.

Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. *Thyroid* 2004; 14 (12): 1056–60.

Little J. Epidemiology of childhood cancer. Lyon: IARC, WHO; 1999. [IARC Scientific Publications, 149].

Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. *Br J Cancer* 2001; 85 (9): 1335–9.

Lubina A, Cohen O, Barchana M, Liphshiz I, Vered I, Sadetzki S, et al. Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. *Thyroid* 2006; 16 (10):1033–40.

Lupinacci RM, Campos FGCM, Araújo SEA, Imperiale AR, Seid VE, Habr-Gama A, et al. Análise comparativa das características clínicas, anátomo-patológicas e sobrevida entre pacientes com câncer colo-retal abaixo e acima de 40 anos de idade. *Revista brasileira de coloproctologia* 2003; 23 (3): 155-62.

Machado PM, Brandão RD, Cavaco BM, Eugenio J, Bento S, Nave M, et al. Screening for a BRCA2 rearrangement in high-risk breast-ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. *J Clin Oncol* 2007; 25 (15): 2027-34.

Mack WJ, Preston-Martin S, Bernstein L, Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. *Ann Epidemiol* 2002; 12 (6): 395-40.

Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB. National survey of patterns of care for brain tumor patients. *J Neurosurg* 1989; 71 (6): 826-35.

Malheiros APR, Teixeira MG, Habr-Gama A, Alcântara PSM. Resultados do tratamento cirúrgico do câncer colo-retal em doentes de idade até 64 anos e de 65 anos ou mais. *Revista brasileira de coloproctologia* 2005; 25(2):128-36.

Malkin, D. Cancer of childhood. In: DeVita, VT, Jr Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5.ed. New York: Lippincott-Raven; 1997. p.2083-91.

Malta DC, Moura L, Souza MFM, Curado MP, Alencar AP, Alencar GP. Tendência de mortalidade do câncer de pulmão, traquéia e brônquios no Brasil, 1980-2003. J Bras Pneumo 2007; 33(5): 536-43.

Manfro G, Dias FL, Soares JRN, Lima RA, Reis T. Relação entre idade, sexo, tratamento realizado e estágio da doença com a sobrevida em pacientes terminais com carcinoma epidermóide de laringe. Revista brasileira de cancerologia 2006; 52(1): 17-24.

Markaki I, Linos D, Linos A. The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer 2003; 39 (13): 1912-9.

Maruyama S, Zago M. O processo de adoecer do portador de colostomia por câncer. Rev Lat Am Enfermagem 2005; 13 (2): 216-22.

Mauad EC, Nogueira JL, Souza JMP, Wohnrath DR, Oliveira ATT, Colli G et al. Câncer gástrico em adultos jovens. Revista brasileira de cancerologia 2000; 46(3): 299-304.

McLemore MR, Miaskowski C, Aouizerat BE, Chen L, Dodd M. Epidemiologic and genetic factors associated with ovarian cancer. Cancer Nurs 2009; 32(4): 281-90.

Menezes AMB, Horta BL, Oliveira ALB, Kaufmann RAC, Duquia R, Diniz A, et al Risco de câncer de pulmão, laringe e esôfago atribuível ao fumo. Rev Saude Publica 2002; 36 (2): 129-34.

Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the stomach in England and Wales up to 2001. Br J Cancer 2008; 99 (Suppl 1): S16-8.

Monk BJ, Herzog TJ. The new era of cervical cancer prevention: HPV vaccination. Gynecol Oncol 2008; 109(suppl2): S1-3.

Monteiro J, Taglietti E, Salem J. Neoplasia colorretal até 40 anos: experiência em cinco anos. Revista brasileira de coloproctologia 2006; 26 (2): 156-61.

Moorthy HK, Venugopal P. Strategies for prostate cancer prevention: review of the literature. Indian J Urol 2008; 24(3): 295-302.

Moura L, Curado MP, Simões EJ, Cezário AC, Urdaneta M. Avaliação do registro de câncer de base populacional do município de Goiânia, Estado de Goiás, Brasil. Epidemiologia e serviços de saúde 2006; 15 (4): 7-17.

Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19 (1): 1-5.

Murray TT, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52 (1): 23-47.

Muscat JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. Cancer 1992; 69 (9): 2244-51.

National Cancer Institute. Previous Version: SEER cancer statistics review, 1975-2005. Disponível em http://seer.cancer.gov/csr/1975_2005/. Acesso em: set 2010.

National Cancer Institute. US National Institute of Health. Probability of Breast Cancer in American Women. Disponível em: <http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer>.

National Cancer Institute. US National Institute of Health. Abortion, miscarriage, and breast cancer risk. Disponível em: <http://www.cancer.gov/cancertopics/factsheet/Risk/abortion-miscarriage>.

National Cancer Institute. US National Institute of Health. BRCA1 and BRCA2: cancer risk and genetic testing. Disponível em: <http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA>.

National Cancer Institute. US National Institute of Health. Researchers identify genetic variations that may increase risk of breast cancer. Disponível em: <http://www.cancer.gov/newscenter/pressreleases/2009/cgemsbreastcancer>.

National Human Genome Research Institute (USA). An open access on-line breast cancer mutation data base. Disponível em: <http://www.research.nhgri.nih.gov/bic/>.

Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. *Curr Opin Obstet Gynecol* 2002; 14 (1): 19-26.

Neves F, Mattos I, Koifman R. Mortalidade por câncer de cólon e reto nas capitais brasileiras no período 1980-1997. *Arq. Gastroenterol* 2005; 42 (1): 63-70.

Neves F, Mattos I, Koifman R. Mortalidade por câncer de colo e reto e consumo alimentar em capitais brasileiras selecionadas *Rev Bras Epidemiol* 2006; 9 (1): 112-20.

Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971–1998/1999. *Aliment Pharmacol Ther* 2003; 17 (5): 655–64.

Nour Sneige. Image-guided biopsies of the breast: technical considerations, diagnostic challenges, and postbiopsy clinical management. In: *MD Anderson Cancer Care. Breast Cancer*. 2.ed. New York: Springer; 2008. p. 167-74.

Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intake and prostate cancer risk the multiethnic cohort study. *Am J Epidemiol* 2007;166:1259–69.

Parkin DM. The Global Health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006; 118 (12): 3030-44.

Parkin DM, Bray F, Devesa SS. Cancer burden in the year 2000. The global picture. *Eur J Cancer* 2001;37 (Suppl 8): S4-66.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55 (2):74-108.

Parkin DM, Kim YH. Current approaches to gastric cancer in Korea. *Gastrointest Cancer Res* 2008; 2 (3): 137-44.

Parkin DM, Stiller CA, Draper GJ, Bieber CA, Terracini B, Toung JL, editors. International incidence of childhood cancer. Lyon: International Agency for Research on Cancer; 1988. vol.I [IARC Scientific Publications, 87].

Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. v. VII. Lyon: International Agency for Research on Cancer; 1997. (IARC Scientific Publications, 143).

Parsonnet J. The incidence of helicobacter pylori infection. *Aliment Pharmacol Ther* 1995; 9(Suppl 2):45–51.

Pinho AA, Mattos MCFI. Validade da citologia cervicovaginal na detecção de lesões pré-neoplásicas e neoplásicas de colo de útero. *Jornal brasileiro de patologia e medicina laboratorial* 2002; 38(3): 225-31.

Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. *Hum Pathol* 2005; 36 (8): 861– 70.

Reiners C. Radioactivity and thyroid cancer. *Hormones* 2009; 8(3): 185-91.

Reis RS, Santos MO, Bloch KV. Colorectal cancer in Porto Alegre and Fortaleza, Brazil: incidence trends and distribution pattern from 1990 to 1999. *Cad Saude Publica* 2009; 25(5): 1046-53.

Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. *Clin Endocrinol (Oxf)* 2005; 62 (2):156–62.

Roder, D.M. The epidemiology of gastric câncer. *Gastric Cancer* 2002; 5 (suppl 1): 5-11.

Rohrmann S, Linseisen J, Key TJ, Jensen MK, Overvad K, Johnsen NF, et al. Alcohol consumption and the risk for prostate cancer in the European Prospective Investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev* 2008; 17(5): 1282-7.

Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao X, et al. Ovarian cancer: pathology, biology, and disease models. *Front Biosci* 2010; 14: 2089–102.

Russi, M, Dubrow R, Flannery JT, Cullen MR, Mayne ST. Occupational exposure to machining fluids and laryngeal cancer risk: contrasting results using two separate control groups. *Am J Ind Med* 1997; 31(2): 166–71.

Santos-Filho SD, Missailids S, da Fonseca AS, Filho MB. Prostate cancer, treatment modalities and complications: an evaluation of the scientific literature. *Braz Arch Biol Technol* 2008; 51: 51-6.

Sartor S, Eluf-Neto J, Travier N, Wünsch Filho V, Arcuri ASA, Kowalski LP, et al. Riscos ocupacionais para o câncer de laringe: um estudo caso-controle. *Cad Saude Publica* 2007; 23 (6): 1473-81.

Sato N, Ito Y, Ioka Y, Tanaka M, Tsukuma H. Gender differences in stomach cancer survival in Osaka, Japan: analyses using relative survival model. *Jpn J Clin Oncol* 2009; 39(10): 690–4.

Scottish Cancer Intelligence Unit. Trends in cancer survival in Scotland 1971-1995. Edinburgh: Information & Statistics Division; 2000.

Sjödahl K, Lu Y, Nilsen TI, Ye W, Hveem K, Vatten L, et al. Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. *Int J Cancer* 2007; 120 (1):128–32.

Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J. Increasing thyroid cancer incidence in Lithuania in 1978–2003. *BMC Cancer* 2006; 6:284.

Sociedade Brasileira de Cancerologia. Disponível em: <http://www.sbcancer.org.br/final/arquivos/digestivo.doc>.

Sorrell MD, Schafer MD. Hepatocellular carcinoma. *The Lancet* 1999; 353 (9160): 1253-7.

South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1999. Incidence and mortality 1999. Adelaide: Openbook; 2000.

Swart R, Downey L, Lang J, Thompson PA, Livingston RB & Stopeck AT. Breast Cancer. Updated: May 26, 2010;

eMedicine Specialties > Oncology > Carcinoma of the Breast. Disponível em: <http://emedicine.medscape.com/article/283561>. Acesso em: set 2010.

Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. The Swedish two-county trial twenty years later. Updated mortality results and new insights from long-term follow-up. *Radiol Clin North Am* 2000; 38 (4): 625-51.

Trakatelli M, Ulrich C, del Marmol V, Euvard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. *Br J Dermatol* 2007; 156 (Suppl. 3): 1-7.

Tsuji DH, Sennes LU, Imamura R. Câncer da laringe. *Prática hospitalar* 2005; 7 (38): 60-5.

Uehara C, Jamnik S, Santoro IL. Câncer de Pulmão. *Medicina* 1998; 31: 266-76.

Uehara C, Santoro I, Jamnik S. Câncer de pulmão: comparação entre os sexos. *Jornal de pneumologia* 2000; 26 (6): 286-90.

Valadão M, Castro L. Câncer colo-retal hereditário. *Rev Col Bras Cir* 2007; 34 (3): 193-200.

Varaldo C. Câncer de fígado já é a terceira causa de mortalidade. Disponível em: http://www.hepato.com/p_cancer/mortes_por_cancer_2010_02_01.html

Vassallo JA, Barrios E. Actualización ponderada de los factores de riesgo del cáncer. Montevideo: Comisión de Lucha contra el Cáncer; 2003.

Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. *Lancet Oncol* 2007; 8 (9): 784-96.

Verdecchia A, Santaquilani M, Sant M. Survival for cancer patients in Europe. *Ann Ist Super Sanita* 2009; 45 (3): 315-24.

Wey EK, Wolin KY, Colditz GA. Time course of risk factors in cancer etiology and progression. *J Clin Oncol* 2010; 28 (26): 1-6.

World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington (DC): AICR; 2007.

World Health Organization. Tavassoli FA, Devilee P, editors. Classification of tumours. pathology and genetics. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 9-109.

World Health Organization. World Cancer Report, 2008. Lyon: IARC, 2009.

World Health Organization. Cancer. Geneva: World Health Organization; c2009. Disponível em URL: <http://www.who.int/mediacentre/factsheets/fs297/en/index.html>

World Health Organization. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H, editors. Trends in cancer incidence and mortality. IARC Scientific Publications No. 121. Lyon: IARC; 1993. p 193-224.

Wünsch Filho V, Moncau J. Mortalidade por câncer no Brasil 1980-1995: padrões regionais e tendências temporais. *Rev Assoc Med Bras* 2002; 48 (3): 250-7.

Zamboni, M. Epidemiologia do câncer do pulmão. *Jornal de pneumologia* 2002; 28 (1): 41-7.

Zarater CE. La nueva clasificación de la O.M.S. 2005. Lesiones precursoras y los tumores de la laringe, hipofaringe y tráquea. *Revista española de patología* 2007; 40 (1): 3-10.

Zarur JM. Modelo experimental de quimioembolização hepática [monografia]. Fortaleza (CE): Universidade Federal do Ceará; 2004. Disponível em: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=166 Acesso em: set 2010.

Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. *Cell Prolif* 2007; 40 (6): 921–35.

Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. *Cancer Causes Control* 2009; 20(5): 691–8.

Annex I : Quality Indicators Per Primary site, for Latin America, 1998 to 2002

Male

Table 87

Topographies		MV(%)		DCO(%)		M/I(%)	
		Lower	Upper	Lower	Upper	Lower	Upper
C00-10/C07-08	Lips, Tongue, oral cavity and oropharynx	-	-	-	-	-	-
C15	Esophagus	71.1	98.8	0.0	18.1	55.3	106.9
C16	Stomach	74.2	99.2	4.0	23.3	41.6	112.5
C18-21	Large intestine, anal canal and anus	76.2	97.9	0.0	22.7	29.8	87.7
C22	Liver	23.9	100.0	0.0	41.5	61.0	209.9
C25	Pancreas	17.9	91.1	0.0	51.1	75.0	157.4
C32	Larynx	81.5	100.0	0.0	6.8	36.8	80.0
C33-34	Trachea, bronchus and lungs	51.0	92.3	0.0	34.4	66.2	123.0
C43	Skin melanoma	74.1	100.0	0.0	25.9	10.1	70.4
C50	Breast	83.4	100.0	0.0	9.1	7.7	162.5
C53	Body of the uterus	-	-	-	-	-	-
C61	Prostate	99.8	78.0	2.5	12.3	17.4	58.1
C70-72	Central Nervous System	45.7	84.1	0.0	41.2	37.1	93.6
C73	Thyroid	83.3	100.0	0.0	16.7	7.8	50.0
C91-95	Leukemia	58.5	100.0	0.0	23.1	16.2	79.3
C81-85, C96	Lymphoma	76.1	100.0	0.0	11.4	13.0	94.3
C00-96, D46	All primary invasive malignant neoplasias	-	-	-	-	-	-
C00-96, D46/ C44	All primary invasive malignant neoplasias, except skin	73.3	97.8	1.3	17.5	36.9	88.6

(*) Argentina, Bahia Blanca (1998-2002); Brazil, Federal District (1998-2001); Brasil, Cuiabá (2000-2002); Brazil, Goiânia (1999-2002); Brazil, São Paulo (1998-2002); Chile, Valdivia (1998-2002); Colombia, Cali (1998-2002); Costa Rica (1998-2002); Ecuador, Quito (1998-2002); France, Martinique (1998-2002); Peru, Trujillo (1998-2002).

Sources: Cancer Incidence in Five Continents, Vol IX - IARC

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Female

Table 88


Topography		MV(%)		DCO(%)		M/I(%)	
		Lower	Upper	Lower	Upper	Lower	Upper
C00-10/C07-08	Lips, Tongue, oral cavity and oropharynx	-	-	-	-	-	-
C15	Esophagus	60.0	100.0	0.0	16.7	48.4	100.0
C16	Stomach	63.7	99.4	3.0	28.0	38.8	97.6
C18-21	Large intestine, anal canal and anus	72.9	96.4	4.2	21.4	28.6	93.3
C22	Liver	20.6	100.0	0.0	51.2	63.5	280.0
C25	Pancreas	26.1	77.9	0.0	57.1	84.3	119.9
C32	Larynx	68.1	100.0	0.0	11.1	12.5	300.0
C33-34	Trachea, bronchus and lungs	41.2	89.2	0.0	35.2	62.0	153.8
C43	Skin melanoma	89.7	100.0	0.0	6.9	13.2	45.8
C50	Breast	82.2	99.1	0.6	6.6	19.4	41.7
C53	Body of the uterus	85.6	98.5	1.1	5.6	15.5	44.0
C61	Prostate	-	-	-	-	-	-
C70-72	Central Nervous System	50.0	89.5	0.0	34.8	26.9	81.5
C73	Thyroid	72.1	100.0	0.0	5.9	3.3	47.1
C91-95	Leukemia	51.0	100.0	0.0	30.6	12.8	78.6
C81-85, C96	Lymphoma	74.1	100.0	0.0	15.5	5.6	69.8
C00-96, D46	All primary invasive malignant neoplasias	-	-	-	-	-	-
C00-96, D46/ C44	All primary invasive malignant neoplasias, except skin	75.9	95.5	1.5	14.4	30.6	69.6

(*) Argentina, Bahia Blanca (1998-2002); Brazil, Federal District (1998-2001); Brasil, Cuiabá (2000-2002); Brazil, Goiânia (1999-2002); Brazil, São Paulo (1998-2002); Chile, Valdivia (1998-2002); Colombia, Cali (1998-2002); Costa Rica (1998-2002); Ecuador, Quito (1998-2002); France, Martinique (1998-2002); Peru, Trujillo (1998-2002).

Sources: Cancer Incidence in Five Continents, Vol IX - IARC

MS/INCA/Conprev/Divisão de Informação e Análise de Situação

Annex II : Operation Flow Chart of a PBCR



print version

ISBN 978-85-7318-220-0



9 788573 182200

electronic version

ISBN 978-85-7318-221-7



9 788573 182217



**Organização
Pan-Americana
da Saúde**

*Escritório Regional para as Américas da
Organização Mundial da Saúde*

REPRESENTAÇÃO NO BRASIL



Ministério da
Saúde

